KR20220092645A - Liver cancer detection kit or device, and detection method - Google Patents

Abstract

A kit or device for detecting liver cancer, and a detection method are provided. The present invention relates to a kit or device for detecting liver cancer comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting liver cancer comprising measuring the miRNA in vitro.

Description

Liver cancer detection kit or device and detection method

The present invention provides a kit or device for the detection of liver cancer comprising a nucleic acid capable of specifically binding to a specific miRNA used for examination of the presence or absence of disease for liver cancer in a subject, and expression of the miRNA using the nucleic acid It relates to a method for detecting liver cancer, comprising measuring the amount.

The liver is the largest organ in the body located on the upper right side of the abdomen, and its main role is to metabolize nutrients and detoxify and discharge harmful substances. According to the statistics of cancer by site in Japan in 2011 launched by the National Cancer Research Center Cancer Countermeasure Information Center, a national research and development corporation, the number of patients with liver cancer is 47,271, that is, 1 in 35 Japanese people will develop liver cancer. As a result, this number of patients is the sixth most common cancer site. Also, men are nearly twice as likely to be affected than women. The number of deaths due to liver cancer increased to 30,690 for both men and women, making it the 4th most common cancer site in the number of deaths. In addition, in the United States, the estimated number of patients with liver cancer in 2014 is 33,190, and about 23,000 of them are said to die (Non-Patent Document 1).

In general, primary liver cancer often refers to hepatocellular carcinoma accounting for about 80% of all primary liver cancers, but there are also rarer carcinomas, such as intrahepatic cholangiocarcinoma and cholangiocystic adenocarcinoma, which account for 1 to 20% of all primary liver cancers.

The degree of progression of liver cancer is defined in Non-Patent Document 2 by dividing it into hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Here, in particular, hepatocellular carcinoma is classified into stage I (T1/N0/M0), stage II (T2), depending on the extent of tumor spread (T0 to 4), lymph node metastasis (N0, N1), and distant metastasis (M0, M1). /N0/M0), Stage IIIA (T3a/N0/M0), Stage IIIB (T3b/N0/M0), Stage IIIC (T4/N0/M0), Stage IVA (N1/M0), Stage IVB (M1) are classified

The 5-year relative survival rate of liver cancer varies depending on the stage of progression. According to Non-Patent Document 1, in cancers localized in the liver (stage 1, stage 2, and some stage 3), 28%, and when metastasis is confirmed in the vicinity of the liver (stage IIIC, stage IVA), 7%, distant 2% of cases with confirmed metastasis (stage IVB) are reported. Therefore, if liver cancer can be detected and treated at an early stage before metastasis is confirmed, it greatly contributes to the improvement of survival rate.

The main treatment of liver cancer is surgical treatment, which consists mainly of resection or liver transplantation, local therapy, which kills the cancer by injection or cauterization by puncture, and hepatic artery embolization. are used together In particular, when cancer is not confirmed in blood vessels or peripheral sites in early liver cancer, partial resection of the liver is often used to cure it (Non-Patent Document 1). On the other hand, even if the cancer exists locally, liver transplantation is preferable when resection is not possible due to reasons such as a large tumor diameter and proximity to blood vessels, and systemic drug therapy or radiation therapy when metastasis is further confirmed This is done (Non-Patent Document 1).

As described in Non-Patent Document 1, the primary examination for liver cancer includes imaging examinations such as ultrasound examination, CT examination, MRI examination, and angiography examination in addition to examination and palpation. Moreover, AFP (?-petprotein), PIVKA-II (Pivkatu), etc. are known as a tumor marker for liver cancer detection, and it uses together with ultrasound examination and implements in many cases. If these primary examinations reveal suspicious findings of liver cancer, as a secondary examination, a pathological examination is performed in which cells or tissues are collected and examined under a microscope by inserting a needle into the lesion.

On the other hand, since it is known that the most important cause of liver cancer is long-term infection with hepatitis B and C viruses, when liver cancer is suspected, a hepatitis virus test may be performed in addition to the primary test.

Although it is a research stage, as shown in Patent Documents 1 to 5, a method for detecting liver cancer using the expression level of microRNA (miRNA) in a biological sample including blood or liver tissue has been reported.

In Patent Document 1, miRNAs in tissues, hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-miR-92a-2-5p and hsa-miR-92b-5p, are used as markers for leukemia, breast cancer and A method for detecting liver cancer is shown.

Patent Document 2 discloses hsa-miR-23a-3p, hsa-miR-23b-3p, hsa-miR-24-3p, hsa-miR-557, hsa-miR-564, hsa- Methods for diagnosing various cancers using miRNAs such as miR-614, hsa-miR-150-3p, and hsa-miR-486-3p as markers have been reported.

In Patent Document 3, miRNAs such as hsa-miR-23b-3p, hsa-miR-30c-1-3p, hsa-miR-125a-3p, and hsa-miR-486-3p in tissues and body fluids are used as markers for liver cancer Methods for detecting various diseases, including

Patent Document 4 discloses miRNAs such as hsa-miR-16-5p, hsa-miR-92a-3p, hsa-miR-663a, hsa-miR-1913, and hsa-miR-625-3p contained in vesicles circulating in body fluid. A method for detecting various conditions including liver cancer using a protein as a marker has been shown.

Patent Document 5 discloses that hsa-miR-187-5p, hsa-miR-92a-3p, hsa-miR-16-5p, and hsa-miR-30c-1-3p in plasma are markers of colon cancer, liver cancer, and lung cancer. is indicated.

International Publication No. 2010/123043 US Patent Application Publication No. 2011/003704 International Publication No. 2010/054386 International Publication No. 2012/174282 International Publication No. 2011/076142

American Cancer Society 「Liver Cancer」, 2013, p.5~8, 14~15, 17~23, 27~41 Sobin, L. et al., 「TNM Classification of Malignant Tumors 7th Edition」 2010, p.104-107 HCCN Guidelines 「Hepatobiliary Cancer 2nd Edition」, 2014 MS-4 Zhang, B and Yang, B., 1999 Journal of Medical Screening, Vol. 6(2), p.108-110 Takahashi, A. et al., 2008, World Journal of Gastroenterology, Vol. 14(1), p.129-31

An object of the present invention is to find a novel liver cancer tumor marker, and to provide a method for effectively detecting liver cancer using a nucleic acid capable of specifically binding to the marker.

Liver cancer is a cancer that is difficult to detect early because the cancer progresses without symptoms. Moreover, since most of the liver is stored in the right rib, detection by palpation is difficult. Currently, an effective liver cancer screening method has not been established for the general public without liver cancer risk such as hepatitis virus infection or liver cirrhosis (Non-Patent Document 1). Ultrasound examination is a widely used screening method for liver cancer because it is easy and has a low burden on the patient. Therefore, it is considered preferable to use it in combination with a tumor marker (nonpatent literature 3). Although AFP is known as a tumor marker for liver cancer detection, when an increase in AFP is confirmed, liver cancer has already advanced and it is unresectable, or it has metastasized outside the liver in many cases (Nonpatent literature 1). In addition, while it has been reported that some liver cancers do not produce AFP, AFP is also elevated in cancers other than liver cancer, such as testicular cancer and ovarian cancer, and non-cancer liver diseases, such as persistent hepatitis virus infection. Since it is known that it also increases, it is considered as a marker with low specificity (nonpatent literature 1). For example, if another cancer is mistakenly diagnosed as liver cancer, an opportunity for appropriate treatment may be missed, or an unnecessary financial and physical burden will be imposed on the patient by applying the wrong medical treatment. In addition, according to the results of a large-scale screening study targeting hepatitis B-infected and persistent hepatitis patients (Non-Patent Document 4), the detection sensitivity of liver cancer by the AFP test was only 69%, making it suitable for use as a screening test for liver cancer. For this reason, the inspection performance is insufficient. Further, although CT examination and MRI examination are capable of detecting liver cancer with high performance, they are not suitable for widespread use as primary examinations because they require a special apparatus and are expensive.

In addition, although it is in the research stage, there are reports that use the expression level of microRNA (miRNA) in biological samples including blood as follows, but none of them have been put into practical use.

In Patent Document 1, miRNAs in blood cells and tissues, hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-miR-92a-2-5p and hsa-miR-92b-5p, are used as markers for leukemia. , methods for detecting breast and liver cancer are shown. However, this detection method is not preferable as an examination method because tissue excision by surgical operation is essential to obtain a sample, and this process imposes a heavy physical burden on the patient. In addition, Patent Document 1 does not have a description regarding detection performance such as specific precision, sensitivity, specificity, etc. for discriminating liver cancer with respect to the present detection method, and therefore lacks industrial practicality.

Patent Document 2 discloses hsa-miR-23a-3p, hsa-miR-23b-3p, hsa-miR-24-3p, hsa-miR-557, hsa-miR-564, hsa- Methods for diagnosing various cancers using miRNAs such as miR-614, hsa-miR-150-3p, and hsa-miR-486-3p as markers have been reported. However, in Patent Document 2, there is no description of a specific method for diagnosing liver cancer using the present detection method, and there is no description of detection performance such as precision, sensitivity, and specificity for discriminating liver cancer, so it lacks industrial practicality.

In Patent Document 3, miRNAs such as hsa-miR-23b-3p, hsa-miR-30c-1-3p, hsa-miR-125a-3p, and hsa-miR-486-3p in tissues and body fluids are used as markers for liver cancer Methods for detecting various diseases, including However, this detection method is based on the experimental results of a mouse model, and it is unclear about the detection of liver cancer in a human. In addition, Patent Document 3 lacks industrial practicability because there is no description of detection performance such as precision, sensitivity, and specificity for discriminating liver cancer.

Patent Document 4 discloses miRNAs such as hsa-miR-16-5p, hsa-miR-92a-3p, hsa-miR-663a, hsa-miR-1913, and hsa-miR-625-3p contained in vesicles circulating in body fluid. A method for detecting various conditions including liver cancer using a protein as a marker has been shown. However, Patent Document 4 does not describe a specific method for diagnosing liver cancer using the present detection method, and the miRNA marker is not verified in an independent sample group, so the reliability is low.

Patent Document 5 discloses that hsa-miR-187-5p, hsa-miR-92a-3p, hsa-miR-16-5p, and hsa-miR-30c-1-3p in plasma are markers of colon cancer, liver cancer, and lung cancer. is indicated. However, these markers are markers for discriminating the colorectal cancer group from the group consisting of liver cancer, lung cancer, and healthy individuals, and are not markers for detecting liver cancer.

As described above, in the detection of liver cancer, the performance of existing tumor markers is low, and performance and detection methods are not specifically indicated for markers in the research stage. There is a possibility that unnecessary additional examinations may be performed due to false detection of the device, and treatment opportunities may be lost due to the failure to detect a liver cancer patient. In addition, since measuring tens to hundreds of miRNAs increases the cost of testing, it is difficult to use for large-scale screening such as medical examinations. In addition, since it is undesirable to collect liver tissue for measuring tumor markers due to its high invasiveness to the patient, it is possible to detect it from blood that can be collected with low invasiveness, and convert liver cancer patients into liver cancer patients and healthy individuals. A high-precision liver cancer marker that can accurately identify a healthy body is required. In particular, since liver cancer can be improved in survival by early detection and treatment, and can be cured by partial resection of the liver in many cases, a high-sensitivity liver cancer marker that can detect even low-grade liver cancer is longed for.

As a result of intensive studies to solve the above problems, the present inventors found several genes usable for detection markers of liver cancer from blood that can be collected with low invasiveness, and used nucleic acids capable of specifically binding to these genes to prevent liver cancer It came to complete this invention by finding a thing which can be detected significantly.

<Summary of the invention>

That is, the present invention has the following characteristics.

(1) liver cancer markers, miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641 , miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p , miR-6717-5p, miR-6870-5p, miR-663b, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706 , miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p , miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR -6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6784-5p, miR-6749 -5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791 -5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR -6820-5p, miR-6777-5p, miR-3917, miR-5787, miR-4286, miR-6877-5p, miR-1225-3p, miR-6088, miR-6800-5p, miR -1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR -5001-5p, miR-1228-5p, miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805 -3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR -7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR -6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343 -5p, miR-1247-3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744 -5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR -4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p , miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR- 6724-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR- At least one or more polynucleotides selected from the group consisting of 4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p and miR-6836-3p and specific A kit for the detection of liver cancer, comprising a nucleic acid capable of binding to.

(2) miR-1343-3p is hsa-miR-1343-3p, miR-6726-5p is hsa-miR-6726-5p, miR-6515-3p is hsa-miR-6515-3p, miR- 4651 is hsa-miR-4651, miR-4257 is hsa-miR-4257, miR-3188 is hsa-miR-3188, miR-6131 is hsa-miR-6131, miR-6766-3p is hsa- miR-6766-3p, miR-7641 is hsa-miR-7641, miR-1249 is hsa-miR-1249, miR-3679-3p is hsa-miR-3679-3p, miR-6787-5p is hsa-miR-6787-5p, miR-4454 is hsa-miR-4454, miR-3135b is hsa-miR-3135b, miR-6765-3p is hsa-miR-6765-3p, miR-7975 is hsa-miR-7975, miR-204-3p is hsa-miR-204-3p, miR-7977 is hsa-miR-7977, miR-7110-5p is hsa-miR-7110-5p, miR- 6717-5p is hsa-miR-6717-5p, miR-6870-5p is hsa-miR-6870-5p, miR-663b is hsa-miR-663b, miR-6875-5p is hsa-miR-6875 -5p, miR-8072 is hsa-miR-8072, miR-6816-5p is hsa-miR-6816-5p, miR-4281 is hsa-miR-4281, miR-6729-5p is hsa-miR -6729-5p, miR-8069 is hsa-miR-8069, miR-4706 is hsa-miR-4706, miR-7108-5p is hsa-miR-7108-5p, miR-4433b-3p is hsa -miR-4433b-3p, miR-6893-5p is hsa-miR-6893-5p, miR-6857-5p is hsa-miR-6857-5p, miR-1227-5p is hsa-miR-1227- 5p , miR-6741-5p is hsa-miR-6741-5p, miR-451a is hsa-miR-451a, miR-8063 is hsa-miR-8063, miR-3622a-5p is hsa-miR-3622a -5p, miR-615-5p is hsa-miR-615-5p, miR-128-1-5p is hsa-miR-128-1-5p, miR-6825-5p is hsa-miR-6825- 5p, miR-1260b is hsa-miR-1260b, miR-4433-3p is hsa-miR-4433-3p, miR-4665-5p is hsa-miR-4665-5p, miR-7845-5p is hsa-miR-7845-5p, miR-1908-5p is hsa-miR-1908-5p, miR-6840-3p is hsa-miR-6840-3p, miR-6765-5p is hsa-miR-6765 -5p, miR-296-5p is hsa-miR-296-5p, miR-3675-3p is hsa-miR-3675-3p, miR-6781-5p is hsa-miR-6781-5p, miR -423-5p is hsa-miR-423-5p, miR-3663-3p is hsa-miR-3663-3p, miR-6784-5p is hsa-miR-6784-5p, miR-6749-5p is hsa-miR-6749-5p, miR-1231 is hsa-miR-1231, miR-4746-3p is hsa-miR-4746-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-4758-5p is hsa-miR-4758-5p, miR-3679-5p is hsa-miR-3679-5p, miR-3184-5p is hsa-miR-3184-5p, miR-6125 is hsa -miR-6125, miR-6721-5p is hsa-miR-6721-5p, miR-6791-5p is hsa-miR-6791-5p, miR-3185 is hsa-miR-3185, miR-1260a is hsa-miR-1260a, and miR-3197 is hsa-miR-3197, miR-6845-5p is hsa-miR-6845-5p, miR-6887-5p is hsa-miR-6887-5p, miR-6738-5p is hsa-miR-6738-5p , miR-6872-3p is hsa-miR-6872-3p, miR-4497 is hsa-miR-4497, miR-1229-5p is hsa-miR-1229-5p, miR-6820-5p is hsa -miR-6820-5p, miR-6777-5p is hsa-miR-6777-5p, miR-3917 is hsa-miR-3917, miR-5787 is hsa-miR-5787, miR-4286 is hsa -miR-4286, miR-6877-5p is hsa-miR-6877-5p, miR-1225-3p is hsa-miR-1225-3p, miR-6088 is hsa-miR-6088, miR-6800 -5p is hsa-miR-6800-5p, miR-1246 is hsa-miR-1246, miR-4467 is hsa-miR-4467, miR-4419b is hsa-miR-4419b, miR-1914-3p is hsa-miR-1914-3p, miR-4632-5p is hsa-miR-4632-5p, miR-1915-5p is hsa-miR-1915-5p, miR-3940-5p is hsa-miR- 3940-5p, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-6746-5p is hsa-miR-6746-5p, miR-5001-5p is hsa-miR-5001 -5p, miR-1228-5p is hsa-miR-1228-5p, miR-5572 is hsa-miR-5572, miR-4327 is hsa-miR-4327, miR-4638-5p is hsa-miR -4638-5p, miR-6799-5p is hsa-miR-6799-5p, miR-6861-5p is hsa-miR-6861-5p, miR-6727-5p is hsa-miR-6727-5p , miR-4513 is hsa- miR-4513, miR-6805-3p is hsa-miR-6805-3p, miR-6808-5p is hsa-miR-6808-5p, miR-4449 is hsa-miR-4449, miR-1199- 5p is hsa-miR-1199-5p, miR-1275 is hsa-miR-1275, miR-4792 is hsa-miR-4792, miR-4443 is hsa-miR-4443, miR-6891-5p is hsa-miR-6891-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6807-5p is hsa-miR-6807-5p, miR-7150 is hsa-miR-7150, miR-4534 is hsa-miR-4534, miR-4476 is hsa-miR-4476, miR-4649-5p is hsa-miR-4649-5p, miR-4525 is hsa-miR-4525, miR- 1915-3p is hsa-miR-1915-3p, miR-4516 is hsa-miR-4516, miR-4417 is hsa-miR-4417, miR-642b-3p is hsa-miR-642b-3p, miR-3141 is hsa-miR-3141, miR-5100 is hsa-miR-5100, miR-6848-5p is hsa-miR-6848-5p, miR-4739 is hsa-miR-4739, miR- 4459 is hsa-miR-4459, miR-1237-5p is hsa-miR-1237-5p, miR-296-3p is hsa-miR-296-3p, miR-4665-3p is hsa-miR-4665 -3p, miR-6786-5p is hsa-miR-6786-5p, miR-4258 is hsa-miR-4258, miR-6510-5p is hsa-miR-6510-5p, miR-1343-5p is hsa-miR-1343-5p, miR-1247-3p is hsa-miR-1247-3p, miR-6805-5p is hsa-miR-6805-5p, miR-4492 is hsa-miR-4492 , miR-1469 is hsa-miR-1469, miR-1268b is hsa-miR-1268b, miR-6858-5p is hsa-miR-6858-5p, miR-3937 is hsa-miR-3937, miR -939-5p is hsa-miR-939-5p, miR-3656 is hsa-miR-3656, miR-744-5p is hsa-miR-744-5p, miR-4687-3p is hsa-miR- 4687-3p, miR-4763-3p is hsa-miR-4763-3p, miR-3620-5p is hsa-miR-3620-5p, miR-3195 is hsa-miR-3195, miR-6842- 5p is hsa-miR-6842-5p, miR-4707-5p is hsa-miR-4707-5p, miR-642a-3p is hsa-miR-642a-3p, miR-7113-3p is hsa-miR -7113-3p, miR-4728-5p is hsa-miR-4728-5p, miR-5195-3p is hsa-miR-5195-3p, miR-1185-1-3p is hsa-miR-1185- 1-3p, miR-6774-5p is hsa-miR-6774-5p, miR-8059 is hsa-miR-8059, miR-3131 is hsa-miR-3131, miR-7847-3p is hsa- miR-7847-3p, miR-4463 is hsa-miR-4463, miR-128-2-5p is hsa-miR-128-2-5p, miR-4508 is hsa-miR-4508, miR- 6806-5p is hsa-miR-6806-5p, miR-7111-5p is hsa-miR-7111-5p, miR-6782-5p is hsa-miR-6782-5p, miR-4734 is hsa-miR -4734, miR-3162-5p is hsa-miR-3162-5p, miR-887-3p is hsa-miR-887-3p, miR-6752-5p is hsa-miR-6752-5p, miR -6724-5p is hsa-miR-6724-5p, miR-6757-5p is hsa-miR-6757-5p, miR-4448 is hsa-miR-4448, miR-671-5p is hsa-miR-671-5p, miR-3178 is hsa-miR-3178 , miR-4725-3p is hsa-miR-4725-3p, miR-940 is hsa-miR-940, miR-6789-5p is hsa-miR-6789-5p, miR-4484 is hsa-miR -4484, miR-4634 is hsa-miR-4634, miR-4745-5p is hsa-miR-4745-5p, miR-4730 is hsa-miR-4730, miR-6803-5p is hsa-miR -6803-5p, miR-6798-5p is hsa-miR-6798-5p, miR-3648 is hsa-miR-3648, miR-4783-3p is hsa-miR-4783-3p, and miR- The kit according to (1), wherein 6836-3p is hsa-miR-6836-3p.

(3) polynucleotides in which the nucleic acids are represented by the following (a) to (e):

(a) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases; that snippet,

(b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729;

(c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more a fragment thereof comprising consecutive bases,

(d) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or a nucleotide sequence in which u is t in the nucleotide sequence, and

(e) a polynucleotide that hybridizes with the polynucleotide of any one of (a) to (d) under stringent conditions;

The kit according to (1) or (2), which is a polynucleotide selected from the group consisting of.

(4) miR-23b-3p, miR-23a-3p, miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, which are other liver cancer markers in the kit; miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p and miR-663a The kit according to any one of (1) to (3), further comprising a nucleic acid capable of specifically binding to at least one or more polynucleotides selected from the group consisting of.

(5) miR-23b-3p is hsa-miR-23b-3p, miR-23a-3p is hsa-miR-23a-3p, miR-625-3p is hsa-miR-625-3p, miR- 1228-3p is hsa-miR-1228-3p, miR-614 is hsa-miR-614, miR-1913 is hsa-miR-1913, miR-92a-2-5p is hsa-miR-92a-2 -5p, miR-187-5p is hsa-miR-187-5p, miR-16-5p is hsa-miR-16-5p, miR-92b-3p is hsa-miR-92b-3p, miR -150-3p is hsa-miR-150-3p, miR-564 is hsa-miR-564, miR-125a-3p is hsa-miR-125a-3p, miR-92b-5p is hsa-miR- The kit according to (4), wherein miR-92a-3p is hsa-miR-92a-3p, and miR-663a is hsa-miR-663a.

(6) Polynucleotides wherein the nucleic acids are represented by the following (f) to (j):

(f) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;

(g) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183;

(h) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising;

(i) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, and

(j) a polynucleotide that hybridizes with the polynucleotide of any one of (f) to (i) under stringent conditions;

The kit according to (4) or (5), which is a polynucleotide selected from the group consisting of.

(7) miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR- 6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR-5698, miR-371a- 5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, Any one of (1) to (6), further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-6124, miR-6778-5p, miR-557 and miR-6090 The kit described in one.

(8) miR-4688 is hsa-miR-4688, miR-4648 is hsa-miR-4648, miR-6085 is hsa-miR-6085, miR-6126 is hsa-miR-6126, miR-6880 -5p is hsa-miR-6880-5p, miR-328-5p is hsa-miR-328-5p, miR-6768-5p is hsa-miR-6768-5p, miR-3180 is hsa-miR- 3180, miR-6087 is hsa-miR-6087, miR-1273g-3p is hsa-miR-1273g-3p, miR-1225-5p is hsa-miR-1225-5p, miR-3196 is hsa- miR-3196, miR-4695-5p is hsa-miR-4695-5p, miR-6732-5p is hsa-miR-6732-5p, miR-638 is hsa-miR-638, miR-6813- 5p is hsa-miR-6813-5p, miR-665 is hsa-miR-665, miR-486-3p is hsa-miR-486-3p, miR-4466 is hsa-miR-4466, miR- 30c-1-3p is hsa-miR-30c-1-3p, miR-3621 is hsa-miR-3621, miR-6743-5p is hsa-miR-6743-5p, miR-4298 is hsa-miR -4298, miR-4741 is hsa-miR-4741, miR-3619-3p is hsa-miR-3619-3p, miR-6824-5p is hsa-miR-6824-5p, miR-5698 is hsa -miR-5698, miR-371a-5p is hsa-miR-371a-5p, miR-4488 is hsa-miR-4488, miR-1233-5p is hsa-miR-1233-5p, miR-4723 -5p is hsa-miR-4723-5p, miR-24-3p is hsa-miR-24-3p, miR-1238-5p is hsa-miR-1238-5p, miR-4442 is hsa-miR- 4442, and miR-3928-3p is hsa-miR-3928-3p, miR-6716-5p is hsa-miR-6716-5p, miR-6089 is hsa-miR-6089, miR-6124 is hsa-miR-6124, miR-6778- The kit according to (7), wherein 5p is hsa-miR-6778-5p, miR-557 is hsa-miR-557, and miR-6090 is hsa-miR-6090.

(9) Polynucleotides wherein the nucleic acids are represented by the following (k) to (o):

(k) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;

(l) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224;

(m) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising;

(n) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, and

(o) a polynucleotide that hybridizes with the polynucleotide of any one of (k) to (n) under stringent conditions;

The kit according to (7) or (8), which is a polynucleotide selected from the group consisting of.

(10) The kit contains at least two or more nucleic acids capable of specifically binding to each of at least two or more polynucleotides selected from all liver cancer markers described in (1) or (2), (1) to (9) ) as described in any one of the kits.

(11) liver cancer markers, miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641 , miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p , miR-6717-5p, miR-6870-5p, miR-663b, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706 , miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p , miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR -6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6784-5p, miR-6749 -5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791 -5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR -6820-5p, miR-6777-5p, miR-3917, miR-5787, miR-4286, miR-6877-5p, miR-1225-3p, miR-6088, miR-6800-5p, mi R-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR-1228-5p, miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR- 6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR- 1343-5p, miR-1247-3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR- 744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2- 5p, miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR -6724-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR -4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p and at least one polynucleotide selected from the group consisting of miR-6836-3p and specificity A device for detecting liver cancer, comprising a nucleic acid capable of binding positively.

(12) miR-1343-3p is hsa-miR-1343-3p, miR-6726-5p is hsa-miR-6726-5p, miR-6515-3p is hsa-miR-6515-3p, miR- 4651 is hsa-miR-4651, miR-4257 is hsa-miR-4257, miR-3188 is hsa-miR-3188, miR-6131 is hsa-miR-6131, miR-6766-3p is hsa- miR-6766-3p, miR-7641 is hsa-miR-7641, miR-1249 is hsa-miR-1249, miR-3679-3p is hsa-miR-3679-3p, miR-6787-5p is hsa-miR-6787-5p, miR-4454 is hsa-miR-4454, miR-3135b is hsa-miR-3135b, miR-6765-3p is hsa-miR-6765-3p, miR-7975 is hsa-miR-7975, miR-204-3p is hsa-miR-204-3p, miR-7977 is hsa-miR-7977, miR-7110-5p is hsa-miR-7110-5p, miR- 6717-5p is hsa-miR-6717-5p, miR-6870-5p is hsa-miR-6870-5p, miR-663b is hsa-miR-663b, miR-6875-5p is hsa-miR-6875 -5p, miR-8072 is hsa-miR-8072, miR-6816-5p is hsa-miR-6816-5p, miR-4281 is hsa-miR-4281, miR-6729-5p is hsa-miR -6729-5p, miR-8069 is hsa-miR-8069, miR-4706 is hsa-miR-4706, miR-7108-5p is hsa-miR-7108-5p, miR-4433b-3p is hsa -miR-4433b-3p, miR-6893-5p is hsa-miR-6893-5p, miR-6857-5p is hsa-miR-6857-5p, miR-1227-5p is hsa-miR-1227- 5 p, miR-6741-5p is hsa-miR-6741-5p, miR-451a is hsa-miR-451a, miR-8063 is hsa-miR-8063, miR-3622a-5p is hsa-miR- 3622a-5p, miR-615-5p is hsa-miR-615-5p, miR-128-1-5p is hsa-miR-128-1-5p, miR-6825-5p is hsa-miR-6825 -5p, miR-1260b is hsa-miR-1260b, miR-4433-3p is hsa-miR-4433-3p, miR-4665-5p is hsa-miR-4665-5p, miR-7845-5p is hsa-miR-7845-5p, miR-1908-5p is hsa-miR-1908-5p, miR-6840-3p is hsa-miR-6840-3p, miR-6765-5p is hsa-miR- 6765-5p, miR-296-5p is hsa-miR-296-5p, miR-3675-3p is hsa-miR-3675-3p, miR-6781-5p is hsa-miR-6781-5p, miR-423-5p is hsa-miR-423-5p, miR-3663-3p is hsa-miR-3663-3p, miR-6784-5p is hsa-miR-6784-5p, miR-6749-5p is hsa-miR-6749-5p, miR-1231 is hsa-miR-1231, miR-4746-3p is hsa-miR-4746-3p, miR-6780b-5p is hsa-miR-6780b-5p; , miR-4758-5p is hsa-miR-4758-5p, miR-3679-5p is hsa-miR-3679-5p, miR-3184-5p is hsa-miR-3184-5p, miR-6125 is hsa-miR-6125, miR-6721-5p is hsa-miR-6721-5p, miR-6791-5p is hsa-miR-6791-5p, miR-3185 is hsa-miR-3185, miR- 1260a is hsa-miR-1260a, miR-3197 is hsa-miR-3197, miR-6845-5p is hsa-miR-6845-5p, miR-6887-5p is hsa-miR-6887-5p, miR-6738-5p is hsa-miR-6738-5p , miR-6872-3p is hsa-miR-6872-3p, miR-4497 is hsa-miR-4497, miR-1229-5p is hsa-miR-1229-5p, miR-6820-5p is hsa -miR-6820-5p, miR-6777-5p is hsa-miR-6777-5p, miR-3917 is hsa-miR-3917, miR-5787 is hsa-miR-5787, miR-4286 is hsa -miR-4286, miR-6877-5p is hsa-miR-6877-5p, miR-1225-3p is hsa-miR-1225-3p, miR-6088 is hsa-miR-6088, miR-6800 -5p is hsa-miR-6800-5p, miR-1246 is hsa-miR-1246, miR-4467 is hsa-miR-4467, miR-4419b is hsa-miR-4419b, miR-1914-3p is hsa-miR-1914-3p, miR-4632-5p is hsa-miR-4632-5p, miR-1915-5p is hsa-miR-1915-5p, miR-3940-5p is hsa-miR- 3940-5p, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-6746-5p is hsa-miR-6746-5p, miR-5001-5p is hsa-miR-5001 -5p, miR-1228-5p is hsa-miR-1228-5p, miR-5572 is hsa-miR-5572, miR-4327 is hsa-miR-4327, miR-4638-5p is hsa-miR -4638-5p, miR-6799-5p is hsa-miR-6799-5p, miR-6861-5p is hsa-miR-6861-5p, miR-6727-5p is hsa-miR-6727-5p , miR-4513 is hsa -miR-4513, miR-6805-3p is hsa-miR-6805-3p, miR-6808-5p is hsa-miR-6808-5p, miR-4449 is hsa-miR-4449, miR-1199 -5p is hsa-miR-1199-5p, miR-1275 is hsa-miR-1275, miR-4792 is hsa-miR-4792, miR-4443 is hsa-miR-4443, miR-6891-5p is hsa-miR-6891-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6807-5p is hsa-miR-6807-5p, miR-7150 is hsa-miR-7150 , miR-4534 is hsa-miR-4534, miR-4476 is hsa-miR-4476, miR-4649-5p is hsa-miR-4649-5p, miR-4525 is hsa-miR-4525, miR -1915-3p is hsa-miR-1915-3p, miR-4516 is hsa-miR-4516, miR-4417 is hsa-miR-4417, miR-642b-3p is hsa-miR-642b-3p , miR-3141 is hsa-miR-3141, miR-5100 is hsa-miR-5100, miR-6848-5p is hsa-miR-6848-5p, miR-4739 is hsa-miR-4739, miR -4459 is hsa-miR-4459, miR-1237-5p is hsa-miR-1237-5p, miR-296-3p is hsa-miR-296-3p, miR-4665-3p is hsa-miR- 4665-3p, miR-6786-5p is hsa-miR-6786-5p, miR-4258 is hsa-miR-4258, miR-6510-5p is hsa-miR-6510-5p, miR-1343- 5p is hsa-miR-1343-5p, miR-1247-3p is hsa-miR-1247-3p, miR-6805-5p is hsa-miR-6805-5p, miR-4492 is hsa-miR-4492 this and miR-1469 is hsa-miR-1469, miR-1268b is hsa-miR-1268b, miR-6858-5p is hsa-miR-6858-5p, miR-3937 is hsa-miR-3937, miR-939-5p is hsa-miR-939-5p, miR-3656 is hsa-miR-3656, miR-744-5p is hsa-miR-744-5p, miR-4687-3p is hsa-miR -4687-3p, miR-4763-3p is hsa-miR-4763-3p, miR-3620-5p is hsa-miR-3620-5p, miR-3195 is hsa-miR-3195, miR-6842 -5p is hsa-miR-6842-5p, miR-4707-5p is hsa-miR-4707-5p, miR-642a-3p is hsa-miR-642a-3p, miR-7113-3p is hsa- miR-7113-3p, miR-4728-5p is hsa-miR-4728-5p, miR-5195-3p is hsa-miR-5195-3p, miR-1185-1-3p is hsa-miR-1185 -1-3p, miR-6774-5p is hsa-miR-6774-5p, miR-8059 is hsa-miR-8059, miR-3131 is hsa-miR-3131, miR-7847-3p is hsa -miR-7847-3p, miR-4463 is hsa-miR-4463, miR-128-2-5p is hsa-miR-128-2-5p, miR-4508 is hsa-miR-4508, miR -6806-5p is hsa-miR-6806-5p, miR-7111-5p is hsa-miR-7111-5p, miR-6782-5p is hsa-miR-6782-5p, miR-4734 is hsa- miR-4734, miR-3162-5p is hsa-miR-3162-5p, miR-887-3p is hsa-miR-887-3p, miR-6752-5p is hsa-miR-6752-5p, miR-6724-5p is hsa-miR-6724-5p, miR-6757-5p is hsa-miR-6757-5p, miR-4448 is hsa-miR-4448, miR-671-5p is hsa-miR-671-5p, miR-3178 is hsa-miR-3178 , miR-4725-3p is hsa-miR-4725-3p, miR-940 is hsa-miR-940, miR-6789-5p is hsa-miR-6789-5p, miR-4484 is hsa-miR -4484, miR-4634 is hsa-miR-4634, miR-4745-5p is hsa-miR-4745-5p, miR-4730 is hsa-miR-4730, miR-6803-5p is hsa-miR -6803-5p, miR-6798-5p is hsa-miR-6798-5p, miR-3648 is hsa-miR-3648, miR-4783-3p is hsa-miR-4783-3p, and miR- The device according to (11), wherein 6836-3p is hsa-miR-6836-3p.

(13) Polynucleotides wherein the nucleic acids are represented by the following (a) to (e):

(a) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases; that snippet,

(b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729;

(c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more a fragment thereof comprising consecutive bases,

(d) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or a nucleotide sequence in which u is t in the nucleotide sequence, and

(e) a polynucleotide that hybridizes with the polynucleotide of any one of (a) to (d) under stringent conditions;

The device according to (11) or (12), which is a polynucleotide selected from the group consisting of.

(14) the device is another liver cancer marker miR-23b-3p, miR-23a-3p, miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p and miR-663a The device according to any one of (11) to (13), further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of.

(15) miR-23b-3p is hsa-miR-23b-3p, miR-23a-3p is hsa-miR-23a-3p, miR-625-3p is hsa-miR-625-3p, miR- 1228-3p is hsa-miR-1228-3p, miR-614 is hsa-miR-614, miR-1913 is hsa-miR-1913, miR-92a-2-5p is hsa-miR-92a-2 -5p, miR-187-5p is hsa-miR-187-5p, miR-16-5p is hsa-miR-16-5p, miR-92b-3p is hsa-miR-92b-3p, miR -150-3p is hsa-miR-150-3p, miR-564 is hsa-miR-564, miR-125a-3p is hsa-miR-125a-3p, miR-92b-5p is hsa-miR- The device according to (14), wherein miR-92a-3p is hsa-miR-92a-3p, and miR-663a is hsa-miR-663a.

(16) Polynucleotides wherein the nucleic acids are represented by the following (f) to (j):

(f) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;

(g) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183;

(h) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising;

(i) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, and

(j) a polynucleotide that hybridizes with the polynucleotide of any one of (f) to (i) under stringent conditions;

The device according to (14) or (15), which is a polynucleotide selected from the group consisting of.

(17) miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR- 6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR-5698, miR-371a- 5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, Any of (11) to (16), further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-6124, miR-6778-5p, miR-557 and miR-6090 A device as described in one.

(18) miR-4688 is hsa-miR-4688, miR-4648 is hsa-miR-4648, miR-6085 is hsa-miR-6085, miR-6126 is hsa-miR-6126, miR-6880 -5p is hsa-miR-6880-5p, miR-328-5p is hsa-miR-328-5p, miR-6768-5p is hsa-miR-6768-5p, miR-3180 is hsa-miR- 3180, miR-6087 is hsa-miR-6087, miR-1273g-3p is hsa-miR-1273g-3p, miR-1225-5p is hsa-miR-1225-5p, miR-3196 is hsa- miR-3196, miR-4695-5p is hsa-miR-4695-5p, miR-6732-5p is hsa-miR-6732-5p, miR-638 is hsa-miR-638, miR-6813- 5p is hsa-miR-6813-5p, miR-665 is hsa-miR-665, miR-486-3p is hsa-miR-486-3p, miR-4466 is hsa-miR-4466, miR- 30c-1-3p is hsa-miR-30c-1-3p, miR-3621 is hsa-miR-3621, miR-6743-5p is hsa-miR-6743-5p, miR-4298 is hsa-miR -4298, miR-4741 is hsa-miR-4741, miR-3619-3p is hsa-miR-3619-3p, miR-6824-5p is hsa-miR-6824-5p, miR-5698 is hsa -miR-5698, miR-371a-5p is hsa-miR-371a-5p, miR-4488 is hsa-miR-4488, miR-1233-5p is hsa-miR-1233-5p, miR-4723 -5p is hsa-miR-4723-5p, miR-24-3p is hsa-miR-24-3p, miR-1238-5p is hsa-miR-1238-5p, miR-4442 is hsa-miR- 4442, and miR-3928-3p is hsa-miR-3928-3p, miR-6716-5p is hsa-miR-6716-5p, miR-6089 is hsa-miR-6089, miR-6124 is hsa-miR-6124, miR-6778 The device according to (17), wherein -5p is hsa-miR-6778-5p, miR-557 is hsa-miR-557, and miR-6090 is hsa-miR-6090.

(19) Polynucleotides wherein the nucleic acids are represented by the following (k) to (o):

(k) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;

(l) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224;

(m) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising;

(n) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, and

(o) a polynucleotide that hybridizes with the polynucleotide of any one of (k) to (n) under stringent conditions;

The device according to (17) or (18), which is a polynucleotide selected from the group consisting of.

(20) The device according to any one of (11) to (19), wherein the device is a device for measurement by a hybridization technique.

(21) The device according to (20), wherein the hybridization technique is a nucleic acid array technique.

(22) (11) to (21), wherein the device comprises at least two or more nucleic acids capable of specifically binding to each of at least two or more polynucleotides selected from all liver cancer markers described in (11) or (12). ), the device according to any one of.

(23) using the kit according to any one of (1) to (10) or the device according to any one of (11) to (22) to measure the expression level of the target nucleic acid in the sample of the subject; A method for detecting liver cancer, comprising in vitro evaluation of whether or not a subject has liver cancer using the measured expression level and a control expression level of a healthy body measured similarly.

(24) The method according to (23), wherein the subject is a human.

(25) The method according to (23) or (24), wherein the sample is blood, serum or plasma.

<Definition of Terms>

The terms used in this specification have the following definitions.

Indications with abbreviations for nucleotides, polynucleotides, DNA, RNA, etc. are in accordance with the "Guidelines for Creation of Specifications Containing Base Sequences or Amino Acid Sequences" (Japanese Patent Office Edition) and customs in the technical field. make it as

In the present specification, "polynucleotide" is used with respect to a nucleic acid including any of RNA, DNA, and RNA/DNA (chimera). In addition, the DNA includes any of cDNA, genomic DNA, and synthetic DNA. In addition, the RNA includes any one of total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. In the present specification, "synthetic DNA" and "synthetic RNA" are artificially produced using, for example, an automatic nucleic acid synthesizer based on a predetermined base sequence (either a natural sequence or a non-natural sequence may be used). refers to DNA and RNA. In the present specification, "non-native sequence" is intended to be used in a broad sense, and is different from the native sequence, for example, a sequence containing substitution, deletion, insertion and/or addition of one or more nucleotides (that is, , mutant sequences), sequences including one or more modified nucleotides (ie, modified sequences), and the like. Also, in the present specification, polynucleotide is used interchangeably with nucleic acid.

In the present specification, a "fragment" is a polynucleotide having a nucleotide sequence of a continuous portion of a polynucleotide, and preferably has a length of 15 bases or more, preferably 17 bases or more, more preferably 19 bases or more.

As used herein, the term "gene" is intended to include not only RNA and double-stranded DNA, but also single-stranded DNA such as a positive strand (or sense strand) or complementary strand (or antisense strand) constituting the same. used In addition, it is not particularly limited according to the length.

Accordingly, in the present specification, unless otherwise specified, "gene" refers to double-stranded DNA including human genomic DNA, single-stranded DNA (correct strand), and single-stranded DNA having a sequence complementary to the corresponding positive strand including cDNA (complementary chain), microRNAs (miRNAs), and fragments thereof, and transcripts. In addition, the "gene" is not only a "gene" represented by a specific nucleotide sequence (or SEQ ID NO), but also RNA having a biological function equivalent to the RNA encoded by these, for example, a homologue (ie, homolog or ortholog) , "nucleic acids" encoding variants, such as gene polymorphisms, and derivatives. As a "nucleic acid" encoding such a homologue, mutant or derivative, specifically, under stringent conditions described below, the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 765, or u in the nucleotide sequence is t "Nucleic acid" which has a nucleotide sequence which hybridizes with the complementary sequence of a nucleotide sequence is mentioned. In addition, the "gene" does not imply a difference in the functional region, and may include, for example, an expression control region, a code region, an exon, or an intron. In addition, a "gene" may be contained in a cell, it may be released outside a cell, and may exist independently, and may exist in the state enclosed in the vesicle called an exosome.

As used herein, the term "exosome" is a vesicle encased in a lipid bilayer secreted from a cell. Exosomes are somewhat derived from endosomes, and when released to the extracellular environment, they may contain "genes" such as RNA and DNA or biological substances such as proteins. It is known that exosomes are contained in body fluids such as blood, serum, plasma, serum, and lymph.

As used herein, the term "transcription product" refers to RNA synthesized using the DNA sequence of a gene as a template. RNA is synthesized in the form where RNA polymerase binds to a site called a promoter located upstream of the gene, and ribonucleotides are attached to the 3' end so as to be complementary to the base sequence of DNA. This RNA includes not only the gene itself, but also the entire sequence from the transcription initiation point to the end of the polyA sequence, including expression control regions, coding regions, exons or introns.

In the present specification, unless otherwise specified, "microRNA (miRNA)" is a protein complex that is transcribed as an RNA precursor having a hairpin-like structure, is cleaved by a dsRNA cleaving enzyme having RNase III cleavage activity, and is called RISC. 15 to 25 base non-coding RNA introduced into and involved in mRNA translation inhibition is intended for use. In addition, "miRNA" as used herein refers to not only "miRNA" represented by a specific nucleotide sequence (or SEQ ID NO), but also precursors (pre-miRNA, pri-miRNA) of the "miRNA", and these and biological functions Equivalent miRNAs such as homologs (ie homologs or orthologs), variants such as genetic polymorphisms, and derivatives are also included. As such precursors, homologues, mutants or derivatives, specifically, it can be identified by miRBase release 20 (http://www.mirbase.org/), and among SEQ ID NOs: 1-765 under stringent conditions described below. and "miRNA" having a nucleotide sequence that hybridizes with a complementary sequence of any one specific nucleotide sequence represented by any one. In addition, the "miRNA" used herein may be a gene product of a miR gene, and such gene product is a mature miRNA (for example, 15 to 25 bases or 19 to 25 bases involved in the translation inhibition of mRNA as described above). of non-coding RNA) or miRNA precursors (eg, pre-miRNA or pri-miRNA as above).

As used herein, the term "probe" includes a polynucleotide used for specifically detecting RNA generated by gene expression or a polynucleotide derived therefrom and/or a polynucleotide complementary thereto.

As used herein, the term "primer" includes a polynucleotide that specifically recognizes and amplifies RNA generated by gene expression or a polynucleotide derived therefrom, and/or a polynucleotide complementary thereto.

Here, the complementary polynucleotide (complementary chain, reverse chain) refers to a nucleotide sequence defined by any one of SEQ ID NOs: 1 to 765, or a polynucleotide consisting of a nucleotide sequence in which u is t in the nucleotide sequence. It refers to a polynucleotide having a base-complementary relationship based on a base pair relationship such as A:T(U) or G:C with respect to the full-length sequence or its partial sequence (herein, for convenience, this is referred to as a regular chain). However, such a complementary chain is not limited to the case where it completely forms a complementary sequence with the base sequence of the target normal chain, and has a complementary relationship to the extent that it can hybridize with the target normal chain under stringent conditions. it could be anything

As used herein, the term "stringent conditions" refers to a degree to which the nucleic acid probe is greater than that of other sequences (eg, the mean of the background measurement value + the standard error of the background measurement value × 2 or more), and the target sequence It refers to the conditions for hybridization with respect to Stringent conditions are sequence-dependent and depend on the environment in which hybridization is performed. By controlling the stringency of the hybridization and/or washing conditions, a target sequence that is 100% complementary to a nucleic acid probe can be identified. Specific examples of "stringent conditions" will be described later.

In the present specification, "Tm value" means the temperature at which the double chain portion of the polynucleotide is denatured into a single chain, and the double chain and the single chain exist in a ratio of 1:1.

In the present specification, the term "variant" means a natural variant due to polymorphism, mutation, etc. in the case of a nucleic acid, a nucleotide sequence of any one of SEQ ID NOs: 1 to 765, or a nucleotide sequence in which u is t in the nucleotide sequence, or its A variant comprising deletion, substitution, addition, or insertion of one or two or more bases in a subsequence, or about 90% or more, about 95% or more, about 97% or more, about 98% or more, with each or a subsequence of the corresponding nucleotide sequence It refers to a nucleic acid that hybridizes under stringent conditions as defined above with a mutant exhibiting % or more, about 99% or more % identity, or a polynucleotide or oligonucleotide containing the nucleotide sequence or a subsequence thereof.

In this specification, "several" means about 10, 9, 8, 7, 6, 5, 4, 3, or two integers.

In the present specification, mutants can be produced using well-known techniques such as site-directed mutagenesis and mutagenesis using PCR.

In the present specification, "% identity" can be determined using the BLAST or FASTA protein or gene search system, with or without introducing a gap (Zheng Zhang et al., 2000, J. Comput). Biol., vol. 7, p203-214; Altschul, S. F. et al., 1990, Journal of Molecular Biology, vol. 215, p403-410; Pearson, W. R. et al., 1988, Proc. Natl. Acad. Sci. U.S.A., vol. 85, p2444-2448).

As used herein, the term "derivative" refers to a modified nucleic acid, but is not limited to, for example, a fluorophore-labeled derivative, a modified nucleotide (eg halogen, alkyl such as methyl, alkoxy such as methoxy, thio, carboxymethyl, etc.) Derivatives containing nucleotides and bases containing the group of nucleotides that have undergone reorganization, double bond saturation, deamination, substitution of oxygen molecules with sulfur molecules, etc.), PNA (peptide nucleic acid; Nielsen, P. E. et al., 1991) Years, Science, Vol. 254, p1497-500), LNA (locked nucleic acid; Obika, S. et al., 1998, Tetrahedron Lett., Vol. 39, p5401-5404) and the like.

In the present specification, the "nucleic acid" capable of specifically binding to a polynucleotide selected from the group of miRNAs, which is a liver cancer marker, is a synthesized or prepared nucleic acid, and specifically includes a "nucleic acid probe" or "primer", In order to detect the presence or absence of liver cancer in the liver, or to diagnose the presence or absence of morbidity of liver cancer, degree of morbidity, presence or absence or degree of improvement of liver cancer, sensitivity to treatment of liver cancer, or prevention, improvement or It is used directly or indirectly to screen candidates useful for treatment. These include, in relation to the morbidity of liver cancer, in vivo, in particular, in a specimen such as blood or urine, a transcript represented by any one of SEQ ID NOs: 1 to 765 or its cDNA synthesis nucleic acid that can be specifically recognized and bound. nucleotides, oligonucleotides and polynucleotides. Based on the above properties, these nucleotides, oligonucleotides and polynucleotides can be effectively used as probes for detecting the gene expressed in vivo, in tissues or cells, and as primers for amplifying the gene expressed in vivo. can

The term "detection" used in this specification can be substituted with the terms inspection, measurement, detection, or decision support. In addition, in this specification, the term "evaluation" is used in the meaning including supporting a diagnosis or evaluation based on a test result or a measurement result.

As used herein, "subject" refers to humans, primates including chimpanzees, pets such as dogs and cats, domestic animals such as cattle, horses, sheep and goats, and mammals such as rodents such as mice and rats. it means. In addition, a "healthy body" is also such a mammal, and means an animal which is not afflicted with the cancer to be detected.

As used herein, "liver cancer" means "primary liver cancer" that occurs primarily in the liver, and includes, for example, "hepatocellular carcinoma" and "hepatocyte-biliary cell mixed cancer" in which cells of the liver are cancerous. make it as

As used herein, "P" or "P value" indicates the probability of observing a statistic that is more extreme than the statistic actually calculated from data under the null hypothesis in a statistical test. Therefore, it can be considered that there is a significant difference between the comparison objects, as "P" or "P value" is smaller.

In this specification, "sensitivity" means a value of (number of true positives)/(number of true positives + number of false negatives). When sensitivity is high, it becomes possible to detect liver cancer at an early stage, and it leads to complete resection of a cancer part, and a fall of the recurrence rate.

In the present specification, "specificity" means (number of true negatives)/ (number of true negatives + number of false positives). If the specificity is high, unnecessary additional tests due to erroneous diagnosis of a healthy body as a liver cancer patient are prevented, leading to a reduction in burden on the patient and reduction of medical expenses.

In this specification, "precision" means a value of (number of true positives + number of true negatives)/(number of total cases). Accuracy represents the ratio of correct discrimination results for all samples, and serves as the first index for evaluating detection performance.

In the present specification, the term "subject" to be determined, detected or diagnosed refers to tissues and biological materials in which the expression of the gene of the present invention changes according to the occurrence of liver cancer, the progression of liver cancer, and the exertion of a therapeutic effect on liver cancer. . Specifically, hepatic tissue and its surrounding vessels, lymph nodes and organs, and organs suspected of metastasis, skin, and body fluids such as blood, urine, saliva, sweat, and tissue exudate, serum prepared from blood, plasma, other, feces , hair, etc. It also refers to a biological sample extracted from these, specifically, a gene such as RNA or miRNA.

As used herein, the term "hsa-miR-1343-3p gene" or "hsa-miR-1343-3p" refers to the hsa-miR-1343-3p gene described in SEQ ID NO: 1 (miRBase Accession No. MIMAT0019776) or other species homologs or orthologs. The hsa-miR-1343-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-1343-3p" is known as "hsa-mir-1343" (miRBase Accession No. MI0017320, SEQ ID NO: 225) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6726-5p gene" or "hsa-miR-6726-5p" refers to the hsa-miR-6726-5p gene described in SEQ ID NO: 2 (miRBase Accession No. MIMAT0027353) or other species homologs or orthologs. The hsa-miR-6726-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6726-5p" is known as "hsa-mir-6726" (miRBase Accession No. MI0022571, SEQ ID NO: 226) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6515-3p gene" or "hsa-miR-6515-3p" refers to the hsa-miR-6515-3p gene shown in SEQ ID NO: 3 (miRBase Accession No. MIMAT0025487) or other species homologs or orthologs. The hsa-miR-6515-3p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, p4025-4040. In addition, "hsa-miR-6515-3p" is known as "hsa-mir-6515" (miRBase Accession No. MI0022227, SEQ ID NO: 227) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4651 gene" or "hsa-miR-4651" refers to the hsa-miR-4651 gene (miRBase Accession No. MIMAT0019715) described in SEQ ID NO: 4 or other species homologs. or orthologs, etc. The hsa-miR-4651 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. Also, as a precursor of "hsa-miR-4651", "hsa-mir-4651" (miRBase Accession No. MI0017279, SEQ ID NO: 228) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4257 gene" or "hsa-miR-4257" refers to the hsa-miR-4257 gene (miRBase Accession No. MIMAT0016878) described in SEQ ID NO: 5 or other biological species homologs. or orthologs, etc. The hsa-miR-4257 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. Also, as a precursor of "hsa-miR-4257", "hsa-mir-4257" (miRBase Accession No. MI0015856, SEQ ID NO: 229) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-3188 gene" or "hsa-miR-3188" refers to the hsa-miR-3188 gene (miRBase Accession No. MIMAT0015070) set forth in SEQ ID NO: 6 or other biological species homologs. or orthologs, etc. The hsa-miR-3188 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3188" is known as a precursor thereof "hsa-mir-3188" (miRBase Accession No. MI0014232, SEQ ID NO: 230) having a hairpin-like structure.

As used herein, the term "hsa-miR-6131 gene" or "hsa-miR-6131" refers to the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO: 7 or other biological species homologs. or orthologs, etc. The hsa-miR-6131 gene can be obtained by the method described in Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p552-564. In addition, "hsa-miR-6131" is known as "hsa-mir-6131" (miRBase Accession No. MI0021276, SEQ ID NO: 231) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6766-3p gene" or "hsa-miR-6766-3p" refers to the hsa-miR-6766-3p gene shown in SEQ ID NO: 8 (miRBase Accession No. MIMAT0027433) or other species homologs or orthologs. The hsa-miR-6766-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6766-3p" is known as "hsa-mir-6766" (miRBase Accession No. MI0022611, SEQ ID NO: 232) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-7641 gene" or "hsa-miR-7641" refers to the hsa-miR-7641 gene (miRBase Accession No. MIMAT0029782) shown in SEQ ID NO: 9 or other biological species homologs. or orthologs, etc. The hsa-miR-7641 gene can be obtained by the method described in Yoo JK et al., 2013, Arch Pharm Res, Vol. 36, p353-358. In addition, "hsa-miR-7641" is a precursor thereof, "hsa-mir-7641-1", "hsa-mir-7641-2" taking a hairpin-like structure (miRBase Accession No. MI0024975, MI0024976, SEQ ID NO: 233) , 234) are known.

As used herein, the term "hsa-miR-1249 gene" or "hsa-miR-1249" refers to the hsa-miR-1249 gene (miRBase Accession No. MIMAT0005901) set forth in SEQ ID NO: 10 or other biological species homologs. or orthologs, etc. The hsa-miR-1249 gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, p610-621. In addition, as a precursor of "hsa-miR-1249", "hsa-mir-1249" (miRBase Accession No. MI0006384, SEQ ID NO: 235) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-3679-3p gene" or "hsa-miR-3679-3p" refers to the hsa-miR-3679-3p gene shown in SEQ ID NO: 11 (miRBase Accession No. MIMAT0018105) or other species homologs or orthologs. The hsa-miR-3679-3p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, "hsa-miR-3679-3p" is known as "hsa-mir-3679" (miRBase Accession No. MI0016080, SEQ ID NO: 236) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6787-5p gene" or "hsa-miR-6787-5p" refers to the hsa-miR-6787-5p gene shown in SEQ ID NO: 12 (miRBase Accession No. MIMAT0027474) or other species homologs or orthologs. The hsa-miR-6787-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6787-5p" is known as "hsa-mir-6787" (miRBase Accession No. MI0022632, SEQ ID NO: 237) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4454 gene" or "hsa-miR-4454" refers to the hsa-miR-4454 gene (miRBase Accession No. MIMAT0018976) described in SEQ ID NO: 13 or other species homologs. or orthologs, etc. The hsa-miR-4454 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4454", "hsa-mir-4454" (miRBase Accession No. MI0016800, SEQ ID NO: 238) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-3135b gene" or "hsa-miR-3135b" refers to the hsa-miR-3135b gene (miRBase Accession No. MIMAT0018985) described in SEQ ID NO: 14 or other species homologs. or orthologs, etc. The hsa-miR-3135b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-3135b", "hsa-mir-3135b" (miRBase Accession No. MI0016809, SEQ ID NO: 239) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6765-3p gene" or "hsa-miR-6765-3p" refers to the hsa-miR-6765-3p gene shown in SEQ ID NO: 15 (miRBase Accession No. MIMAT0027431) or other species homologs or orthologs. The hsa-miR-6765-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6765-3p" is known as "hsa-mir-6765" (miRBase Accession No. MI0022610, SEQ ID NO: 240) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-7975 gene" or "hsa-miR-7975" refers to the hsa-miR-7975 gene (miRBase Accession No. MIMAT0031178) described in SEQ ID NO: 16 or other species homologs. or orthologs, etc. The hsa-miR-7975 gene can be obtained by the method described in Velthut-Meikas A et al., 2013, Mol Endocrinol, online edition. Also, as a precursor of "hsa-miR-7975", "hsa-mir-7975" (miRBase Accession No. MI0025751, SEQ ID NO: 241) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-204-3p gene" or "hsa-miR-204-3p" refers to the hsa-miR-204-3p gene shown in SEQ ID NO: 17 (miRBase Accession No. MIMAT0022693) or other species homologs or orthologs. The hsa-miR-204-3p gene can be obtained by the method described in Lim LP et al., 2003, Science, Vol. 299, p1540. In addition, "hsa-miR-204-3p" is known as "hsa-mir-204" (miRBase Accession No. MI0000284, SEQ ID NO: 242) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-7977 gene" or "hsa-miR-7977" refers to the hsa-miR-7977 gene (miRBase Accession No. MIMAT0031180) described in SEQ ID NO: 18 or other species homologs. or orthologs, etc. The hsa-miR-7977 gene can be obtained by the method described in Velthut-Meikas A et al., 2013, Mol Endocrinol, online edition. In addition, "hsa-miR-7977" is known as "hsa-mir-7977" (miRBase Accession No. MI0025753, SEQ ID NO: 243) having a hairpin-like structure as its precursor.

The term "hsa-miR-7110-5p gene" or "hsa-miR-7110-5p" as used herein refers to the hsa-miR-7110-5p gene shown in SEQ ID NO: 19 (miRBase Accession No. MIMAT0028117) or other species homologs or orthologs. The hsa-miR-7110-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-7110-5p" is known as "hsa-mir-7110" (miRBase Accession No. MI0022961, SEQ ID NO: 244) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6717-5p gene" or "hsa-miR-6717-5p" refers to the hsa-miR-6717-5p gene shown in SEQ ID NO: 20 (miRBase Accession No. MIMAT0025846) or other species homologs or orthologs. The hsa-miR-6717-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, p330-335. In addition, "hsa-miR-6717-5p" is known as "hsa-mir-6717" (miRBase Accession No. MI0022551, SEQ ID NO: 245) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6870-5p gene" or "hsa-miR-6870-5p" refers to the hsa-miR-6870-5p gene (miRBase Accession No. MIMAT0027640) shown in SEQ ID NO: 21. or other species homologs or orthologs. The hsa-miR-6870-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. Also, "hsa-miR-6870-5p" is known as "hsa-mir-6870" (miRBase Accession No. MI0022717, SEQ ID NO: 246) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-663b gene" or "hsa-miR-663b" refers to the hsa-miR-663b gene (miRBase Accession No. MIMAT0005867) set forth in SEQ ID NO: 22 or other species homologs. or orthologs, etc. The hsa-miR-663b gene can be obtained by the method described in Takada S et al., 2008, Leukemia, Vol. 22, p1274-1278. In addition, "hsa-miR-663b" is known as "hsa-mir-663b" (miRBase Accession No. MI0006336, SEQ ID NO: 247) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6875-5p gene" or "hsa-miR-6875-5p" refers to the hsa-miR-6875-5p gene shown in SEQ ID NO: 23 (miRBase Accession No. MIMAT0027650) or other species homologs or orthologs. The hsa-miR-6875-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6875-5p" is known as "hsa-mir-6875" (miRBase Accession No. MI0022722, SEQ ID NO: 248) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-8072 gene" or "hsa-miR-8072" refers to the hsa-miR-8072 gene (miRBase Accession No. MIMAT0030999) set forth in SEQ ID NO: 24 or other biological species homologs. or orthologs, etc. The hsa-miR-8072 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, vol. 39, p480-487. In addition, "hsa-mir-8072" (miRBase Accession No. MI0025908, SEQ ID NO: 249) which takes a hairpin-like structure as a precursor thereof is known as "hsa-miR-8072".

As used herein, the term "hsa-miR-6816-5p gene" or "hsa-miR-6816-5p" refers to the hsa-miR-6816-5p gene described in SEQ ID NO: 25 (miRBase Accession No. MIMAT0027532) or other species homologs or orthologs. The hsa-miR-6816-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6816-5p" is known as "hsa-mir-6816" (miRBase Accession No. MI0022661, SEQ ID NO: 250) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4281 gene" or "hsa-miR-4281" refers to the hsa-miR-4281 gene (miRBase Accession No. MIMAT0016907) described in SEQ ID NO: 26 or other species homologs. or orthologs, etc. The hsa-miR-4281 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of "hsa-miR-4281", "hsa-mir-4281" (miRBase Accession No. MI0015885, SEQ ID NO: 251) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6729-5p gene" or "hsa-miR-6729-5p" refers to the hsa-miR-6729-5p gene shown in SEQ ID NO: 27 (miRBase Accession No. MIMAT0027359) or other species homologs or orthologs. The hsa-miR-6729-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6729-5p" is known as "hsa-mir-6729" (miRBase Accession No. MI0022574, SEQ ID NO: 252) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-8069 gene" or "hsa-miR-8069" refers to the hsa-miR-8069 gene (miRBase Accession No. MIMAT0030996) set forth in SEQ ID NO: 28 or other species homologs. or orthologs, etc. The hsa-miR-8069 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, vol. 39, p480-487. Also, as a precursor of "hsa-miR-8069", "hsa-mir-8069" (miRBase Accession No. MI0025905, SEQ ID NO: 253) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4706 gene" or "hsa-miR-4706" refers to the hsa-miR-4706 gene (miRBase Accession No. MIMAT0019806) set forth in SEQ ID NO: 29 or other biological species homologs. or orthologs, etc. The hsa-miR-4706 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4706" is known as "hsa-mir-4706" (miRBase Accession No. MI0017339, SEQ ID NO: 254) having a hairpin-like structure as its precursor.

The term "hsa-miR-7108-5p gene" or "hsa-miR-7108-5p" as used herein refers to the hsa-miR-7108-5p gene shown in SEQ ID NO: 30 (miRBase Accession No. MIMAT0028113) or other species homologs or orthologs. The hsa-miR-7108-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-7108-5p" is known as "hsa-mir-7108" (miRBase Accession No. MI0022959, SEQ ID NO: 255) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4433b-3p gene" or "hsa-miR-4433b-3p" refers to the hsa-miR-4433b-3p gene shown in SEQ ID NO: 31 (miRBase Accession No. MIMAT0030414) or other species homologs or orthologs. The hsa-miR-4433b-3p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. In addition, "hsa-miR-4433b-3p" is known as "hsa-mir-4433b" (miRBase Accession No. MI0025511, SEQ ID NO: 256) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6893-5p gene" or "hsa-miR-6893-5p" refers to the hsa-miR-6893-5p gene (miRBase Accession No. MIMAT0027686) set forth in SEQ ID NO: 32. or other species homologs or orthologs. The hsa-miR-6893-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6893-5p" is known as "hsa-mir-6893" (miRBase Accession No. MI0022740, SEQ ID NO: 257) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6857-5p gene" or "hsa-miR-6857-5p" refers to the hsa-miR-6857-5p gene shown in SEQ ID NO: 33 (miRBase Accession No. MIMAT0027614) or other species homologs or orthologs. The hsa-miR-6857-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6857-5p" is known as "hsa-mir-6857" (miRBase Accession No. MI0022703, SEQ ID NO: 258) having a hairpin-like structure as its precursor.

The term "hsa-miR-1227-5p gene" or "hsa-miR-1227-5p" as used herein refers to the hsa-miR-1227-5p gene shown in SEQ ID NO: 34 (miRBase Accession No. MIMAT0022941) or other species homologs or orthologs. The hsa-miR-1227-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1227-5p" is known as "hsa-mir-1227" (miRBase Accession No. MI0006316, SEQ ID NO: 259) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6741-5p gene" or "hsa-miR-6741-5p" refers to the hsa-miR-6741-5p gene shown in SEQ ID NO: 35 (miRBase Accession No. MIMAT0027383) or other species homologs or orthologs. The hsa-miR-6741-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6741-5p" is known as "hsa-mir-6741" (miRBase Accession No. MI0022586, SEQ ID NO: 260) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-451a gene" or "hsa-miR-451a" refers to the hsa-miR-451a gene (miRBase Accession No. MIMAT0001631) described in SEQ ID NO: 36 or other biological species homologs. or orthologs, etc. The hsa-miR-451a gene can be obtained by the method described in Altuvia Y et al., 2005, Nucleic Acids Res, vol. 33, p2697-2706. Also, as a precursor of "hsa-miR-451a", "hsa-mir-451a" (miRBase Accession No. MI0001729, SEQ ID NO: 261) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-8063 gene" or "hsa-miR-8063" refers to the hsa-miR-8063 gene (miRBase Accession No. MIMAT0030990) described in SEQ ID NO: 37 or other species homologs. or orthologs, etc. The hsa-miR-8063 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, vol. 39, p480-487. In addition, "hsa-miR-8063" is known as "hsa-mir-8063" (miRBase Accession No. MI0025899, SEQ ID NO: 262) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3622a-5p gene" or "hsa-miR-3622a-5p" refers to the hsa-miR-3622a-5p gene shown in SEQ ID NO: 38 (miRBase Accession No. MIMAT0018003) or other species homologs or orthologs. The hsa-miR-3622a-5p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p58. In addition, "hsa-miR-3622a-5p" is known as "hsa-mir-3622a" (miRBase Accession No. MI0016013, SEQ ID NO: 263) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-615-5p gene" or "hsa-miR-615-5p" refers to the hsa-miR-615-5p gene shown in SEQ ID NO: 39 (miRBase Accession No. MIMAT0004804) or other species homologs or orthologs. The hsa-miR-615-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol.103, p3687-3692. In addition, "hsa-miR-615-5p" is known as "hsa-mir-615" (miRBase Accession No. MI0003628, SEQ ID NO: 264) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-128-1-5p gene" or "hsa-miR-128-1-5p" refers to the hsa-miR-128-1-5p gene shown in SEQ ID NO: 40 ( miRBase Accession No. MIMAT0026477) or other species homologs or orthologs. The hsa-miR-128-1-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, p735-739. In addition, "hsa-miR-128-1-5p" is known as "hsa-mir-128-1" (miRBase Accession No. MI0000447, SEQ ID NO: 265) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6825-5p gene" or "hsa-miR-6825-5p" refers to the hsa-miR-6825-5p gene (miRBase Accession No. MIMAT0027550) set forth in SEQ ID NO: 41. or other species homologs or orthologs. The hsa-miR-6825-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6825-5p" is known as "hsa-mir-6825" (miRBase Accession No. MI0022670, SEQ ID NO: 266) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1260b gene" or "hsa-miR-1260b" refers to the hsa-miR-1260b gene (miRBase Accession No. MIMAT0015041) set forth in SEQ ID NO: 42 or other species homologs. or orthologs, etc. The hsa-miR-1260b gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Also, as a precursor of "hsa-miR-1260b", "hsa-mir-1260b" (miRBase Accession No. MI0014197, SEQ ID NO: 267) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4433-3p gene" or "hsa-miR-4433-3p" refers to the hsa-miR-4433-3p gene described in SEQ ID NO: 43 (miRBase Accession No. MIMAT0018949) or other species homologs or orthologs. The hsa-miR-4433-3p gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4433-3p" is known as "hsa-mir-4433" (miRBase Accession No. MI0016773, SEQ ID NO: 268) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4665-5p gene" or "hsa-miR-4665-5p" refers to the hsa-miR-4665-5p gene described in SEQ ID NO: 44 (miRBase Accession No. MIMAT0019739) or other species homologs or orthologs. The hsa-miR-4665-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4665-5p" is known as "hsa-mir-4665" (miRBase Accession No. MI0017295, SEQ ID NO: 269) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-7845-5p gene" or "hsa-miR-7845-5p" refers to the hsa-miR-7845-5p gene (miRBase Accession No. MIMAT0030420) set forth in SEQ ID NO: 45. or other species homologs or orthologs. The hsa-miR-7845-5p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. In addition, "hsa-miR-7845-5p" is known as "hsa-mir-7845" (miRBase Accession No. MI0025515, SEQ ID NO: 270) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1908-5p gene" or "hsa-miR-1908-5p" refers to the hsa-miR-1908-5p gene (miRBase Accession No. MIMAT0007881) shown in SEQ ID NO: 46. or other species homologs or orthologs. The hsa-miR-1908-5p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, p2496-2505. In addition, "hsa-miR-1908-5p" is known as "hsa-mir-1908" (miRBase Accession No. MI0008329, SEQ ID NO: 271) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6840-3p gene" or "hsa-miR-6840-3p" refers to the hsa-miR-6840-3p gene described in SEQ ID NO: 47 (miRBase Accession No. MIMAT0027583) or other species homologs or orthologs. The hsa-miR-6840-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6840-3p" is known as "hsa-mir-6840" (miRBase Accession No. MI0022686, SEQ ID NO: 272) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6765-5p gene" or "hsa-miR-6765-5p" refers to the hsa-miR-6765-5p gene described in SEQ ID NO: 48 (miRBase Accession No. MIMAT0027430) or other species homologs or orthologs. The hsa-miR-6765-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6765-5p" is known as "hsa-mir-6765" (miRBase Accession No. MI0022610, SEQ ID NO: 240) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-296-5p gene" or "hsa-miR-296-5p" refers to the hsa-miR-296-5p gene (miRBase Accession No. MIMAT0000690) shown in SEQ ID NO: 49. or other species homologs or orthologs. The hsa-miR-296-5p gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell, Vol. 5, p351-358. In addition, "hsa-miR-296-5p" is known as "hsa-mir-296" (miRBase Accession No. MI0000747, SEQ ID NO: 273) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3675-3p gene" or "hsa-miR-3675-3p" refers to the hsa-miR-3675-3p gene shown in SEQ ID NO: 50 (miRBase Accession No. MIMAT0018099) or other species homologs or orthologs. The hsa-miR-3675-3p gene can be obtained by the method described in Vaz C et al., 2010, BMC Genomics, Vol. 11, p288. In addition, "hsa-miR-3675-3p" is known as "hsa-mir-3675" (miRBase Accession No. MI0016076, SEQ ID NO: 274) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6781-5p gene" or "hsa-miR-6781-5p" refers to the hsa-miR-6781-5p gene shown in SEQ ID NO: 51 (miRBase Accession No. MIMAT0027462) or other species homologs or orthologs. The hsa-miR-6781-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6781-5p" is known as "hsa-mir-6781" (miRBase Accession No. MI0022626, SEQ ID NO: 275) which takes a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-423-5p gene" or "hsa-miR-423-5p" refers to the hsa-miR-423-5p gene shown in SEQ ID NO: 52 (miRBase Accession No. MIMAT0004748) or other species homologs or orthologs. The hsa-miR-423-5p gene can be obtained by the method described in Kasashima K et al., 2004, Biochem Biophys Res Commun, Vol. 322, p403-410. In addition, "hsa-miR-423-5p" is known as "hsa-mir-423" (miRBase Accession No. MI0001445, SEQ ID NO: 276) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3663-3p gene" or "hsa-miR-3663-3p" refers to the hsa-miR-3663-3p gene (miRBase Accession No. MIMAT0018085) set forth in SEQ ID NO: 53. or other species homologs or orthologs. The hsa-miR-3663-3p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. In addition, "hsa-miR-3663-3p" is known as "hsa-mir-3663" (miRBase Accession No. MI0016064, SEQ ID NO: 277) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6784-5p gene" or "hsa-miR-6784-5p" refers to the hsa-miR-6784-5p gene (miRBase Accession No. MIMAT0027468) set forth in SEQ ID NO: 54. or other species homologs or orthologs. The hsa-miR-6784-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6784-5p" is known as "hsa-mir-6784" (miRBase Accession No. MI0022629, SEQ ID NO: 278) which takes a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6749-5p gene" or "hsa-miR-6749-5p" refers to the hsa-miR-6749-5p gene shown in SEQ ID NO: 55 (miRBase Accession No. MIMAT0027398) or other species homologs or orthologs. The hsa-miR-6749-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6749-5p" is known as "hsa-mir-6749" (miRBase Accession No. MI0022594, SEQ ID NO: 279) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1231 gene" or "hsa-miR-1231" refers to the hsa-miR-1231 gene (miRBase Accession No. MIMAT0005586) set forth in SEQ ID NO: 56 or other biological species homologs. or orthologs, etc. The hsa-miR-1231 gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1231" is known as "hsa-mir-1231" (miRBase Accession No. MI0006321, SEQ ID NO: 280) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4746-3p gene" or "hsa-miR-4746-3p" refers to the hsa-miR-4746-3p gene (miRBase Accession No. MIMAT0019881) shown in SEQ ID NO: 57. or other species homologs or orthologs. The hsa-miR-4746-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4746-3p" is known as "hsa-mir-4746" (miRBase Accession No. MI0017385, SEQ ID NO: 281) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6780b-5p gene" or "hsa-miR-6780b-5p" refers to the hsa-miR-6780b-5p gene (miRBase Accession No. MIMAT0027572) shown in SEQ ID NO: 58. or other species homologs or orthologs. The hsa-miR-6780b-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6780b-5p" is known as "hsa-mir-6780b" (miRBase Accession No. MI0022681, SEQ ID NO: 282) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4758-5p gene" or "hsa-miR-4758-5p" refers to the hsa-miR-4758-5p gene described in SEQ ID NO: 59 (miRBase Accession No. MIMAT0019903) or other species homologs or orthologs. The hsa-miR-4758-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4758-5p" is known as "hsa-mir-4758" (miRBase Accession No. MI0017399, SEQ ID NO: 283) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3679-5p gene" or "hsa-miR-3679-5p" refers to the hsa-miR-3679-5p gene shown in SEQ ID NO: 60 (miRBase Accession No. MIMAT0018104) or other species homologs or orthologs. The hsa-miR-3679-5p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, "hsa-miR-3679-5p" is known as "hsa-mir-3679" (miRBase Accession No. MI0016080, SEQ ID NO: 236) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3184-5p gene" or "hsa-miR-3184-5p" refers to the hsa-miR-3184-5p gene described in SEQ ID NO: 61 (miRBase Accession No. MIMAT0015064) or other species homologs or orthologs. The hsa-miR-3184-5p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3184-5p" is known as "hsa-mir-3184" (miRBase Accession No. MI0014226, SEQ ID NO: 284) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6125 gene" or "hsa-miR-6125" refers to the hsa-miR-6125 gene (miRBase Accession No. MIMAT0024598) set forth in SEQ ID NO: 62 or other biological species homologs. or orthologs, etc. The hsa-miR-6125 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, vol. 86, p5278-5287. Also, as a precursor of "hsa-miR-6125", "hsa-mir-6125" (miRBase Accession No. MI0021259, SEQ ID NO: 285) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6721-5p gene" or "hsa-miR-6721-5p" refers to the hsa-miR-6721-5p gene shown in SEQ ID NO: 63 (miRBase Accession No. MIMAT0025852) or other species homologs or orthologs. The hsa-miR-6721-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, p330-335. In addition, "hsa-miR-6721-5p" is known as "hsa-mir-6721" (miRBase Accession No. MI0022556, SEQ ID NO: 286) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6791-5p gene" or "hsa-miR-6791-5p" refers to the hsa-miR-6791-5p gene shown in SEQ ID NO: 64 (miRBase Accession No. MIMAT0027482) or other species homologs or orthologs. The hsa-miR-6791-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6791-5p" is known as "hsa-mir-6791" (miRBase Accession No. MI0022636, SEQ ID NO: 287) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3185 gene" or "hsa-miR-3185" refers to the hsa-miR-3185 gene (miRBase Accession No. MIMAT0015065) set forth in SEQ ID NO: 65 or other biological species homologs. or orthologs, etc. The hsa-miR-3185 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Also, as a precursor of "hsa-miR-3185", "hsa-mir-3185" (miRBase Accession No. MI0014227, SEQ ID NO: 288) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1260a gene" or "hsa-miR-1260a" refers to the hsa-miR-1260a gene (miRBase Accession No. MIMAT0005911) set forth in SEQ ID NO: 66 or other biological species homologs. or orthologs, etc. The hsa-miR-1260a gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, p610-621. In addition, "hsa-miR-1260a" is known as "hsa-mir-1260a" (miRBase Accession No. MI0006394, SEQ ID NO: 289) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3197 gene" or "hsa-miR-3197" refers to the hsa-miR-3197 gene (miRBase Accession No. MIMAT0015082) set forth in SEQ ID NO: 67 or other biological species homologs. or orthologs, etc. The hsa-miR-3197 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Further, "hsa-miR-3197" is known as "hsa-mir-3197" (miRBase Accession No. MI0014245, SEQ ID NO: 290) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6845-5p gene" or "hsa-miR-6845-5p" refers to the hsa-miR-6845-5p gene (miRBase Accession No. MIMAT0027590) set forth in SEQ ID NO: 68. or other species homologs or orthologs. The hsa-miR-6845-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6845-5p" is known as "hsa-mir-6845" (miRBase Accession No. MI0022691, SEQ ID NO: 291) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6887-5p gene" or "hsa-miR-6887-5p" refers to the hsa-miR-6887-5p gene described in SEQ ID NO: 69 (miRBase Accession No. MIMAT0027674) or other species homologs or orthologs. The hsa-miR-6887-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6887-5p" is known as "hsa-mir-6887" (miRBase Accession No. MI0022734, SEQ ID NO: 292) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6738-5p gene" or "hsa-miR-6738-5p" refers to the hsa-miR-6738-5p gene described in SEQ ID NO: 70 (miRBase Accession No. MIMAT0027377) or other species homologs or orthologs. The hsa-miR-6738-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6738-5p" is known as "hsa-mir-6738" (miRBase Accession No. MI0022583, SEQ ID NO: 293) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6872-3p gene" or "hsa-miR-6872-3p" refers to the hsa-miR-6872-3p gene described in SEQ ID NO: 71 (miRBase Accession No. MIMAT0027645) or other species homologs or orthologs. The hsa-miR-6872-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6872-3p" is known as "hsa-mir-6872" (miRBase Accession No. MI0022719, SEQ ID NO: 294) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4497 gene" or "hsa-miR-4497" refers to the hsa-miR-4497 gene described in SEQ ID NO: 72 (miRBase Accession No. MIMAT0019032) or other biological species homologs. or orthologs, etc. The hsa-miR-4497 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4497", "hsa-mir-4497" (miRBase Accession No. MI0016859, SEQ ID NO: 295) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1229-5p gene" or "hsa-miR-1229-5p" refers to the hsa-miR-1229-5p gene described in SEQ ID NO: 73 (miRBase Accession No. MIMAT0022942) or other species homologs or orthologs. The hsa-miR-1229-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1229-5p" is known as "hsa-mir-1229" (miRBase Accession No. MI0006319, SEQ ID NO: 296) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6820-5p gene" or "hsa-miR-6820-5p" refers to the hsa-miR-6820-5p gene described in SEQ ID NO: 74 (miRBase Accession No. MIMAT0027540) or other species homologs or orthologs. The hsa-miR-6820-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6820-5p" is known as "hsa-mir-6820" (miRBase Accession No. MI0022665, SEQ ID NO: 297) which takes a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6777-5p gene" or "hsa-miR-6777-5p" refers to the hsa-miR-6777-5p gene described in SEQ ID NO: 75 (miRBase Accession No. MIMAT0027454) or other species homologs or orthologs. The hsa-miR-6777-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6777-5p" is known as "hsa-mir-6777" (miRBase Accession No. MI0022622, SEQ ID NO: 298) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3917 gene" or "hsa-miR-3917" refers to the hsa-miR-3917 gene (miRBase Accession No. MIMAT00118191) set forth in SEQ ID NO: 76 or other biological species homologs. or orthologs, etc. The hsa-miR-3917 gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. Also, as a precursor of "hsa-miR-3917", "hsa-mir-3917" (miRBase Accession No. MI0016423, SEQ ID NO: 299) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-5787 gene" or "hsa-miR-5787" refers to the hsa-miR-5787 gene (miRBase Accession No. MIMAT0023252) set forth in SEQ ID NO: 77 or other biological species homologs. or orthologs, etc. The hsa-miR-5787 gene can be obtained by the method described in Yoo H et al., 2011, Biochem Biophys Res Commun, Vol. 415, p567-572. In addition, "hsa-miR-5787" is known as "hsa-mir-5787" (miRBase Accession No. MI0019797, SEQ ID NO: 300) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4286 gene" or "hsa-miR-4286" refers to the hsa-miR-4286 gene (miRBase Accession No. MIMAT0016916) set forth in SEQ ID NO: 78 or other species homologs. or orthologs, etc. The hsa-miR-4286 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. Also, as a precursor of "hsa-miR-4286", "hsa-mir-4286" (miRBase Accession No. MI0015894, SEQ ID NO: 301) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6877-5p gene" or "hsa-miR-6877-5p" refers to the hsa-miR-6877-5p gene described in SEQ ID NO: 79 (miRBase Accession No. MIMAT0027654) or other species homologs or orthologs. The hsa-miR-6877-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. Further, "hsa-miR-6877-5p" is known as "hsa-mir-6877" (miRBase Accession No. MI0022724, SEQ ID NO: 302) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1225-3p gene" or "hsa-miR-1225-3p" refers to the hsa-miR-1225-3p gene described in SEQ ID NO: 80 (miRBase Accession No. MIMAT0005573) or other species homologs or orthologs. The hsa-miR-1225-3p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1225-3p" is known as "hsa-mir-1225" (miRBase Accession No. MI0006311, SEQ ID NO: 303) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6088 gene" or "hsa-miR-6088" refers to the hsa-miR-6088 gene (miRBase Accession No. MIMAT0023713) set forth in SEQ ID NO: 81 or other biological species homologs. or orthologs, etc. The hsa-miR-6088 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, p2049-2057. Also, as a precursor of "hsa-miR-6088", "hsa-mir-6088" (miRBase Accession No. MI0020365, SEQ ID NO: 304) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6800-5p gene" or "hsa-miR-6800-5p" refers to the hsa-miR-6800-5p gene (miRBase Accession No. MIMAT0027500) set forth in SEQ ID NO: 82. or other species homologs or orthologs. The hsa-miR-6800-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6800-5p" is known as "hsa-mir-6800" (miRBase Accession No. MI0022645, SEQ ID NO: 305) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1246 gene" or "hsa-miR-1246" refers to the hsa-miR-1246 gene (miRBase Accession No. MIMAT0005898) set forth in SEQ ID NO: 83 or other biological species homologs. or orthologs, etc. The hsa-miR-1246 gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, p610-621. Also, as a precursor of "hsa-miR-1246", "hsa-mir-1246" (miRBase Accession No. MI0006381, SEQ ID NO: 306) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4467 gene" or "hsa-miR-4467" refers to the hsa-miR-4467 gene (miRBase Accession No. MIMAT0018994) set forth in SEQ ID NO: 84 or other biological species homologs. or orthologs, etc. The hsa-miR-4467 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, "hsa-miR-4467" is known as "hsa-mir-4467" (miRBase Accession No. MI0016818, SEQ ID NO: 307) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4419b gene" or "hsa-miR-4419b" refers to the hsa-miR-4419b gene (miRBase Accession No. MIMAT0019034) set forth in SEQ ID NO: 85 or other biological species homologs. or orthologs, etc. The hsa-miR-4419b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4419b", "hsa-mir-4419b" (miRBase Accession No. MI0016861, SEQ ID NO: 308) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1914-3p gene" or "hsa-miR-1914-3p" refers to the hsa-miR-1914-3p gene described in SEQ ID NO: 86 (miRBase Accession No. MIMAT0007890) or other species homologs or orthologs. The hsa-miR-1914-3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, p2496-2505. In addition, "hsa-miR-1914-3p" is known as "hsa-mir-1914" (miRBase Accession No. MI0008335, SEQ ID NO: 309) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4632-5p gene" or "hsa-miR-4632-5p" refers to the hsa-miR-4632-5p gene (miRBase Accession No. MIMAT0022977) set forth in SEQ ID NO: 87. or other species homologs or orthologs. The hsa-miR-4632-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4632-5p" is known as "hsa-mir-4632" (miRBase Accession No. MI0017259, SEQ ID NO: 310) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1915-5p gene" or "hsa-miR-1915-5p" refers to the hsa-miR-1915-5p gene described in SEQ ID NO: 88 (miRBase Accession No. MIMAT0007891) or other species homologs or orthologs. The hsa-miR-1915-5p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, p2496-2505. In addition, "hsa-miR-1915-5p" is known as "hsa-mir-1915" (miRBase Accession No. MI0008336, SEQ ID NO: 311) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3940-5p gene" or "hsa-miR-3940-5p" refers to the hsa-miR-3940-5p gene described in SEQ ID NO: 89 (miRBase Accession No. MIMAT0019229) or other species homologs or orthologs. The hsa-miR-3940-5p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. In addition, "hsa-miR-3940-5p" is known as "hsa-mir-3940" (miRBase Accession No. MI0016597, SEQ ID NO: 312) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1185-2-3p gene" or "hsa-miR-1185-2-3p" refers to the hsa-miR-1185-2-3p gene shown in SEQ ID NO: 90 ( miRBase Accession No. MIMAT0022713) or other species homologs or orthologs. The hsa-miR-1185-2-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p1289-1298. In addition, "hsa-miR-1185-2-3p" is known as "hsa-mir-1185-2" (miRBase Accession No. MI0003821, SEQ ID NO: 313) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6746-5p gene" or "hsa-miR-6746-5p" refers to the hsa-miR-6746-5p gene described in SEQ ID NO: 91 (miRBase Accession No. MIMAT0027392) or other species homologs or orthologs. The hsa-miR-6746-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6746-5p" is known as "hsa-mir-6746" (miRBase Accession No. MI0022591, SEQ ID NO: 314) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-5001-5p gene" or "hsa-miR-5001-5p" refers to the hsa-miR-5001-5p gene described in SEQ ID NO: 92 (miRBase Accession No. MIMAT0021021) or other species homologs or orthologs. The hsa-miR-5001-5p gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol, Vol. 8, p378-383. Further, "hsa-miR-5001-5p" is known as "hsa-mir-5001" (miRBase Accession No. MI0017867, SEQ ID NO: 315) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1228-5p gene" or "hsa-miR-1228-5p" refers to the hsa-miR-1228-5p gene described in SEQ ID NO: 93 (miRBase Accession No. MIMAT0005582) or other species homologs or orthologs. The hsa-miR-1228-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1228-5p" is known as "hsa-mir-1228" (miRBase Accession No. MI0006318, SEQ ID NO: 316) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-5572 gene" or "hsa-miR-5572" refers to the hsa-miR-5572 gene (miRBase Accession No. MIMAT0022260) described in SEQ ID NO: 94 or other biological species homologs. or orthologs, etc. The hsa-miR-5572 gene can be obtained by the method described in Tandon M et al., 2012, Oral Dis, Vol. 18, p127-131. Also, as a precursor of "hsa-miR-5572", "hsa-mir-5572" (miRBase Accession No. MI0019117, SEQ ID NO: 317) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4327 gene" or "hsa-miR-4327" refers to the hsa-miR-4327 gene (miRBase Accession No. MIMAT0016889) described in SEQ ID NO: 95 or other biological species homologs. or orthologs, etc. The hsa-miR-4327 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of "hsa-miR-4327", "hsa-mir-4327" (miRBase Accession No. MI0015867, SEQ ID NO: 318) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4638-5p gene" or "hsa-miR-4638-5p" refers to the hsa-miR-4638-5p gene shown in SEQ ID NO: 96 (miRBase Accession No. MIMAT0019695) or other species homologs or orthologs. The hsa-miR-4638-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4638-5p" is known as "hsa-mir-4638" (miRBase Accession No. MI0017265, SEQ ID NO: 319) having a hairpin-like structure as its precursor.

The term "hsa-miR-6799-5p gene" or "hsa-miR-6799-5p" as used herein refers to the hsa-miR-6799-5p gene shown in SEQ ID NO: 97 (miRBase Accession No. MIMAT0027498) or other species homologs or orthologs. The hsa-miR-6799-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6799-5p" is known as "hsa-mir-6799" (miRBase Accession No. MI0022644, SEQ ID NO: 320) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6861-5p gene" or "hsa-miR-6861-5p" refers to the hsa-miR-6861-5p gene shown in SEQ ID NO: 98 (miRBase Accession No. MIMAT0027623) or other species homologs or orthologs. The hsa-miR-6861-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6861-5p" is known as "hsa-mir-6861" (miRBase Accession No. MI0022708, SEQ ID NO: 321) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6727-5p gene" or "hsa-miR-6727-5p" refers to the hsa-miR-6727-5p gene shown in SEQ ID NO: 99 (miRBase Accession No. MIMAT0027355) or other species homologs or orthologs. The hsa-miR-6727-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6727-5p" is known as "hsa-mir-6727" (miRBase Accession No. MI0022572, SEQ ID NO: 322) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4513 gene" or "hsa-miR-4513" refers to the hsa-miR-4513 gene (miRBase Accession No. MIMAT0019050) described in SEQ ID NO: 100 or other species homologs. or orthologs, etc. The hsa-miR-4513 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Further, "hsa-miR-4513" is known as "hsa-mir-4513" (miRBase Accession No. MI0016879, SEQ ID NO: 323) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6805-3p gene" or "hsa-miR-6805-3p" refers to the hsa-miR-6805-3p gene described in SEQ ID NO: 101 (miRBase Accession No. MIMAT0027511) or other species homologs or orthologs. The hsa-miR-6805-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6805-3p" is known as "hsa-mir-6805" (miRBase Accession No. MI0022650, SEQ ID NO: 324) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6808-5p gene" or "hsa-miR-6808-5p" refers to the hsa-miR-6808-5p gene shown in SEQ ID NO: 102 (miRBase Accession No. MIMAT0027516) or other species homologs or orthologs. The hsa-miR-6808-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6808-5p" is known as "hsa-mir-6808" (miRBase Accession No. MI0022653, SEQ ID NO: 325) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4449 gene" or "hsa-miR-4449" refers to the hsa-miR-4449 gene (miRBase Accession No. MIMAT0018968) described in SEQ ID NO: 103 or other biological species homologs. or orthologs, etc. The hsa-miR-4449 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4449", "hsa-mir-4449" (miRBase Accession No. MI0016792, SEQ ID NO: 326) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1199-5p gene" or "hsa-miR-1199-5p" refers to the hsa-miR-1199-5p gene shown in SEQ ID NO: 104 (miRBase Accession No. MIMAT0031119) or other species homologs or orthologs. The hsa-miR-1199-5p gene can be obtained by the method described in Salvi A et al., 2013, Int J Oncol, vol. 42, p391-402. In addition, "hsa-miR-1199-5p" is known as "hsa-mir-1199" (miRBase Accession No. MI0020340, SEQ ID NO: 327) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1275 gene" or "hsa-miR-1275" refers to the hsa-miR-1275 gene (miRBase Accession No. MIMAT0005929) set forth in SEQ ID NO: 105 or other biological species homologs. or orthologs, etc. The hsa-miR-1275 gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, p610-621. Also, as a precursor of "hsa-miR-1275", "hsa-mir-1275" (miRBase Accession No. MI0006415, SEQ ID NO: 328) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4792 gene" or "hsa-miR-4792" refers to the hsa-miR-4792 gene described in SEQ ID NO: 106 (miRBase Accession No. MIMAT0019964) or other biological species homologs. or orthologs, etc. The hsa-miR-4792 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4792" is known as "hsa-mir-4792" (miRBase Accession No. MI0017439, SEQ ID NO: 329) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4443 gene" or "hsa-miR-4443" refers to the hsa-miR-4443 gene (miRBase Accession No. MIMAT0018961) set forth in SEQ ID NO: 107 or other biological species homologs. or orthologs, etc. The hsa-miR-4443 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4443" (miRBase Accession No. MI0016786, SEQ ID NO: 330) which takes a hairpin-like structure as a precursor thereof is known as "hsa-miR-4443".

As used herein, the term "hsa-miR-6891-5p gene" or "hsa-miR-6891-5p" refers to the hsa-miR-6891-5p gene described in SEQ ID NO: 108 (miRBase Accession No. MIMAT0027682) or other species homologs or orthologs. The hsa-miR-6891-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6891-5p" is known as "hsa-mir-6891" (miRBase Accession No. MI0022738, SEQ ID NO: 331) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6826-5p gene" or "hsa-miR-6826-5p" refers to the hsa-miR-6826-5p gene described in SEQ ID NO: 109 (miRBase Accession No. MIMAT0027552) or other species homologs or orthologs. The hsa-miR-6826-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6826-5p" is known as "hsa-mir-6826" (miRBase Accession No. MI0022671, SEQ ID NO: 332) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6807-5p gene" or "hsa-miR-6807-5p" refers to the hsa-miR-6807-5p gene shown in SEQ ID NO: 110 (miRBase Accession No. MIMAT0027514) or other species homologs or orthologs. The hsa-miR-6807-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6807-5p" is known as "hsa-mir-6807" (miRBase Accession No. MI0022652, SEQ ID NO: 333) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-7150 gene" or "hsa-miR-7150" refers to the hsa-miR-7150 gene (miRBase Accession No. MIMAT0028211) set forth in SEQ ID NO: 111 or other biological species homologs. or orthologs, etc. The hsa-miR-7150 gene can be obtained by the method described in Oulas A et al., 2009, Nucleic Acids Res, vol. 37, p3276-3287. In addition, as a precursor of "hsa-miR-7150", "hsa-mir-7150" (miRBase Accession No. MI0023610, SEQ ID NO: 334) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4534 gene" or "hsa-miR-4534" refers to the hsa-miR-4534 gene (miRBase Accession No. MIMAT0019073) set forth in SEQ ID NO: 112 or other species homologs. or orthologs, etc. The hsa-miR-4534 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4534", "hsa-mir-4534" (miRBase Accession No. MI0016901, SEQ ID NO: 335) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4476 gene" or "hsa-miR-4476" refers to the hsa-miR-4476 gene (miRBase Accession No. MIMAT0019003) set forth in SEQ ID NO: 113 or other biological species homologs. or orthologs, etc. The hsa-miR-4476 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4476", "hsa-mir-4476" (miRBase Accession No. MI0016828, SEQ ID NO: 336) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4649-5p gene" or "hsa-miR-4649-5p" refers to the hsa-miR-4649-5p gene described in SEQ ID NO: 114 (miRBase Accession No. MIMAT0019711) or other species homologs or orthologs. The hsa-miR-4649-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4649-5p" is known as "hsa-mir-4649" (miRBase Accession No. MI0017276, SEQ ID NO: 337) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4525 gene" or "hsa-miR-4525" refers to the hsa-miR-4525 gene (miRBase Accession No. MIMAT0019064) set forth in SEQ ID NO: 115 or other biological species homologs. or orthologs, etc. The hsa-miR-4525 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4525", "hsa-mir-4525" (miRBase Accession No. MI0016892, SEQ ID NO: 338) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1915-3p gene" or "hsa-miR-1915-3p" refers to the hsa-miR-1915-3p gene described in SEQ ID NO: 116 (miRBase Accession No. MIMAT0007892) or other species homologs or orthologs. The hsa-miR-1915-3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, p2496-2505. In addition, "hsa-miR-1915-3p" is known as "hsa-mir-1915" (miRBase Accession No. MI0008336, SEQ ID NO: 311) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4516 gene" or "hsa-miR-4516" refers to the hsa-miR-4516 gene (miRBase Accession No. MIMAT0019053) set forth in SEQ ID NO: 117 or other biological species homologs. or orthologs, etc. The hsa-miR-4516 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4516", "hsa-mir-4516" (miRBase Accession No. MI0016882, SEQ ID NO: 339) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4417 gene" or "hsa-miR-4417" refers to the hsa-miR-4417 gene (miRBase Accession No. MIMAT0018929) described in SEQ ID NO: 118 or other species homologs. or orthologs, etc. The hsa-miR-4417 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4417", "hsa-mir-4417" (miRBase Accession No. MI0016753, SEQ ID NO: 340) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-642b-3p gene" or "hsa-miR-642b-3p" refers to the hsa-miR-642b-3p gene described in SEQ ID NO: 119 (miRBase Accession No. MIMAT0018444) or other species homologs or orthologs. The hsa-miR-642b-3p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p58. In addition, "hsa-miR-642b-3p" is known as "hsa-mir-642b" (miRBase Accession No. MI0016685, SEQ ID NO: 341) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3141 gene" or "hsa-miR-3141" refers to the hsa-miR-3141 gene (miRBase Accession No. MIMAT0015010) set forth in SEQ ID NO: 120 or other biological species homologs. or orthologs, etc. The hsa-miR-3141 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, as a precursor of "hsa-miR-3141", "hsa-mir-3141" (miRBase Accession No. MI0014165, SEQ ID NO: 342) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-5100 gene" or "hsa-miR-5100" refers to the hsa-miR-5100 gene (miRBase Accession No. MIMAT0022259) set forth in SEQ ID NO: 121 or other biological species homologs. or orthologs, etc. The hsa-miR-5100 gene can be obtained by the method described in Tandon M et al., 2012, Oral Dis, Vol. 18, p127-131. Also, as a precursor of "hsa-miR-5100", "hsa-mir-5100" (miRBase Accession No. MI0019116, SEQ ID NO: 343) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6848-5p gene" or "hsa-miR-6848-5p" refers to the hsa-miR-6848-5p gene described in SEQ ID NO: 122 (miRBase Accession No. MIMAT0027596) or other species homologs or orthologs. The hsa-miR-6848-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6848-5p" is known as "hsa-mir-6848" (miRBase Accession No. MI0022694, SEQ ID NO: 344) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4739 gene" or "hsa-miR-4739" refers to the hsa-miR-4739 gene described in SEQ ID NO: 123 (miRBase Accession No. MIMAT0019868) or other biological species homologs. or orthologs, etc. The hsa-miR-4739 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. Also, as a precursor of "hsa-miR-4739", "hsa-mir-4739" (miRBase Accession No. MI0017377, SEQ ID NO: 345) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4459 gene" or "hsa-miR-4459" refers to the hsa-miR-4459 gene (miRBase Accession No. MIMAT0018981) set forth in SEQ ID NO: 124 or other biological species homologs. or orthologs, etc. The hsa-miR-4459 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4459", "hsa-mir-4459" (miRBase Accession No. MI0016805, SEQ ID NO: 346) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1237-5p gene" or "hsa-miR-1237-5p" refers to the hsa-miR-1237-5p gene shown in SEQ ID NO: 125 (miRBase Accession No. MIMAT0022946) or other species homologs or orthologs. The hsa-miR-1237-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1237-5p" is known as "hsa-mir-1237" (miRBase Accession No. MI0006327, SEQ ID NO: 347) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-296-3p gene" or "hsa-miR-296-3p" refers to the hsa-miR-296-3p gene shown in SEQ ID NO: 126 (miRBase Accession No. MIMAT0004679) or other species homologs or orthologs. The hsa-miR-296-3p gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell, Vol. 5, p351-358. In addition, "hsa-miR-296-3p" is known as "hsa-mir-296" (miRBase Accession No. MI0000747, SEQ ID NO: 273) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4665-3p gene" or "hsa-miR-4665-3p" refers to the hsa-miR-4665-3p gene described in SEQ ID NO: 127 (miRBase Accession No. MIMAT0019740) or other species homologs or orthologs. The hsa-miR-4665-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4665-3p" is known as "hsa-mir-4665" (miRBase Accession No. MI0017295, SEQ ID NO: 269) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6786-5p gene" or "hsa-miR-6786-5p" refers to the hsa-miR-6786-5p gene shown in SEQ ID NO: 128 (miRBase Accession No. MIMAT0027472) or other species homologs or orthologs. The hsa-miR-6786-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6786-5p" is known as "hsa-mir-6786" (miRBase Accession No. MI0022631, SEQ ID NO: 348) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4258 gene" or "hsa-miR-4258" refers to the hsa-miR-4258 gene (miRBase Accession No. MIMAT0016879) set forth in SEQ ID NO: 129 or other biological species homologs. or orthologs, etc. The hsa-miR-4258 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. Also, as a precursor of "hsa-miR-4258", "hsa-mir-4258" (miRBase Accession No. MI0015857, SEQ ID NO: 349) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6510-5p gene" or "hsa-miR-6510-5p" refers to the hsa-miR-6510-5p gene shown in SEQ ID NO: 130 (miRBase Accession No. MIMAT0025476) or other species homologs or orthologs. The hsa-miR-6510-5p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, Vol. 20, p4025-4040. In addition, "hsa-miR-6510-5p" is known as "hsa-mir-6510" (miRBase Accession No. MI0022222, SEQ ID NO: 350) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1343-5p gene" or "hsa-miR-1343-5p" refers to the hsa-miR-1343-5p gene described in SEQ ID NO: 131 (miRBase Accession No. MIMAT0027038) or other species homologs or orthologs. The hsa-miR-1343-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-1343-5p" is known as "hsa-mir-1343" (miRBase Accession No. MI0017320, SEQ ID NO: 225) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1247-3p gene" or "hsa-miR-1247-3p" refers to the hsa-miR-1247-3p gene described in SEQ ID NO: 132 (miRBase Accession No. MIMAT0022721) or other species homologs or orthologs. The hsa-miR-1247-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, p610-621. In addition, "hsa-miR-1247-3p" is known as "hsa-mir-1247" (miRBase Accession No. MI0006382, SEQ ID NO: 351) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6805-5p gene" or "hsa-miR-6805-5p" refers to the hsa-miR-6805-5p gene shown in SEQ ID NO: 133 (miRBase Accession No. MIMAT0027510) or other species homologs or orthologs. The hsa-miR-6805-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6805-5p" is known as "hsa-mir-6805" (miRBase Accession No. MI0022650, SEQ ID NO: 324) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4492 gene" or "hsa-miR-4492" refers to the hsa-miR-4492 gene (miRBase Accession No. MIMAT0019027) set forth in SEQ ID NO: 134 or other biological species homologs. or orthologs, etc. The hsa-miR-4492 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4492", "hsa-mir-4492" (miRBase Accession No. MI0016854, SEQ ID NO: 352) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1469 gene" or "hsa-miR-1469" refers to the hsa-miR-1469 gene (miRBase Accession No. MIMAT0007347) set forth in SEQ ID NO: 135 or other biological species homologs. or orthologs, etc. The hsa-miR-1469 gene can be obtained by the method described in Kawaji H et al., 2008, BMC Genomics, Vol. 9, p157. Also, as a precursor of "hsa-miR-1469", "hsa-mir-1469" (miRBase Accession No. MI0007074, SEQ ID NO: 353) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1268b gene" or "hsa-miR-1268b" refers to the hsa-miR-1268b gene (miRBase Accession No. MIMAT0018925) set forth in SEQ ID NO: 136 or other species homologs. or orthologs, etc. The hsa-miR-1268b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-1268b", "hsa-mir-1268b" (miRBase Accession No. MI0016748, SEQ ID NO: 354) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6858-5p gene" or "hsa-miR-6858-5p" refers to the hsa-miR-6858-5p gene described in SEQ ID NO: 137 (miRBase Accession No. MIMAT0027616) or other species homologs or orthologs. The hsa-miR-6858-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6858-5p" is known as "hsa-mir-6858" (miRBase Accession No. MI0022704, SEQ ID NO: 355) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3937 gene" or "hsa-miR-3937" refers to the hsa-miR-3937 gene (miRBase Accession No. MIMAT0018352) set forth in SEQ ID NO: 138 or other biological species homologs. or orthologs, etc. The hsa-miR-3937 gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. In addition, "hsa-miR-3937" is known as a precursor thereof "hsa-mir-3937" (miRBase Accession No. MI0016593, SEQ ID NO: 356) having a hairpin-like structure.

As used herein, the term "hsa-miR-939-5p gene" or "hsa-miR-939-5p" refers to the hsa-miR-939-5p gene described in SEQ ID NO: 139 (miRBase Accession No. MIMAT0004982) or other species homologs or orthologs. The hsa-miR-939-5p gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res, Vol. 67, p6031-6043. In addition, "hsa-miR-939-5p" is known as "hsa-mir-939" (miRBase Accession No. MI0005761, SEQ ID NO: 357) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3656 gene" or "hsa-miR-3656" refers to the hsa-miR-3656 gene (miRBase Accession No. MIMAT0018076) set forth in SEQ ID NO: 140 or other biological species homologs. or orthologs, etc. The hsa-miR-3656 gene can be obtained by the method described in Meiri E et al., 2010, Nucleic Acids Res, vol. 38, p6234-6246. Also, as a precursor of "hsa-miR-3656", "hsa-mir-3656" (miRBase Accession No. MI0016056, SEQ ID NO: 358) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-744-5p gene" or "hsa-miR-744-5p" refers to the hsa-miR-744-5p gene described in SEQ ID NO: 141 (miRBase Accession No. MIMAT0004945) or other species homologs or orthologs. The hsa-miR-744-5p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p1289-1298. In addition, "hsa-miR-744-5p" is known as "hsa-mir-744" (miRBase Accession No. MI0005559, SEQ ID NO: 359) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4687-3p gene" or "hsa-miR-4687-3p" refers to the hsa-miR-4687-3p gene (miRBase Accession No. MIMAT0019775) set forth in SEQ ID NO: 142. or other species homologs or orthologs. The hsa-miR-4687-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4687-3p" is known as "hsa-mir-4687" (miRBase Accession No. MI0017319, SEQ ID NO: 360) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4763-3p gene" or "hsa-miR-4763-3p" refers to the hsa-miR-4763-3p gene described in SEQ ID NO: 143 (miRBase Accession No. MIMAT0019913) or other species homologs or orthologs. The hsa-miR-4763-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4763-3p" is known as "hsa-mir-4763" (miRBase Accession No. MI0017404, SEQ ID NO: 361) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3620-5p gene" or "hsa-miR-3620-5p" refers to the hsa-miR-3620-5p gene described in SEQ ID NO: 144 (miRBase Accession No. MIMAT0022967) or other biological species homologs or orthologs. The hsa-miR-3620-5p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p58. In addition, "hsa-miR-3620-5p" is known as "hsa-mir-3620" (miRBase Accession No. MI0016011, SEQ ID NO: 362) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3195 gene" or "hsa-miR-3195" refers to the hsa-miR-3195 gene (miRBase Accession No. MIMAT0015079) set forth in SEQ ID NO: 145 or other biological species homologs. or orthologs, etc. The hsa-miR-3195 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, as a precursor of "hsa-miR-3195", "hsa-mir-3195" (miRBase Accession No. MI0014240, SEQ ID NO: 363) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6842-5p gene" or "hsa-miR-6842-5p" refers to the hsa-miR-6842-5p gene (miRBase Accession No. MIMAT0027586) set forth in SEQ ID NO: 146. or other species homologs or orthologs. The hsa-miR-6842-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6842-5p" is known as "hsa-mir-6842" (miRBase Accession No. MI0022688, SEQ ID NO: 364) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4707-5p gene" or "hsa-miR-4707-5p" refers to the hsa-miR-4707-5p gene shown in SEQ ID NO: 147 (miRBase Accession No. MIMAT0019807) or other species homologs or orthologs. The hsa-miR-4707-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4707-5p" is known as "hsa-mir-4707" (miRBase Accession No. MI0017340, SEQ ID NO: 365) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-642a-3p gene" or "hsa-miR-642a-3p" refers to the hsa-miR-642a-3p gene shown in SEQ ID NO: 148 (miRBase Accession No. MIMAT0020924) or other species homologs or orthologs. The hsa-miR-642a-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p3687-3692. In addition, "hsa-miR-642a-3p" is known as "hsa-mir-642a" (miRBase Accession No. MI0003657, SEQ ID NO: 366) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-7113-3p gene" or "hsa-miR-7113-3p" refers to the hsa-miR-7113-3p gene described in SEQ ID NO: 149 (miRBase Accession No. MIMAT0028124) or other species homologs or orthologs. The hsa-miR-7113-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-7113-3p" is known as "hsa-mir-7113" (miRBase Accession No. MI0022964, SEQ ID NO: 367) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4728-5p gene" or "hsa-miR-4728-5p" refers to the hsa-miR-4728-5p gene shown in SEQ ID NO: 150 (miRBase Accession No. MIMAT0019849) or other species homologs or orthologs. The hsa-miR-4728-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4728-5p" is known as "hsa-mir-4728" (miRBase Accession No. MI0017365, SEQ ID NO: 368) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-5195-3p gene" or "hsa-miR-5195-3p" refers to the hsa-miR-5195-3p gene described in SEQ ID NO: 151 (miRBase Accession No. MIMAT0021127) or other species homologs or orthologs. The hsa-miR-5195-3p gene can be obtained by the method described in Schotte D et al., 2011, Leukemia, Vol. 25, p1389-1399. Also, "hsa-miR-5195-3p" is known as "hsa-mir-5195" (miRBase Accession No. MI0018174, SEQ ID NO: 369) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1185-1-3p gene" or "hsa-miR-1185-1-3p" refers to the hsa-miR-1185-1-3p gene shown in SEQ ID NO: 152 ( miRBase Accession No. MIMAT0022838) or other species homologs or orthologs. The hsa-miR-1185-1-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p1289-1298. In addition, "hsa-miR-1185-1-3p" is known as "hsa-mir-1185-1" (miRBase Accession No. MI0003844, SEQ ID NO: 370) having a hairpin-like structure as its precursor.

The term "hsa-miR-6774-5p gene" or "hsa-miR-6774-5p" as used herein refers to the hsa-miR-6774-5p gene described in SEQ ID NO: 153 (miRBase Accession No. MIMAT0027448) or other species homologs or orthologs. The hsa-miR-6774-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6774-5p" is known as "hsa-mir-6774" (miRBase Accession No. MI0022619, SEQ ID NO: 371) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-8059 gene" or "hsa-miR-8059" refers to the hsa-miR-8059 gene (miRBase Accession No. MIMAT0030986) set forth in SEQ ID NO: 154 or other biological species homologs. or orthologs, etc. The hsa-miR-8059 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, vol. 39, p480-487. In addition, "hsa-miR-8059" is known as "hsa-mir-8059" (miRBase Accession No. MI0025895, SEQ ID NO: 372) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3131 gene" or "hsa-miR-3131" refers to the hsa-miR-3131 gene (miRBase Accession No. MIMAT0014996) set forth in SEQ ID NO: 155 or other biological species homologs. or orthologs, etc. The hsa-miR-3131 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Also, as a precursor of "hsa-miR-3131", "hsa-mir-3131" (miRBase Accession No. MI0014151, SEQ ID NO: 373) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-7847-3p gene" or "hsa-miR-7847-3p" refers to the hsa-miR-7847-3p gene described in SEQ ID NO: 156 (miRBase Accession No. MIMAT0030422) or other species homologs or orthologs. The hsa-miR-7847-3p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. In addition, "hsa-miR-7847-3p" is known as "hsa-mir-7847" (miRBase Accession No. MI0025517, SEQ ID NO: 374) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4463 gene" or "hsa-miR-4463" refers to the hsa-miR-4463 gene described in SEQ ID NO: 157 (miRBase Accession No. MIMAT0018987) or other biological species homologs. or orthologs, etc. The hsa-miR-4463 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Volume 116, e118-e127. In addition, "hsa-miR-4463" is known as "hsa-mir-4463" (miRBase Accession No. MI0016811, SEQ ID NO: 375) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-128-2-5p gene" or "hsa-miR-128-2-5p" refers to the hsa-miR-128-2-5p gene shown in SEQ ID NO: 158 ( miRBase Accession No. MIMAT0031095) or other species homologs or orthologs. The hsa-miR-128-2-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, p735-739. In addition, "hsa-miR-128-2-5p" is known as "hsa-mir-128-2" (miRBase Accession No. MI0000727, SEQ ID NO: 376) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4508 gene" or "hsa-miR-4508" refers to the hsa-miR-4508 gene (miRBase Accession No. MIMAT0019045) set forth in SEQ ID NO: 159 or other biological species homologs. or orthologs, etc. The hsa-miR-4508 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4508", "hsa-mir-4508" (miRBase Accession No. MI0016872, SEQ ID NO: 377) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6806-5p gene" or "hsa-miR-6806-5p" refers to the hsa-miR-6806-5p gene described in SEQ ID NO: 160 (miRBase Accession No. MIMAT0027512) or other species homologs or orthologs. The hsa-miR-6806-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6806-5p" is known as "hsa-mir-6806" (miRBase Accession No. MI0022651, SEQ ID NO: 378) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-7111-5p gene" or "hsa-miR-7111-5p" refers to the hsa-miR-7111-5p gene described in SEQ ID NO: 161 (miRBase Accession No. MIMAT0028119) or other species homologs or orthologs. The hsa-miR-7111-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-7111-5p" is known as "hsa-mir-7111" (miRBase Accession No. MI0022962, SEQ ID NO: 379) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6782-5p gene" or "hsa-miR-6782-5p" refers to the hsa-miR-6782-5p gene described in SEQ ID NO: 162 (miRBase Accession No. MIMAT0027464) or other species homologs or orthologs. The hsa-miR-6782-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6782-5p" is known as "hsa-mir-6782" (miRBase Accession No. MI0022627, SEQ ID NO: 380) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4734 gene" or "hsa-miR-4734" refers to the hsa-miR-4734 gene described in SEQ ID NO: 163 (miRBase Accession No. MIMAT0019859) or other biological species homologs. or orthologs, etc. The hsa-miR-4734 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. Also, as a precursor of "hsa-miR-4734", "hsa-mir-4734" (miRBase Accession No. MI0017371, SEQ ID NO: 381) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-3162-5p gene" or "hsa-miR-3162-5p" refers to the hsa-miR-3162-5p gene described in SEQ ID NO: 164 (miRBase Accession No. MIMAT0015036) or other species homologs or orthologs. The hsa-miR-3162-5p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3162-5p" is known as "hsa-mir-3162" (miRBase Accession No. MI0014192, SEQ ID NO: 382) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-887-3p gene" or "hsa-miR-887-3p" refers to the hsa-miR-887-3p gene shown in SEQ ID NO: 165 (miRBase Accession No. MIMAT0004951) or other species homologs or orthologs. The hsa-miR-887-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p1289-1298. In addition, "hsa-miR-887-3p" is known as "hsa-mir-887" (miRBase Accession No. MI0005562, SEQ ID NO: 383) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6752-5p gene" or "hsa-miR-6752-5p" refers to the hsa-miR-6752-5p gene described in SEQ ID NO: 166 (miRBase Accession No. MIMAT0027404) or other species homologs or orthologs. The hsa-miR-6752-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6752-5p" is known as "hsa-mir-6752" (miRBase Accession No. MI0022597, SEQ ID NO: 384) having a hairpin-like structure as its precursor.

The term "hsa-miR-6724-5p gene" or "hsa-miR-6724-5p" as used herein refers to the hsa-miR-6724-5p gene described in SEQ ID NO: 167 (miRBase Accession No. MIMAT0025856) or other species homologs or orthologs. The hsa-miR-6724-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, p330-335. In addition, "hsa-miR-6724-5p" is known as "hsa-mir-6724" (miRBase Accession No. MI0022559, SEQ ID NO: 385) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-23b-3p gene" or "hsa-miR-23b-3p" refers to the hsa-miR-23b-3p gene described in SEQ ID NO: 168 (miRBase Accession No. MIMAT0000418) or other species homologs or orthologs. The hsa-miR-23b-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, p735-739. In addition, "hsa-miR-23b-3p" is known as "hsa-mir-23b" (miRBase Accession No. MI0000439, SEQ ID NO: 386) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-23a-3p gene" or "hsa-miR-23a-3p" refers to the hsa-miR-23a-3p gene described in SEQ ID NO: 169 (miRBase Accession No. MIMAT0000078) or other species homologs or orthologs. The hsa-miR-23a-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, Vol. 294, p853-858. In addition, "hsa-miR-23a-3p" is known as "hsa-mir-23a" (miRBase Accession No. MI0000079, SEQ ID NO: 387) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-625-3p gene" or "hsa-miR-625-3p" refers to the hsa-miR-625-3p gene shown in SEQ ID NO: 170 (miRBase Accession No. MIMAT0004808) or other species homologs or orthologs. The hsa-miR-625-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci U.S.A., Vol. 103, p3687-3692. In addition, "hsa-miR-625-3p" is known as "hsa-mir-625" (miRBase Accession No. MI0003639, SEQ ID NO: 388) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1228-3p gene" or "hsa-miR-1228-3p" refers to the hsa-miR-1228-3p gene described in SEQ ID NO: 171 (miRBase Accession No. MIMAT0005583) or other species homologs or orthologs. The hsa-miR-1228-3p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1228-3p" is known as "hsa-mir-1228" (miRBase Accession No. MI0006318, SEQ ID NO: 316) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-614 gene" or "hsa-miR-614" refers to the hsa-miR-614 gene (miRBase Accession No. MIMAT0003282) set forth in SEQ ID NO: 172 or other biological species homologs. or orthologs, etc. The hsa-miR-614 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol.103, p3687-3692. Also, as a precursor of "hsa-miR-614", "hsa-mir-614" (miRBase Accession No. MI0003627, SEQ ID NO: 389) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1913 gene" or "hsa-miR-1913" refers to the hsa-miR-1913 gene (miRBase Accession No. MIMAT0007888) set forth in SEQ ID NO: 173 or other biological species homologs. or orthologs, etc. The hsa-miR-1913 gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, p2496-2505. In addition, "hsa-miR-1913" is known as "hsa-mir-1913" (miRBase Accession No. MI0008334, SEQ ID NO: 390) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-92a-2-5p gene" or "hsa-miR-92a-2-5p" refers to the hsa-miR-92a-2-5p gene shown in SEQ ID NO: 174 ( miRBase Accession No. MIMAT0004508) or other species homologs or orthologs. The hsa-miR-92a-2-5p gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev, Vol. 16, p720-728. In addition, "hsa-miR-92a-2-5p" is known as "hsa-mir-92a-2" (miRBase Accession No. MI0000094, SEQ ID NO: 391) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-187-5p gene" or "hsa-miR-187-5p" refers to the hsa-miR-187-5p gene (miRBase Accession No. MIMAT0004561) set forth in SEQ ID NO: 175. or other species homologs or orthologs. The hsa-miR-187-5p gene can be obtained by the method described in Lim LP et al., 2003, Science, Vol. 299, p1540. In addition, "hsa-miR-187-5p" is known as "hsa-mir-187" (miRBase Accession No. MI0000274, SEQ ID NO: 392) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-16-5p gene" or "hsa-miR-16-5p" refers to the hsa-miR-16-5p gene described in SEQ ID NO: 176 (miRBase Accession No. MIMAT0000069) or other species homologs or orthologs. The hsa-miR-16-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, Vol. 294, p853-858. In addition, "hsa-miR-16-5p" is a precursor thereof, "hsa-mir-16-1" and "hsa-mir-16-2", which have a hairpin-like structure (miRBase Accession No. MI0000070, MI0000115, sequence Nos. 393, 394) are known.

As used herein, the term "hsa-miR-92b-3p gene" or "hsa-miR-92b-3p" refers to the hsa-miR-92b-3p gene described in SEQ ID NO: 177 (miRBase Accession No. MIMAT0003218) or other species homologs or orthologs. The hsa-miR-92b-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p3687-3692. In addition, "hsa-miR-92b-3p" is known as "hsa-mir-92b" (miRBase Accession No. MI0003560, SEQ ID NO: 395) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-150-3p gene" or "hsa-miR-150-3p" refers to the hsa-miR-150-3p gene shown in SEQ ID NO: 178 (miRBase Accession No. MIMAT0004610) or other species homologs or orthologs. The hsa-miR-150-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, p735-739. In addition, "hsa-miR-150-3p" is known as "hsa-mir-150" (miRBase Accession No. MI0000479, SEQ ID NO: 396) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-564 gene" or "hsa-miR-564" refers to the hsa-miR-564 gene (miRBase Accession No. MIMAT0003228) set forth in SEQ ID NO: 179 or other biological species homologs. or orthologs, etc. The hsa-miR-564 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol.103, p3687-3692. Also, as a precursor of "hsa-miR-564", "hsa-mir-564" (miRBase Accession No. MI0003570, SEQ ID NO: 397) having a hairpin-like structure is known.

The term "hsa-miR-125a-3p gene" or "hsa-miR-125a-3p" as used herein refers to the hsa-miR-125a-3p gene shown in SEQ ID NO: 180 (miRBase Accession No. MIMAT0004602) or other species homologs or orthologs. The hsa-miR-125a-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, p735-739. In addition, "hsa-miR-125a-3p" is known as "hsa-mir-125a" (miRBase Accession No. MI0000469, SEQ ID NO: 398) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-92b-5p gene" or "hsa-miR-92b-5p" refers to the hsa-miR-92b-5p gene described in SEQ ID NO: 181 (miRBase Accession No. MIMAT0004792) or other species homologs or orthologs. The hsa-miR-92b-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol.103, p3687-3692. In addition, "hsa-miR-92b-5p" is known as "hsa-mir-92b" (miRBase Accession No. MI0003560, SEQ ID NO: 395) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-92a-3p gene" or "hsa-miR-92a-3p" refers to the hsa-miR-92a-3p gene (miRBase Accession No. MIMAT0000092) set forth in SEQ ID NO: 182. or other species homologs or orthologs. The hsa-miR-92a-3p gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev, Vol. 16, p720-728. In addition, "hsa-miR-92a-3p" is "hsa-mir-92a-1" and "hsa-mir-92a-2" which take a hairpin-like structure as its precursor (miRBase Accession No. MI0000093, MI0000094, sequence Nos. 399, 391) are known.

As used herein, the term "hsa-miR-663a gene" or "hsa-miR-663a" refers to the hsa-miR-663a gene (miRBase Accession No. MIMAT0003326) set forth in SEQ ID NO: 183 or other biological species homologs. or orthologs, etc. The hsa-miR-663a gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol.103, p3687-3692. In addition, "hsa-miR-663a" is known as "hsa-mir-663a" (miRBase Accession No. MI0003672, SEQ ID NO: 400) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4688 gene" or "hsa-miR-4688" refers to the hsa-miR-4688 gene (miRBase Accession No. MIMAT0019777) set forth in SEQ ID NO: 184 or other biological species homologs. or orthologs, etc. The hsa-miR-4688 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. Also, as a precursor of "hsa-miR-4688", "hsa-mir-4688" (miRBase Accession No. MI0017321, SEQ ID NO: 401) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4648 gene" or "hsa-miR-4648" refers to the hsa-miR-4648 gene (miRBase Accession No. MIMAT0019710) set forth in SEQ ID NO: 185 or other biological species homologs. or orthologs, etc. The hsa-miR-4648 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, as a precursor of "hsa-miR-4648", "hsa-mir-4648" (miRBase Accession No. MI0017275, SEQ ID NO: 402) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6085 gene" or "hsa-miR-6085" refers to the hsa-miR-6085 gene (miRBase Accession No. MIMAT0023710) set forth in SEQ ID NO: 186 or other biological species homologs. or orthologs, etc. The hsa-miR-6085 gene can be obtained by the method described in Voellenkle C et al., 2012, RNA, Vol. 18, p472-484. Further, "hsa-miR-6085" is known as "hsa-mir-6085" (miRBase Accession No. MI0020362, SEQ ID NO: 403) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6126 gene" or "hsa-miR-6126" refers to the hsa-miR-6126 gene (miRBase Accession No. MIMAT0024599) set forth in SEQ ID NO: 187 or other biological species homologs. or orthologs, etc. The hsa-miR-6126 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, Vol. 86, p5278-5287. Also, as a precursor of "hsa-miR-6126", "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6880-5p gene" or "hsa-miR-6880-5p" refers to the hsa-miR-6880-5p gene described in SEQ ID NO: 188 (miRBase Accession No. MIMAT0027660) or other species homologs or orthologs. The hsa-miR-6880-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6880-5p" is known as "hsa-mir-6880" (miRBase Accession No. MI0022727, SEQ ID NO: 405) which takes a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-328-5p gene" or "hsa-miR-328-5p" refers to the hsa-miR-328-5p gene described in SEQ ID NO: 189 (miRBase Accession No. MIMAT0026486) or other species homologs or orthologs. The hsa-miR-328-5p gene can be obtained by the method described in Kim J et al., 2004, Proc Natl Acad Sci USA, vol. 101, p360-365. In addition, "hsa-miR-328-5p" is known as "hsa-mir-328" (miRBase Accession No. MI0000804, SEQ ID NO: 406) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6768-5p gene" or "hsa-miR-6768-5p" refers to the hsa-miR-6768-5p gene described in SEQ ID NO: 190 (miRBase Accession No. MIMAT0027436) or other species homologs or orthologs. The hsa-miR-6768-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6768-5p" is known as "hsa-mir-6768" (miRBase Accession No. MI0022613, SEQ ID NO: 407) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3180 gene" or "hsa-miR-3180" refers to the hsa-miR-3180 gene (miRBase Accession No. MIMAT0018178) set forth in SEQ ID NO: 191 or other biological species homologs. or orthologs, etc. The hsa-miR-3180 gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, "hsa-miR-3180" is a precursor thereof, "hsa-mir-3180-4", "hsa-mir-3180-5", which have a hairpin-like structure (miRBase Accession No. MI0016408, MI0016409, SEQ ID NO: 408) , 409) are known.

As used herein, the term "hsa-miR-6087 gene" or "hsa-miR-6087" refers to the hsa-miR-6087 gene (miRBase Accession No. MIMAT0023712) set forth in SEQ ID NO: 192 or other biological species homologs. or orthologs, etc. The hsa-miR-6087 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, p2049-2057. In addition, "hsa-miR-6087" is known as "hsa-mir-6087" (miRBase Accession No. MI0020364, SEQ ID NO: 410) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1273g-3p gene" or "hsa-miR-1273g-3p" refers to the hsa-miR-1273g-3p gene described in SEQ ID NO: 193 (miRBase Accession No. MIMAT0022742) or other species homologs or orthologs. The hsa-miR-1273g-3p gene can be obtained by the method described in Reshmi G et al., 2011, Genomics, vol. 97, p333-340. In addition, "hsa-miR-1273g-3p" is known as "hsa-mir-1273g" (miRBase Accession No. MI0018003, SEQ ID NO: 411) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-1225-5p gene" or "hsa-miR-1225-5p" refers to the hsa-miR-1225-5p gene described in SEQ ID NO: 194 (miRBase Accession No. MIMAT0005572) or other species homologs or orthologs. The hsa-miR-1225-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1225-5p" is known as "hsa-mir-1225" (miRBase Accession No. MI0006311, SEQ ID NO: 303) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3196 gene" or "hsa-miR-3196" refers to the hsa-miR-3196 gene (miRBase Accession No. MIMAT0015080) set forth in SEQ ID NO: 195 or other biological species homologs. or orthologs, etc. The hsa-miR-3196 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, as a precursor of "hsa-miR-3196", "hsa-mir-3196" (miRBase Accession No. MI0014241, SEQ ID NO: 412) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4695-5p gene" or "hsa-miR-4695-5p" refers to the hsa-miR-4695-5p gene described in SEQ ID NO: 196 (miRBase Accession No. MIMAT0019788) or other species homologs or orthologs. The hsa-miR-4695-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4695-5p" is known as "hsa-mir-4695" (miRBase Accession No. MI0017328, SEQ ID NO: 413) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6732-5p gene" or "hsa-miR-6732-5p" refers to the hsa-miR-6732-5p gene described in SEQ ID NO: 197 (miRBase Accession No. MIMAT0027365) or other species homologs or orthologs. The hsa-miR-6732-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6732-5p" is known as "hsa-mir-6732" (miRBase Accession No. MI0022577, SEQ ID NO: 414) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-638 gene" or "hsa-miR-638" refers to the hsa-miR-638 gene (miRBase Accession No. MIMAT0003308) set forth in SEQ ID NO: 198 or other biological species homologs. or orthologs, etc. The hsa-miR-638 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol.103, p3687-3692. Also, as a precursor of "hsa-miR-638", "hsa-mir-638" (miRBase Accession No. MI0003653, SEQ ID NO: 415) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6813-5p gene" or "hsa-miR-6813-5p" refers to the hsa-miR-6813-5p gene described in SEQ ID NO: 199 (miRBase Accession No. MIMAT0027526) or other species homologs or orthologs. The hsa-miR-6813-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6813-5p" is known as "hsa-mir-6813" (miRBase Accession No. MI0022658, SEQ ID NO: 416) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-665 gene" or "hsa-miR-665" refers to the hsa-miR-665 gene (miRBase Accession No. MIMAT0004952) set forth in SEQ ID NO: 200 or other biological species homologs. or orthologs, etc. The hsa-miR-665 gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p1289-1298. Also, as a precursor of "hsa-miR-665", "hsa-mir-665" (miRBase Accession No. MI0005563, SEQ ID NO: 417) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-486-3p gene" or "hsa-miR-486-3p" refers to the hsa-miR-486-3p gene described in SEQ ID NO: 201 (miRBase Accession No. MIMAT0004762) or other species homologs or orthologs. The hsa-miR-486-3p gene can be obtained by the method described in Fu H et al., 2005, FEBS Lett, Vol. 579, p3849-3854. In addition, "hsa-miR-486-3p" is a precursor thereof, "hsa-mir-486" and "hsa-mir-486-2", which have a hairpin-like structure (miRBase Accession No. MI0002470, MI0023622, SEQ ID NO: 418) , 419) are known.

As used herein, the term "hsa-miR-4466 gene" or "hsa-miR-4466" refers to the hsa-miR-4466 gene (miRBase Accession No. MIMAT0018993) set forth in SEQ ID NO: 202 or other biological species homologs. or orthologs, etc. The hsa-miR-4466 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4466", "hsa-mir-4466" (miRBase Accession No. MI0016817, SEQ ID NO: 420) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-30c-1-3p gene" or "hsa-miR-30c-1-3p" refers to the hsa-miR-30c-1-3p gene shown in SEQ ID NO: 203 ( miRBase Accession No. MIMAT0004674) or other species homologs or orthologs. The hsa-miR-30c-1-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, p735-739. In addition, "hsa-miR-30c-1-3p" is known as "hsa-mir-30c-1" (miRBase Accession No. MI0000736, SEQ ID NO: 421) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3621 gene" or "hsa-miR-3621" refers to the hsa-miR-3621 gene (miRBase Accession No. MIMAT0018002) set forth in SEQ ID NO: 204 or other biological species homologs. or orthologs, etc. The hsa-miR-3621 gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p58. Also, as a precursor of "hsa-miR-3621", "hsa-mir-3621" (miRBase Accession No. MI0016012, SEQ ID NO: 422) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6743-5p gene" or "hsa-miR-6743-5p" refers to the hsa-miR-6743-5p gene described in SEQ ID NO: 205 (miRBase Accession No. MIMAT0027387) or other species homologs or orthologs. The hsa-miR-6743-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6743-5p" is known as "hsa-mir-6743" (miRBase Accession No. MI0022588, SEQ ID NO: 423) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4298 gene" or "hsa-miR-4298" refers to the hsa-miR-4298 gene (miRBase Accession No. MIMAT0016852) set forth in SEQ ID NO: 206 or other biological species homologs. or orthologs, etc. The hsa-miR-4298 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, Vol. 4, e7192. In addition, as a precursor of "hsa-miR-4298", "hsa-mir-4298" (miRBase Accession No. MI0015830, SEQ ID NO: 424) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4741 gene" or "hsa-miR-4741" refers to the hsa-miR-4741 gene (miRBase Accession No. MIMAT0019871) described in SEQ ID NO: 207 or other species homologs. or orthologs, etc. The hsa-miR-4741 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4741" is known as "hsa-mir-4741" (miRBase Accession No. MI0017379, SEQ ID NO: 425) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3619-3p gene" or "hsa-miR-3619-3p" refers to the hsa-miR-3619-3p gene described in SEQ ID NO: 208 (miRBase Accession No. MIMAT0019219) or other species homologs or orthologs. The hsa-miR-3619-3p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p58. In addition, "hsa-miR-3619-3p" is known as "hsa-mir-3619" (miRBase Accession No. MI0016009, SEQ ID NO: 426) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6824-5p gene" or "hsa-miR-6824-5p" refers to the hsa-miR-6824-5p gene described in SEQ ID NO: 209 (miRBase Accession No. MIMAT0027548) or other species homologs or orthologs. The hsa-miR-6824-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6824-5p" is known as "hsa-mir-6824" (miRBase Accession No. MI0022669, SEQ ID NO: 427) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-5698 gene" or "hsa-miR-5698" refers to the hsa-miR-5698 gene (miRBase Accession No. MIMAT0022491) set forth in SEQ ID NO: 210 or other biological species homologs. or orthologs, etc. The hsa-miR-5698 gene can be obtained by the method described in Watahiki A et al., 2011, PLoS One, Vol. 6, e24950. Also, as a precursor of "hsa-miR-5698", "hsa-mir-5698" (miRBase Accession No. MI0019305, SEQ ID NO: 428) having a hairpin-like structure is known.

The term "hsa-miR-371a-5p gene" or "hsa-miR-371a-5p" as used herein refers to the hsa-miR-371a-5p gene described in SEQ ID NO: 211 (miRBase Accession No. MIMAT0004687) or other species homologs or orthologs. The hsa-miR-371a-5p gene can be obtained by the method described in Suh MR et al., 2004, Dev Biol, Vol. 270, p488-498. In addition, "hsa-miR-371a-5p" is known as "hsa-mir-371a" (miRBase Accession No. MI0000779, SEQ ID NO: 429) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4488 gene" or "hsa-miR-4488" refers to the hsa-miR-4488 gene (miRBase Accession No. MIMAT0019022) set forth in SEQ ID NO: 212 or other biological species homologs. or orthologs, etc. The hsa-miR-4488 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, as a precursor of "hsa-miR-4488", "hsa-mir-4488" (miRBase Accession No. MI0016849, SEQ ID NO: 430) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-1233-5p gene" or "hsa-miR-1233-5p" refers to the hsa-miR-1233-5p gene described in SEQ ID NO: 213 (miRBase Accession No. MIMAT0022943) or other species homologs or orthologs. The hsa-miR-1233-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1233-5p" is a precursor thereof, "hsa-mir-1233-1", "hsa-mir-1233-2" taking a hairpin-like structure (miRBase Accession No. MI0006323, MI0015973, sequence Nos. 431, 432) are known.

As used herein, the term "hsa-miR-4723-5p gene" or "hsa-miR-4723-5p" refers to the hsa-miR-4723-5p gene described in SEQ ID NO: 214 (miRBase Accession No. MIMAT0019838) or other species homologs or orthologs. The hsa-miR-4723-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4723-5p" is known as "hsa-mir-4723" (miRBase Accession No. MI0017359, SEQ ID NO: 433) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-24-3p gene" or "hsa-miR-24-3p" refers to the hsa-miR-24-3p gene shown in SEQ ID NO: 215 (miRBase Accession No. MIMAT0000080) or other species homologs or orthologs. The hsa-miR-24-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, Vol. 294, p853-858. In addition, "hsa-miR-24-3p" is a precursor thereof, "hsa-mir-24-1", "hsa-mir-24-2" taking a hairpin-like structure (miRBase Accession No. MI0000080, MI0000081, sequence Nos. 434, 435) are known.

As used herein, the term "hsa-miR-1238-5p gene" or "hsa-miR-1238-5p" refers to the hsa-miR-1238-5p gene described in SEQ ID NO: 216 (miRBase Accession No. MIMAT0022947) or other species homologs or orthologs. The hsa-miR-1238-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, p328-336. In addition, "hsa-miR-1238-5p" is known as "hsa-mir-1238" (miRBase Accession No. MI0006328, SEQ ID NO: 436) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4442 gene" or "hsa-miR-4442" refers to the hsa-miR-4442 gene (miRBase Accession No. MIMAT0018960) described in SEQ ID NO: 217 or other species homologs. or orthologs, etc. The hsa-miR-4442 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4442", "hsa-mir-4442" (miRBase Accession No. MI0016785, SEQ ID NO: 437) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-3928-3p gene" or "hsa-miR-3928-3p" refers to the hsa-miR-3928-3p gene described in SEQ ID NO: 218 (miRBase Accession No. MIMAT0018205) or other species homologs or orthologs. The hsa-miR-3928-3p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. In addition, "hsa-miR-3928-3p" is known as "hsa-mir-3928" (miRBase Accession No. MI0016438, SEQ ID NO: 438) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6716-5p gene" or "hsa-miR-6716-5p" refers to the hsa-miR-6716-5p gene described in SEQ ID NO: 219 (miRBase Accession No. MIMAT0025844) or other species homologs or orthologs. The hsa-miR-6716-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, p330-335. In addition, "hsa-miR-6716-5p" is known as "hsa-mir-6716" (miRBase Accession No. MI0022550, SEQ ID NO: 439) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6089 gene" or "hsa-miR-6089" refers to the hsa-miR-6089 gene (miRBase Accession No. MIMAT0023714) set forth in SEQ ID NO: 220 or other biological species homologs. or orthologs, etc. The hsa-miR-6089 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, p2049-2057. In addition, "hsa-miR-6089" is "hsa-mir-6089-1" and "hsa-mir-6089-2" which take a hairpin-like structure as a precursor thereof (miRBase Accession No. MI0020366, MI0023563, SEQ ID NO: 440 , 441) are known.

As used herein, the term "hsa-miR-6124 gene" or "hsa-miR-6124" refers to the hsa-miR-6124 gene (miRBase Accession No. MIMAT0024597) set forth in SEQ ID NO: 221 or other biological species homologs. or orthologs, etc. The hsa-miR-6124 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, Vol. 86, p5278-5287. Also, as a precursor of "hsa-miR-6124", "hsa-mir-6124" (miRBase Accession No. MI0021258, SEQ ID NO: 442) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6778-5p gene" or "hsa-miR-6778-5p" refers to the hsa-miR-6778-5p gene set forth in SEQ ID NO: 222 (miRBase Accession No. MIMAT0027456) or other species homologs or orthologs. The hsa-miR-6778-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6778-5p" is known as "hsa-mir-6778" (miRBase Accession No. MI0022623, SEQ ID NO: 443) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-557 gene" or "hsa-miR-557" refers to the hsa-miR-557 gene (miRBase Accession No. MIMAT0003221) set forth in SEQ ID NO: 223 or other biological species homologs. or orthologs, etc. The hsa-miR-557 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p3687-3692. In addition, as a precursor of "hsa-miR-557", "hsa-mir-557" (miRBase Accession No. MI0003563, SEQ ID NO: 444) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6090 gene" or "hsa-miR-6090" refers to the hsa-miR-6090 gene (miRBase Accession No. MIMAT0023715) set forth in SEQ ID NO: 224 or other biological species homologs. or orthologs, etc. The hsa-miR-6090 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, p2049-2057. In addition, "hsa-miR-6090" is known as "hsa-mir-6090" (miRBase Accession No. MI0020367, SEQ ID NO: 445) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6757-5p gene" or "hsa-miR-6757-5p" refers to the hsa-miR-6757-5p gene (miRBase Accession No. MIMAT0027414) set forth in SEQ ID NO: 714. or other species homologs or orthologs. The hsa-miR-6757-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, p1634-1645. In addition, "hsa-miR-6757-5p" is known as "hsa-mir-6757" (miRBase Accession No. MI0022602, SEQ ID NO: 730) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4448 gene" or "hsa-miR-4448" refers to the hsa-miR-4448 gene described in SEQ ID NO: 715 (miRBase Accession No. MIMAT0018967) or other biological species homologs. Or orthologs, etc. The hsa-miR-4448 gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4448" is known as "hsa-mir-4448" (miRBase Accession No. MI0016791, SEQ ID NO: 731) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-671-5p gene" or "hsa-miR-671-5p" refers to the hsa-miR-671-5p gene described in SEQ ID NO: 716 (miRBase Accession No. MIMAT0003880) or other species homologs or orthologs. The hsa-miR-671-5p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p1289-1298. In addition, "hsa-miR-671-5p" is known as "hsa-mir-671" (miRBase Accession No. MI0003760, SEQ ID NO: 732) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3178 gene" or "hsa-miR-3178" refers to the hsa-miR-3178 gene (miRBase Accession No. MIMAT0015055) set forth in SEQ ID NO: 717 or other biological species homologs. Or orthologs, etc. The hsa-miR-3178 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685. In addition, as a precursor of "hsa-miR-3178", "hsa-mir-3178" (miRBase Accession No. MI0014212, SEQ ID NO: 733) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4725-3p gene" or "hsa-miR-4725-3p" refers to the hsa-miR-4725-3p gene described in SEQ ID NO: 718 (miRBase Accession No. MIMAT0019844) or other species homologs or orthologs. The hsa-miR-4725-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4725-3p" is known as "hsa-mir-4725" (miRBase Accession No. MI0017362, SEQ ID NO: 734) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-940 gene" or "hsa-miR-940" refers to the hsa-miR-940 gene (miRBase Accession No. MIMAT0004983) set forth in SEQ ID NO: 719 or other biological species homologs. Or orthologs, etc. The hsa-miR-940 gene can be obtained by the method described in Lui WO et al., 2007, A Cancer Res., vol. 67, p6031-6043. Also, as a precursor of "hsa-miR-940", "hsa-mir-940" (miRBase Accession No. MI0005762, SEQ ID NO: 735) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-6789-5p gene" or "hsa-miR-6789-5p" refers to the hsa-miR-6789-5p gene set forth in SEQ ID NO: 720 (miRBase Accession No. MIMAT0027478) or other species homologs or orthologs. The hsa-miR-6789-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., No. 22, p1634-1645. Further, "hsa-miR-6789-5p" is known as "hsa-mir-6789" (miRBase Accession No. MI0022634, SEQ ID NO: 736) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4484 gene" or "hsa-miR-4484" refers to the hsa-miR-4484 gene (miRBase Accession No. MIMAT0019018) described in SEQ ID NO: 721 or other species homologs. Or orthologs, etc. The hsa-miR-4484 gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Also, as a precursor of "hsa-miR-4484", "hsa-mir-4484" (miRBase Accession No. MI0016845, SEQ ID NO: 737) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4634 gene" or "hsa-miR-4634" refers to the hsa-miR-4634 gene (miRBase Accession No. MIMAT0019691) set forth in SEQ ID NO: 722 or other biological species homologs. Or orthologs, etc. The hsa-miR-4634 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., vol. 71, p78-86. Also, as a precursor of "hsa-miR-4634", "hsa-mir-4634" (miRBase Accession No. MI0017261, SEQ ID NO: 738) having a hairpin-like structure is known.

As used herein, the term "hsa-miR-4745-5p gene" or "hsa-miR-4745-5p" refers to the hsa-miR-4745-5p gene set forth in SEQ ID NO: 723 (miRBase Accession No. MIMAT0019878) or other species homologs or orthologs. The hsa-miR-4745-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4745-5p" is known as "hsa-mir-4745" (miRBase Accession No. MI0017384, SEQ ID NO: 739) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4730 gene" or "hsa-miR-4730" refers to the hsa-miR-4730 gene (miRBase Accession No. MIMAT0019852) set forth in SEQ ID NO: 724 or other biological species homologs. Or orthologs, etc. The hsa-miR-4730 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. Also, "hsa-miR-4730" is known as "hsa-mir-4730" (miRBase Accession No. MI0017367, SEQ ID NO: 740) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" refers to the hsa-miR-6803-5p gene described in SEQ ID NO: 725 (miRBase Accession No. MIMAT0027506) or other species homologs or orthologs. The hsa-miR-6803-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6803-5p" is known as "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6798-5p gene" or "hsa-miR-6798-5p" refers to the hsa-miR-6798-5p gene described in SEQ ID NO: 726 (miRBase Accession No. MIMAT0027496) or other species homologs or orthologs. The hsa-miR-6798-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. In addition, "hsa-miR-6798-5p" is known as "hsa-mir-6798" (miRBase Accession No. MI0022643, SEQ ID NO: 742) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-3648 gene" or "hsa-miR-3648" refers to the hsa-miR-3648 gene (miRBase Accession No. MIMAT0018068) described in SEQ ID NO: 727 or other biological species homologs. Or orthologs, etc. The hsa-miR-3648 gene can be obtained by the method described in Meiri E et al., 2010, Nucleic Acids Res, vol. 38, p6234-6246. Further, "hsa-miR-3648" is known as "hsa-mir-3648" (miRBase Accession No. MI0016048, SEQ ID NO: 743) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-4783-3p gene" or "hsa-miR-4783-3p" refers to the hsa-miR-4783-3p gene described in SEQ ID NO: 728 (miRBase Accession No. MIMAT0019947) or other species homologs or orthologs. The hsa-miR-4783-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, p78-86. In addition, "hsa-miR-4783-3p" is known as "hsa-mir-4783" (miRBase Accession No. MI0017428, SEQ ID NO: 744) having a hairpin-like structure as its precursor.

As used herein, the term "hsa-miR-6836-3p gene" or "hsa-miR-6836-3p" refers to the hsa-miR-6836-3p gene (miRBase Accession No. MIMAT0027575) set forth in SEQ ID NO: 729. or other species homologs or orthologs. The hsa-miR-6836-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., No. 22, p1634-1645. In addition, "hsa-miR-6836-3p" is known as "hsa-mir-6836" (miRBase Accession No. MI0022682, SEQ ID NO: 745) having a hairpin-like structure as its precursor.

In addition, when mature miRNAs are cut as mature miRNAs from RNA precursors having a hairpin-like structure, 1 to the basal line before and after the sequence are cut short or long, or when base substitution occurs to form a mutant , and is called isomiR (Morin RD. et al., 2008, Genome Res., Vol. 18, p.610-621). In miRBase Release20, in addition to the nucleotide sequence represented by any one of SEQ ID NOs: 1-224 and 714-729, variants and fragments of the nucleotide sequence represented by any one of SEQ ID NOs: 446-713 and 746-765 called a number of isomiR are also shown. have. These mutants can also be obtained as miRNAs having a nucleotide sequence shown in any one of SEQ ID NOs: 1-224 and 714-729.

That is, SEQ ID NOs: 1, 3, 4, 6, 7, 10, 11, 13, 14, 16, 17, 20, 22, 26, 29, 36, 38, 39, 40, 42, 43, 44 of the present invention , 46, 49, 52, 59, 60, 62, 63, 65, 66, 67, 72, 76, 77, 78, 81, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93 , 94, 96, 100, 103, 105, 106, 107, 113, 114, 115, 116, 117, 118, 119, 120, 121, 123, 124, 125, 126, 130, 132, 134, 136, 139 , 140, 141, 142, 143, 144, 145, 147, 148, 150, 151, 152, 155, 157, 158, 159, 163, 164, 165, 167, 168, 169, 170, 171, 172, 173 , 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 187, 189, 191, 192, 193, 195, 196, 198, 200, 201, 202, 203, 206 , 207, 210, 211, 212, 213, 214, 215, 217, 218, 219, 220, 221, 715, 716, 717, 718, 719, 721, 723, 724, 727 and 728; or Among the variants of the polynucleotide consisting of a nucleotide sequence in which u is t in the nucleotide sequence, for example, as the longest variant registered in miRBase Release 20, SEQ ID NOs: 446, 448, 450, 452, 454, 456, 458, respectively , 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494, 496, 498, 500, 502, 504, 506, 508 , 510, 512, 514, 516, 518, 520, 522, 524, 52 6, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, 556, 558, 560, 562, 564, 566, 568, 570, 572, 574, 576, 578, 580, 582, 584, 586, 588, 590, 592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 622, 624, 626, 628, 630, 632, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, 680, 682, 684, 686, 688, 690, 692, 694, 696, 698, 700, 702, 704, 706, 708, 710, 712, 746, 748, 750, 752, 754, 756, and polynucleotides represented by 758, 760, 762 and 764.

In addition, SEQ ID NOs: 1, 3, 4, 6, 7, 10, 11, 13, 14, 16, 17, 20, 22, 26, 29, 36, 38, 39, 40, 42, 43, 44 of the present invention , 46, 49, 52, 59, 60, 62, 63, 65, 66, 67, 72, 76, 77, 78, 81, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93 , 94, 96, 100, 103, 105, 106, 107, 113, 114, 115, 116, 117, 118, 119, 120, 121, 123, 124, 125, 126, 130, 132, 134, 136, 139 , 140, 141, 142, 143, 144, 145, 147, 148, 150, 151, 152, 155, 157, 158, 159, 163, 164, 165, 167, 168, 169, 170, 171, 172, 173 , 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 187, 189, 191, 192, 193, 195, 196, 198, 200, 201, 202, 203, 206 , 207, 210, 211, 212, 213, 214, 215, 217, 218, 219, 220, 221, 715, 716, 717, 718, 719, 721, 723, 724, 727 and 728; or Among the variants of the polynucleotide consisting of a nucleotide sequence in which u is t in the nucleotide sequence, for example, it is the shortest mutant registered in miRBase Release 20, and SEQ ID NOs: 447, 449, 451, 453, 455, 457, 459, respectively , 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485, 487, 489, 491, 493, 495, 497, 499, 501, 503, 505, 507, 509 , 511, 513, 515, 517, 519, 521, 523, 525, 527, 529, 531, 533, 535, 537, 539, 541, 543, 545, 547, 549, 551, 553, 555, 557, 559, 561, 563, 565, 567, 569, 571, 573, 575, 577, 579, 581, 583, 585, 587, 589, 591, 593, 595, 597, 599, 601, 603, 605, 607, 609, 611, 613, 615, 617, 619, 621, 623, 625, 627, 629, 631, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, 679, 681, 683, 685, 687, 689, 691, 693, 695, 697, 699, 701, 703, 705, 707, 709, 711, 713, 747, 749, 751, 753, 755, 757, and polynucleotides of the sequences represented by 759, 761, 763 and 765.

In addition to these variants and fragments, polynucleotides which are a number of isomiRs of SEQ ID NOs: 1-224 and 714-729 registered with miRBase can be mentioned. Further, examples of the polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 1-224 and 714-729 include polynucleotides represented by any one of SEQ ID NOs: 225-445 and 730-745, which are precursors, respectively.

Table 1 lists the names of genes and miRBase Accession No. (registration number) represented by SEQ ID NOs: 1-765.

As used herein, "specifically capable of binding" means that the nucleic acid probe or primer used in the present invention binds to a specific target nucleic acid and cannot substantially bind other nucleic acids.

[Table 1]

This specification includes the contents described in the specification and drawings of Japanese Patent Application No. 2014-124880, which is the basis of the priority of the present application.

(Effects of the Invention)

ADVANTAGE OF THE INVENTION According to this invention, it became possible to detect liver cancer easily and with high precision. For example, it is possible to easily detect whether or not the patient has liver cancer by using several miRNA measurement values in the blood, serum and/or plasma of a patient that can be collected with low invasiveness as an index.

1 is a nucleotide sequence of hsa-miR-1343-5p represented by SEQ ID NO: 131 and hsa-miR-1343-3p represented by SEQ ID NO: 1 generated from hsa-mir-1343 represented by SEQ ID NO: 225 as a precursor; represents the relationship of
The left diagram of FIG. 2 shows the measured values of hsa-miR-1343-3p (SEQ ID NO: 1) of healthy subjects (100 patients) and liver cancer patients (34 patients) selected as the learning sample group as the vertical axis, respectively. A horizontal line in the figure indicates a threshold value (7.09) for discriminating both groups, which is optimized by Fisher's discriminant analysis. The right diagram of FIG. 2 shows the measured values of hsa-miR-1343-3p (SEQ ID NO: 1) of healthy subjects (50 patients) and liver cancer patients (16 patients) selected as the test sample group as the vertical axis, respectively. A horizontal line in the figure indicates a threshold value (7.09) for discriminating both groups set in the learning sample group.
The left diagram of FIG. 3 shows the measured values of hsa-miR-1343-3p (SEQ ID NO: 1) of healthy subjects (100 patients, Dong-Rami) and liver cancer patients (34 patients, triangle) selected as the learning sample group as the horizontal axis, and hsa The measured values of -miR-6726-5p (SEQ ID NO: 2) are shown as the vertical axis, respectively. A line in the figure indicates a discriminant function (0=0.77x+y-15.07) for discriminating both groups optimized by Fisher's discriminant analysis. The right diagram of FIG. 3 shows the measured values of hsa-miR-1343-3p (SEQ ID NO: 1) of healthy subjects (50 people, Dong-Rami) and liver cancer patients (16 people, triangle) selected as the test sample group as the horizontal axis, and hsa The measured values of -miR-6726-5p (SEQ ID NO: 2) are shown as the vertical axis, respectively. The line in the figure indicates the threshold (0=0.77x+y-15.07) for discriminating both groups set in the learning sample group.
The upper diagram of FIG. 4 shows 35 patients with liver cancer, 99 patients with healthy body, 72 patients with colon cancer, 61 patients with biliary tract cancer, 35 patients with colorectal cancer, 38 patients with stomach cancer, 25 patients with esophageal cancer, and pancreatic cancer selected as the learning sample group. Also hsa-miR-6131 (SEQ ID NO: 7), hsa-miR-642a-3p (SEQ ID NO: 148), hsa-miR-7641 (SEQ ID NO: 9), hsa-miR-6729-5p (SEQ ID NO: 9) in 16 patients with benign disease Using Fisher's discriminant analysis from the measurements of number 27), the discriminant was constructed (0.88xhsa-miR-6131-1.58xhsa-miR-642a-3p+0.39xhsa-miR-7641-0.33xhsa-miR-6729- 5p + 5.19), the discriminant score obtained from the discriminant is shown on the vertical axis, and the sample group on the horizontal axis. A dotted line in the figure indicates a discriminant boundary that discriminates both groups in which the discriminant score is 0. The lower figure of FIG. 4 shows 17 patients with liver cancer, 51 patients with healthy body, 28 patients with colon cancer, 37 patients with biliary tract cancer, 15 patients with colorectal cancer, 12 patients with stomach cancer, 25 patients with esophageal cancer, and pancreatic cancer selected as the test sample group. 5 hsa-miR-6131 (SEQ ID NO: 7), hsa-miR-642a-3p (SEQ ID NO: 148), hsa-miR-7641 (SEQ ID NO: 9), hsa-miR-6729-5p (SEQ ID NO: 9) in 5 patients with benign disease For the measured value of No. 27), the discriminant score obtained from the discriminant created in the learning sample group is shown as the vertical axis, and the sample group is shown as the horizontal axis. A dotted line in the figure indicates a discriminant boundary that discriminates both groups in which the discriminant score is 0.

Hereinafter, the present invention will be described in more detail.

1. Liver cancer target nucleic acid

Main target nucleic acids as liver cancer markers for detecting the presence and/or absence of liver cancer or liver cancer cells using the nucleic acid probe or primer for liver cancer detection as defined above of the present invention include hsa-miR-1343-3p, hsa- miR-6726-5p, hsa-miR-6515-3p, hsa-miR-4651, hsa-miR-4257, hsa-miR-3188, hsa-miR-6131, hsa-miR-6766-3p, hsa-miR- 7641, hsa-miR-1249, hsa-miR-3679-3p, hsa-miR-6787-5p, hsa-miR-4454, hsa-miR-3135b, hsa-miR-6765-3p, hsa-miR-7975, hsa-miR-204-3p, hsa-miR-7977, hsa-miR-7110-5p, hsa-miR-6717-5p, hsa-miR-6870-5p, hsa-miR-663b, hsa-miR-6875- 5p, hsa-miR-8072, hsa-miR-6816-5p, hsa-miR-4281, hsa-miR-6729-5p, hsa-miR-8069, hsa-miR-4706, hsa-miR-7108-5p, hsa-miR-4433b-3p, hsa-miR-6893-5p, hsa-miR-6857-5p, hsa-miR-1227-5p, hsa-miR-6741-5p, hsa-miR-451a, hsa-miR- 8063, hsa-miR-3622a-5p, hsa-miR-615-5p, hsa-miR-128-1-5p, hsa-miR-6825-5p, hsa-miR-1260b, hsa-miR-4433-3p, hsa-miR-4665-5p, hsa-miR-7845-5p, hsa-miR-1908-5p, hsa-miR-6840-3p, hsa-miR-6765-5p, hsa-miR-296-5p, hsa- miR-3675-3p, hsa-miR-6781-5p, hsa-miR-423-5p, hsa-miR-3663-3p, hsa-miR-6784-5p, hsa-miR-6749-5p, hsa-miR- 1231, hsa-miR -4746-3p, hsa-miR-6780b-5p, hsa-miR-4758-5p, hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-6125, hsa-miR-6721-5p , hsa-miR-6791-5p, hsa-miR-3185, hsa-miR-1260a, hsa-miR-3197, hsa-miR-6845-5p, hsa-miR-6887-5p, hsa-miR-6738-5p , hsa-miR-6872-3p, hsa-miR-4497, hsa-miR-1229-5p, hsa-miR-6820-5p, hsa-miR-6777-5p, hsa-miR-3917, hsa-miR-5787 , hsa-miR-4286, hsa-miR-6877-5p, hsa-miR-1225-3p, hsa-miR-6088, hsa-miR-6800-5p, hsa-miR-1246, hsa-miR-4467, hsa -miR-4419b, hsa-miR-1914-3p, hsa-miR-4632-5p, hsa-miR-1915-5p, hsa-miR-3940-5p, hsa-miR-1185-2-3p, hsa-miR -6746-5p, hsa-miR-5001-5p, hsa-miR-1228-5p, hsa-miR-5572, hsa-miR-4327, hsa-miR-4638-5p, hsa-miR-6799-5p, hsa -miR-6861-5p, hsa-miR-6727-5p, hsa-miR-4513, hsa-miR-6805-3p, hsa-miR-6808-5p, hsa-miR-4449, hsa-miR-1199-5p , hsa-miR-1275, hsa-miR-4792, hsa-miR-4443, hsa-miR-6891-5p, hsa-miR-6826-5p, hsa-miR-6807-5p, hsa-miR-7150, hsa -miR-4534, hsa-miR-4476, hsa-miR-4649-5p, hsa-miR-4525, hsa-miR-1915-3p, hsa-miR-4516, hsa-miR-4417, hsa-miR-642b -3p, hsa-mi R-3141, hsa-miR-5100, hsa-miR-6848-5p, hsa-miR-4739, hsa-miR-4459, hsa-miR-1237-5p, hsa-miR-296-3p, hsa-miR- 4665-3p, hsa-miR-6786-5p, hsa-miR-4258, hsa-miR-6510-5p, hsa-miR-1343-5p, hsa-miR-1247-3p, hsa-miR-6805-5p, hsa-miR-4492, hsa-miR-1469, hsa-miR-1268b, hsa-miR-6858-5p, hsa-miR-3937, hsa-miR-939-5p, hsa-miR-3656, hsa-miR- 744-5p, hsa-miR-4687-3p, hsa-miR-4763-3p, hsa-miR-3620-5p, hsa-miR-3195, hsa-miR-6842-5p, hsa-miR-4707-5p, hsa-miR-642a-3p, hsa-miR-7113-3p, hsa-miR-4728-5p, hsa-miR-5195-3p, hsa-miR-1185-1-3p, hsa-miR-6774-5p, hsa-miR-8059, hsa-miR-3131, hsa-miR-7847-3p, hsa-miR-4463, hsa-miR-128-2-5p, hsa-miR-4508, hsa-miR-6806-5p, hsa-miR-7111-5p, hsa-miR-6782-5p, hsa-miR-4734, hsa-miR-3162-5p, hsa-miR-887-3p, hsa-miR-6752-5p, hsa-miR- 6724-5p, hsa-miR-6757-5p, hsa-miR-4448, hsa-miR-671-5p, hsa-miR-3178, hsa-miR-4725-3p, hsa-miR-940, hsa-miR- 6789-5p, hsa-miR-4484, hsa-miR-4634, hsa-miR-4745-5p, hsa-miR-4730, hsa-miR-6803-5p, hsa-miR-6798-5p, hsa-miR- 3648, hsa-miR-4783-3p and hsa-m At least one or more miRNAs selected from the group consisting of iR-6836-3p may be used. In addition, other liver cancer markers that can be combined with these miRNAs, namely hsa-miR-23b-3p, hsa-miR-23a-3p, hsa-miR-625-3p, hsa-miR-1228-3p, hsa-miR-614 , hsa-miR-1913, hsa-miR-92a-2-5p, hsa-miR-187-5p, hsa-miR-16-5p, hsa-miR-92b-3p, hsa-miR-150-3p, hsa At least one miRNA selected from the group consisting of -miR-564, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR-92a-3p and hsa-miR-663a is also preferable as the target nucleic acid. can be used Also other hepatocarcinoma markers that can be combined with these miRNAs, namely hsa-miR-4688, hsa-miR-4648, hsa-miR-6085, hsa-miR-6126, hsa-miR-6880-5p, hsa-miR-328 -5p, hsa-miR-6768-5p, hsa-miR-3180, hsa-miR-6087, hsa-miR-1273g-3p, hsa-miR-1225-5p, hsa-miR-3196, hsa-miR-4695 -5p, hsa-miR-6732-5p, hsa-miR-638, hsa-miR-6813-5p, hsa-miR-665, hsa-miR-486-3p, hsa-miR-4466, hsa-miR-30c -1-3p, hsa-miR-3621, hsa-miR-6743-5p, hsa-miR-4298, hsa-miR-4741, hsa-miR-3619-3p, hsa-miR-6824-5p, hsa-miR -5698, hsa-miR-371a-5p, hsa-miR-4488, hsa-miR-1233-5p, hsa-miR-4723-5p, hsa-miR-24-3p, hsa-miR-1238-5p, hsa -miR-4442, hsa-miR-3928-3p, hsa-miR-6716-5p, hsa-miR-6089, hsa-miR-6124, hsa-miR-6778-5p, hsa-miR-557 and hsa-miR At least one or more miRNAs selected from the group consisting of -6090 can also be preferably used as the target nucleic acid.

The miRNA includes, for example, a human gene (ie, hsa-miR-1343-3p, hsa-miR-6726-5p, hsa- miR-6515-3p, hsa-miR-4651, hsa-miR-4257, hsa-miR-3188, hsa-miR-6131, hsa-miR-6766-3p, hsa-miR-7641, hsa-miR-1249, hsa-miR-3679-3p, hsa-miR-6787-5p, hsa-miR-4454, hsa-miR-3135b, hsa-miR-6765-3p, hsa-miR-7975, hsa-miR-204-3p, hsa-miR-7977, hsa-miR-7110-5p, hsa-miR-6717-5p, hsa-miR-6870-5p, hsa-miR-663b, hsa-miR-6875-5p, hsa-miR-8072, hsa-miR-6816-5p, hsa-miR-4281, hsa-miR-6729-5p, hsa-miR-8069, hsa-miR-4706, hsa-miR-7108-5p, hsa-miR-4433b-3p, hsa-miR-6893-5p, hsa-miR-6857-5p, hsa-miR-1227-5p, hsa-miR-6741-5p, hsa-miR-451a, hsa-miR-8063, hsa-miR-3622a- 5p, hsa-miR-615-5p, hsa-miR-128-1-5p, hsa-miR-6825-5p, hsa-miR-1260b, hsa-miR-4433-3p, hsa-miR-4665-5p, hsa-miR-7845-5p, hsa-miR-1908-5p, hsa-miR-6840-3p, hsa-miR-6765-5p, hsa-miR-296-5p, hsa-miR-3675-3p, hsa- miR-6781-5p, hsa-miR-423-5p, hsa-miR-3663-3p, hsa-miR-6784-5p, hsa-miR-6749-5p, hsa-miR-1231, hsa-miR-4746- 3p, hsa-miR- 6780b-5p, hsa-miR-4758-5p, hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-6125, hsa-miR-6721-5p, hsa-miR-6791-5p, hsa-miR-3185, hsa-miR-1260a, hsa-miR-3197, hsa-miR-6845-5p, hsa-miR-6887-5p, hsa-miR-6738-5p, hsa-miR-6872-3p, hsa-miR-4497, hsa-miR-1229-5p, hsa-miR-6820-5p, hsa-miR-6777-5p, hsa-miR-3917, hsa-miR-5787, hsa-miR-4286, hsa- miR-6877-5p, hsa-miR-1225-3p, hsa-miR-6088, hsa-miR-6800-5p, hsa-miR-1246, hsa-miR-4467, hsa-miR-4419b, hsa-miR- 1914-3p, hsa-miR-4632-5p, hsa-miR-1915-5p, hsa-miR-3940-5p, hsa-miR-1185-2-3p, hsa-miR-6746-5p, hsa-miR- 5001-5p, hsa-miR-1228-5p, hsa-miR-5572, hsa-miR-4327, hsa-miR-4638-5p, hsa-miR-6799-5p, hsa-miR-6861-5p, hsa- miR-6727-5p, hsa-miR-4513, hsa-miR-6805-3p, hsa-miR-6808-5p, hsa-miR-4449, hsa-miR-1199-5p, hsa-miR-1275, hsa- miR-4792, hsa-miR-4443, hsa-miR-6891-5p, hsa-miR-6826-5p, hsa-miR-6807-5p, hsa-miR-7150, hsa-miR-4534, hsa-miR- 4476, hsa-miR-4649-5p, hsa-miR-4525, hsa-miR-1915-3p, hsa-miR-4516, hsa-miR-4417, hsa-miR-642b-3p, hsa-miR-3141, hsa-miR-51 00, hsa-miR-6848-5p, hsa-miR-4739, hsa-miR-4459, hsa-miR-1237-5p, hsa-miR-296-3p, hsa-miR-4665-3p, hsa-miR- 6786-5p, hsa-miR-4258, hsa-miR-6510-5p, hsa-miR-1343-5p, hsa-miR-1247-3p, hsa-miR-6805-5p, hsa-miR-4492, hsa- miR-1469, hsa-miR-1268b, hsa-miR-6858-5p, hsa-miR-3937, hsa-miR-939-5p, hsa-miR-3656, hsa-miR-744-5p, hsa-miR- 4687-3p, hsa-miR-4763-3p, hsa-miR-3620-5p, hsa-miR-3195, hsa-miR-6842-5p, hsa-miR-4707-5p, hsa-miR-642a-3p, hsa-miR-7113-3p, hsa-miR-4728-5p, hsa-miR-5195-3p, hsa-miR-1185-1-3p, hsa-miR-6774-5p, hsa-miR-8059, hsa- miR-3131, hsa-miR-7847-3p, hsa-miR-4463, hsa-miR-128-2-5p, hsa-miR-4508, hsa-miR-6806-5p, hsa-miR-7111-5p, hsa-miR-6782-5p, hsa-miR-4734, hsa-miR-3162-5p, hsa-miR-887-3p, hsa-miR-6752-5p, hsa-miR-6724-5p, hsa-miR- 6757-5p, hsa-miR-4448, hsa-miR-671-5p, hsa-miR-3178, hsa-miR-4725-3p, hsa-miR-940, hsa-miR-6789-5p, hsa-miR- 4484, hsa-miR-4634, hsa-miR-4745-5p, hsa-miR-4730, hsa-miR-6803-5p, hsa-miR-6798-5p, hsa-miR-3648, hsa-miR-4783- 3p, hsa-miR-6836-3p, hsa-miR -23b-3p, hsa-miR-23a-3p, hsa-miR-625-3p, hsa-miR-1228-3p, hsa-miR-614, hsa-miR-1913, hsa-miR-92a-2-5p , hsa-miR-187-5p, hsa-miR-16-5p, hsa-miR-92b-3p, hsa-miR-150-3p, hsa-miR-564, hsa-miR-125a-3p, hsa-miR -92b-5p, hsa-miR-92a-3p, hsa-miR-663a, hsa-miR-4688, hsa-miR-4648, hsa-miR-6085, hsa-miR-6126, hsa-miR-6880-5p , hsa-miR-328-5p, hsa-miR-6768-5p, hsa-miR-3180, hsa-miR-6087, hsa-miR-1273g-3p, hsa-miR-1225-5p, hsa-miR-3196 , hsa-miR-4695-5p, hsa-miR-6732-5p, hsa-miR-638, hsa-miR-6813-5p, hsa-miR-665, hsa-miR-486-3p, hsa-miR-4466 , hsa-miR-30c-1-3p, hsa-miR-3621, hsa-miR-6743-5p, hsa-miR-4298, hsa-miR-4741, hsa-miR-3619-3p, hsa-miR-6824 -5p, hsa-miR-5698, hsa-miR-371a-5p, hsa-miR-4488, hsa-miR-1233-5p, hsa-miR-4723-5p, hsa-miR-24-3p, hsa-miR -1238-5p, hsa-miR-4442, hsa-miR-3928-3p, hsa-miR-6716-5p, hsa-miR-6089, hsa-miR-6124, hsa-miR-6778-5p, hsa-miR -557 and hsa-miR-6090), its homologues, its transcripts, and variants or derivatives thereof. Here, genes, homologues, transcripts, mutants and derivatives are as defined above.

A preferred target nucleic acid is a human gene comprising the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 765, or a transcript thereof, more preferably the transcript, that is, miRNA, pri-miRNA or pre-miRNA that is a precursor RNA thereof to be.

The first target gene is a hsa-miR-1343-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The second target gene is the hsa-miR-6726-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The third target gene is the hsa-miR-6515-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fourth target gene is the hsa-miR-4651 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fifth target gene is the hsa-miR-4257 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The sixth target gene is a hsa-miR-3188 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The seventh target gene is the hsa-miR-6131 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The eighth target gene is the hsa-miR-6766-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The ninth target gene is the hsa-miR-7641 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The tenth target gene is an hsa-miR-1249 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The eleventh target gene is an hsa-miR-3679-3p gene, a homologue thereof, a transcript thereof, or a mutant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twelfth target gene is a hsa-miR-6787-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirteenth target gene is an hsa-miR-4454 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fourteenth target gene is an hsa-miR-3135b gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fifteenth target gene is the hsa-miR-6765-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The sixteenth target gene is a hsa-miR-7975 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The seventeenth target gene is an hsa-miR-204-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The eighteenth target gene is a hsa-miR-7977 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The nineteenth target gene is a hsa-miR-7110-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twentieth target gene is an hsa-miR-6717-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twenty-first target gene is a hsa-miR-6870-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twenty-second target gene is an hsa-miR-663b gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twenty-third target gene is an hsa-miR-6875-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twenty-fourth target gene is a hsa-miR-8072 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twenty-fifth target gene is a hsa-miR-6816-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twenty-sixth target gene is a hsa-miR-4281 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twenty-seventh target gene is a hsa-miR-6729-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twenty-eighth target gene is an hsa-miR-8069 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The twenty-ninth target gene is an hsa-miR-4706 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirtieth target gene is an hsa-miR-7108-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirty-first target gene is an hsa-miR-4433b-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirty-second target gene is an hsa-miR-6893-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirty-third target gene is an hsa-miR-6857-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirty-fourth target gene is an hsa-miR-1227-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirty-fifth target gene is a hsa-miR-6741-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirty-sixth target gene is an hsa-miR-451a gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirty-seventh target gene is a hsa-miR-8063 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirty-eighth target gene is a hsa-miR-3622a-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The thirty-ninth target gene is a hsa-miR-615-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fortieth target gene is a hsa-miR-128-1-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The forty-one target gene is an hsa-miR-6825-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The forty-two target gene is an hsa-miR-1260b gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The forty-third target gene is an hsa-miR-4433-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The forty-fourth target gene is an hsa-miR-4665-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The forty-fifth target gene is an hsa-miR-7845-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The forty-sixth target gene is an hsa-miR-1908-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The forty-seventh target gene is an hsa-miR-6840-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The forty-eighth target gene is a hsa-miR-6765-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The forty-ninth target gene is an hsa-miR-296-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fifty target gene is a hsa-miR-3675-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 51 st target gene is an hsa-miR-6781-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 52 target gene is an hsa-miR-423-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fifty-third target gene is an hsa-miR-3663-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fifty-fourth target gene is an hsa-miR-6784-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fifty-fifth target gene is a hsa-miR-6749-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The fifty-sixth target gene is a hsa-miR-1231 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 57th target gene is an hsa-miR-4746-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 58th target gene is a hsa-miR-6780b-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 59th target gene is a hsa-miR-4758-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 60th target gene is a hsa-miR-3679-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 61 st target gene is an hsa-miR-3184-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 62nd target gene is a hsa-miR-6125 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 63rd target gene is a hsa-miR-6721-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 64 th target gene is a hsa-miR-6791-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 65 th target gene is an hsa-miR-3185 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 66 th target gene is an hsa-miR-1260a gene, a homologue thereof, a transcript thereof, or a mutant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 67th target gene is a hsa-miR-3197 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 68th target gene is an hsa-miR-6845-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 69th target gene is a hsa-miR-6887-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 70th target gene is a hsa-miR-6738-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 71 st target gene is an hsa-miR-6872-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The seventy-second target gene is an hsa-miR-4497 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 73rd target gene is an hsa-miR-1229-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 74th target gene is a hsa-miR-6820-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The seventy-fifth target gene is an hsa-miR-6777-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 76th target gene is an hsa-miR-3917 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 77th target gene is an hsa-miR-5787 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 78th target gene is an hsa-miR-4286 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 79th target gene is an hsa-miR-6877-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The eighty target gene is an hsa-miR-1225-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of the 81st is a hsa-miR-6088 gene, a homologue thereof, a transcript thereof, or a mutant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 82 target gene is an hsa-miR-6800-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of the 83rd is a hsa-miR-1246 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 84 th target gene is a hsa-miR-4467 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The eighty-fifth target gene is a hsa-miR-4419b gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of the 86th is a hsa-miR-1914-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 87th target gene is an hsa-miR-4632-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 88th target gene is a hsa-miR-1915-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 89th target gene is a hsa-miR-3940-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of the ninety is hsa-miR-1185-2-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 91 st target gene is a hsa-miR-6746-5p gene, a homologue thereof, a transcript thereof, or a mutant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 92 th target gene is an hsa-miR-5001-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 93 th target gene is an hsa-miR-1228-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 94th target gene is a hsa-miR-5572 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The ninety-fifth target gene is a hsa-miR-4327 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 96th target gene is a hsa-miR-4638-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 97th target gene is a hsa-miR-6799-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The ninety-eighth target gene is a hsa-miR-6861-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 99th target gene is a hsa-miR-6727-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 100th target gene is a hsa-miR-4513 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 101 st target gene is a hsa-miR-6805-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 102 th target gene is a hsa-miR-6808-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 103 target gene is a hsa-miR-4449 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 104th target gene is an hsa-miR-1199-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 105th target gene is a hsa-miR-1275 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 106th target gene is an hsa-miR-4792 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 107th target gene is a hsa-miR-4443 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 108th target gene is a hsa-miR-6891-5p gene, a homolog thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 109th target gene is a hsa-miR-6826-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 110 th target gene is an hsa-miR-6807-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 111 target gene is a hsa-miR-7150 gene, a homologue thereof, a transcript thereof, or a mutant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of the 112 is a hsa-miR-4534 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 113 target gene is an hsa-miR-4476 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 114 th target gene is a hsa-miR-4649-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 115 target gene is a hsa-miR-4525 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 116th target gene is an hsa-miR-1915-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 117th target gene is a hsa-miR-4516 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 118th target gene is a hsa-miR-4417 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 119th target gene is a hsa-miR-642b-3p gene, a homolog thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 120 th target gene is an hsa-miR-3141 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 121st target gene is a hsa-miR-5100 gene, a homologue thereof, a transcript thereof, or a mutant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 122 target gene is an hsa-miR-6848-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 123 th target gene is a hsa-miR-4739 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 124 target gene is a hsa-miR-4459 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 125 th target gene is a hsa-miR-1237-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 126 th target gene is an hsa-miR-296-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 127 target gene is a hsa-miR-4665-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 128 th target gene is a hsa-miR-6786-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 129th target gene is a hsa-miR-4258 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 130 th target gene is an hsa-miR-6510-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 131 st target gene is an hsa-miR-1343-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 132 target gene is a hsa-miR-1247-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 133 target gene is a hsa-miR-6805-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 134 target gene is a hsa-miR-4492 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 135 th target gene is an hsa-miR-1469 gene, a homologue thereof, a transcript thereof, or a mutant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 136 th target gene is an hsa-miR-1268b gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 137 target gene is a hsa-miR-6858-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 138 target gene is an hsa-miR-3937 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 139th target gene is a hsa-miR-939-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 140th target gene is a hsa-miR-3656 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 141 target gene is an hsa-miR-744-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 142 target gene is a hsa-miR-4687-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of the 143rd is an hsa-miR-4763-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 144th target gene is a hsa-miR-3620-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 145 target gene is a hsa-miR-3195 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 146th target gene is a hsa-miR-6842-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 147th target gene is a hsa-miR-4707-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 148th target gene is a hsa-miR-642a-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 149th target gene is a hsa-miR-7113-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 150th target gene is a hsa-miR-4728-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 151st target gene is an hsa-miR-5195-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 152 target gene is an hsa-miR-1185-1-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 153 target gene is an hsa-miR-6774-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 154 target gene is a hsa-miR-8059 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 155th target gene is a hsa-miR-3131 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 156 target gene is a hsa-miR-7847-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 157 target gene is a hsa-miR-4463 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 158th target gene is a hsa-miR-128-2-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 159th target gene is an hsa-miR-4508 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 160th target gene is a hsa-miR-6806-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 161 target gene is an hsa-miR-7111-5p gene, a homologue thereof, a transcript thereof, or a mutant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of 162 is a hsa-miR-6782-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of 163 is a hsa-miR-4734 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of the 164 is a hsa-miR-3162-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 165 target gene is a hsa-miR-887-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 166th target gene is a hsa-miR-6752-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 167th target gene is a hsa-miR-6724-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of 168 is a hsa-miR-23b-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There are known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 2 and Patent Document 3).

The 169th target gene is a hsa-miR-23a-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 2).

The 170th target gene is an hsa-miR-625-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 4).

The 171 target gene is a hsa-miR-1228-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 172 target gene is a hsa-miR-614 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 2).

The 173 target gene is an hsa-miR-1913 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 4).

The 174th target gene is a hsa-miR-92a-2-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there are known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 1).

The 175th target gene is a hsa-miR-187-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 5).

The 176th target gene is an hsa-miR-16-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 4 and Patent Document 5).

The 177th target gene is an hsa-miR-92b-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there are known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 1).

The 178th target gene is an hsa-miR-150-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 2).

The 179th target gene is an hsa-miR-564 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 2).

The 180th target gene is an hsa-miR-125a-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there are known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 3).

The 181 target gene is an hsa-miR-92b-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there are known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 1).

The 182 target gene is a hsa-miR-92a-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 1, Patent Document 4, and Patent Document 5).

The target gene of 183 is a hsa-miR-663a gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 4).

The 184th target gene is a hsa-miR-4688 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 185th target gene is a hsa-miR-4648 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 186 target gene is a hsa-miR-6085 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 187th target gene is a hsa-miR-6126 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 188th target gene is an hsa-miR-6880-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 189th target gene is an hsa-miR-328-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of the 190 th is a hsa-miR-6768-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 191 target gene is a hsa-miR-3180 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 192 th target gene is an hsa-miR-6087 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 193 th target gene is a hsa-miR-1273g-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 194 target gene is a hsa-miR-1225-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 195th target gene is a hsa-miR-3196 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 196th target gene is a hsa-miR-4695-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 197th target gene is a hsa-miR-6732-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 198th target gene is a hsa-miR-638 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 199th target gene is an hsa-miR-6813-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 200 th target gene is an hsa-miR-665 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 201 target gene is an hsa-miR-486-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There are known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 2 and Patent Document 3).

The 202 target gene is a hsa-miR-4466 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 203 th target gene is an hsa-miR-30c-1-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 3 and Patent Document 5).

The 204 target gene is a hsa-miR-3621 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 205th target gene is a hsa-miR-6743-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 206th target gene is a hsa-miR-4298 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 207 target gene is a hsa-miR-4741 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of 208 is a hsa-miR-3619-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of 209 is a hsa-miR-6824-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 210th target gene is an hsa-miR-5698 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 211 th target gene is an hsa-miR-371a-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 212th target gene is an hsa-miR-4488 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of 213 is a hsa-miR-1233-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 214 target gene is a hsa-miR-4723-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 215 target gene is an hsa-miR-24-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 2).

The 216 th target gene is a hsa-miR-1238-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 217th target gene is a hsa-miR-4442 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 218 th target gene is a hsa-miR-3928-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 219th target gene is an hsa-miR-6716-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 220 target gene is a hsa-miR-6089 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 221 target gene is a hsa-miR-6124 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 222 target gene is a hsa-miR-6778-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The target gene of 223 is a hsa-miR-557 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. There have been known reports that a change in the expression of a native gene or its transcript can become a marker of liver cancer (Patent Document 2).

The target gene of 224 is a hsa-miR-6090 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. So far, there is no known report that a change in the expression of a native gene or its transcript can be a marker of liver cancer.

The 225 target gene is a hsa-miR-6757-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 226 target gene is a hsa-miR-4448 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 227th target gene is a hsa-miR-671-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 228th target gene is a hsa-miR-3178 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The target gene of 229 is a hsa-miR-4725-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 230 target gene is a hsa-miR-940 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 231 target gene is a hsa-miR-6789-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 232th target gene is an hsa-miR-4484 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 233 th target gene is an hsa-miR-4634 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 234 target gene is a hsa-miR-4745-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 235th target gene is a hsa-miR-4730 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 236 target gene is a hsa-miR-6803-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 237 target gene is a hsa-miR-6798-5p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 238th target gene is a hsa-miR-3648 gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of a gene or its transcript that can be a marker of liver cancer.

The 239 target gene is an hsa-miR-4783-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

The 240th target gene is an hsa-miR-6836-3p gene, a homologue thereof, a transcript thereof, or a variant or derivative thereof. Until now, there have been no reports of changes in the expression of genes or their transcripts that can be a marker of liver cancer.

2. Nucleic acid probe or primer for detection of liver cancer

In the present invention, the nucleic acid capable of specifically binding to the target nucleic acid as the liver cancer marker can be used as a nucleic acid for detecting or diagnosing liver cancer, for example, a nucleic acid probe or primer.

In the present invention, the nucleic acid probe or primer usable for detecting liver cancer or diagnosing liver cancer is a target nucleic acid as the liver cancer marker, for example, human-derived hsa-miR-1343-3p, hsa-miR-6726. -5p, hsa-miR-6515-3p, hsa-miR-4651, hsa-miR-4257, hsa-miR-3188, hsa-miR-6131, hsa-miR-6766-3p, hsa-miR-7641, hsa -miR-1249, hsa-miR-3679-3p, hsa-miR-6787-5p, hsa-miR-4454, hsa-miR-3135b, hsa-miR-6765-3p, hsa-miR-7975, hsa-miR -204-3p, hsa-miR-7977, hsa-miR-7110-5p, hsa-miR-6717-5p, hsa-miR-6870-5p, hsa-miR-663b, hsa-miR-6875-5p, hsa -miR-8072, hsa-miR-6816-5p, hsa-miR-4281, hsa-miR-6729-5p, hsa-miR-8069, hsa-miR-4706, hsa-miR-7108-5p, hsa-miR -4433b-3p, hsa-miR-6893-5p, hsa-miR-6857-5p, hsa-miR-1227-5p, hsa-miR-6741-5p, hsa-miR-451a, hsa-miR-8063, hsa -miR-3622a-5p, hsa-miR-615-5p, hsa-miR-128-1-5p, hsa-miR-6825-5p, hsa-miR-1260b, hsa-miR-4433-3p, hsa-miR -4665-5p, hsa-miR-7845-5p, hsa-miR-1908-5p, hsa-miR-6840-3p, hsa-miR-6765-5p, hsa-miR-296-5p, hsa-miR-3675 -3p, hsa-miR-6781-5p, hsa-miR-423-5p, hsa-miR-3663-3p, hsa-miR-6784-5p, hsa-miR-6749-5p, hsa-miR-1231, hsa -miR-47 46-3p, hsa-miR-6780b-5p, hsa-miR-4758-5p, hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-6125, hsa-miR-6721-5p, hsa-miR-6791-5p, hsa-miR-3185, hsa-miR-1260a, hsa-miR-3197, hsa-miR-6845-5p, hsa-miR-6887-5p, hsa-miR-6738-5p, hsa-miR-6872-3p, hsa-miR-4497, hsa-miR-1229-5p, hsa-miR-6820-5p, hsa-miR-6777-5p, hsa-miR-3917, hsa-miR-5787, hsa-miR-4286, hsa-miR-6877-5p, hsa-miR-1225-3p, hsa-miR-6088, hsa-miR-6800-5p, hsa-miR-1246, hsa-miR-4467, hsa- miR-4419b, hsa-miR-1914-3p, hsa-miR-4632-5p, hsa-miR-1915-5p, hsa-miR-3940-5p, hsa-miR-1185-2-3p, hsa-miR- 6746-5p, hsa-miR-5001-5p, hsa-miR-1228-5p, hsa-miR-5572, hsa-miR-4327, hsa-miR-4638-5p, hsa-miR-6799-5p, hsa- miR-6861-5p, hsa-miR-6727-5p, hsa-miR-4513, hsa-miR-6805-3p, hsa-miR-6808-5p, hsa-miR-4449, hsa-miR-1199-5p, hsa-miR-1275, hsa-miR-4792, hsa-miR-4443, hsa-miR-6891-5p, hsa-miR-6826-5p, hsa-miR-6807-5p, hsa-miR-7150, hsa- miR-4534, hsa-miR-4476, hsa-miR-4649-5p, hsa-miR-4525, hsa-miR-1915-3p, hsa-miR-4516, hsa-miR-4417, hsa-miR-642b- 3p, hsa-miR-3 141, hsa-miR-5100, hsa-miR-6848-5p, hsa-miR-4739, hsa-miR-4459, hsa-miR-1237-5p, hsa-miR-296-3p, hsa-miR-4665- 3p, hsa-miR-6786-5p, hsa-miR-4258, hsa-miR-6510-5p, hsa-miR-1343-5p, hsa-miR-1247-3p, hsa-miR-6805-5p, hsa- miR-4492, hsa-miR-1469, hsa-miR-1268b, hsa-miR-6858-5p, hsa-miR-3937, hsa-miR-939-5p, hsa-miR-3656, hsa-miR-744- 5p, hsa-miR-4687-3p, hsa-miR-4763-3p, hsa-miR-3620-5p, hsa-miR-3195, hsa-miR-6842-5p, hsa-miR-4707-5p, hsa- miR-642a-3p, hsa-miR-7113-3p, hsa-miR-4728-5p, hsa-miR-5195-3p, hsa-miR-1185-1-3p, hsa-miR-6774-5p, hsa- miR-8059, hsa-miR-3131, hsa-miR-7847-3p, hsa-miR-4463, hsa-miR-128-2-5p, hsa-miR-4508, hsa-miR-6806-5p, hsa- miR-7111-5p, hsa-miR-6782-5p, hsa-miR-4734, hsa-miR-3162-5p, hsa-miR-887-3p, hsa-miR-6752-5p, hsa-miR-6724- 5p, hsa-miR-6757-5p, hsa-miR-4448, hsa-miR-671-5p, hsa-miR-3178, hsa-miR-4725-3p, hsa-miR-940, hsa-miR-6789- 5p, hsa-miR-4484, hsa-miR-4634, hsa-miR-4745-5p, hsa-miR-4730, hsa-miR-6803-5p, hsa-miR-6798-5p, hsa-miR-3648, hsa-miR-4783-3p, or hsa-mi R-6836-3p, or combinations thereof, or homologues thereof, transcripts thereof, variants or derivatives thereof, and hsa-miR-23b-3p, hsa-miR- 23a-3p, hsa-miR-625-3p, hsa-miR-1228-3p, hsa-miR-614, hsa-miR-1913, hsa-miR-92a-2-5p, hsa-miR-187-5p, hsa-miR-16-5p, hsa-miR-92b-3p, hsa-miR-150-3p, hsa-miR-564, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR- 92a-3p, or hsa-miR-663a, or a combination thereof, or homologues thereof, transcripts thereof, variants or derivatives thereof, and hsa-miR-4688, hsa which may be optionally combined with them -miR-4648, hsa-miR-6085, hsa-miR-6126, hsa-miR-6880-5p, hsa-miR-328-5p, hsa-miR-6768-5p, hsa-miR-3180, hsa-miR -6087, hsa-miR-1273g-3p, hsa-miR-1225-5p, hsa-miR-3196, hsa-miR-4695-5p, hsa-miR-6732-5p, hsa-miR-638, hsa-miR -6813-5p, hsa-miR-665, hsa-miR-486-3p, hsa-miR-4466, hsa-miR-30c-1-3p, hsa-miR-3621, hsa-miR-6743-5p, hsa -miR-4298, hsa-miR-4741, hsa-miR-3619-3p, hsa-miR-6824-5p, hsa-miR-5698, hsa-miR-371a-5p, hsa-miR-4488, hsa-miR -1233-5p, hsa-miR-4723-5p, hsa-miR-24-3p, hsa-miR-1238-5p, hsa-miR-4442, hsa-miR-3928-3p, hsa-miR-6716-5p , hsa-miR-6089, hsa-miR -Presence, expression level of -6124, hsa-miR-6778-5p, hsa-miR-557, or hsa-miR-6090, or a combination thereof, or a homologue thereof, a transcript thereof, a variant or derivative thereof or to qualitatively and/or quantitatively determine the abundance.

The expression level of the target nucleic acids may increase or decrease depending on the type of the target nucleic acid in a subject suffering from liver cancer compared with a healthy body (hereinafter referred to as "increase/decrease"). ). Therefore, the nucleic acid of the present invention measures the expression level of the target nucleic acid in a body fluid derived from a subject (eg, human) suspected of having liver cancer and a body fluid derived from a healthy body, and compares them to detect liver cancer. can be used effectively for

A nucleic acid probe or primer usable in the present invention is a nucleic acid probe capable of specifically binding to a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs: 1 to 167 and 714 to 729, or SEQ ID NOs: 1 to 167 and 714 to 729 A primer for amplifying a polynucleotide comprising a nucleotide sequence represented by at least one of

The nucleic acid probe or primer usable in the present invention is also a nucleic acid probe capable of specifically binding to a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs: 168 to 183, or at least one of SEQ ID NOs: 168 to 183 A primer for amplifying a polynucleotide consisting of a nucleotide sequence may be included.

The nucleic acid probe or primer usable in the present invention is also a nucleic acid probe capable of specifically binding to a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs: 184 to 224, or at least one of SEQ ID NOs: 184 to 224 A primer for amplifying a polynucleotide consisting of a nucleotide sequence may be further included.

Specifically, the nucleic acid probe or primer is a polynucleotide group comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 765, or a nucleotide sequence in which u is t in the nucleotide sequence, and a polynucleotide group complementary thereto; A group of polynucleotides each hybridizing with DNA comprising a nucleotide sequence complementary to the nucleotide sequence (described later) under stringent conditions (described later), a polynucleotide group complementary thereto, and 15 or more in the nucleotide sequence of the polynucleotide group , preferably a combination of one or a plurality of polynucleotides selected from the group of polynucleotides containing 17 or more consecutive bases. These polynucleotides can be used as nucleic acid probes and primers for detecting the liver cancer marker, which is a target nucleic acid.

More specifically, examples of the nucleic acid probe or primer usable in the present invention are one or more polynucleotides selected from the group consisting of the following polynucleotides (a) to (e).

(a) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729, or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases; the fragment comprising;

(b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729;

(c) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 A fragment thereof comprising one or more consecutive bases;

(d) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729, or a nucleotide sequence in which u is t in the nucleotide sequence, and

(e) A polynucleotide that hybridizes with the polynucleotide of any one of (a) to (d) under stringent conditions.

The nucleic acid probe or primer that can be used in the present invention is, in addition to at least one or more polynucleotides selected from the group consisting of the polynucleotides (a) to (e), the polynucleotides shown in the following (f) to (j). It may include a polynucleotide selected from the group consisting of.

(f) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;

(g) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183;

(h) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183, or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising

(i) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183, or a nucleotide sequence in which u is t in the nucleotide sequence, and

(j) A polynucleotide that hybridizes with the polynucleotide of any one of (f) to (i) under stringent conditions.

The nucleic acid probe or primer that can be used in the present invention is, in addition to at least one or more polynucleotides selected from the group consisting of the polynucleotides (a) to (j), the polynucleotides shown in the following (k) to (o). It may include a polynucleotide selected from the group consisting of.

(k) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;

(l) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224;

(m) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224, or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising

(n) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224, or a nucleotide sequence in which u is t in the nucleotide sequence, and

(o) A polynucleotide that hybridizes with the polynucleotide of any one of (k) to (n) under stringent conditions.

In the polynucleotide, "the fragment comprising 15 or more consecutive bases" in the nucleotide sequence of each polynucleotide, for example, less than the total number of bases in the sequence from 15 consecutive, less than the total number of bases in the sequence from 17, 19 Although it can include the number of bases in a range, such as less than the total number of bases of a sequence, it shall not be limited to these.

The polynucleotides or fragments thereof used in the present invention may be either DNA or RNA.

The above polynucleotides usable in the present invention can be produced using general techniques such as DNA recombination technology, PCR method, and a method by an automatic DNA/RNA synthesizer.

DNA recombination techniques and PCR methods are, for example, Ausubel et al., Current Protocols in Molecular Biology, John Willey & Sons, US (1993); The technique described in Sambrook et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory Press, US (1989), etc. can be used.

hsa-miR-1343-3p, hsa-miR-6726-5p, hsa-miR-6515-3p, hsa-miR-4651, hsa-miR-4257 derived from human represented by SEQ ID NOs: 1-224 and 714-729 , hsa-miR-3188, hsa-miR-6131, hsa-miR-6766-3p, hsa-miR-7641, hsa-miR-1249, hsa-miR-3679-3p, hsa-miR-6787-5p, hsa -miR-4454, hsa-miR-3135b, hsa-miR-6765-3p, hsa-miR-7975, hsa-miR-204-3p, hsa-miR-7977, hsa-miR-7110-5p, hsa-miR -6717-5p, hsa-miR-6870-5p, hsa-miR-663b, hsa-miR-6875-5p, hsa-miR-8072, hsa-miR-6816-5p, hsa-miR-4281, hsa-miR -6729-5p, hsa-miR-8069, hsa-miR-4706, hsa-miR-7108-5p, hsa-miR-4433b-3p, hsa-miR-6893-5p, hsa-miR-6857-5p, hsa -miR-1227-5p, hsa-miR-6741-5p, hsa-miR-451a, hsa-miR-8063, hsa-miR-3622a-5p, hsa-miR-615-5p, hsa-miR-128-1 -5p, hsa-miR-6825-5p, hsa-miR-1260b, hsa-miR-4433-3p, hsa-miR-4665-5p, hsa-miR-7845-5p, hsa-miR-1908-5p, hsa -miR-6840-3p, hsa-miR-6765-5p, hsa-miR-296-5p, hsa-miR-3675-3p, hsa-miR-6781-5p, hsa-miR-423-5p, hsa-miR -3663-3p, hsa-miR-6784-5p, hsa-miR-6749-5p, hsa-miR-1231, hsa-miR-4746-3p, hsa-miR-6780b-5p, hsa-miR-4758-5p , hsa-miR-3679-5p, hsa-miR-3184-5p, hsa-miR-6125, hsa-miR-6721-5p, hsa-miR-6791-5p, hsa-miR-3185, hsa-miR-1260a, hsa-miR-3197, hsa- miR-6845-5p, hsa-miR-6887-5p, hsa-miR-6738-5p, hsa-miR-6872-3p, hsa-miR-4497, hsa-miR-1229-5p, hsa-miR-6820- 5p, hsa-miR-6777-5p, hsa-miR-3917, hsa-miR-5787, hsa-miR-4286, hsa-miR-6877-5p, hsa-miR-1225-3p, hsa-miR-6088, hsa-miR-6800-5p, hsa-miR-1246, hsa-miR-4467, hsa-miR-4419b, hsa-miR-1914-3p, hsa-miR-4632-5p, hsa-miR-1915-5p, hsa-miR-3940-5p, hsa-miR-1185-2-3p, hsa-miR-6746-5p, hsa-miR-5001-5p, hsa-miR-1228-5p, hsa-miR-5572, hsa- miR-4327, hsa-miR-4638-5p, hsa-miR-6799-5p, hsa-miR-6861-5p, hsa-miR-6727-5p, hsa-miR-4513, hsa-miR-6805-3p, hsa-miR-6808-5p, hsa-miR-4449, hsa-miR-1199-5p, hsa-miR-1275, hsa-miR-4792, hsa-miR-4443, hsa-miR-6891-5p, hsa- miR-6826-5p, hsa-miR-6807-5p, hsa-miR-7150, hsa-miR-4534, hsa-miR-4476, hsa-miR-4649-5p, hsa-miR-4525, hsa-miR- 1915-3p, hsa-miR-4516, hsa-miR-4417, hsa-miR-642b-3p, hsa-miR-3141, hsa-miR-5100, hsa-miR-6848-5p, hsa-miR-4739, hsa-miR- 4459, hsa-miR-1237-5p, hsa-miR-296-3p, hsa-miR-4665-3p, hsa-miR-6786-5p, hsa-miR-4258, hsa-miR-6510-5p, hsa- miR-1343-5p, hsa-miR-1247-3p, hsa-miR-6805-5p, hsa-miR-4492, hsa-miR-1469, hsa-miR-1268b, hsa-miR-6858-5p, hsa- miR-3937, hsa-miR-939-5p, hsa-miR-3656, hsa-miR-744-5p, hsa-miR-4687-3p, hsa-miR-4763-3p, hsa-miR-3620-5p, hsa-miR-3195, hsa-miR-6842-5p, hsa-miR-4707-5p, hsa-miR-642a-3p, hsa-miR-7113-3p, hsa-miR-4728-5p, hsa-miR- 5195-3p, hsa-miR-1185-1-3p, hsa-miR-6774-5p, hsa-miR-8059, hsa-miR-3131, hsa-miR-7847-3p, hsa-miR-4463, hsa- miR-128-2-5p, hsa-miR-4508, hsa-miR-6806-5p, hsa-miR-7111-5p, hsa-miR-6782-5p, hsa-miR-4734, hsa-miR-3162- 5p, hsa-miR-887-3p, hsa-miR-6752-5p, hsa-miR-6724-5p, hsa-miR-6757-5p, hsa-miR-4448, hsa-miR-671-5p, hsa- miR-3178, hsa-miR-4725-3p, hsa-miR-940, hsa-miR-6789-5p, hsa-miR-4484, hsa-miR-4634, hsa-miR-4745-5p, hsa-miR- 4730, hsa-miR-6803-5p, hsa-miR-6798-5p, hsa-miR-3648, hsa-miR-4783-3p, hsa-miR-6836-3p, hsa-miR-23b-3p, hsa- miR-23a-3p, hsa-miR-625-3p, hs a-miR-1228-3p, hsa-miR-614, hsa-miR-1913, hsa-miR-92a-2-5p, hsa-miR-187-5p, hsa-miR-16-5p, hsa-miR- 92b-3p, hsa-miR-150-3p, hsa-miR-564, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR-92a-3p, hsa-miR-663a, hsa- miR-4688, hsa-miR-4648, hsa-miR-6085, hsa-miR-6126, hsa-miR-6880-5p, hsa-miR-328-5p, hsa-miR-6768-5p, hsa-miR- 3180, hsa-miR-6087, hsa-miR-1273g-3p, hsa-miR-1225-5p, hsa-miR-3196, hsa-miR-4695-5p, hsa-miR-6732-5p, hsa-miR- 638, hsa-miR-6813-5p, hsa-miR-665, hsa-miR-486-3p, hsa-miR-4466, hsa-miR-30c-1-3p, hsa-miR-3621, hsa-miR- 6743-5p, hsa-miR-4298, hsa-miR-4741, hsa-miR-3619-3p, hsa-miR-6824-5p, hsa-miR-5698, hsa-miR-371a-5p, hsa-miR- 4488, hsa-miR-1233-5p, hsa-miR-4723-5p, hsa-miR-24-3p, hsa-miR-1238-5p, hsa-miR-4442, hsa-miR-3928-3p, hsa- miR-6716-5p, hsa-miR-6089, hsa-miR-6124, hsa-miR-6778-5p, hsa-miR-557 and hsa-miR-6090 are known, and as described above, their acquisition methods are also known. have. For this reason, by cloning this gene, a polynucleotide as a nucleic acid probe or primer usable in the present invention can be prepared.

Such a nucleic acid probe or primer can be chemically synthesized using an automatic DNA synthesizer. The phosphoramidite method is generally used for this synthesis, and single-stranded DNA of up to about 100 bases can be automatically synthesized by this method. Automated DNA synthesizers are commercially available from Polygen, ABI, Applied BioSystems, and the like, for example.

Alternatively, the polynucleotide of the present invention can also be prepared by cDNA cloning. As the cDNA cloning technique, for example, microRNA Cloning Kit Wako or the like can be used.

Here, the sequence of the nucleic acid probe and primer for detecting the polynucleotide comprising the nucleotide sequence shown in any one of SEQ ID NOs: 1-224 and 714-729 does not exist in vivo as miRNA or its precursor. For example, the nucleotide sequences represented by SEQ ID NO: 1 and SEQ ID NO: 131 are generated from the precursor represented by SEQ ID NO: 225, but this precursor has a hairpin-like structure as shown in FIG. 1, and SEQ ID NO: 1 And the nucleotide sequence represented by SEQ ID NO: 131 has a mismatch sequence with each other. For this reason, there is no case in which a nucleotide sequence completely complementary to the nucleotide sequence represented by SEQ ID NO: 1 or SEQ ID NO: 131 is naturally generated in vivo. Similarly, nucleic acid probes and primers for detecting the nucleotide sequence represented by any one of SEQ ID NOs: 1-224 and 714-729 have an artificial nucleotide sequence that does not exist in a living body.

3. Kit or device for liver cancer detection

The present invention also provides a polynucleotide that can be used as a nucleic acid probe or primer in the present invention for measuring a target nucleic acid as a liver cancer marker (this may include a mutant, fragment, or derivative; hereinafter referred to as a polynucleotide for detection) Provided is a kit or device for detecting liver cancer comprising one or a plurality of).

The target nucleic acid, which is a liver cancer marker in the present invention, is preferably selected from the following group 1:

miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249, miR- 3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717-5p, miR-6870-5p, miR-663b, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR-6840-3p, miR- 6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6784-5p, miR-6749-5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR- 6777-5p, miR-3917, miR-5787, miR-4286, miR-6877-5p, miR-1225-3p, miR-6088, miR-6800-5p, miR-1246, miR-4 467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR-1228-5p, miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR- 6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR- 4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR- 1247-3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR- 4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6724-5p, miR -6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR -4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p and miR-6836-3p.

Optionally, additional target nucleic acids that can be used for measurement are preferably selected from the following group 2: miR-23b-3p, miR-23a-3p, miR-625-3p, miR-1228-3p, miR -614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR -92b-5p, miR-92a-3p and miR-663a.

Optionally, additional target nucleic acids that can be used for further measurement are preferably selected from the following group 3: miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR- 328-5p, miR-6768-5p, miR-3180, miR-6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619- 3p, miR-6824-5p, miR-5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, miR-6124, miR-6778-5p, miR-557 and miR-6090.

The kit or device of the present invention is a nucleic acid capable of specifically binding to the target nucleic acid as the liver cancer marker, preferably the nucleic acid probe or primer described in 2 above, specifically 1 selected from the polynucleotides described in 2 above or and a plurality of polynucleotides or variants thereof.

Specifically, the kit or device of the present invention contains (or consists of) a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729, or a nucleotide sequence in which u is t in the nucleotide sequence. Nucleotides, polynucleotides containing (or consisting of) its complementary sequence, polynucleotides that hybridize under stringent conditions with those polynucleotides, or 15 or more consecutive bases of their polynucleotide sequence It may include at least one or more variants or fragments.

The kit or device of the present invention also comprises (or consists of) a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183, or a nucleotide sequence in which u is t in the nucleotide sequence, a complementary sequence thereof A polynucleotide comprising (or consisting of), a polynucleotide that hybridizes with its polynucleotide under stringent conditions, or a variant or fragment comprising 15 or more consecutive bases of their polynucleotide sequence 1 It may contain more than one.

The kit or device of the present invention is also a polynucleotide comprising (or consisting of) a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224, or a nucleotide sequence in which u is t in the nucleotide sequence, and its complementary A polynucleotide comprising (or consisting of) a sequence, a polynucleotide that hybridizes with the polynucleotide under stringent conditions, or a variant or fragment comprising 15 or more consecutive bases of the polynucleotide sequence It may contain more than one.

The fragment that can be included in the kit or device of the present invention is, for example, one or more, preferably two or more polynucleotides selected from the group consisting of the following (1) to (3).

(1) A polynucleotide comprising 15 or more consecutive bases in a nucleotide sequence in which u is t in the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729, or a complementary sequence thereof.

(2) A polynucleotide comprising 15 or more consecutive bases in a nucleotide sequence in which u is t in the nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183, or a complementary sequence thereof.

(3) A polynucleotide comprising 15 or more consecutive bases in the nucleotide sequence in which u is t in the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224, or a complementary sequence thereof.

In a preferred embodiment, the polynucleotide consists of a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729, or a nucleotide sequence in which u is t in the nucleotide sequence, and a polynucleotide consisting of a complementary sequence thereof Nucleotides, polynucleotides that hybridize under stringent conditions with polynucleotides thereof, or variants containing 15 or more, preferably 17 or more, more preferably 19 or more consecutive bases thereof.

In a preferred embodiment, the polynucleotide comprises a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183, or a nucleotide sequence in which u is t in the nucleotide sequence, a polynucleotide comprising a complementary sequence thereof, A polynucleotide that hybridizes under stringent conditions with a polynucleotide of

In a preferred embodiment, the polynucleotide comprises a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224, or a nucleotide sequence in which u is t in the nucleotide sequence, a polynucleotide comprising a complementary sequence thereof, A polynucleotide that hybridizes under stringent conditions with a polynucleotide of

In a preferred embodiment, the fragment may be a polynucleotide comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive bases.

In the present invention, the size of the fragment of the polynucleotide in the nucleotide sequence of each polynucleotide, for example, less than the total number of bases in the sequence from 15 consecutive, less than the total number of bases in the sequence from 17, less than the total number of bases in the sequence from 19, etc. is the number of bases in the range of

As a combination of the polynucleotides constituting the kit or device of the present invention, specifically, SEQ ID NOs shown in Table 1 (corresponding to miRNA markers in Table 1, SEQ ID NOs: 1-224 and 714-729) Any combination of the above polynucleotides comprising a nucleotide sequence or its complementary sequence is mentioned, but these are merely examples, and all other possible combinations are included in the present invention.

For example, as the combination constituting a kit or device for discriminating liver cancer and a healthy body in the present invention, it is preferable to combine two or more polynucleotides comprising the nucleotide sequence represented by the SEQ ID NO shown in Table 1 In general, sufficient performance can be obtained by a combination of the two.

Specifically, two combinations of polynucleotides consisting of a nucleotide sequence or a complementary sequence thereof for discriminating liver cancer and a healthy body, two selected from the polynucleotides consisting of the nucleotide sequences shown in SEQ ID NOs: 1-224 and 714-729 Among the combinations, a combination comprising at least one or more polynucleotides comprising the nucleotide sequences shown in the newly discovered SEQ ID NOs: 1 to 167 and 714 to 729 is preferable.

In addition, as a combination of polynucleotides having carcinoma specificity that can discriminate liver cancer from not only healthy individuals but also other cancers, for example, SEQ ID NOs: 1, 2, 3, 5, 7, 9, 12, 17, 20, 22, 27, 28, 29, 38, 39, 44, 46, 48, 51, 54, 61, 76, 89, 93, 101, 109, 116, 123, 132, 134, 136, 148, 150, 151, 155, 157, 164, 166, 167, 172, 180, 186, 188, 189, 197, 198, 214, 216, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, At least one polynucleotide selected from the group consisting of a polynucleotide consisting of the nucleotide sequence represented by 726, 727, 728 and 729 or its complementary sequence (hereinafter, this group is referred to as "carcinoma-specific polynucleotide group 1"); , and a plurality of combinations of polynucleotides of other SEQ ID NOs are preferred.

In addition, as a combination of polynucleotides having carcinoma specificity that can discriminate liver cancer from not only healthy individuals but also other cancers, a combination of a plurality of polynucleotides selected from carcinoma specific polynucleotide group 1 is more preferable.

In addition, it is a combination of polynucleotides having carcinoma specificity that can discriminate liver cancer from not only healthy individuals but also other cancers. Among the combinations of a plurality of polynucleotides selected from carcinoma specific polynucleotide group 1, it is included in carcinoma specific polynucleotide group 1. SEQ ID NOs: 1, 3, 7, 9, 22, 38, 44, 134, 148, 155, 157, 164, 167, 172, 214, 714, 715, 716 and 717, or a complementary sequence thereof A combination comprising at least one polynucleotide selected from the group consisting of polynucleotides (hereinafter, this group is referred to as "carcinoma-specific polynucleotide group 2") is more preferable.

As the number of combinations of the polynucleotides having the carcinoma specificity, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more combinations are possible. However, more preferably, it is a combination of four or more, and in general, sufficient performance can be acquired by four combinations.

Hereinafter, without limitation, the nucleotide sequence represented by SEQ ID NO: 1 represented by SEQ ID NO: 3 polynucleotides selected from the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 or its complementary sequence, and carcinoma-specific polynucleotide group 1 Or a combination of polynucleotides comprising a complementary sequence thereof is exemplified below.

(1) Combination of SEQ ID NOs: 1, 7, 9, 148 (markers: hsa-miR-1343-3p, hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p)

(2) Combination of SEQ ID NOs: 1, 9, 155, 172 (markers: hsa-miR-1343-3p, hsa-miR-7641, hsa-miR-3131, hsa-miR-614)

(3) Combination of SEQ ID NOs: 1, 9, 148, 155 (markers: hsa-miR-1343-3p, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-3131)

(4) Combination of SEQ ID NOs: 1, 155, 172, 715 (markers: hsa-miR-1343-3p, hsa-miR-3131, hsa-miR-614, hsa-miR-4448)

(5) Combination of SEQ ID NOs: 1, 155, 164, 715 (markers: hsa-miR-1343-3p, hsa-miR-3131, hsa-miR-3162-5p, hsa-miR-4448)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 3 or three polynucleotides selected from carcinoma-specific polynucleotide group 1 consisting of a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 3 or its complementary sequence, or a nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 3, 7, 9, 148 (markers: hsa-miR-6515-3p, hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p)

(2) Combination of SEQ ID NOs: 3, 22, 27, 46 (markers: hsa-miR-6515-3p, hsa-miR-663b, hsa-miR-6729-5p, hsa-miR-1908-5p)

(3) Combination of SEQ ID NOs: 1, 3, 29, 155 (markers: hsa-miR-1343-3p, hsa-miR-6515-3p, hsa-miR-4706, hsa-miR-3131)

(4) Combination of SEQ ID NOs: 1, 3, 151, 155 (markers: hsa-miR-1343-3p, hsa-miR-6515-3p, hsa-miR-5195-3p, hsa-miR-3131)

(5) Combination of SEQ ID NOs: 3, 7, 148, 715 (markers: hsa-miR-6515-3p, hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-4448)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 7 or a nucleotide sequence represented by SEQ ID NO: 3 polynucleotides selected from carcinoma-specific polynucleotide group 1 and a polynucleotide consisting of a complementary sequence thereof Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 28, 148, 717 (markers: hsa-miR-6131, hsa-miR-8069, hsa-miR-642a-3p, hsa-miR-3178)

(2) Combination of SEQ ID NOs: 7, 9, 148, 186 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-6085)

(3) Combination of SEQ ID NOs: 7, 148, 172, 715 (markers: hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-614, hsa-miR-4448)

(4) Combination of SEQ ID NOs: 7, 9, 148, 723 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-4745-5p)

(5) Combination of SEQ ID NOs: 7, 9, 28, 148 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-8069, hsa-miR-642a-3p)

In addition, the nucleotide sequence represented by SEQ ID NO: represented by SEQ ID NO: of three polynucleotides selected from the polynucleotide and carcinoma-specific polynucleotide group 1 comprising, but not limited to, the nucleotide sequence represented by SEQ ID NO: 9 or a complementary sequence thereof, or Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 157 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-4463)

(2) Combination of SEQ ID NOs: 7, 9, 148, 722 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-4634)

(3) Combination of SEQ ID NOs: 7, 9, 27, 148 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-6729-5p, hsa-miR-642a-3p)

(4) Combination of SEQ ID NOs: 7, 9, 148, 725 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-6803-5p)

(5) Combination of SEQ ID NOs: 7, 9, 148, 729 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-6836-3p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 22 or the nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 22, 148 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-663b, hsa-miR-642a-3p)

(2) Combination of SEQ ID NOs: 7, 22, 28, 148 (markers: hsa-miR-6131, hsa-miR-663b, hsa-miR-8069, hsa-miR-642a-3p)

(3) Combination of SEQ ID NOs: 7, 22, 148, 189 (markers: hsa-miR-6131, hsa-miR-663b, hsa-miR-642a-3p, hsa-miR-328-5p)

(4) Combination of SEQ ID NOs: 2, 7, 22, 148 (markers: hsa-miR-6726-5p, hsa-miR-6131, hsa-miR-663b, hsa-miR-642a-3p)

(5) Combination of SEQ ID NOs: 7, 22, 148, 720 (markers: hsa-miR-6131, hsa-miR-663b, hsa-miR-642a-3p, hsa-miR-6789-5p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 38 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma specific polynucleotide group 1 represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 38, 148 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-3622a-5p, hsa-miR-642a-3p)

(2) Combination of SEQ ID NOs: 7, 38, 51, 148 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-6781-5p, hsa-miR-642a-3p)

(3) Combination of SEQ ID NOs: 7, 38, 148, 718 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-4725-3p)

(4) Combination of SEQ ID NOs: 7, 38, 148, 216 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-1238-5p)

(5) Combination of SEQ ID NOs: 7, 38, 148, 728 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-4783-3p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 44 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1, the nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 44, 148 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-4665-5p, hsa-miR-642a-3p)

(2) Combination of SEQ ID NOs: 7, 44, 123, 148 (markers: hsa-miR-6131, hsa-miR-4665-5p, hsa-miR-4739, hsa-miR-642a-3p)

(3) Combination of SEQ ID NOs: 7, 38, 44, 148 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-4665-5p, hsa-miR-642a-3p)

(4) Combination of SEQ ID NOs: 7, 44, 148, 723 (markers: hsa-miR-6131, hsa-miR-4665-5p, hsa-miR-642a-3p, hsa-miR-4745-5p)

(5) Combination of SEQ ID NOs: 7, 44, 48, 148 (markers: hsa-miR-6131, hsa-miR-4665-5p, hsa-miR-6765-5p, hsa-miR-642a-3p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 134 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1, the nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 134, 148 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-4492, hsa-miR-642a-3p)

(2) Combination of SEQ ID NOs: 7, 134, 148, 724 (markers: hsa-miR-6131, hsa-miR-4492, hsa-miR-642a-3p, hsa-miR-4730)

(3) Combination of SEQ ID NOs: 7, 22, 134, 148 (markers: hsa-miR-6131, hsa-miR-663b, hsa-miR-4492, hsa-miR-642a-3p)

(4) Combination of SEQ ID NOs: 7, 134, 148, 189 (markers: hsa-miR-6131, hsa-miR-4492, hsa-miR-642a-3p, hsa-miR-328-5p)

(5) Combination of SEQ ID NOs: 7, 134, 148, 714 (markers: hsa-miR-6131, hsa-miR-4492, hsa-miR-642a-3p, hsa-miR-6757-5p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 148 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1 The nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 726 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-6798-5p)

(2) Combination of SEQ ID NOs: 7, 9, 148, 151 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-5195-3p)

(3) Combination of SEQ ID NOs: 7, 9, 109, 148 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-6826-5p, hsa-miR-642a-3p)

(4) Combination of SEQ ID NOs: 5, 7, 9, 148 (markers: hsa-miR-4257, hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p)

(5) Combination of SEQ ID NOs: 7, 9, 76, 148 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-3917, hsa-miR-642a-3p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 155 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1 The nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 155 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-3131)

(2) Combination of SEQ ID NOs: 7, 38, 148, 155 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-3131)

(3) Combination of SEQ ID NOs: 1, 9, 155, 167 (markers: hsa-miR-1343-3p, hsa-miR-7641, hsa-miR-3131, hsa-miR-6724-5p)

(4) Combination of SEQ ID NOs: 1, 3, 155, 715 (markers: hsa-miR-1343-3p, hsa-miR-6515-3p, hsa-miR-3131, hsa-miR-4448)

(5) Combination of SEQ ID NOs: 1, 3, 38, 155 (markers: hsa-miR-1343-3p, hsa-miR-6515-3p, hsa-miR-3622a-5p, hsa-miR-3131)

In addition, the nucleotide sequence represented by SEQ ID NO: represented by SEQ ID NO: of three polynucleotides selected from a polynucleotide consisting of a nucleotide sequence represented by SEQ ID NO: 157 or a complementary sequence thereof and a carcinoma-specific polynucleotide group 1 without limitation, or Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 48, 157, 714 (markers: hsa-miR-6131, hsa-miR-6765-5p, hsa-miR-4463, hsa-miR-6757-5p)

(2) Combination of SEQ ID NOs: 7, 38, 148, 157 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-4463)

(3) Combination of SEQ ID NOs: 1, 44, 155, 157 (markers: hsa-miR-1343-3p, hsa-miR-4665-5p, hsa-miR-3131, hsa-miR-4463)

(4) Combination of SEQ ID NOs: 7, 76, 157, 714 (markers: hsa-miR-6131, hsa-miR-3917, hsa-miR-4463, hsa-miR-6757-5p)

(5) Combination of SEQ ID NOs: 7, 148, 157, 189 (markers: hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-4463, hsa-miR-328-5p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 164 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1 The nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 164 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-3162-5p)

(2) Combination of SEQ ID NOs: 7, 76, 164, 714 (markers: hsa-miR-6131, hsa-miR-3917, hsa-miR-3162-5p, hsa-miR-6757-5p)

(3) Combination of SEQ ID NOs: 7, 38, 164, 714 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-3162-5p, hsa-miR-6757-5p)

(4) Combination of SEQ ID NOs: 7, 38, 148, 164 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-3162-5p)

(5) Combination of SEQ ID NOs: 1, 7, 164, 714 (markers: hsa-miR-1343-3p, hsa-miR-6131, hsa-miR-3162-5p, hsa-miR-6757-5p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 167 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1 The nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 167 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-6724-5p)

(2) Combination of SEQ ID NOs: 1, 7, 167, 714 (markers: hsa-miR-1343-3p, hsa-miR-6131, hsa-miR-6724-5p, hsa-miR-6757-5p)

(3) Combination of SEQ ID NOs: 7, 151, 167, 714 (markers: hsa-miR-6131, hsa-miR-5195-3p, hsa-miR-6724-5p, hsa-miR-6757-5p)

(4) Combination of SEQ ID NOs: 7, 148, 167, 189 (markers: hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-6724-5p, hsa-miR-328-5p)

(5) Combination of SEQ ID NOs: 7, 28, 167, 714 (markers: hsa-miR-6131, hsa-miR-8069, hsa-miR-6724-5p, hsa-miR-6757-5p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 172 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1, the nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 172 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-614)

(2) Combination of SEQ ID NOs: 7, 150, 172, 714 (markers: hsa-miR-6131, hsa-miR-4728-5p, hsa-miR-614, hsa-miR-6757-5p)

(3) Combination of SEQ ID NOs: 7, 172, 714, 715 (markers: hsa-miR-6131, hsa-miR-614, hsa-miR-6757-5p, hsa-miR-4448)

(4) Combination of SEQ ID NOs: 7, 38, 155, 172 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-3131, hsa-miR-614)

(5) Combination of SEQ ID NOs: 1, 2, 155, 172 (markers: hsa-miR-1343-3p, hsa-miR-6726-5p, hsa-miR-3131, hsa-miR-614)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 214 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1, the nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 214 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-4723-5p)

(2) Combination of SEQ ID NOs: 7, 148, 189, 214 (markers: hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-328-5p, hsa-miR-4723-5p)

(3) Combination of SEQ ID NOs: 2, 7, 148, 214 (markers: hsa-miR-6726-5p, hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-4723-5p)

(4) Combination of SEQ ID NOs: 1, 7, 214, 714 (markers: hsa-miR-1343-3p, hsa-miR-6131, hsa-miR-4723-5p, hsa-miR-6757-5p)

(5) Combination of SEQ ID NOs: 7, 39, 148, 214 (markers: hsa-miR-6131, hsa-miR-615-5p, hsa-miR-642a-3p, hsa-miR-4723-5p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 714 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1, the nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 714 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-6757-5p)

(2) Combination of SEQ ID NOs: 7, 54, 148, 714 (markers: hsa-miR-6131, hsa-miR-6784-5p, hsa-miR-642a-3p, hsa-miR-6757-5p)

(3) Combination of SEQ ID NOs: 7, 148, 151, 714 (markers: hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-5195-3p, hsa-miR-6757-5p)

(4) Combination of SEQ ID NOs: 7, 38, 148, 714 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-6757-5p)

(5) Combination of SEQ ID NOs: 7, 28, 148, 714 (markers: hsa-miR-6131, hsa-miR-8069, hsa-miR-642a-3p, hsa-miR-6757-5p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 715 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1, a nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 2, 7, 148, 715 (markers: hsa-miR-6726-5p, hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-4448)

(2) Combination of SEQ ID NOs: 7, 9, 148, 715 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-4448)

(3) Combination of SEQ ID NOs: 7, 17, 148, 715 (markers: hsa-miR-6131, hsa-miR-204-3p, hsa-miR-642a-3p, hsa-miR-4448)

(4) Combination of SEQ ID NOs: 7, 38, 148, 715 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-4448)

(5) Combination of SEQ ID NOs: 7, 148, 715, 725 (markers: hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-6803-5p, hsa-miR-4448)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 716 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1, the nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 716 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-671-5p)

(2) Combination of SEQ ID NOs: 7, 148, 714, 716 (markers: hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-6757-5p, hsa-miR-671-5p)

(3) Combination of SEQ ID NOs: 2, 7, 148, 716 (markers: hsa-miR-6726-5p, hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-671-5p)

(4) Combination of SEQ ID NOs: 7, 38, 148, 716 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-671-5p)

(5) Combination of SEQ ID NOs: 7, 148, 715, 716 (markers: hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-4448, hsa-miR-671-5p)

In addition, without limitation, the nucleotide sequence represented by SEQ ID NO: 717 or a polynucleotide consisting of a complementary sequence thereof and three polynucleotides selected from carcinoma-specific polynucleotide group 1, the nucleotide sequence represented by SEQ ID NO: Combinations of polynucleotides comprising their complementary sequences are exemplified below.

(1) Combination of SEQ ID NOs: 7, 9, 148, 717 (markers: hsa-miR-6131, hsa-miR-7641, hsa-miR-642a-3p, hsa-miR-3178)

(2) Combination of SEQ ID NOs: 7, 38, 148, 717 (markers: hsa-miR-6131, hsa-miR-3622a-5p, hsa-miR-642a-3p, hsa-miR-3178)

(3) Combination of SEQ ID NOs: 7, 27, 148, 717 (markers: hsa-miR-6131, hsa-miR-6729-5p, hsa-miR-642a-3p, hsa-miR-3178)

(4) Combination of SEQ ID NOs: 7, 44, 148, 717 (markers: hsa-miR-6131, hsa-miR-4665-5p, hsa-miR-642a-3p, hsa-miR-3178)

(5) Combination of SEQ ID NOs: 7, 148, 715, 717 (markers: hsa-miR-6131, hsa-miR-642a-3p, hsa-miR-4448, hsa-miR-3178)

In the kit or device of the present invention, in addition to the polynucleotide of the present invention described above (this may include a mutant, fragment or derivative), a known polynucleotide capable of detecting liver cancer or Polynucleotides that will be modified may also be included.

In addition to the polynucleotides of the present invention described above, the kit of the present invention can also contain antibodies for measuring known liver cancer test markers such as AFP, CEA, CA19-9 and PIVKA-II.

The polynucleotides included in the kit of the present invention may be packaged in different containers individually or in any combination.

The kit of the present invention may include a kit for extracting nucleic acid (eg, total RNA) from a body fluid, cell or tissue, a fluorescent substance for labeling, an enzyme and medium for nucleic acid amplification, instructions for use, and the like.

The device of the present invention is a device for measuring cancer markers to which, for example, a nucleic acid such as a polynucleotide according to the present invention described above is bound or adhered in a solid phase. Examples of the solid material are plastic, paper, glass, silicone, and the like, and from the viewpoint of easiness in processing, a preferable solid material is plastic. The shape of the solid phase is arbitrary, for example, a square, annular, a narrow rectangle, a film shape, and the like. The device of the present invention includes, for example, a device for measurement by a hybridization technique, and specifically, a blotting device, a nucleic acid array (eg, a microarray, a DNA chip, an RNA chip, etc.), etc. are exemplified do.

Nucleic acid array technology is a method of spotting nucleic acids using a high-density dispenser called a spotter or arrayer on the surface of a solid phase subjected to surface treatment such as introduction of L-lysine coat or functional groups such as amino and carboxyl groups as needed, nozzle Using a method such as a method of injecting nucleic acids into a solid phase using an inkjet in which minute droplets are ejected by a piezoelectric element or the like, or a method of sequentially synthesizing nucleotides on a solid phase, the nucleic acids are bound or attached one by one to a chip, etc. It is a technology for manufacturing an array of , and measuring the target nucleic acid by hybridization using the array.

The kit or device of the present invention comprises at least one or more, preferably at least two or more, more preferably at least 3 or more, most preferably at least 5 or more of all of the miRNAs that are liver cancer markers of Group 1. and a nucleic acid capable of specifically binding to each of the nucleotides. The kit or device of the present invention may also optionally contain at least one or more, preferably at least 2 or more, more preferably at least 3 or more, most preferably at least 5 of the miRNAs that are liver cancer markers of Group 2 above. From the above, it may include a nucleic acid capable of specifically binding to each of all polynucleotides. The kit or device of the present invention may also optionally contain at least one or more, preferably at least 2 or more, more preferably at least 3 or more, most preferably at least 5 miRNAs of the group 3 liver cancer marker. From the above, it may include a nucleic acid capable of specifically binding to each of all polynucleotides.

The kit or device of the present invention can be used for the detection of liver cancer described below.

4. How to detect liver cancer

The present invention also provides the following groups in the sample: miR-1343-3p, miR-6726-5p by using the kit or device of the present invention (including the nucleic acid usable in the present invention) described in 3 above. , miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249, miR-3679-3p, miR-6787-5p, miR -4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717-5p, miR-6870-5p, miR-663b, miR -6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, miR-7108-5p, miR-4433b-3p, miR-6893-5p , miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615-5p, miR-128-1-5p, miR-6825 -5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR-6840-3p, miR-6765-5p, miR-296-5p, miR -3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6784-5p, miR-6749-5p, miR-1231, miR-4746-3p, miR-6780b-5p , miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185, miR-1260a, miR-3197, miR-6845 -5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6777-5p, miR-391 7, miR-5787, miR-4286, miR-6877-5p, miR-1225-3p, miR-6088, miR-6800-5p, miR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR-1228-5p, miR-5572, miR- 4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-1199- 5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237- 5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-1247-3p, miR-6805-5p, miR- 4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687-3p, miR-4763-3p, miR- 3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1- 3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR-4508, miR-6806-5p, miR -7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6724-5p, miR-6757-5p, miR-4448, miR -671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR-6803-5p, miR The expression level of a liver cancer-derived gene selected from -6798-5p, miR-3648, miR-4783-3p and miR-6836-3p, and optionally the following groups: miR-23b-3p, miR-23a-3p , miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150 The expression level of a liver cancer-derived gene selected from -3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p and miR-663a, and optionally miR-4688, miR-4648 , miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, miR-1273g-3p, miR-1225-5p, miR-3196 , miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR -6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR-5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p , miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, miR-6124, miR-6778-5p, miR-557 and miR-6090 as me In vitro measurement of the expression level of a liver cancer-derived gene expressed by at least one expression level of the expressed liver cancer-derived gene, and a subject suspected of having liver cancer and a healthy person (including a non-liver cancer patient) For samples such as blood, serum, plasma, etc. collected from Provided is a method for detecting liver cancer, which includes evaluating that a subject is afflicted with liver cancer when there is a statistically significant difference.

The method of the present invention enables early diagnosis of cancer with low invasiveness, high sensitivity and specificity, and thus results in early treatment and improvement of prognosis, and is also used for monitoring disease hatred, surgical, and radiotherapy. , and monitoring the effectiveness of chemotherapeutic treatment.

In the method of extracting a liver cancer-derived gene from a specimen such as blood, serum, or plasma according to the present invention, it is prepared by adding a reagent for RNA extraction in 3D-Gene (registered trademark) RNA extraction reagent from liquid sample kit (Toray Corporation). Although it is particularly preferable to do so, a general acid phenol method (Acid Guanidinium-Phenol-Chloroform (AGPC) method) may be used, Trizol (registered trademark) (Life Technologies) may be used, Trizol (life technologies) or Isogen (Nipponjin Co., Ltd.) may be prepared by adding a reagent for RNA extraction containing acidic phenol. Also, kits such as miRNeasy (registered trademark) Mini Kit (Qiagen) can be used, but are not limited to these methods.

The present invention also provides use of the kit or device of the present invention for in vitro detection of a liver cancer-derived miRNA gene expression product in a subject-derived sample.

In the method of the present invention, the kit or device comprising the polynucleotides usable in the present invention, as described above, singly or in all possible combinations is used.

In the detection or (gene) diagnosis of liver cancer of the present invention, the polynucleotide contained in the kit or device of the present invention can be used as a probe or primer. When used as a primer, Life Technologies' TaqMan (registered trademark) MicroRNA Assays, Qiagen's miScript PCR System, etc. can be used, but it is not limited to these methods.

The polynucleotide included in the kit or device of the present invention is a hybridization technique such as Northern blot method, Southern blot method, in situ hybridization method, Northern hybridization method, Southern hybridization method, quantitative RT-PCR In a known method for specifically detecting a specific gene, such as a quantitative amplification technique such as a method, it can be used as a primer or a probe according to a conventional method. As the sample to be measured, body fluids such as blood, serum, plasma, urine, etc. of the subject are collected according to the type of detection method used. Alternatively, the total RNA prepared by the above method may be used in such a bodily fluid, or various polynucleotides containing cDNA prepared based on the RNA may be used.

The kit or device of the present invention is useful for diagnosing liver cancer or detecting the presence or absence of disease. Specifically, the detection of liver cancer using the kit or device is detected by using a sample such as blood, serum, plasma, urine, etc. from a subject suspected of having liver cancer, and a nucleic acid probe or primer included in the kit or device. It can be carried out by detecting the expression level of the gene to be used in vitro. A nucleotide sequence represented by at least one of SEQ ID NOs: 1 to 167 and 714 to 729 in a sample of blood, serum, plasma, urine, etc. of a subject suspected of having liver cancer or a complementary sequence thereof, and in some cases A polynucleotide (the variant thereof) consisting of a nucleotide sequence represented by one or more of SEQ ID NOs: 168 to 183 or a complementary sequence thereof, and, in some cases, a nucleotide sequence represented by one or more of SEQ ID NOs: 184 to 224 or a complementary sequence thereof , fragments or derivatives)), when there is a statistically significant difference between the expression level of the target miRNA marker measured by It can be evaluated that the subject is suffering from liver cancer.

The method of the present invention can be combined with imaging methods such as ultrasound examination, CT examination, MRI examination, and angiography examination. The method of the present invention can specifically detect liver cancer, and can substantially discriminate it from cancers other than liver cancer.

A method for detecting that a sample using the kit or device of the present invention does not contain an expression product of a liver cancer-derived gene, or contains an expression product of a gene derived from liver cancer, is a subject's blood, serum, plasma, urine, etc. The presence or absence of liver cancer by collecting body fluid of to evaluate or detect liver cancer. In addition, by using the liver cancer detection method of the present invention, for example, in a liver cancer patient, when a therapeutic agent is administered for the improvement of the disease, the presence or absence of improvement of the disease or the degree of improvement can be evaluated or diagnosed. .

The method of the present invention comprises, for example, the following steps (a), (b) and (c):

(a) contacting a subject-derived sample with the polynucleotide in the kit or device of the present invention in vitro;

(b) measuring the expression level of the target nucleic acid in the sample using the polynucleotide as a nucleic acid probe or primer;

(c) evaluating the presence or absence of liver cancer (cells) in the subject based on the result of (b).

Specifically, the present invention relates to miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641 , miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p , miR-6717-5p, miR-6870-5p, miR-663b, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706 , miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p , miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR -6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6784-5p, miR-6749 -5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791 -5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR -6820-5p, miR-6777-5p, miR-3917, miR-5787, miR-4286, miR-6877-5p, miR-1225-3p, miR-6088, miR-6800-5p, m iR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR-1228-5p, miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR- 6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR- 1343-5p, miR-1247-3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR- 744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2- 5p, miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, mi R-6724-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, At least one selected from the group consisting of miR-4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p and miR-6836-3p, preferably Measures the expression level of a target nucleic acid in a sample of a subject using a nucleic acid capable of specifically binding to at least two or more polynucleotides, and uses the measured control expression level of a healthy body as the measured expression level for the test Provided is a method for detecting liver cancer, comprising in vitro evaluation of a body that is afflicted with or not afflicted with liver cancer.

In this specification, "evaluation" is not a judgment by a doctor, but evaluation support based on the result of an in vitro test.

As described above, in a preferred embodiment of the method of the present invention, specifically, miR-1343-3p is hsa-miR-1343-3p, miR-6726-5p is hsa-miR-6726-5p, and miR- 6515-3p is hsa-miR-6515-3p, miR-4651 is hsa-miR-4651, miR-4257 is hsa-miR-4257, miR-3188 is hsa-miR-3188, miR-6131 is hsa-miR-6131, miR-6766-3p is hsa-miR-6766-3p, miR-7641 is hsa-miR-7641, miR-1249 is hsa-miR-1249, miR-3679-3p is hsa-miR-3679-3p, miR-6787-5p is hsa-miR-6787-5p, miR-4454 is hsa-miR-4454, miR-3135b is hsa-miR-3135b, miR-6765- 3p is hsa-miR-6765-3p, miR-7975 is hsa-miR-7975, miR-204-3p is hsa-miR-204-3p, miR-7977 is hsa-miR-7977, miR- 7110-5p is hsa-miR-7110-5p, miR-6717-5p is hsa-miR-6717-5p, miR-6870-5p is hsa-miR-6870-5p, miR-663b is hsa-miR -663b, miR-6875-5p is hsa-miR-6875-5p, miR-8072 is hsa-miR-8072, miR-6816-5p is hsa-miR-6816-5p, miR-4281 is hsa -miR-4281, miR-6729-5p is hsa-miR-6729-5p, miR-8069 is hsa-miR-8069, miR-4706 is hsa-miR-4706, miR-7108-5p is hsa -miR-7108-5p, miR-4433b-3p is hsa-miR-4433b-3p, miR-6893-5p is hsa-miR-6893-5p, miR-6857-5p is hsa-miR-68 57-5p, miR-1227-5p is hsa-miR-1227-5p, miR-6741-5p is hsa-miR-6741-5p, miR-451a is hsa-miR-451a, miR-8063 is hsa-miR-8063, miR-3622a-5p is hsa-miR-3622a-5p, miR-615-5p is hsa-miR-615-5p, miR-128-1-5p is hsa-miR-128 -1-5p, miR-6825-5p is hsa-miR-6825-5p, miR-1260b is hsa-miR-1260b, miR-4433-3p is hsa-miR-4433-3p, miR-4665 -5p is hsa-miR-4665-5p, miR-7845-5p is hsa-miR-7845-5p, miR-1908-5p is hsa-miR-1908-5p, miR-6840-3p is hsa- miR-6840-3p, miR-6765-5p is hsa-miR-6765-5p, miR-296-5p is hsa-miR-296-5p, miR-3675-3p is hsa-miR-3675-3p , miR-6781-5p is hsa-miR-6781-5p, miR-423-5p is hsa-miR-423-5p, miR-3663-3p is hsa-miR-3663-3p, miR-6784 -5p is hsa-miR-6784-5p, miR-6749-5p is hsa-miR-6749-5p, miR-1231 is hsa-miR-1231, miR-4746-3p is hsa-miR-4746- 3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-4758-5p is hsa-miR-4758-5p, miR-3679-5p is hsa-miR-3679-5p, miR- 3184-5p is hsa-miR-3184-5p, miR-6125 is hsa-miR-6125, miR-6721-5p is hsa-miR-6721-5p, miR-6791-5p is hsa-miR-6791 -5p, miR-3185 is hsa-miR-3185, m iR-1260a is hsa-miR-1260a, miR-3197 is hsa-miR-3197, miR-6845-5p is hsa-miR-6845-5p, miR-6887-5p is hsa-miR-6887-5p , miR-6738-5p is hsa-miR-6738-5p, miR-6872-3p is hsa-miR-6872-3p, miR-4497 is hsa-miR-4497, miR-1229-5p is hsa -miR-1229-5p, miR-6820-5p is hsa-miR-6820-5p, miR-6777-5p is hsa-miR-6777-5p, miR-3917 is hsa-miR-3917, miR -5787 is hsa-miR-5787, miR-4286 is hsa-miR-4286, miR-6877-5p is hsa-miR-6877-5p, miR-1225-3p is hsa-miR-1225-3p , miR-6088 is hsa-miR-6088, miR-6800-5p is hsa-miR-6800-5p, miR-1246 is hsa-miR-1246, miR-4467 is hsa-miR-4467, miR -4419b is hsa-miR-4419b, miR-1914-3p is hsa-miR-1914-3p, miR-4632-5p is hsa-miR-4632-5p, miR-1915-5p is hsa-miR- 1915-5p, miR-3940-5p is hsa-miR-3940-5p, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-6746-5p is hsa-miR-6746 -5p, miR-5001-5p is hsa-miR-5001-5p, miR-1228-5p is hsa-miR-1228-5p, miR-5572 is hsa-miR-5572, miR-4327 is hsa -miR-4327, miR-4638-5p is hsa-miR-4638-5p, miR-6799-5p is hsa-miR-6799-5p, miR-6861-5p is hsa-miR-6861-5p , miR-6727- 5p is hsa-miR-6727-5p, miR-4513 is hsa-miR-4513, miR-6805-3p is hsa-miR-6805-3p, miR-6808-5p is hsa-miR-6808-5p , miR-4449 is hsa-miR-4449, miR-1199-5p is hsa-miR-1199-5p, miR-1275 is hsa-miR-1275, miR-4792 is hsa-miR-4792, miR-4443 is hsa-miR-4443, miR-6891-5p is hsa-miR-6891-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6807-5p is hsa-miR -6807-5p, miR-7150 is hsa-miR-7150, miR-4534 is hsa-miR-4534, miR-4476 is hsa-miR-4476, miR-4649-5p is hsa-miR-4649 -5p, miR-4525 is hsa-miR-4525, miR-1915-3p is hsa-miR-1915-3p, miR-4516 is hsa-miR-4516, miR-4417 is hsa-miR-4417 , miR-642b-3p is hsa-miR-642b-3p, miR-3141 is hsa-miR-3141, miR-5100 is hsa-miR-5100, miR-6848-5p is hsa-miR-6848 -5p, miR-4739 is hsa-miR-4739, miR-4459 is hsa-miR-4459, miR-1237-5p is hsa-miR-1237-5p, miR-296-3p is hsa-miR -296-3p, miR-4665-3p is hsa-miR-4665-3p, miR-6786-5p is hsa-miR-6786-5p, miR-4258 is hsa-miR-4258, miR-6510 -5p is hsa-miR-6510-5p, miR-1343-5p is hsa-miR-1343-5p, miR-1247-3p is hsa-miR-1247-3p, miR-6805-5p is hsa- mi R-6805-5p, miR-4492 is hsa-miR-4492, miR-1469 is hsa-miR-1469, miR-1268b is hsa-miR-1268b, miR-6858-5p is hsa-miR- 6858-5p, miR-3937 is hsa-miR-3937, miR-939-5p is hsa-miR-939-5p, miR-3656 is hsa-miR-3656, miR-744-5p is hsa- miR-744-5p, miR-4687-3p is hsa-miR-4687-3p, miR-4763-3p is hsa-miR-4763-3p, miR-3620-5p is hsa-miR-3620-5p , miR-3195 is hsa-miR-3195, miR-6842-5p is hsa-miR-6842-5p, miR-4707-5p is hsa-miR-4707-5p, miR-642a-3p is hsa -miR-642a-3p, miR-7113-3p is hsa-miR-7113-3p, miR-4728-5p is hsa-miR-4728-5p, miR-5195-3p is hsa-miR-5195- 3p, miR-1185-1-3p is hsa-miR-1185-1-3p, miR-6774-5p is hsa-miR-6774-5p, miR-8059 is hsa-miR-8059, miR- 3131 is hsa-miR-3131, miR-7847-3p is hsa-miR-7847-3p, miR-4463 is hsa-miR-4463, miR-128-2-5p is hsa-miR-128-2 -5p, miR-4508 is hsa-miR-4508, miR-6806-5p is hsa-miR-6806-5p, miR-7111-5p is hsa-miR-7111-5p, miR-6782-5p is hsa-miR-6782-5p, miR-4734 is hsa-miR-4734, miR-3162-5p is hsa-miR-3162-5p, miR-887-3p is hsa-miR-887-3p; , miR-6752-5p is hsa-miR-6752-5 p, miR-6724-5p is hsa-miR-6724-5p, miR-6757-5p is hsa-miR-6757-5p, miR-4448 is hsa-miR-4448, miR-671-5p is hsa-miR-671-5p, miR-3178 is hsa-miR-3178, miR-4725-3p is hsa-miR-4725-3p, miR-940 is hsa-miR-940, miR-6789- 5p is hsa-miR-6789-5p, miR-4484 is hsa-miR-4484, miR-4634 is hsa-miR-4634, miR-4745-5p is hsa-miR-4745-5p, miR- 4730 is hsa-miR-4730, miR-6803-5p is hsa-miR-6803-5p, miR-6798-5p is hsa-miR-6798-5p, miR-3648 is hsa-miR-3648, miR-4783-3p is hsa-miR-4783-3p, and miR-6836-3p is hsa-miR-6836-3p.

Further, in a preferred embodiment of the method of the present invention, specifically, a nucleic acid (specifically, a probe or a primer) is a polynucleotide represented by the following (a) to (e):

(a) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729, or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases; the fragment comprising;

(b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729;

(c) a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729, or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 A fragment thereof comprising more than one consecutive base,

(d) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729, or a nucleotide sequence in which u is t in the nucleotide sequence, and

(e) a polynucleotide that hybridizes with the polynucleotide of any one of (a) to (d) under stringent conditions;

is selected from the group consisting of

In the method of the present invention, miR-23b-3p, miR-23a-3p, miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187 at least selected from -5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p and miR-663a A nucleic acid capable of specifically binding to one or more polynucleotides may be used.

In a preferred embodiment, such new nucleic acids are specifically, miR-23b-3p is hsa-miR-23b-3p, miR-23a-3p is hsa-miR-23a-3p, and miR-625-3p is hsa -miR-625-3p, miR-1228-3p is hsa-miR-1228-3p, miR-614 is hsa-miR-614, miR-1913 is hsa-miR-1913, miR-92a-2 -5p is hsa-miR-92a-2-5p, miR-187-5p is hsa-miR-187-5p, miR-16-5p is hsa-miR-16-5p, miR-92b-3p is hsa-miR-92b-3p, miR-150-3p is hsa-miR-150-3p, miR-564 is hsa-miR-564, miR-125a-3p is hsa-miR-125a-3p, miR-92b-5p is hsa-miR-92b-5p, miR-92a-3p is hsa-miR-92a-3p, and miR-663a is hsa-miR-663a.

Further, in a preferred embodiment, specifically, such a nucleic acid is a polynucleotide shown in the following (f) to (j):

(f) a polynucleotide comprising the base sequence represented by any one of SEQ ID NOs: 168 to 183, or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases ,

(g) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183;

(h) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183, or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising

(i) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183, or a nucleotide sequence in which u is t in the nucleotide sequence, and

(j) a polynucleotide that hybridizes with the polynucleotide of any one of (f) to (i) under stringent conditions;

is selected from the group consisting of

In the method of the present invention, miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, miR -1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466 , miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR-5698, miR-371a-5p, miR -4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, miR-6124 , miR-6778-5p, miR-557, and miR-6090 may be used a nucleic acid capable of specifically binding to at least one or more polynucleotides selected from the group consisting of.

In a preferred embodiment, such new nucleic acids are specifically, wherein miR-4688 is hsa-miR-4688, miR-4648 is hsa-miR-4648, miR-6085 is hsa-miR-6085, and miR-6126 is hsa-miR-6126, miR-6880-5p is hsa-miR-6880-5p, miR-328-5p is hsa-miR-328-5p, miR-6768-5p is hsa-miR-6768-5p , miR-3180 is hsa-miR-3180, miR-6087 is hsa-miR-6087, miR-1273g-3p is hsa-miR-1273g-3p, miR-1225-5p is hsa-miR-1225 -5p, miR-3196 is hsa-miR-3196, miR-4695-5p is hsa-miR-4695-5p, miR-6732-5p is hsa-miR-6732-5p, miR-638 is hsa -miR-638, miR-6813-5p is hsa-miR-6813-5p, miR-665 is hsa-miR-665, miR-486-3p is hsa-miR-486-3p, miR-4466 is hsa-miR-4466, miR-30c-1-3p is hsa-miR-30c-1-3p, miR-3621 is hsa-miR-3621, miR-6743-5p is hsa-miR-6743- 5p, miR-4298 is hsa-miR-4298, miR-4741 is hsa-miR-4741, miR-3619-3p is hsa-miR-3619-3p, miR-6824-5p is hsa-miR- 6824-5p, miR-5698 is hsa-miR-5698, miR-371a-5p is hsa-miR-371a-5p, miR-4488 is hsa-miR-4488, miR-1233-5p is hsa- miR-1233-5p, miR-4723-5p is hsa-miR-4723-5p, miR-24-3p is hsa-miR-24-3p, miR-1238-5p is hsa-miR-1238-5p and miR-4442 is hsa-miR-4442, miR-3928-3p is hsa-miR-3928-3p, miR-6716-5p is hsa-miR-6716-5p, miR-6089 is hsa-miR-6089, miR -6124 is hsa-miR-6124, miR-6778-5p is hsa-miR-6778-5p, miR-557 is hsa-miR-557, and miR-6090 is hsa-miR-6090.

Further, in a preferred embodiment, specifically, such nucleic acids are polynucleotides shown in the following (k) to (o):

(k) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224, or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases ,

(l) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224;

(m) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224, or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising

(n) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224, or a nucleotide sequence in which u is t in the nucleotide sequence, and

(o) a polynucleotide that hybridizes with the polynucleotide of any one of (k) to (n) under stringent conditions;

It is a polynucleotide selected from the group consisting of.

Examples of the sample used in the method of the present invention include a sample prepared from a body fluid such as a biological tissue (preferably a liver tissue) of a subject, blood, serum, plasma, urine, or the like. Specifically, an RNA-containing sample prepared from the tissue, a sample containing a polynucleotide prepared therefrom, body fluids such as blood, serum, plasma, and urine, and a part or all of the subject's biological tissue (biopsy) ), etc. or biological tissues extracted by surgery, from which samples for measurement can be prepared.

As used herein, a subject refers to a mammal such as, but not limited to, a human, a monkey, a mouse, a rat, and the like, and is preferably a human.

In the method of the present invention, the steps can be changed according to the type of the specimen used as the measurement target.

When RNA is used as a measurement target, the detection of liver cancer (cells) is performed, for example, in the following steps (a), (b) and (c):

(a) binding RNA prepared from a sample of a subject or a complementary polynucleotide (cDNA) transcribed therefrom with a polynucleotide in the kit or device of the present invention;

(b) RNA from a specimen bound to the polynucleotide or cDNA synthesized from the RNA is subjected to hybridization using the polynucleotide as a nucleic acid probe or quantitative RT-PCR using the polynucleotide as a primer Steps to be measured by

(c) evaluating the presence or absence of liver cancer (expression of a derived gene) based on the measurement result of (b);

may include

In order to detect, test, evaluate or diagnose liver cancer (derived gene expression) in vitro according to the present invention, for example, various hybridization methods can be used. As such a hybridization method, for example, Northern blot method, Southern blot method, RT-PCR method, DNA chip analysis method, in situ hybridization method, Northern hybridization method, Southern hybridization method, etc. can be used. .

When the Northern blot method is used, the presence or absence of expression of each gene in RNA and the expression level thereof can be detected and measured by using the nucleic acid probe that can be used in the present invention. Specifically, a nucleic acid probe (complementary strand) is labeled with a radioactive isotope ( ³² P, ³³ P, ³⁵ S, etc.) or a fluorescent substance, and then transferred to a nylon membrane or the like according to a commercial method. After hybridization, a signal derived from a marker (radioisotope or fluorescent substance) of the formed DNA/RNA double chain is detected by a radiation detector (BAS-1800II (Fujishashin Film Co., Ltd.) or the like) or fluorescence A method of detecting and measuring with a detector (eg, STORM 865 (GE Healthcare) can be exemplified).

When the quantitative RT-PCR method is used, the presence or absence of gene expression in RNA and the expression level thereof can be detected and measured by using the primers usable in the present invention. Specifically, a pair of primers of the present invention (a pair of primers (binding to the cDNA and a method of hybridizing cDNA with cDNA, performing PCR by a conventional method, and detecting the resulting double-stranded DNA can be exemplified. In addition, as a method for detecting double-stranded DNA, the PCR is performed using primers previously labeled with a radioactive isotope or a fluorescent substance, and the PCR product is electrophoresed on an agarose gel, and double-stranded DNA is stained with ethidium bromide or the like. and a method for detecting by transferring the resulting double-stranded DNA to a nylon membrane or the like according to a conventional method, followed by hybridization with a labeled nucleic acid probe.

When nucleic acid array analysis is used, an RNA chip or a DNA chip in which the nucleic acid probe (single-stranded or double-stranded) of the present invention is attached to a substrate (solid phase) is used. A region to which a nucleic acid probe is attached is called a probe spot, and a region to which a nucleic acid probe is not attached is called a blank spot. Gene groups immobilized on a substrate are generally referred to as nucleic acid chips, nucleic acid arrays, microarrays, etc., and DNA or RNA arrays include DNA or RNA macroarrays and DNA or RNA microarrays. In the case of chips, all of them are included. As a DNA chip, 3D-Gene (trademark) Human miRNA Oligo chip (Toray Industries, Ltd.) can be used, but it is not limited to this.

Although the measurement of the DNA chip is not limited, for example, an image detector (Typhoon 9410 (GE Healthcare), 3D-Gene (registered trademark) scanner (Toray Industries, Ltd.) etc.) is exemplified by, for example, a signal derived from a marker of a nucleic acid probe. can be used) to exemplify detection and measurement methods.

As used herein, the term "stringent condition" refers to a greater degree of a nucleic acid probe with respect to other sequences as described above (for example, the mean of the background measurement + the standard error of the background measurement × 2 or more measured values) ), which is a condition for hybridization to the target sequence.

Stringent conditions are defined by the conditions of hybridization and subsequent washing. The conditions for the hybridization are not limited, but for example, 30°C to 60°C, and 1 to 24 hours in a solution containing SSC, a surfactant, formamide, dextran sulfate, a blocking agent, and the like. Here, 1×SSC is an aqueous solution (pH 7.0) containing 150 mM sodium chloride and 15 mM sodium citrate, and the surfactant includes SDS (sodium dodecyl sulfate), Triton, or Tween. As hybridization conditions, 3-10xSSC and 0.1-1% SDS are included more preferably. As another condition defining stringent conditions, the cleaning conditions after hybridization include, for example, a solution containing 0.5×SSC and 0.1% SDS at 30°C, and 0.2×SSC and 0.1% SDS at 30°C. and conditions such as continuous washing with a solution containing Even if the complementary chain is washed under these conditions, it is preferable to maintain a state of hybridization with the target straight chain. Specifically, as such a complementary chain, a chain consisting of a base sequence that is in a completely complementary relationship with the base sequence of the target normal chain, and at least 80%, preferably at least 85%, more preferably at least 90% of the corresponding chain Or at least 95%, for example, a chain consisting of a nucleotide sequence having at least 98% or at least 99% identity may be exemplified.

For other examples of "stringent conditions" in these hybridizations, see, for example, Sambrook, J. & Russel, D., Molecular Cloning, A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, 2001 1 It is described in the first volume 7.42 to 7.45, the second volume 8.9 to 8.17, etc. issued on the 15th of a month, and can be used in the present invention.

As an example of the conditions for performing PCR using the polynucleotide fragment in the kit of the present invention as a primer, a PCR buffer having a composition such as 10 mM Tris-HCL (pH8.3), 50 mM KCL, 1-2 mM MgCl ₂ is used. and processing for about 15 seconds to 1 minute at Tm value +5 to 10°C calculated from the sequence of the primer. As a calculation method of such a Tm value, Tm value = 2x(the number of adenine residues + the number of thymine residues) + 4x (the number of guanine residues + the number of cytosine residues), etc. are mentioned.

In addition, when the quantitative RT-PCR method is used, TaqMan (registered trademark) MicroRNA Assays (Life Technologies): LNA (registered trademark)-based MicroRNA PCR (Exiqon): Ncode (registered trademark) miRNA qRT-PCT kit (invitrogen) G) and the like, a commercially available measurement kit specially designed for quantitatively measuring miRNA may be used.

Although not limited to calculation of gene expression level, for example, Statistical analysis of gene expression microarray data (Speed T., Chapman and Hall/CRC), and A beginner's guide Microarray gene expression data analysis (Causton H.C. et al., Blackwell publishing) The statistical processing described in et al. can be used in the present invention. For example, to the average value of the measured values of the blank spots on the DNA chip, 2 times, preferably 3 times, more preferably 6 times the standard deviation of the measured values of the blank spots is added, and the signal value is greater than that value. A probe spot can be considered a detection spot. In addition, the average value of the measured values of the blank spot can be regarded as the background and subtracted from the measured value of the probe spot to obtain the gene expression level. For the missing value of the gene expression level, it is excluded from the analysis target, preferably substituted with the minimum value of the gene expression level in each DNA chip, or more preferably 0.1 is subtracted from the logarithmic value of the minimum gene expression level. value can be substituted. Further, in order to remove the low signal gene, 2 to the 6th power, preferably 2 to the 8th power, more preferably 20% or more, preferably 50% or more, more preferably 80% or more of the number of measurement samples. In most cases, only genes having a gene expression level of 2 to the power of 10 or more can be selected as analysis targets. Although it does not limit as normalization (normalization) of a gene expression level, For example, global normalization and quantile normalization (Bolstad, B.M. et al., 2003, Bioinformatics, vol. 19, p185-193) etc. are mentioned.

The present invention also measures the expression level of a target gene or gene in a sample derived from a subject using the polynucleotide, kit, device (eg, chip) for detection of the present invention, or a combination thereof, and is derived from a liver cancer patient. A method of determining or evaluating whether a sample contains and/or does not contain a liver cancer-derived gene by creating a discriminant (discriminatory function) using the gene expression level of a sample of do.

That is, the present invention also provides that a specimen contains a liver cancer-derived gene or does not contain a liver cancer-derived gene using the polynucleotide, kit, device (eg, chip), or a combination thereof for detection of the present invention. Determining or evaluating whether or not the target gene (target nucleic acid) in the plurality of known samples is measured in the first step, the measured value of the expression level of the target gene obtained in the first step in vitro The second step of creating a discriminant using the teacher sample, the third step of measuring the expression level of the target gene in the subject-derived sample in vitro as in the first step, the third step obtained in the second step Substitute the measured value of the expression level of the target gene obtained in the third step into the discriminant, and based on the result obtained from the discriminant, the sample contains a liver cancer-derived gene or does not contain a liver cancer-derived gene. A method comprising a fourth step of determining or evaluating that do. Here, although a discriminant can be created using Fisher's discriminant analysis, nonlinear discriminant analysis by Maharanobis distance, a neural network, Support Vector Machine (SVM), etc., it is not limited to these.

Linear discriminant analysis is a method of determining group membership by using Equation 1 as a discriminant when the boundary of group classification is a straight line or hyperplane. Here, x is the explanatory variable, w is the coefficient of the explanatory variable, and w ₀ is an integer term.

[Number 1]

The value obtained by the discriminant is called a discriminant score, and the measured value of the newly given data set is used as an explanatory variable and substituted into the discriminant, and the group classification can be discriminated by the sign of the discriminant score.

Fisher's discriminant analysis, a type of linear discriminant analysis, is a dimensional reduction method to select a dimension suitable for class discrimination. (Venables, WN et al., Modern Applied Statistics with S. Fourth edition. Springer., 2002). In Fisher's discriminant analysis, the projection direction (w) that maximizes Equation 2 is found. Here, μ is the average of the inputs, n _g is the number of data belonging to the class (g), and μ _g is the average of the inputs of the data belonging to the class (g). The numerator and denominator are the inter-class variance and intra-class variance when the data is projected in the direction of the vector w, respectively, and the discriminant coefficient w _i is obtained by maximizing this ratio (Kanamori Takafumi et al., "Pattern Recognition", Kyoritsu Publishing (2009), Richard O. et al., Pattern Classification Second Edition., Wiley-Interscience, 2000).

[Number 2]

The Maharanobis distance is calculated by Equation 3 in consideration of the data correlation, and can be used as a nonlinear discriminant analysis for discriminating a group close to the Maharanobis distance from each group as a affiliation group. Here, μ is the center vector of each group, and S ^-1 is the inverse of the variance covariance matrix of that group. The centroid vector is calculated from the explanatory variable (x), and an average vector or a median vector may be used.

[Number 3]

SVM is a discriminant analysis method devised by V. Vapnik (The Nature of Statistical Leaning Theory, Springer, 1995). The group classification to be classified uses a specific data item of a known data set as an explanatory variable and the group classification to be classified as an objective variable, and determines a boundary called a hyperplane for correctly classifying the data set into a known group classification, , determine the discriminant that classifies the data using the corresponding boundary. In addition, the corresponding discriminant can discriminate the group classification by substituting the measured value of the newly given data set as an explanatory variable into the corresponding discriminant. In addition, the discrimination result at this time may be a group to be classified, a probability of being classified into a group to be classified, or a distance from the hyperplane. In SVM, as a method for dealing with a nonlinear problem, a method of performing nonlinear transformation of a feature vector into a high dimension and performing linear identification in the space is known. An expression in which the dot product of two elements in a space mapped nonlinearly is expressed only by an input in each first space is called a kernel. kernel is available. It is possible to construct an optimal discriminant, i.e., a discriminant, only by calculating the kernel while mapping to a higher dimension by the kernel, avoiding the calculation of features in the mapped space in reality (e.g., Hideki Asou et al., Statistical Sciences). Frontier 6 「Statistics New Concepts and Methods of Pattern Recognition and Learning」, Iwanami Bookstore (2004), Nello Cristianini et al., Introduction to SVM, Kyoritz Publishing (2008)).

C-support vector classification (C-SVC), a type of SVM method, creates a hyperplane by learning from two groups of explanatory variables, and determines which group an unknown data set is classified into (C. Cortes et al. , 1995, Machine Learning, vol. 20, p273-297).

A calculation example of the C-SVC discriminant usable in the method of the present invention is shown below. First, all subjects are divided into two groups: liver cancer patients and healthy subjects. In order to determine that the subject is a liver cancer patient or a healthy body, for example, a liver biopsy may be used.

Next, a data set (hereinafter, a learning sample group) consisting of the gene expression levels of the serum-derived samples of the two classified groups is prepared, and genes showing a clear difference in gene expression levels between the two groups are set as explanatory variables. , determine the discriminant by C-SVC with the relevant group classification as the objective variables (eg, -1 and +1). Equation 4 is the objective function to optimize, where e is all input vectors, y is the objective variable, a is the Lagrange undefined multiplier vector, Q is the correction value matrix, and C is the parameter that adjusts the constraint.

[Number 4]

Equation 5 is the finally obtained discriminant, and the group belonging to can be determined by the sign of the value obtained by the discriminant. Here, x is a support vector, y is a label indicating group membership, a is a corresponding coefficient, b is an integer term, and K is a kernel function.

[Number 5]

As the kernel function, for example, the RBF kernel defined by Equation 6 can be used. Here, x is a support vector and γ is a kernel parameter that adjusts the complexity of the hyperplane.

[Number 6]

In addition to these, as a method for determining or evaluating whether a subject-derived sample contains and/or does not contain the expression of a target gene derived from liver cancer, or to evaluate the expression level compared to a control derived from a healthy body, a neural network, Methods such as k-proximity, decision tree, and logistic regression can be selected.

The method of the present invention comprises, for example, the following steps (a), (b) and (c):

(a) a polynucleotide for detecting the expression level of a target gene in a sample already known to be a tissue containing a liver cancer-derived gene derived from a liver cancer patient and/or a tissue not containing a liver cancer-derived gene derived from a healthy body; measuring using a kit or device (eg, a DNA chip);

(b) creating the discriminant of Equations 1 to 3, 5 and 6 from the measured value of the expression level measured in (a);

(c) the expression level of the target gene in the subject-derived sample is measured using the polynucleotide, kit, or device for detection according to the present invention (for example, a DNA chip), and in the discriminant created in (b) Substituting the measured values, determining or evaluating whether the sample contains and/or does not contain a target gene derived from liver cancer based on the obtained results, or evaluating the expression level compared to a control derived from a healthy body;

may include Here, x in the formulas of formulas 1 to 3, 5 and 6 is an explanatory variable, including a value obtained by measuring a polynucleotide selected from the polynucleotides described in Section 2 or a fragment thereof, etc., specifically The explanatory variable for discriminating between a liver cancer patient and a healthy body of the present invention is, for example, the gene expression level selected from the following (1) to (3).

(1) the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or its complementary sequence, measured by any one of DNA containing 15 or more consecutive bases in the serum of a liver cancer patient or healthy body gene expression level in

(2) Gene expression in the serum of a liver cancer patient or healthy body as measured by any one of DNA containing 15 or more consecutive bases in the nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or its complementary sequence amount.

(3) Gene expression in the serum of a liver cancer patient or healthy body as measured by any one of DNA containing 15 or more consecutive bases in the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or its complementary sequence amount.

As described above, as a method for determining or evaluating whether a subject-derived sample contains and/or does not contain a liver cancer-derived gene, the discriminant created in the learning sample group is required to create the discriminant, and the In order to increase the discriminant precision of the discriminant, it is necessary to use a gene with a clear difference between the two groups in the learning sample group for the discriminant.

In addition, it is preferable to determine the gene to be used for the explanatory variable of the discriminant as follows. First, using the comprehensive gene expression level of the liver cancer patient group as the learning sample group and the comprehensive gene expression level of the healthy group as the data set, the P value of the t-test, which is a parametric analysis, and the P value of the Mann-Whitney's U test, which is a non-parametric analysis, are used as data sets. The magnitude of the difference in the expression level of each gene between the two groups is calculated using the value or the P value of the Wilcoxon test.

If the risk rate (significance level) of the P value obtained by the test is, for example, less than 5%, 1%, or 0.01%, it can be considered statistically significant.

In order to correct the increase in the probability of the first type of error due to the repeated test, it can be corrected by a known method, for example, Bonferroni, Holm et al. (For example, by Yasushi Nagata et al. , 「Basics of Statistical Multiple Comparison Method」, Scientist Inc. (2007)). To illustrate the Bonferroni correction, for example, the P value obtained by the test is multiplied by the number of iterations of the test, i.e., the number of genes used for interpretation, and compared with the desired level of significance, thereby generating the first kind of error in the test as a whole. probability can be reduced.

In addition, it is not a test, but between the gene expression level of the liver cancer patient group and the gene expression level of the healthy group, the absolute value (fold change) of the expression ratio of the median of each gene expression level is calculated and used as an explanatory variable of the discriminant. You can also choose a gene. In addition, the ROC curve may be prepared using the gene expression levels of the liver cancer patient group and the healthy group, and the gene used for the explanatory variable of the discriminant may be selected based on the AUROC value.

Next, a discriminant that can be calculated by the various methods described above is created using an arbitrary number of genes having a large difference in gene expression levels determined here. As a method of constructing a discriminant that obtains the maximum discriminant precision, for example, a method of constructing a discriminant with all combinations of genes that satisfy the significance level of the P value, or a gene expression using a gene used to create the discriminant There is a method of repeating evaluation while increasing the amount difference one by one in the order of greatest difference (Furey TS. et al., 2000, Bioinformatics, Vol. 16, p906-14). With respect to this discriminant, the gene expression level of a separate independent liver cancer patient or healthy body is substituted into the explanatory variable, and the discrimination result of the group to which the independent liver cancer patient or healthy body belongs is calculated. In other words, by evaluating the discriminant constructed using the found diagnostic gene set and diagnostic gene set in an independent sample group, a diagnostic gene set capable of detecting more common liver cancer and a method for discriminating liver cancer can be found.

In addition, it is preferable to use the split-sample method for evaluation of the discriminant performance (disambiguation property) of the discriminant. That is, the data set is divided into a learning sample group and a test sample group, the selection of genes by statistical test in the learning sample group and the creation of a discriminant are performed, and the result of discriminating the test sample group by the discriminant and the test sample group Using the true group to which this belongs, precision, sensitivity, and specificity are calculated, and discrimination performance is evaluated. On the other hand, without dividing the data set, the selection of genes and the creation of a discriminant by statistical test using the entire sample are performed, and the newly prepared sample is discriminated by the discriminant, and precision, sensitivity, and specificity are calculated, Discriminant performance may also be evaluated.

The present invention provides a polynucleotide for detection or disease diagnosis useful for diagnosis and treatment of liver cancer, a method for detecting liver cancer using the polynucleotide, and a liver cancer detection kit and device comprising the polynucleotide. In particular, in the method of the present invention, in the method of the present invention, for example, AFP, CEA, CA19-9 and/or In spite of being judged to be negative by a known tumor marker such as PIVKA-II, a gene expressed in serum derived from a patient whose liver cancer was finally found to be present by a detailed examination such as computed tomography using a contrast medium and liver cancer By comparing the genes expressed in serum derived from a non-existent patient, a diagnostic gene set and discriminant exhibiting precision exceeding AFP, CEA, CA19-9 and/or PIVKA-II can be constructed.

For example, one or two or more of the above polynucleotides based on a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or a complementary sequence thereof as described above, and, in some cases, SEQ ID NOs: 168 to 183 1 or 2 or more of the polynucleotides above based on the nucleotide sequence or its complementary sequence represented by any one of Any combination from the above polynucleotides is used as a diagnostic gene set. Further, a discriminant is constructed using the expression level of the diagnostic gene set in a sample derived from a liver cancer patient whose diagnosis result is a class I and a sample derived from a class II healthy body. As a result, by measuring the expression level of the diagnostic gene set in an unknown sample, it is possible to discriminate between those containing the liver cancer-derived gene and those not containing the liver cancer-derived gene with the highest accuracy of 100%.

Example

The present invention will be more specifically described by way of the following examples. However, it is assumed that the scope of the present invention is not limited by these examples.

[Reference Example 1]

<Collection of samples from liver cancer patients and healthy subjects>

100 healthy individuals who obtained an informed outlet and 34 patients with liver cancer with no confirmed primary cancer other than liver cancer (stage I 15 cases, stage II 9 cases, stage IIIA 5 cases, stage IIIB 2 cases, stage IIIC cases Serum was collected from each of 1 case, stage IV 2 cases) using a Venoject II vacuum collection tube VP-AS109K60 (Terumo Co., Ltd.), and it was set as a learning sample group. Similarly, from 50 healthy subjects who obtained an informed outlet and 16 patients with liver cancer for which no primary cancer other than liver cancer was confirmed (Stage I 9 cases, Stage II 5 cases, Stage IIIA 2 cases), a Venoject II vacuum collection tube was collected. Serum was respectively collected using VP-AS109K60 (Terumo Corporation), and it was set as the test sample group.

<Extraction of total RNA>

RNA in 3D-Gene (registered trademark) RNA extraction reagent from liquid sample kit (Toray Industries, Ltd.) from 300 μL of serum each obtained from a total of 200 individuals from 150 healthy subjects and 50 liver cancer patients in the above learning sample group and test sample group as a sample. Using the extraction reagent, total RNA was obtained according to the protocol set by the company.

<Measurement of gene expression level>

As a sample, 3D-Gene (registered trademark) miRNA Labeling kit (Toray Industries, Ltd.) was used for total RNA obtained from the serum of 200 healthy subjects from 150 healthy subjects and 50 patients with liver cancer in the above learning sample group and test sample group. MiRNA was fluorescently labeled according to the protocol (ver2.20) prescribed by . As an oligo DNA chip, a 3D-Gene (registered trademark) Human miRNA Oligo chip (Toray Corporation) equipped with a probe having a sequence complementary to 2,555 types of miRNAs among miRNAs registered in miRBase release 20 is used, Hybridization of the miRNA in total RNA and the probe on the DNA chip under stringent conditions according to the protocol set by the company, and washing after hybridization was carried out. The DNA chip was scanned using a 3D-Gene (registered trademark) scanner (Toray Corporation), images were acquired, and fluorescence intensity was quantified by 3D-Gene (registered trademark) Extraction (Toray Corporation). The numerical fluorescence intensity is converted to a logarithmic value with a base of 2 to be the gene expression level, the blank value is subtracted, and 0.1 is subtracted from the logarithmic value of the minimum value of the gene expression level in each DNA chip. replaced with a value. As a result, comprehensive miRNA gene expression levels were obtained for the sera of 50 liver cancer patients and the sera of 150 healthy subjects. Calculation and statistical analysis using the quantified miRNA gene expression level is R language 3.0.2 (R Development Core Team (2013). R:A language and environment for statistical computing. R Foundation for Statistical Computing, URL http://www .R-project.org/) and MASS package 7.3-30 (Venables, W. N. & Ripley, B.D. (2002) Modern Applied Statistics with S. Fourth Edition. Springer, New York. ISBN 0-387-95457-0) it was carried out

[Reference Example 2]

<Collection of specimens for cancer other than liver cancer>

72 patients with colon cancer, 61 patients with biliary tract cancer, 38 patients with gastric cancer, 25 patients with esophageal cancer, 35 patients with colorectal cancer, and 16 patients with benign pancreatic biliary tract cancer, who had no confirmed cancer in other organs for which an informed outlet was obtained. Serum was collected from each person using a Benoject II vacuum collection tube VP-AS109K 60 (Terumo Co., Ltd.), and 35 liver cancer patients of Reference Example 1 and 99 healthy subjects were combined to form a study sample group. Similarly, 28 patients with colon cancer, 37 patients with biliary tract cancer, 12 patients with gastric cancer, 25 patients with esophageal cancer, 15 patients with colorectal cancer, and patients with benign pancreatic biliary disease, whose cancer was not confirmed in other organs for which an informed outlet was obtained. Serum was collected from 5 patients using a Benoject II vacuum collection tube VP-AS109K 60 (Terumo Co., Ltd.), and 17 patients with liver cancer in which no cancer was confirmed in organs other than the liver cancer of Reference Example 1, healthy subjects 51 people were combined to form a test sample group. Subsequent operations were performed in the same manner as in Reference Example 1.

[Example 1]

<Selection of a genetic marker using a sample from a learning sample group and evaluation method for liver cancer discrimination performance of a single genetic marker using a sample from a test sample group>

In this example, a genetic marker for discriminating liver cancer from a healthy body is selected from the learning sample group, and the liver cancer discrimination performance of each of the selected genetic markers in a test sample group independent from the learning sample group is evaluated. reviewed.

Specifically, first, the miRNA expression levels of the learning sample group and the test sample group obtained in the reference example were summed and normalized by quantile normalization.

Next, the gene for diagnosis was selected using the learning sample group. Here, in either the liver cancer patient group of the learning sample group or the healthy body group of the learning sample group, only genes having a gene expression level of 2 to the 6th power or more in 50% or more samples are selected in order to obtain a more reliable diagnostic marker did. In addition, as a gene with statistical significance for discriminating between the liver cancer patient group and the healthy group, the P value obtained from the two-sided t test assuming equal variance for each gene expression level was corrected for Bonferroni, and a gene satisfying p < 0.01 was selected. It was obtained as a genetic marker used for explanatory variables of the discriminant and is listed in Table 2.

In this way, hsa-miR-1343-3p, hsa-miR-6726-5p, hsa-miR-6515-3p, hsa-miR-4651, hsa-miR-4257, hsa- miR-3188, hsa-miR-6131, hsa-miR-6766-3p, hsa-miR-7641, hsa-miR-1249, hsa-miR-3679-3p, hsa-miR-6787-5p, hsa-miR- 4454, hsa-miR-3135b, hsa-miR-6765-3p, hsa-miR-7975, hsa-miR-204-3p, hsa-miR-7977, hsa-miR-7110-5p, hsa-miR-6717- 5p, hsa-miR-6870-5p, hsa-miR-663b, hsa-miR-6875-5p, hsa-miR-8072, hsa-miR-6816-5p, hsa-miR-4281, hsa-miR-6729- 5p, hsa-miR-8069, hsa-miR-4706, hsa-miR-7108-5p, hsa-miR-4433b-3p, hsa-miR-6893-5p, hsa-miR-6857-5p, hsa-miR- 1227-5p, hsa-miR-6741-5p, hsa-miR-451a, hsa-miR-8063, hsa-miR-3622a-5p, hsa-miR-615-5p, hsa-miR-128-1-5p, hsa-miR-6825-5p, hsa-miR-1260b, hsa-miR-4433-3p, hsa-miR-4665-5p, hsa-miR-7845-5p, hsa-miR-1908-5p, hsa-miR- 6840-3p, hsa-miR-6765-5p, hsa-miR-296-5p, hsa-miR-3675-3p, hsa-miR-6781-5p, hsa-miR-423-5p, hsa-miR-3663- 3p, hsa-miR-6784-5p, hsa-miR-6749-5p, hsa-miR-1231, hsa-miR-4746-3p, hsa-miR-6780b-5p, hsa-miR-4758-5p, hsa- miR-3679-5p, hsa-m iR-3184-5p, hsa-miR-6125, hsa-miR-6721-5p, hsa-miR-6791-5p, hsa-miR-3185, hsa-miR-1260a, hsa-miR-3197, hsa-miR- 6845-5p, hsa-miR-6887-5p, hsa-miR-6738-5p, hsa-miR-6872-3p, hsa-miR-4497, hsa-miR-1229-5p, hsa-miR-6820-5p, hsa-miR-6777-5p, hsa-miR-3917, hsa-miR-5787, hsa-miR-4286, hsa-miR-6877-5p, hsa-miR-1225-3p, hsa-miR-6088, hsa- miR-6800-5p, hsa-miR-1246, hsa-miR-4467, hsa-miR-4419b, hsa-miR-1914-3p, hsa-miR-4632-5p, hsa-miR-1915-5p, hsa- miR-3940-5p, hsa-miR-1185-2-3p, hsa-miR-6746-5p, hsa-miR-5001-5p, hsa-miR-1228-5p, hsa-miR-5572, hsa-miR- 4327, hsa-miR-4638-5p, hsa-miR-6799-5p, hsa-miR-6861-5p, hsa-miR-6727-5p, hsa-miR-4513, hsa-miR-6805-3p, hsa- miR-6808-5p, hsa-miR-4449, hsa-miR-1199-5p, hsa-miR-1275, hsa-miR-4792, hsa-miR-4443, hsa-miR-6891-5p, hsa-miR- 6826-5p, hsa-miR-6807-5p, hsa-miR-7150, hsa-miR-4534, hsa-miR-4476, hsa-miR-4649-5p, hsa-miR-4525, hsa-miR-1915- 3p, hsa-miR-4516, hsa-miR-4417, hsa-miR-642b-3p, hsa-miR-3141, hsa-miR-5100, hsa-miR-6848-5p, hsa-miR-4739, hsa- miR-4459, hsa-miR-1237-5p, hsa-miR-296-3p, hsa-miR-4665-3p, hsa-miR-6786-5p, hsa-miR-4258, hsa-miR-6510-5p, hsa-miR- 1343-5p, hsa-miR-1247-3p, hsa-miR-6805-5p, hsa-miR-4492, hsa-miR-1469, hsa-miR-1268b, hsa-miR-6858-5p, hsa-miR- 3937, hsa-miR-939-5p, hsa-miR-3656, hsa-miR-744-5p, hsa-miR-4687-3p, hsa-miR-4763-3p, hsa-miR-3620-5p, hsa- miR-3195, hsa-miR-6842-5p, hsa-miR-4707-5p, hsa-miR-642a-3p, hsa-miR-7113-3p, hsa-miR-4728-5p, hsa-miR-5195- 3p, hsa-miR-1185-1-3p, hsa-miR-6774-5p, hsa-miR-8059, hsa-miR-3131, hsa-miR-7847-3p, hsa-miR-4463, hsa-miR- 128-2-5p, hsa-miR-4508, hsa-miR-6806-5p, hsa-miR-7111-5p, hsa-miR-6782-5p, hsa-miR-4734, hsa-miR-3162-5p, hsa-miR-887-3p, hsa-miR-6752-5p, hsa-miR-6724-5p, hsa-miR-23b-3p, hsa-miR-23a-3p, hsa-miR-625-3p, hsa- miR-1228-3p, hsa-miR-614, hsa-miR-1913, hsa-miR-92a-2-5p, hsa-miR-187-5p, hsa-miR-16-5p, hsa-miR-92b- 3p, hsa-miR-150-3p, hsa-miR-564, hsa-miR-125a-3p, hsa-miR-92b-5p, hsa-miR-92a-3p, hsa-miR-663a genes in healthy body It was found as a marker for liver cancer.

Among them, the newly discovered gene as a marker for screening for the presence or absence of liver cancer is a polynucleotide comprising the nucleotide sequences shown in SEQ ID NOs: 1-167.

In addition, a discriminant for determining the presence or absence of liver cancer was created by Fisher's discriminant analysis using the expression level of these genes as an index. That is, a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 183 newly found in the presence of a learning sample group is input into Formula 2 to create a discriminant, and the calculated precision, sensitivity, and specificity are shown in Table 3 showed Table 4 shows the discriminant coefficients and integer terms at that time.

The precision, sensitivity, and specificity in the test sample group were calculated using the discriminant created above, and the discrimination performance of the selected polynucleotide was verified in an independent sample (Table 3). For example, when the measured expression level of the nucleotide sequence represented by SEQ ID NO: 1 is compared between healthy subjects (100 persons) and liver cancer patients (34 persons) of the learning sample group, the measured value of gene expression level of the liver cancer patient group with respect to the healthy body group It was shown that this was significantly lower (refer to the left side of Fig. 2), and this result was also reproducible in healthy subjects (50 patients) and liver cancer patients (16 patients) in the test sample group (see the right side of Fig. 2). Similarly, also in the other polynucleotides represented by SEQ ID NOs: 2 to 183, results (Table 2) of significantly lower (-) or higher (+) measured values of the gene expression level of the liver cancer patient group compared to the healthy body group (Table 2) were obtained, and these results could be verified in the test sample group. Further, for example, with respect to the nucleotide sequence represented by SEQ ID NO: 1, using the threshold (7.09) for discriminating both groups set in the learning sample group, the accuracy of liver cancer detection was calculated. There were 15 positive cases, 49 true negative cases, 1 false positive case, and 1 false negative case. From these values, the detection performance was obtained with a precision of 97%, a sensitivity of 94%, and a specificity of 98%. In this way, the detection performance of all polynucleotides represented by SEQ ID NOs: 1-183 was calculated, and is shown in Table 3.

Likewise, SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39, 40, 41, 43, 44, 45, 46, 47, 48, 50, 51, 54, 55, 56, 57, 58, 60, 61, 62, 63, 64, 65, 68, 73, 80, 86, 88, 91, 93, 94, 99, 114, 117, 170, 171, 172, 173, 174 and 175 72 polynucleotides consisting of a nucleotide sequence have a sensitivity of 93.8%, 93.8%, 93.8%, 87.5%, 75%, 87.5%, 62.5%, 81.2%, 93.8%, 93.8%, 75%, 93.8%, 62.5%, 93.8%, 56.2%, 56.2%, 56.2%, 93.8%, 68.8%, 87.5%, 93.8%, 81.2%, 87.5%, 62.5%, 56.2%, 68.8%, 81.2%, 81.2% , 62.5%, 87.5%, 68.8%, 75%, 75%, 75%, 62.5%, 93.8%, 75%, 56.2%, 62.5%, 62.5%, 68.8%, 87.5%, 75%, 62.5%, 75 %, 68.8%, 62.5%, 68.8%, 68.8%, 68.8%, 62.5%, 62.5%, 75%, 62.5%, 75%, 68.8%, 56.2%, 81.2%, 68.8%, 56.2%, 62.5%, 56.2%, 56.2%, 68.8%, 56.2%, 62.5%, 87.5%, 87.5%, 75%, 68.8%, 62.5% and 81.2% (Table 3). Here, from the comparative example described later, the sensitivity of AFP, which was the most sensitive among the four existing markers in the test sample group, was 53.3% (Table 5), so in the test sample group, for example, SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39, 40, 41, 43, 44, 45, 46, 47, 48, 50, 51, 54, 55, 56, 57, 58, 60, 61, 62, 72 polynucleotides comprising the nucleotide sequence represented by 63, 64, 65, 68, 73, 80, 86, 88, 91, 93, 94, 99, 114, 117, 170, 171, 172, 173, 174 and 175 could prove to discriminate liver cancer with sensitivity higher than AFP alone.

In addition, for example, seven polynucleotides comprising the nucleotide sequence represented by SEQ ID NOs: 1, 6, 15, 31, 46, 50, and 58 accurately detect all nine stage 1 liver cancer samples included in the test sample group. It was diagnosed as liver cancer. Therefore, these polynucleotides can detect liver cancer at an early stage and contribute to the early diagnosis of liver cancer.

[Example 2]

<Evaluation method for liver cancer discrimination performance by combination of a plurality of genetic markers using the test sample group samples>

In this Example, a method for evaluating liver cancer discrimination performance by combining the genetic markers selected in Example 1 was examined. Specifically, measurement of the expression level of any one of the polynucleotides consisting of the nucleotide sequence shown in SEQ ID NOs: 1-167 newly found among the polynucleotides consisting of the nucleotide sequence shown in SEQ ID NOs: 1-183 selected in Example 1 Fisher's discriminant analysis was performed on 16,533 two combinations containing at least one value, and a discriminant for determining the presence or absence of liver cancer was constructed. Next, the precision, sensitivity, and specificity in the test sample group were calculated using the discriminant created above, and the discrimination performance of the selected polynucleotide was verified in an independent sample.

For example, when the measured expression level of a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 1 and SEQ ID NO: 2 is compared between healthy subjects (100 people) and liver cancer patients (34 people) of the learning sample group, the healthy body group and A scatter diagram was obtained in which the expression level measurement values of the liver cancer patient group were significantly separated (see the left of Fig. 3), and this result was also reproducible in healthy subjects (50 patients) and liver cancer patients (16 patients) in the test sample group (Fig. 3 see right). Similarly, among the polynucleotides consisting of the nucleotide sequence shown in SEQ ID NOs: 1-183, the expression level of any one of the polynucleotides newly found in the polynucleotides consisting of the nucleotide sequences shown in SEQ ID NOs: 1-167 containing at least one or more values. Even in the two different combinations, a scatter plot was obtained that significantly separated the expression level measurement values between the healthy group and the liver cancer patient group, and these results could be verified in the test sample group. Further, for example, with respect to the nucleotide sequences represented by SEQ ID NO: 1 and SEQ ID NO: 2, a function for discriminating both groups set in the learning sample group (0 = 0.77x + y-15.07) is used to detect liver cancer hit rate As a result of calculating , there were 16 true positives, 50 true negatives, 0 false positives, and 0 false negatives, and from these values, accuracy of 100%, sensitivity of 100%, and specificity of 100% were obtained as detection performance. Similarly, among polynucleotides comprising the nucleotide sequence shown in SEQ ID NOs: 1 to 183, the expression level measurement value of any one of the polynucleotides newly found in the polynucleotide comprising the nucleotide sequence shown in SEQ ID NOs: 1 to 167 is at least one or more The detection performance of all branches of the two combinations including it was computed. As an example, Table 6 shows 182 combinations including the measured expression level of the polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 1 and the detection performance thereof. For example, SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 1 and SEQ ID NO: 3, SEQ ID NO: 1 and SEQ ID NO: 4, and the expression level of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 and SEQ ID NO: 5 All combinations showed sensitivities of 100%, 100%, 100%, 94% and 94%, respectively, in the test sample group. Similarly, as a result of calculating the sensitivity for the combination of the polynucleotide consisting of two nucleotide sequences represented by either SEQ ID NO: 1 and SEQ ID NO: 6 to 251, the sensitivity was 88% or more in all combinations (Table 6), and the existing liver cancer The sensitivity of the marker AFP exceeded 53.3% (Table 5). Accordingly, even when two polynucleotides comprising the nucleotide sequences shown in SEQ ID NOs: 1 to 183 were combined, excellent detection sensitivity for liver cancer was obtained.

In addition, 3, 4, 5, 6, 7, 8, 9, 10 or more of the measured expression level of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NOs: 1-183 By combining them, a marker for detecting liver cancer with even greater sensitivity is obtained. For example, with respect to a polynucleotide consisting of a nucleotide sequence represented by SEQ ID NOs: 1 to 167 newly found among polynucleotides consisting of a nucleotide sequence represented by SEQ ID NOs: 1 to 183 selected in Example 1, in the test sample group Obtain the expression value measured between the healthy group and the liver cancer group, and rank all polynucleotides in descending order of P values by Student's t-test, which shows statistical significance between groups (the lowest P value is 1 above), the liver cancer detection sensitivity of a combination of one to a plurality of polynucleotides was evaluated by adding them one by one from the above polynucleotides to the combination. That is, the order of the combination of polynucleotides in this evaluation is in the reverse order from SEQ ID NO: 167 shown in Table 2 to 166, 165 shown in SEQ ID NO. As a result, the sensitivity in the test sample group was 12.5% for one polynucleotide (SEQ ID NO: 167), 43.8% for two polynucleotides (SEQ ID NO: 166 and 167), and 4 polynucleotides (SEQ ID NO: 164 to 167) 68.8% in, 87.5% in 6 polynucleotides (SEQ ID NOs: 162-167), 93.8% in 10 polynucleotides (SEQ ID NOs: 158-167), 100% in 20 polynucleotides (SEQ ID NOs: 148-167), 30 100% of polynucleotides (SEQ ID NOs: 138-167), 100% of 50 polynucleotides (SEQ ID NOs: 118-167), 100% of 80 polynucleotides (SEQ ID NOs: 88-167), 110 polynucleotides (SEQ ID NOs: 118-167) 58-167), 100% in 150 polynucleotides (SEQ ID NOs: 18-167), and 100% in 167 polynucleotides (SEQ ID NOs: 1-167).

That is, it has been shown that when a plurality of polynucleotides are combined rather than a single polynucleotide or a smaller number of polynucleotides, higher liver cancer discrimination performance can be obtained. Here, the combination of a plurality of polynucleotides is not limited to the case of combining in the order of statistical significance as described above, and any combination of a plurality of polynucleotides can be used for the detection of liver cancer.

From these results, it can be said that all polynucleotides comprising the nucleotide sequences shown in SEQ ID NOs: 1 to 183 are excellent markers for detecting liver cancer.

[Table 2]

[Table 3]

[Table 4]

[Table 5-1]

[Table 5-2]

AFP is 10 ng/mL, CEA is 5 ng/mL, CA19-9 is 37 U/mL, and PIVKA-II is 40 mAU/mL as reference values. Samples showing more than these values are judged as positive, and the sensitivity of each tumor marker is determined. Calculated.

[Table 6]

[Example 3]

<Selection of genetic markers when the entire sample is used and evaluation method of liver cancer discrimination performance of the obtained genetic markers>

In this Example, the samples of the learning sample group and the test sample group used in Examples 1 and 2 were integrated, and genetic markers were selected and liver cancer discrimination performance was evaluated using the entire sample.

Specifically, the miRNA expression levels in the sera of 50 liver cancer patients and 150 healthy subjects obtained in the Reference Example were normalized by quantile normalization. In order to obtain a more reliable diagnostic marker, in the selection of the genetic marker, only genes having a gene expression level of 2 to the 6th power or more in 50% or more samples in either the liver cancer patient group or the healthy group were selected. In addition, in order to obtain statistical significance for discriminating between the liver cancer patient group and the healthy group, Bonferroni correction was performed on the P value obtained from the two-sided t test assuming equal variance for each gene expression level, and genes satisfying p < 0.01 were selected. Genetic markers used for explanatory variables of the discriminant were selected and listed in Table 7. In this way, in addition to the genes shown in Table 2, hsa-miR-4688, hsa-miR-4648, hsa-miR-6085, hsa-miR-6126, hsa-miR-6880 represented by SEQ ID NOs: 184 to 224 -5p, hsa-miR-328-5p, hsa-miR-6768-5p, hsa-miR-3180, hsa-miR-6087, hsa-miR-1273g-3p, hsa-miR-1225-5p, hsa-miR -3196, hsa-miR-4695-5p, hsa-miR-6732-5p, hsa-miR-638, hsa-miR-6813-5p, hsa-miR-665, hsa-miR-486-3p, hsa-miR -4466, hsa-miR-30c-1-3p, hsa-miR-3621, hsa-miR-6743-5p, hsa-miR-4298, hsa-miR-4741, hsa-miR-3619-3p, hsa-miR -6824-5p, hsa-miR-5698, hsa-miR-371a-5p, hsa-miR-4488, hsa-miR-1233-5p, hsa-miR-4723-5p, hsa-miR-24-3p, hsa -miR-1238-5p, hsa-miR-4442, hsa-miR-3928-3p, hsa-miR-6716-5p, hsa-miR-6089, hsa-miR-6124, hsa-miR-6778-5p, hsa The -miR-557 and hsa-miR-6090 genes were found as liver cancer markers for healthy individuals. Similarly to the polynucleotides represented by SEQ ID NOs: 1 to 183, in the polynucleotides represented by SEQ ID NOs: 184 to 224, the measured expression level of the liver cancer patient group compared to the healthy group was significantly lower (-) or high (+) results ( Table 7) was obtained, and these results could be verified in the test sample group. By using the measured expression level of the gene shown in Table 7 alone or in combination with the measured expression level of the gene shown in Table 2, it is possible to discriminate the sample newly obtained by the method described in Examples 1 and 2 have.

[Table 7]

[Example 4]

<Evaluation method for liver cancer-specific discrimination performance by combination of a plurality of genetic markers using the test sample group>

In this example, for the learning sample group of the sample group described in Reference Example 2, in the same manner as in Example 1, liver cancer patients and healthy individuals, colon cancer patients, biliary tract cancer patients, stomach cancer patients, esophageal cancer patients, The gene expression level of miRNA in the serum of a control group consisting of a colorectal cancer patient and a pancreatic biliary tract benign disease patient was compared, and a novel additional diagnostic gene marker was selected. As a result, liver cancer-specific discrimination performance is evaluated using one or two or more markers selected from the group consisting of a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NOs: 714 to 729 and the genetic marker selected in Example 1. did.

Specifically, first, the miRNA expression levels of the learning sample group and the test sample group obtained in Reference Example 2 were normalized by quantile normalization. Next, Fisher's discriminant analysis is performed on 1 to 4 combinations containing at least one or more measured expression levels of any one of the polynucleotides comprising the nucleotide sequences shown in SEQ ID NOs: 1 to 167 and 714 to 729, and liver cancer A discriminant was constructed to determine the presence or absence of . Next, using the liver cancer patient group as the positive sample group, the healthy body group, the colon cancer patient group, the biliary tract cancer patient group, the stomach cancer patient group, the esophageal cancer patient group, the colon cancer patient group and the pancreatic biliary tract cancer patient group as the negative sample group, the discriminant created above was was used to calculate precision, sensitivity, and specificity in the test sample group, and the discrimination performance of the selected polynucleotide was verified in an independent sample.

Most of the polynucleotides consisting of the nucleotide sequence represented by the SEQ ID NO: 1 to 224 and 714 to 729, corresponding to the miRNA markers in Table 1, or a complementary sequence thereof, are relatively in the determination of the presence or absence of liver cancer. It was able to specifically discriminate liver cancer from other cancers while providing high precision, sensitivity and specificity. Examples of polynucleotides capable of specifically binding to a target marker include SEQ ID NOs: 1, 2, 3, 5, 7, 9, 12, 17, 20, 22, 27, 28, 29, 38, 39, 44 , 46, 48, 51, 54, 61, 76, 89, 93, 101, 109, 116, 123, 132, 134, 136, 148, 150, 151, 155, 157, 164, 166, 167, 172, 180 , 186, 188, 189, 197, 198, 214, 216, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728 and 729. Among the combinations of a plurality of polynucleotides selected from the group consisting of polynucleotides consisting of a sequence or a complementary sequence (carcinoma-specific polynucleotide group 1), SEQ ID NOs: 1, 3, 7, 9, 22, 38, 44, 134, 148, 155, 157, 164, 167, 172, 214, 714, 715, 716, and a polynucleotide selected from the group consisting of a polynucleotide comprising a complementary sequence thereof (carcinoma-specific polynucleotide group 2) The combination containing at least one nucleotide was able to specifically discriminate liver cancer from other cancers with high precision.

As the number of combinations of polynucleotides having the carcinoma specificity, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more combinations of the number are possible. , it was able to show more than 90% of discrimination precision in 4 or more combinations.

Specifically, Table 8-1 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 1 or its complementary sequence. "Sequence number" in Table 8-1 represents one polynucleotide or a combination of a plurality of polynucleotides used as SEQ ID NOs (Tables 8-2 to 8-19 are also the same). When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 or its complementary sequence was measured alone (one), the precision was 71.2% in the learning sample group and 73.2% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 1 or its complementary sequence, the highest precision in the learning sample group is 88.1%, the test sample In the group, the precision was 90%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 1 or its complementary sequence, the highest precision in the learning sample group is 90.2%, the test sample In the group, the precision was 90.5%. Further, for example, when measured using four combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 1 or its complementary sequence, the highest precision in the learning sample group is 92.3%, the test sample In the group, the precision was 93.2%.

Table 8-2 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 3 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 3 or its complementary sequence was measured alone (one), the precision was 78.7% in the learning sample group and 73.2% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 3 or its complementary sequence, the highest precision in the learning sample group is 88.7%, the test sample In the group, the precision was 87.4%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 3 or its complementary sequence, the highest precision in the learning sample group is 91.8%, the test sample In the group, the precision was 87.9%. Further, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 3 or its complementary sequence, the highest precision in the learning sample group is 92.9%, the test sample In the group, the precision was 93.2%.

Table 8-3 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 7 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 7 or its complementary sequence was measured alone (one), the precision was 85.5% in the learning sample group and 84.7% in the test sample group. In addition, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 7 or its complementary sequence, the highest precision in the learning sample group is 91.5%, the test sample In the group, the precision was 90.5%. In addition, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 7 or its complementary sequence, the highest precision in the learning sample group is 93.7%, the test sample In the group, the precision was 92.1%. Further, for example, when measured using four combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 7 or its complementary sequence, the highest precision in the learning sample group is 94.4%, the test sample In the group, the precision was 92.6%.

Table 8-4 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 9 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 9 or its complementary sequence was measured using singly (one), the precision was 59.7% in the learning sample group and 59.5% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 9 or its complementary sequence, the highest precision in the learning sample group is 86%, the test sample In the group, the precision was 81.1%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 9 or its complementary sequence, the highest precision in the learning sample group is 91.8%, the test sample In the group, the precision was 84.7%. In addition, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 9 or its complementary sequence, the highest precision in the learning sample group is 94.7%, the test sample In the group, the precision was 92.1%.

Table 8-5 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 22 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 22 or its complementary sequence was measured alone (one), the precision was 76.5% in the learning sample group, and the precision was 78.9% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 22 or its complementary sequence, the highest precision in the learning sample group is 85.8%, the test sample In the group, the precision was 84.7%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 22 or its complementary sequence, the highest precision in the learning sample group is 91.3%, the test sample In the group, the precision was 91.6%. Further, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 22 or a complementary sequence thereof, the highest precision in the learning sample group is 93.7%, the test sample In the group, the precision was 93.7%.

Table 8-6 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 38 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 38 or its complementary sequence was measured alone (one), the precision was 65.5% in the learning sample group and 65.8% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 38 or its complementary sequence, the highest precision in the learning sample group is 86.3%, and the test sample In the group, the precision was 84.2%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 38 or its complementary sequence, the highest precision in the learning sample group is 92.3%, the test sample In the group, the precision was 91.6%. Further, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 38 or its complementary sequence, the highest precision in the learning sample group is 94.2%, the test sample In the group, the precision was 92.1%.

Table 8-7 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 44 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 44 or its complementary sequence was measured alone (one), the precision was 62.6% in the learning sample group and 62.1% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 44 or its complementary sequence, the highest precision in the learning sample group is 90.5%, the test sample In the group, the precision was 86.3%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 44 or its complementary sequence, the highest precision in the learning sample group is 92.9%, the test sample In the group, the precision was 91.1%. Further, for example, when measured using four combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 44 or its complementary sequence, the highest precision in the learning sample group is 93.7%, the test sample In the group, the precision was 91.6%.

Table 8-8 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 134 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 134 or its complementary sequence was measured alone (one), the precision of 53.4% in the learning sample group and 58.9% in the test sample group were shown. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 134 or its complementary sequence, the highest precision in the learning sample group is 87.3%, the test sample In the group, the precision was 84.2%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 134 or its complementary sequence, the highest precision in the learning sample group is 92.9%, the test sample In the group, the precision was 91.1%. Further, for example, when measured using four combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 134 or its complementary sequence, the highest precision in the learning sample group is 93.7%, the test sample In the group, the precision was 92.1%.

Tables 8-9 show the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 148 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 148 or its complementary sequence was measured alone (one), the precision was 73.6% in the learning sample group and 75.3% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 148 or its complementary sequence, the highest precision in the learning sample group is 86.3%, the test sample In the group, the precision was 85.3%. In addition, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 148 or its complementary sequence, the highest precision in the learning sample group is 93.7%, the test sample In the group, the precision was 91.6%. Further, for example, when measured using four combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 148 or its complementary sequence, the highest precision in the learning sample group is 93.7%, the test sample In the group, the precision was 92.1%.

Tables 8-10 show the discrimination precision when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 155 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 155 or its complementary sequence was measured alone (one), the precision was 60.8% in the learning sample group and 58.9% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 155 or its complementary sequence, the highest precision in the learning sample group is 86.5%, the test sample In the group, the precision was 85.8%. In addition, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 155 or its complementary sequence, the highest precision in the learning sample group is 90.5%, the test sample In the group, the precision was 91.6%. Further, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 155 or its complementary sequence, the highest precision in the learning sample group is 93.4%, the test sample In the group, the precision was 91.6%.

Tables 8-11 show the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 157 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 157 or its complementary sequence was measured alone (one), the precision was 70.3% in the learning sample group and 68.9% in the test sample group. Further, for example, when measurement is performed using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 157 or its complementary sequence, the highest precision in the learning sample group is 86.5%, the test sample In the group, the precision was 83.2%. Further, for example, when measurement is performed using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 157 or its complementary sequence, the highest precision in the learning sample group is 91%, the test sample In the group, the precision was 91.6%. Further, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 157 or its complementary sequence, the highest precision in the learning sample group is 93.9%, the test sample In the group, the precision was 92.6%.

Table 8-12 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 164 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 164 or its complementary sequence was measured alone (one), the precision was 72.4% in the learning sample group and 65.8% in the test sample group. In addition, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 164 or its complementary sequence, the highest precision in the learning sample group is 87.6%, the test sample In the group, the precision was 87.4%. In addition, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 164 or its complementary sequence, the highest precision in the learning sample group is 91.5%, the test sample In the group, the precision was 92.1%. Further, for example, when measured using four combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 164 or its complementary sequence, the highest precision in the learning sample group is 92.6%, the test sample In the group, the precision was 90.5%.

Tables 8-13 show the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 167 or its complementary sequence was measured alone (one), the precision was 62.1% in the learning sample group and 57.4% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or its complementary sequence, the highest precision in the learning sample group is 89.2%, the test sample In the group, the precision was 87.4%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or its complementary sequence, the highest precision in the learning sample group is 92.1%, the test sample In the group, the precision was 90%. Further, for example, when measured using four combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or its complementary sequence, the highest precision in the learning sample group is 93.4%, the test sample In the group, the precision was 91.1%.

Tables 8-14 show the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 172 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 172 or its complementary sequence was measured alone (one), the precision was 76.8% in the learning sample group and 75.8% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 172 or its complementary sequence, the highest precision in the learning sample group is 86.3%, the test sample In the group, the precision was 83.7%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 172 or its complementary sequence, the highest precision in the learning sample group is 90.2%, the test sample In the group, the precision was 90.5%. Further, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 172 or its complementary sequence, the highest precision in the learning sample group is 92.1%, the test sample In the group, the precision was 93.2%.

Tables 8-15 show the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 214 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 214 or its complementary sequence was measured alone (one), the precision was 69.5% in the learning sample group and 67.4% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 214 or its complementary sequence, the highest precision in the learning sample group is 89.2%, the test sample In the group, the precision was 87.9%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 214 or its complementary sequence, the highest precision in the learning sample group is 91.5%, the test sample In the group, the precision was 90.5%. Further, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 214 or its complementary sequence, the highest precision in the learning sample group is 93.4%, the test sample In the group, the precision was 92.6%.

Tables 8-16 show the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 714 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 714 or its complementary sequence was measured alone (one), the precision was 44.7% in the learning sample group and 46.8% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 714 or its complementary sequence, the highest precision in the learning sample group is 90.2%, the test sample In the group, the precision was 87.4%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 714 or its complementary sequence, the highest precision in the learning sample group is 92.1%, the test sample In the group, the precision was 91.1%. Further, for example, when measured using four combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 714 or its complementary sequence, the highest precision in the learning sample group is 94.4%, the test sample In the group, the precision was 94.2%.

Tables 8-17 show the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 715 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 715 or its complementary sequence was measured alone (one), the precision was 64.2% in the learning sample group and 65.8% in the test sample group. In addition, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 715 or its complementary sequence, the highest precision in the learning sample group is 87.9%, the test sample In the group, the precision was 86.8%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 715 or its complementary sequence, the highest precision in the learning sample group is 91.8%, the test sample In the group, the precision was 91.1%. In addition, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 715 or its complementary sequence, the highest precision in the learning sample group is 93.9%, the test sample In the group, the precision was 93.2%.

Table 8-18 shows the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 716 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 716 or its complementary sequence was measured alone (one), the precision was 62.6% in the learning sample group and 58.9% in the test sample group. Further, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 716 or a complementary sequence thereof, the highest precision in the learning sample group is 90.2%, the test sample In the group, the precision was 86.3%. In addition, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 716 or its complementary sequence, the highest precision in the learning sample group is 91.3%, the test sample In the group, the precision was 91.6%. Further, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 716 or its complementary sequence, the highest precision in the learning sample group is 93.7%, the test sample In the group, the precision was 92.1%.

Tables 8-19 show the discrimination accuracy when measured using a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 717 or its complementary sequence. When the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 717 or its complementary sequence was measured alone (one), the precision was 70.3% in the learning sample group and 66.3% in the test sample group. In addition, for example, when measured using two combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 717 or its complementary sequence, the highest precision in the learning sample group is 86.8%, the test sample In the group, the precision was 84.7%. Further, for example, when measured using three combinations comprising at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 717 or its complementary sequence, the highest precision in the learning sample group is 92.3%, the test sample In the group, the precision was 90.5%. In addition, for example, when measured using four combinations containing at least one polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 717 or its complementary sequence, the highest precision in the learning sample group is 93.1%, the test sample In the group, the precision was 92.6%.

In addition, by using the expression level measurement value of the nucleotide sequence represented by SEQ ID NOs: 7, 9, 27, and 148, 35 patients with liver cancer, 99 patients with healthy body, 72 patients with colon cancer, 61 patients with biliary tract cancer, and gastric cancer patients in the learning sample group When 38 patients, 25 patients with esophageal cancer, 35 patients with colorectal cancer, and 16 patients with benign pancreatic biliary disease were compared, a scatter plot was obtained in which the discriminant scores of the liver cancer patient group and other groups were significantly separated (Fig. 4), and this result could also be reproduced in the test sample group (refer to the lower drawing of FIG. 4).

[Table 8-1]

[Table 8-2]

[Table 8-3]

[Table 8-4]

[Table 8-5]

[Table 8-6]

[Table 8-7]

[Table 8-8]

[Table 8-9]

[Table 8-10]

[Table 8-11]

[Table 8-12]

[Table 8-13]

[Table 8-14]

[Table 8-15]

[Table 8-16]

[Table 8-17]

[Table 8-18]

[Table 8-19]

[Comparative Example 1]

<Hepatic cancer discrimination performance of existing blood tumor markers>

The blood concentrations of AFP, CEA, CA19-9 and PIVKA-II, which are the existing tumor markers for liver cancer screening, were measured for the learning sample group and the test sample group obtained in Reference Example 1 above. These tumor markers are cancerous when the blood concentration is higher than the standard values described in principle and non-patent document 5 (10 ng/mL for AFP, 5 ng/mL for CEA, 37 U/mL for CA19-9, and 40 mAU/mL for PIVKA-II). is said to have suspicions of Therefore, it is checked whether the blood concentration of each tumor marker exceeds the reference value for each sample, and it is confirmed whether the result determines that the liver cancer patient is cancer, and each existing marker in the learning sample group and the test sample group calculated the sensitivity of These results are shown in Table 5. The sensitivity of AFP, which had the highest sensitivity among the four existing tumor markers measured, was only 56.3% in the learning sample group and 53.3% in the test sample group, indicating that any marker was not useful for detecting liver cancer ( Table 5).

On the other hand, as shown in Tables 3 and 6 of Examples 1 and 2, all polynucleotides comprising the nucleotide sequence shown in SEQ ID NOs: 1 to 183 are one or two showing sensitivity above the existing liver cancer markers. A combination of dogs exists, making it an excellent diagnostic marker.

As shown in the above Examples and Comparative Examples, the kit and the like of the present invention can detect liver cancer more sensitively than existing tumor markers, making it possible to detect liver cancer at an early stage, and as a result, the prospect of cure This high resection operation is possible, which leads to a significant improvement in the survival rate.

(Industrial Applicability)

According to the present invention, since liver cancer can be effectively detected by a simple and inexpensive method, early detection, diagnosis, and treatment of liver cancer become possible. In addition, since the method of the present invention can detect liver cancer in a low-invasive manner using patient blood, it becomes possible to detect liver cancer simply and quickly.

All publications, patents, and patent applications cited in this specification are incorporated herein by reference as they are.

SEQUENCE LISTING <110> Toray Industries, Inc. National Cancer Center <120> Kit or device and method for detecting hepatic cancer <130> PH-6238-PCT <150> JP 2014-124880 <151> 2014-06-18 <160> 765 <170> PatentIn version 3.5 <210> 1 <211> 22 <212> RNA <213> Homo sapiens <400> 1 cuccuggggc ccgcacucuc gc 22 <210> 2 <211> 21 <212> RNA <213> Homo sapiens <400> 2 cgggagcugg ggucugcagg u 21 <210> 3 <211> 20 <212> RNA <213> Homo sapiens <400> 3 ucucuucauc uaccccccag 20 <210> 4 <211> 20 <212> RNA <213> Homo sapiens <400> 4 cggggugggu gagguggggc 20 <210> 5 <211> 18 <212> RNA <213> Homo sapiens <400> 5 ccagaggugg ggacugag 18 <210> 6 <211> 23 <212> RNA <213> Homo sapiens <400> 6 agaggcuuug ugcggauacg ggg 23 <210> 7 <211> 19 <212> RNA <213> Homo sapiens <400> 7 ggcuggucag augggagug 19 <210> 8 <211> 22 <212> RNA <213> Homo sapiens <400> 8 ugauugucuu cccccacccu ca 22 <210> 9 <211> 19 <212> RNA <213> Homo sapiens <400> 9 uugaucucgg aagcuaagc 19 <210> 10 <211> 22 <212> RNA <213> Homo sapiens <400> 10 acgcccuucc cccccuucuu ca 22 <210> 11 <211> 22 <212> RNA <213> Homo sapiens <400> 11 cuucccccca guaaucuuca uc 22 <210> 12 <211> 22 <212> RNA <213> Homo sapiens <400> 12 uggcgggggu agagcuggcu gc 22 <210> 13 <211> 20 <212> RNA <213> Homo sapiens <400> 13 ggauccgagu cacggcacca 20 <210> 14 <211> 22 <212> RNA <213> Homo sapiens <400> 14 ggcuggagcg agugcagugg ug 22 <210> 15 <211> 21 <212> RNA <213> Homo sapiens <400> 15 ucaccuggcu ggcccgccca g 21 <210> 16 <211> 18 <212> RNA <213> Homo sapiens <400> 16 auccuaguca cggcacca 18 <210> 17 <211> 21 <212> RNA <213> Homo sapiens <400> 17 gcugggaagg caaagggacg u 21 <210> 18 <211> 18 <212> RNA <213> Homo sapiens <400> 18 uucccagcca acgcacca 18 <210> 19 <211> 21 <212> RNA <213> Homo sapiens <400> 19 uggggggug gggagagaga g 21 <210> 20 <211> 22 <212> RNA <213> Homo sapiens <400> 20 aggcgaugug gggauguaga ga 22 <210> 21 <211> 19 <212> RNA <213> Homo sapiens <400> 21 ugggggagau ggggguuga 19 <210> 22 <211> 22 <212> RNA <213> Homo sapiens <400> 22 gguggcccgg ccgugccuga gg 22 <210> 23 <211> 21 <212> RNA <213> Homo sapiens <400> 23 ugagggaccc aggacaggag a 21 <210> 24 <211> 20 <212> RNA <213> Homo sapiens <400> 24 ggcggcgggg agguaggcag 20 <210> 25 <211> 21 <212> RNA <213> Homo sapiens <400> 25 uggggcgggg caggucccug c 21 <210> 26 <211> 18 <212> RNA <213> Homo sapiens <400> 26 gggucccggg gagggggg 18 <210> 27 <211> 22 <212> RNA <213> Homo sapiens <400> 27 ugggcgaggg cggcugagcg gc 22 <210> 28 <211> 23 <212> RNA <213> Homo sapiens <400> 28 ggaugguugg gggcggucgg cgu 23 <210> 29 <211> 25 <212> RNA <213> Homo sapiens <400> 29 agcggggagg aagugggcgc ugcuu 25 <210> 30 <211> 21 <212> RNA <213> Homo sapiens <400> 30 guguggccgg caggcgggug g 21 <210> 31 <211> 21 <212> RNA <213> Homo sapiens <400> 31 caggaguggg gggugggacg u 21 <210> 32 <211> 21 <212> RNA <213> Homo sapiens <400> 32 caggcaggug uaggguggag c 21 <210> 33 <211> 22 <212> RNA <213> Homo sapiens <400> 33 uuggggauug ggucaggcca gu 22 <210> 34 <211> 17 <212> RNA <213> Homo sapiens <400> 34 guggggccag gcggugg 17 <210> 35 <211> 22 <212> RNA <213> Homo sapiens <400> 35 gugggugcug gugggagccg ug 22 <210> 36 <211> 22 <212> RNA <213> Homo sapiens <400> 36 aaaccguuac cauuacugag uu 22 <210> 37 <211> 22 <212> RNA <213> Homo sapiens <400> 37 ucaaaaucag gagucggggc uu 22 <210> 38 <211> 22 <212> RNA <213> Homo sapiens <400> 38 caggcacggg agcucaggug ag 22 <210> 39 <211> 22 <212> RNA <213> Homo sapiens <400> 39 gggggucccc ggugcucgga uc 22 <210> 40 <211> 23 <212> RNA <213> Homo sapiens <400> 40 cggggccgua gcacuugucug aga 23 <210> 41 <211> 22 <212> RNA <213> Homo sapiens <400> 41 uggggaggug uggagucagc au 22 <210> 42 <211> 19 <212> RNA <213> Homo sapiens <400> 42 aucccaccac ugccaccau 19 <210> 43 <211> 21 <212> RNA <213> Homo sapiens <400> 43 acaggagugg gggugggaca u 21 <210> 44 <211> 23 <212> RNA <213> Homo sapiens <400> 44 cugggggacg cgugagcgcg agc 23 <210> 45 <211> 21 <212> RNA <213> Homo sapiens <400> 45 aagggacagg gagggucgug g 21 <210> 46 <211> 21 <212> RNA <213> Homo sapiens <400> 46 cggcggggac ggcgauuggu c 21 <210> 47 <211> 22 <212> RNA <213> Homo sapiens <400> 47 gcccaggacu uugugcgggg ug 22 <210> 48 <211> 25 <212> RNA <213> Homo sapiens <400> 48 gugaggcggg gccaggaggg ugugu 25 <210> 49 <211> 21 <212> RNA <213> Homo sapiens <400> 49 agggcccccc cucauccug u 21 <210> 50 <211> 22 <212> RNA <213> Homo sapiens <400> 50 caucucuaag gaacuccccc aa 22 <210> 51 <211> 21 <212> RNA <213> Homo sapiens <400> 51 cgggccggag gucaagggcg u 21 <210> 52 <211> 23 <212> RNA <213> Homo sapiens <400> 52 ugaggggcag agagcgagac uuu 23 <210> 53 <211> 23 <212> RNA <213> Homo sapiens <400> 53 ugagcaccac acaggccggg cgc 23 <210> 54 <211> 20 <212> RNA <213> Homo sapiens <400> 54 gccggggcuu ugggugaggg 20 <210> 55 <211> 22 <212> RNA <213> Homo sapiens <400> 55 ucgggccugg gguuggggga gc 22 <210> 56 <211> 20 <212> RNA <213> Homo sapiens <400> 56 gugucugggc ggacagcugc 20 <210> 57 <211> 21 <212> RNA <213> Homo sapiens <400> 57 agcggugcuc cugcgggccg a 21 <210> 58 <211> 23 <212> RNA <213> Homo sapiens <400> 58 uggggaaggc uuggcaggga aga 23 <210> 59 <211> 23 <212> RNA <213> Homo sapiens <400> 59 gugaguggga gccggugggg cug 23 <210> 60 <211> 23 <212> RNA <213> Homo sapiens <400> 60 ugaggaauug gcagggaagg gga 23 <210> 61 <211> 24 <212> RNA <213> Homo sapiens <400> 61 ugaggggccu cagaccgagc uuuu 24 <210> 62 <211> 20 <212> RNA <213> Homo sapiens <400> 62 gcggaaggcg gagcggcgga 20 <210> 63 <211> 23 <212> RNA <213> Homo sapiens <400> 63 ugggcagggg cuuauuguag gag 23 <210> 64 <211> 22 <212> RNA <213> Homo sapiens <400> 64 ccccuggggc ugggcaggcg ga 22 <210> 65 <211> 23 <212> RNA <213> Homo sapiens <400> 65 agaagaaggc ggucggucug cgg 23 <210> 66 <211> 18 <212> RNA <213> Homo sapiens <400> 66 aucccaccuc ugccacca 18 <210> 67 <211> 23 <212> RNA <213> Homo sapiens <400> 67 ggaggcgcag gcucggaaag gcg 23 <210> 68 <211> 19 <212> RNA <213> Homo sapiens <400> 68 cggggccaga gcaagagc 19 <210> 69 <211> 23 <212> RNA <213> Homo sapiens <400> 69 uggggggaca gauggagagg aca 23 <210> 70 <211> 23 <212> RNA <213> Homo sapiens <400> 70 cgagggguag aagagcacag ggg 23 <210> 71 <211> 21 <212> RNA <213> Homo sapiens <400> 71 cccaugccuc cugccgcggu c 21 <210> 72 <211> 17 <212> RNA <213> Homo sapiens <400> 72 cucggggacg gcugggc 17 <210> 73 <211> 24 <212> RNA <213> Homo sapiens <400> 73 guggguaggg uuugggggag agcg 24 <210> 74 <211> 19 <212> RNA <213> Homo sapiens <400> 74 ugcggcagag cugggguca 19 <210> 75 <211> 23 <212> RNA <213> Homo sapiens <400> 75 acggggaguc aggcaguggu gga 23 <210> 76 <211> 20 <212> RNA <213> Homo sapiens <400> 76 gcucggacug agcagguggg 20 <210> 77 <211> 20 <212> RNA <213> Homo sapiens <400> 77 gggcuggggc gcggggaggu 20 <210> 78 <211> 17 <212> RNA <213> Homo sapiens <400> 78 accccacucc ugguacc 17 <210> 79 <211> 22 <212> RNA <213> Homo sapiens <400> 79 agggccgaag gguggaagcu gc 22 <210> 80 <211> 22 <212> RNA <213> Homo sapiens <400> 80 ugagccccug ugccgccccc ag 22 <210> 81 <211> 20 <212> RNA <213> Homo sapiens <400> 81 agagaugaag cggggggggcg 20 <210> 82 <211> 21 <212> RNA <213> Homo sapiens <400> 82 guaggugaca gucaggggcg g 21 <210> 83 <211> 19 <212> RNA <213> Homo sapiens <400> 83 aauggauuuu uggagcagg 19 <210> 84 <211> 22 <212> RNA <213> Homo sapiens <400> 84 uggcggcggu aguuaugggc uu 22 <210> 85 <211> 18 <212> RNA <213> Homo sapiens <400> 85 gaggcugaag gaagaugg 18 <210> 86 <211> 22 <212> RNA <213> Homo sapiens <400> 86 ggaggggucc cgcacuggga gg 22 <210> 87 <211> 23 <212> RNA <213> Homo sapiens <400> 87 gagggcagcg uggguguggc gga 23 <210> 88 <211> 22 <212> RNA <213> Homo sapiens <400> 88 accuugccuu gcugcccggg cc 22 <210> 89 <211> 20 <212> RNA <213> Homo sapiens <400> 89 guggguuggg gcgggcucug 20 <210> 90 <211> 22 <212> RNA <213> Homo sapiens <400> 90 auauacaggg ggagacucuc au 22 <210> 91 <211> 22 <212> RNA <213> Homo sapiens <400> 91 ccgggagaag gagguggccu gg 22 <210> 92 <211> 24 <212> RNA <213> Homo sapiens <400> 92 agggcuggac ucagcggcgg agcu 24 <210> 93 <211> 21 <212> RNA <213> Homo sapiens <400> 93 gugggcgggg gcaggugugu g 21 <210> 94 <211> 21 <212> RNA <213> Homo sapiens <400> 94 guuggggugc aggggucugc u 21 <210> 95 <211> 19 <212> RNA <213> Homo sapiens <400> 95 ggcuugcaug ggggacugg 19 <210> 96 <211> 21 <212> RNA <213> Homo sapiens <400> 96 acucggcugc gguggacaag u 21 <210> 97 <211> 20 <212> RNA <213> Homo sapiens <400> 97 ggggaggugu gcagggcugg 20 <210> 98 <211> 22 <212> RNA <213> Homo sapiens <400> 98 acuggguagg uggggcucca gg 22 <210> 99 <211> 23 <212> RNA <213> Homo sapiens <400> 99 cucggggcag gcggcuggga gcg 23 <210> 100 <211> 22 <212> RNA <213> Homo sapiens <400> 100 agacugacgg cuggaggccc au 22 <210> 101 <211> 23 <212> RNA <213> Homo sapiens <400> 101 uugcucugcu cccccgcccc cag 23 <210> 102 <211> 22 <212> RNA <213> Homo sapiens <400> 102 caggcaggga ggugggacca ug 22 <210> 103 <211> 22 <212> RNA <213> Homo sapiens <400> 103 cgucccgggg cugcgcgagg ca 22 <210> 104 <211> 20 <212> RNA <213> Homo sapiens <400> 104 ccugagcccg ggccgcgcag 20 <210> 105 <211> 17 <212> RNA <213> Homo sapiens <400> 105 gugggggaga ggcuguc 17 <210> 106 <211> 18 <212> RNA <213> Homo sapiens <400> 106 cggugagcgc ucgcuggc 18 <210> 107 <211> 17 <212> RNA <213> Homo sapiens <400> 107 uuggaggcgu ggguuuu 17 <210> 108 <211> 19 <212> RNA <213> Homo sapiens <400> 108 uaaggagggg gaugagggg 19 <210> 109 <211> 23 <212> RNA <213> Homo sapiens <400> 109 ucaauaggaa agagguggga ccu 23 <210> 110 <211> 22 <212> RNA <213> Homo sapiens <400> 110 gugagccagu ggaauggaga gg 22 <210> 111 <211> 18 <212> RNA <213> Homo sapiens <400> 111 cuggcagggg gagaggua 18 <210> 112 <211> 17 <212> RNA <213> Homo sapiens <400> 112 ggauggagga ggggucu 17 <210> 113 <211> 22 <212> RNA <213> Homo sapiens <400> 113 caggaaggau uuagggacag gc 22 <210> 114 <211> 24 <212> RNA <213> Homo sapiens <400> 114 ugggcgaggg gugggcucuc agag 24 <210> 115 <211> 21 <212> RNA <213> Homo sapiens <400> 115 ggggggaugu gcaugcuggu u 21 <210> 116 <211> 20 <212> RNA <213> Homo sapiens <400> 116 ccccagggcg acgcggcggg 20 <210> 117 <211> 17 <212> RNA <213> Homo sapiens <400> 117 gggagaaggg ucggggc 17 <210> 118 <211> 18 <212> RNA <213> Homo sapiens <400> 118 ggugggcuuc ccggaggg 18 <210> 119 <211> 22 <212> RNA <213> Homo sapiens <400> 119 agacacauuu ggagagggac cc 22 <210> 120 <211> 19 <212> RNA <213> Homo sapiens <400> 120 gagggcgggu ggaggagga 19 <210> 121 <211> 22 <212> RNA <213> Homo sapiens <400> 121 uucagauccc agcggugccu cu 22 <210> 122 <211> 23 <212> RNA <213> Homo sapiens <400> 122 ugggggcugg gaugggccau ggu 23 <210> 123 <211> 25 <212> RNA <213> Homo sapiens <400> 123 aagggagggag gagcggaggg gcccu 25 <210> 124 <211> 22 <212> RNA <213> Homo sapiens <400> 124 ccaggaggcg gaggaggugg ag 22 <210> 125 <211> 21 <212> RNA <213> Homo sapiens <400> 125 cggggggcggg gccgaagcgc g 21 <210> 126 <211> 22 <212> RNA <213> Homo sapiens <400> 126 gaggguuggg uggaggcucu cc 22 <210> 127 <211> 26 <212> RNA <213> Homo sapiens <400> 127 cucggccgcg gcgcguagcc cccgcc 26 <210> 128 <211> 21 <212> RNA <213> Homo sapiens <400> 128 gcgguggggc cggaggggcg u 21 <210> 129 <211> 17 <212> RNA <213> Homo sapiens <400> 129 ccccgccacc gccuugg 17 <210> 130 <211> 22 <212> RNA <213> Homo sapiens <400> 130 cagcagggga gagagaggag uc 22 <210> 131 <211> 22 <212> RNA <213> Homo sapiens <400> 131 uggggagcgg cccccggug gg 22 <210> 132 <211> 24 <212> RNA <213> Homo sapiens <400> 132 ccccgggaac guccagacug gagc 24 <210> 133 <211> 22 <212> RNA <213> Homo sapiens <400> 133 uagggggcgg cuuguggagu gu 22 <210> 134 <211> 17 <212> RNA <213> Homo sapiens <400> 134 ggggcugggc gcgcgcc 17 <210> 135 <211> 22 <212> RNA <213> Homo sapiens <400> 135 cucggcgcgg ggcgcgggcu cc 22 <210> 136 <211> 20 <212> RNA <213> Homo sapiens <400> 136 cgggcguggu ggugggggug 20 <210> 137 <211> 22 <212> RNA <213> Homo sapiens <400> 137 gugaggaggg gcuggcaggg ac 22 <210> 138 <211> 23 <212> RNA <213> Homo sapiens <400> 138 acaggcggcu guagcaaugg ggg 23 <210> 139 <211> 24 <212> RNA <213> Homo sapiens <400> 139 uggggagcug aggcucuggg ggug 24 <210> 140 <211> 17 <212> RNA <213> Homo sapiens <400> 140 ggcgggugcg ggggugg 17 <210> 141 <211> 22 <212> RNA <213> Homo sapiens <400> 141 ugcggggcua gggcuaacag ca 22 <210> 142 <211> 21 <212> RNA <213> Homo sapiens <400> 142 uggcuguugg aggggggcagg c 21 <210> 143 <211> 24 <212> RNA <213> Homo sapiens <400> 143 aggcaggggc uggugcuggg cggg 24 <210> 144 <211> 22 <212> RNA <213> Homo sapiens <400> 144 gugggcuggg cugggcuggg cc 22 <210> 145 <211> 17 <212> RNA <213> Homo sapiens <400> 145 cgcgccgggc ccggguu 17 <210> 146 <211> 22 <212> RNA <213> Homo sapiens <400> 146 ugggggggu cucuagccaa gg 22 <210> 147 <211> 23 <212> RNA <213> Homo sapiens <400> 147 gccccggcgc gggcggguuc ugg 23 <210> 148 <211> 22 <212> RNA <213> Homo sapiens <400> 148 agacacauuu ggagagggaa cc 22 <210> 149 <211> 23 <212> RNA <213> Homo sapiens <400> 149 ccucccugcc cgccucucug cag 23 <210> 150 <211> 23 <212> RNA <213> Homo sapiens <400> 150 ugggagggga gaggcagcaa gca 23 <210> 151 <211> 21 <212> RNA <213> Homo sapiens <400> 151 auccaguucu cugagggggc u 21 <210> 152 <211> 22 <212> RNA <213> Homo sapiens <400> 152 auauacaggg ggagacucuu au 22 <210> 153 <211> 25 <212> RNA <213> Homo sapiens <400> 153 acuugggcag gagggacccu guaug 25 <210> 154 <211> 22 <212> RNA <213> Homo sapiens <400> 154 ggggaacugu agaugaaaag gc 22 <210> 155 <211> 23 <212> RNA <213> Homo sapiens <400> 155 ucgaggacug guggaagggc cuu 23 <210> 156 <211> 21 <212> RNA <213> Homo sapiens <400> 156 cguggaggac gaggaggagg c 21 <210> 157 <211> 17 <212> RNA <213> Homo sapiens <400> 157 gagacugggg uggggcc 17 <210> 158 <211> 23 <212> RNA <213> Homo sapiens <400> 158 gggggccgau acacuguacg aga 23 <210> 159 <211> 17 <212> RNA <213> Homo sapiens <400> 159 gcggggcugg gcgcgcg 17 <210> 160 <211> 24 <212> RNA <213> Homo sapiens <400> 160 uguaggcaug aggcagggcc cagg 24 <210> 161 <211> 22 <212> RNA <213> Homo sapiens <400> 161 ugggggagga aggacaggcc au 22 <210> 162 <211> 25 <212> RNA <213> Homo sapiens <400> 162 uagggguggg ggaauucagg ggugu 25 <210> 163 <211> 22 <212> RNA <213> Homo sapiens <400> 163 gcugcgggcu gcggucaggg cg 22 <210> 164 <211> 23 <212> RNA <213> Homo sapiens <400> 164 uuagggagua gaaggguggg gag 23 <210> 165 <211> 22 <212> RNA <213> Homo sapiens <400> 165 gugaacgggc gccaucccga gg 22 <210> 166 <211> 22 <212> RNA <213> Homo sapiens <400> 166 ggggggugug gagccagggg gc 22 <210> 167 <211> 23 <212> RNA <213> Homo sapiens <400> 167 cugggcccgc ggcgggcgug ggg 23 <210> 168 <211> 21 <212> RNA <213> Homo sapiens <400> 168 aucacauugc cagggauuac c 21 <210> 169 <211> 21 <212> RNA <213> Homo sapiens <400> 169 aucacauugc cagggauuuc c 21 <210> 170 <211> 22 <212> RNA <213> Homo sapiens <400> 170 gacuauagaa cuuuccccccu ca 22 <210> 171 <211> 20 <212> RNA <213> Homo sapiens <400> 171 ucacaccugc cucgcccccc 20 <210> 172 <211> 23 <212> RNA <213> Homo sapiens <400> 172 gaacgccugu ucuugccagg ugg 23 <210> 173 <211> 22 <212> RNA <213> Homo sapiens <400> 173 ucugcccccu ccgcugcugc ca 22 <210> 174 <211> 22 <212> RNA <213> Homo sapiens <400> 174 ggguggggau uuguugcauu ac 22 <210> 175 <211> 22 <212> RNA <213> Homo sapiens <400> 175 ggcuacaaca caggacccgg gc 22 <210> 176 <211> 22 <212> RNA <213> Homo sapiens <400> 176 uagcagcacg uaaauauugg cg 22 <210> 177 <211> 22 <212> RNA <213> Homo sapiens <400> 177 uauugcacuc gucccggccu cc 22 <210> 178 <211> 22 <212> RNA <213> Homo sapiens <400> 178 cuggacagg ccugggggac ag 22 <210> 179 <211> 19 <212> RNA <213> Homo sapiens <400> 179 aggcacggug ucagcaggc 19 <210> 180 <211> 22 <212> RNA <213> Homo sapiens <400> 180 acaggugagg uucuugggag cc 22 <210> 181 <211> 22 <212> RNA <213> Homo sapiens <400> 181 agggacggga cgcggugcag ug 22 <210> 182 <211> 22 <212> RNA <213> Homo sapiens <400> 182 uauugcacuu gucccggccu gu 22 <210> 183 <211> 22 <212> RNA <213> Homo sapiens <400> 183 aggcggggcg ccgcgggacc gc 22 <210> 184 <211> 22 <212> RNA <213> Homo sapiens <400> 184 uaggggcagc agaggaccug gg 22 <210> 185 <211> 20 <212> RNA <213> Homo sapiens <400> 185 ugugggacug caaaugggag 20 <210> 186 <211> 19 <212> RNA <213> Homo sapiens <400> 186 aaggggcugg gggagcaca 19 <210> 187 <211> 18 <212> RNA <213> Homo sapiens <400> 187 gugaaggccc ggcggaga 18 <210> 188 <211> 22 <212> RNA <213> Homo sapiens <400> 188 ugguggagga agagggcagc uc 22 <210> 189 <211> 23 <212> RNA <213> Homo sapiens <400> 189 gggggggcag gaggggcuca ggg 23 <210> 190 <211> 23 <212> RNA <213> Homo sapiens <400> 190 cacacaggaa aagcggggcc cug 23 <210> 191 <211> 19 <212> RNA <213> Homo sapiens <400> 191 uggggcggag cuuccggag 19 <210> 192 <211> 18 <212> RNA <213> Homo sapiens <400> 192 ugaggcgggg gggcgagc 18 <210> 193 <211> 21 <212> RNA <213> Homo sapiens <400> 193 accacugcac uccagccuga g 21 <210> 194 <211> 22 <212> RNA <213> Homo sapiens <400> 194 guggguacgg cccagugggg gg 22 <210> 195 <211> 18 <212> RNA <213> Homo sapiens <400> 195 cggggcggca ggggccuc 18 <210> 196 <211> 22 <212> RNA <213> Homo sapiens <400> 196 caggaggcag ugggcgagca gg 22 <210> 197 <211> 20 <212> RNA <213> Homo sapiens <400> 197 uagggggugg caggcuggcc 20 <210> 198 <211> 25 <212> RNA <213> Homo sapiens <400> 198 agggaucgcg ggcggguggc ggccu 25 <210> 199 <211> 23 <212> RNA <213> Homo sapiens <400> 199 caggggcugg gguuucaggu ucu 23 <210> 200 <211> 20 <212> RNA <213> Homo sapiens <400> 200 accaggaggc ugaggccccu 20 <210> 201 <211> 21 <212> RNA <213> Homo sapiens <400> 201 cggggcagcu caguacagga u 21 <210> 202 <211> 18 <212> RNA <213> Homo sapiens <400> 202 gggugcgggc cggcgggg 18 <210> 203 <211> 22 <212> RNA <213> Homo sapiens <400> 203 cugggagagg guuguuuacu cc 22 <210> 204 <211> 20 <212> RNA <213> Homo sapiens <400> 204 cgcgggucgg ggucugcagg 20 <210> 205 <211> 22 <212> RNA <213> Homo sapiens <400> 205 aaggggcagg gagggguggc cc 22 <210> 206 <211> 22 <212> RNA <213> Homo sapiens <400> 206 cugggacagg aggaggaggc ag 22 <210> 207 <211> 23 <212> RNA <213> Homo sapiens <400> 207 cggggcugucc ggaggggucg gcu 23 <210> 208 <211> 22 <212> RNA <213> Homo sapiens <400> 208 gggaccaucc ugccugcugu gg 22 <210> 209 <211> 22 <212> RNA <213> Homo sapiens <400> 209 guaggggagg uugggccagg ga 22 <210> 210 <211> 22 <212> RNA <213> Homo sapiens <400> 210 ugggggagug cagugauugu gg 22 <210> 211 <211> 20 <212> RNA <213> Homo sapiens <400> 211 acucaaacug ugggggcacu 20 <210> 212 <211> 18 <212> RNA <213> Homo sapiens <400> 212 aggggggcggg cuccggcg 18 <210> 213 <211> 22 <212> RNA <213> Homo sapiens <400> 213 agugggaggc cagggcacgg ca 22 <210> 214 <211> 24 <212> RNA <213> Homo sapiens <400> 214 ugggggagcc augagauaag agca 24 <210> 215 <211> 22 <212> RNA <213> Homo sapiens <400> 215 uggcucaguu cagcaggaac ag 22 <210> 216 <211> 23 <212> RNA <213> Homo sapiens <400> 216 gugaguggga gccccagugu gug 23 <210> 217 <211> 17 <212> RNA <213> Homo sapiens <400> 217 gccggacaag agggagg 17 <210> 218 <211> 22 <212> RNA <213> Homo sapiens <400> 218 ggaggaaccu uggagcuucg gc 22 <210> 219 <211> 20 <212> RNA <213> Homo sapiens <400> 219 ugggaauggg gguaagggcc 20 <210> 220 <211> 24 <212> RNA <213> Homo sapiens <400> 220 ggaggccggg guggggcggg gcgg 24 <210> 221 <211> 20 <212> RNA <213> Homo sapiens <400> 221 gggaaaagga agggggagga 20 <210> 222 <211> 22 <212> RNA <213> Homo sapiens <400> 222 agugggagga caggaggcag gu 22 <210> 223 <211> 23 <212> RNA <213> Homo sapiens <400> 223 guuugcacgg gugggccuug ucu 23 <210> 224 <211> 19 <212> RNA <213> Homo sapiens <400> 224 ggggagcgag gggcggggc 19 <210> 225 <211> 84 <212> RNA <213> Homo sapiens <400> 225 gcuggcgucg gugcugggga gcggcccccg ggugggccuc ugcucuggcc ccuccugggg 60 cccgcacucu cgcucugggc ccgc 84 <210> 226 <211> 61 <212> RNA <213> Homo sapiens <400> 226 gggggcggga gcuggggucu gcagguucgc acugaugccu gcucgcccug ucucccgcua 60 g 61 <210> 227 <211> 57 <212> RNA <213> Homo sapiens <400> 227 cauuggaggg uguggaagac aucugggcca acuugaucu cuucaucuac cccccag 57 <210> 228 <211> 73 <212> RNA <213> Homo sapiens <400> 228 cggcgacggc ggggugggug aggucgggcc ccaagacucg ggguuugccg ggcgccucag 60 uucaccgcgg ccg 73 <210> 229 <211> 86 <212> RNA <213> Homo sapiens <400> 229 ggcuuagaaa cagucccuag guaggauuug gggaggagcu aagaagcccc uacagggccc 60 agaggugggg acugagccuu aguugg 86 <210> 230 <211> 85 <212> RNA <213> Homo sapiens <400> 230 ggcgccuccu gcucugcugu gccgccaggg ccuccccuag cgcgccuucu ggagaggcuu 60 ugugcggaua cggggcugga ggccu 85 <210> 231 <211> 109 <212> RNA <213> Homo sapiens <400> 231 ucccgcauuc ccucugcuuu ggucaggugg ugcccuccuu ccauggguag agccagagau 60 gguggguucu ggcuggucag augggagugg acagagaccc gggguccuc 109 <210> 232 <211> 72 <212> RNA <213> Homo sapiens <400> 232 augagcgggu gggagcagau cuuauugaga guuccuucuc cugcuccuga uugucuuccc 60 ccacccucac ag 72 <210> 233 <211> 61 <212> RNA <213> Homo sapiens <400> 233 ucucguuuga ucucggaagc uaagcagggu ugggccuggu uaguacuugg augggaaacu 60 u 61 <210> 234 <211> 53 <212> RNA <213> Homo sapiens <400> 234 guuugaucuc ggaagcuaag cagggucggg ccugguuagu acuuggaugg gag 53 <210> 235 <211> 66 <212> RNA <213> Homo sapiens <400> 235 gggaggaggg aggagauggg ccaaguuccc ucuggcugga acgcccuucc cccccuucuu 60 caccug 66 <210> 236 <211> 68 <212> RNA <213> Homo sapiens <400> 236 cguggugagg auauggcagg gaaggggagu uucccucuau ucccuucccc ccaguaaucu 60 ucaucaug 68 <210> 237 <211> 61 <212> RNA <213> Homo sapiens <400> 237 ucggcuggcg gggguagagc uggcugcagg cccggccccu cucagcugcu gcccuccucca 60 g 61 <210> 238 <211> 55 <212> RNA <213> Homo sapiens <400> 238 ccggauccga gucacggcac caaauuucau gcguguccgu gugaagagac cacca 55 <210> 239 <211> 68 <212> RNA <213> Homo sapiens <400> 239 ugcccaggcu ggagcgagug caguggugca gucaguccua gcucacugca gccucgaacu 60 ccugggcu 68 <210> 240 <211> 87 <212> RNA <213> Homo sapiens <400> 240 gugaggcggg gccaggaggg uguguggcgu gggugcugcg gggccgucag ggugccugcg 60 ggacgcucac cuggcuggcc cgcccag 87 <210> 241 <211> 68 <212> RNA <213> Homo sapiens <400> 241 gugcaaagag caggaggaca ggggauuuau cucccaaggg agguccccug auccuaguca 60 cggcacca 68 <210> 242 <211> 110 <212> RNA <213> Homo sapiens <400> 242 ggcuacaguc uuucuucaug ugacucgugg acuucccuuu gucauccuau gccugagaau 60 auaugaagga ggcugggaag gcaaagggac guucaauugu caucacuggc 110 <210> 243 <211> 49 <212> RNA <213> Homo sapiens <400> 243 uucccagcca acgcaccaaa aaugauaugg gucuguuguc uggagaaac 49 <210> 244 <211> 86 <212> RNA <213> Homo sapiens <400> 244 ggggcugggg gugguggggag agagagugca cagccagcuc agggauuaaa gcucuuucuc 60 ucucucucuc ucccacuucc cugcag 86 <210> 245 <211> 73 <212> RNA <213> Homo sapiens <400> 245 cugguguuug aggcgaugug gggauguaga gacaacuucc cagucucauu uccucauccu 60 gccaggccac cau 73 <210> 246 <211> 60 <212> RNA <213> Homo sapiens <400> 246 caaggugggg gagauggggg uugaacuuca uuucucaugc ucauccccau cuccuuucag 60 <210> 247 <211> 115 <212> RNA <213> Homo sapiens <400> 247 ggugccgagg gccguccggc auccuaggcg ggucgcugcg guaccucccu ccugucugug 60 gcggugggau cccguggccg uguuuuccug guggcccggc cgugccugag guuuc 115 <210> 248 <211> 72 <212> RNA <213> Homo sapiens <400> 248 gagucugagg gacccaggac aggagaaggc cuauggugau uugcauucuu ccugcccugg 60 cuccauccuc ag 72 <210> 249 <211> 80 <212> RNA <213> Homo sapiens <400> 249 gcgucaagau ggcggcgggg agguaggcag agcaggacgc cgcugcugcc gccgccaccg 60 ccgccuccgc uccagucgcc 80 <210> 250 <211> 66 <212> RNA <213> Homo sapiens <400> 250 ccgagugggg cggggcaggu cccugcaggg acugugacac ugaaggaccu gcaccuucgc 60 ccacag 66 <210> 251 <211> 62 <212> RNA <213> Homo sapiens <400> 251 gcuggggguc ccccgacagu guggagcugg ggccgggucc cggggagggg gguucugggc 60 ag 62 <210> 252 <211> 65 <212> RNA <213> Homo sapiens <400> 252 gagggugggc gagggcggcu gagcggcucc aucccccggc cugcucaucc cccucgcccu 60 cucag 65 <210> 253 <211> 86 <212> RNA <213> Homo sapiens <400> 253 cgccugagcg ugcagcagga caucuuccug accugguaau aauuagguga gaaggauggu 60 ugggggcggu cggcguaacu caggga 86 <210> 254 <211> 82 <212> RNA <213> Homo sapiens <400> 254 gcuacgggga gcggggagga agugggcgcu gcuucugcgu uaucuggaag gagcagccca 60 cuccuguccu gggcucugug gu 82 <210> 255 <211> 87 <212> RNA <213> Homo sapiens <400> 255 guguggccgg caggcgggug ggcgggggcg gccgguggga accccgcccc gccccgcgcc 60 cgcacucacc cgcccgucuc cccacag 87 <210> 256 <211> 102 <212> RNA <213> Homo sapiens <400> 256 uguguucccu auccuccuua ugucccaccc ccacuccugu uugaauauuu caccagaaac 60 aggagugggg ggugggacgu aaggaggaug ggggaaagaa ca 102 <210> 257 <211> 69 <212> RNA <213> Homo sapiens <400> 257 ccgggcaggc agguguaggg uggagcccac uguggcuccu gacucagccc ugcugccuuc 60 accugccag 69 <210> 258 <211> 93 <212> RNA <213> Homo sapiens <400> 258 gcuuguuggg gauuggguca ggccaguguu caagggcccc uccucuagua cucccuguuu 60 guguucugcc acugacuugag cuucucccca cag 93 <210> 259 <211> 88 <212> RNA <213> Homo sapiens <400> 259 guggggccag gcgguggugg gcacugcugg ggugggcaca gcagccaugc agagcgggca 60 uuugaccccg ugccacccuu uuccccag 88 <210> 260 <211> 63 <212> RNA <213> Homo sapiens <400> 260 aauggguggg ugcugguggg agccgugccc uggccacuca uucggcucuc ucccucaccc 60 uag 63 <210> 261 <211> 72 <212> RNA <213> Homo sapiens <400> 261 cuugggaaug gcaaggaaac cguuaccauu acugaguuua guaaugguaa ugguucucuu 60 gcuauaccca ga 72 <210> 262 <211> 81 <212> RNA <213> Homo sapiens <400> 262 uagaggcagu uucaacagau guguagacuu uugauaugag aaauugguuu caaaaucagg 60 agucggggcu uuacugcuuu u 81 <210> 263 <211> 83 <212> RNA <213> Homo sapiens <400> 263 aauagagggu gcacaggcac gggagcucag gugaggcagg gagcugagcu caccugaccu 60 cccaugccug ugcacccucu auu 83 <210> 264 <211> 96 <212> RNA <213> Homo sapiens <400> 264 cucgggaggg gcgggagggg gguccccggu gcucggaucu cgagggugcu uauuguucgg 60 uccgagccug ggucucccuc uuccccccaa cccccc 96 <210> 265 <211> 82 <212> RNA <213> Homo sapiens <400> 265 ugagcuguug gauucggggc cguagcacug ucugaggu uuacauuucu cacagugaac 60 cggucucuuu uucagcugcu uc 82 <210> 266 <211> 66 <212> RNA <213> Homo sapiens <400> 266 gggcaugggg agguguggag ucagcauggg gcuaggaggc cccgcgcuga cccgccuucu 60 ccgcag 66 <210> 267 <211> 89 <212> RNA <213> Homo sapiens <400> 267 ucuccguuua ucccaccacu gccaccauua uugcuacugu ucagcaggug cugcuggugg 60 ugauggugau agucuggugg gggcggugg 89 <210> 268 <211> 81 <212> RNA <213> Homo sapiens <400> 268 cauccuccuu acgucccacc ccccacuccu guuucuggug aaauauucaa acaggagugg 60 gggugggaca uaaggaggau a 81 <210> 269 <211> 79 <212> RNA <213> Homo sapiens <400> 269 cucgaggugc ugggggacgc gugagcgcga gccgcuuccu cacggcucgg ccgcggcgcg 60 uagccccccgc cacaucggg 79 <210> 270 <211> 99 <212> RNA <213> Homo sapiens <400> 270 gcaagggaca gggagggucg uggcgacacu cgcgccagcu cccgggacgg cugggcucgg 60 gcuggucgcc gaccuccgac ccuccacuag augccuggc 99 <210> 271 <211> 80 <212> RNA <213> Homo sapiens <400> 271 cgggaaugcc gcggcgggga cggcgauugg uccguaugug uggugccacc ggccgccggc 60 uccgccccgg cccccgcccc 80 <210> 272 <211> 71 <212> RNA <213> Homo sapiens <400> 272 ugaccacccc cgggcaaaga ccugcagauc cccuguuaga gacgggccca ggacuuugug 60 cggggugccc a 71 <210> 273 <211> 80 <212> RNA <213> Homo sapiens <400> 273 aggacccuuc cagagggccc ccccucaauc cuguugugcc uaauucagag gguugggugg 60 aggcuuccu gaagggcucu 80 <210> 274 <211> 73 <212> RNA <213> Homo sapiens <400> 274 ggaugauaag uuauggggcu ucuguagaga uuucuaugag aacaucucua aggaacuccc 60 ccaaacugaa uuc 73 <210> 275 <211> 64 <212> RNA <213> Homo sapiens <400> 275 aaccccgggc cggaggucaa gggcgucgcu ucucccuaau guugccucuu uuccacggcc 60 ucag 64 <210> 276 <211> 94 <212> RNA <213> Homo sapiens <400> 276 auaaaggaag uuaggcugag gggcagagag cgagacuuuu cuauuuucca aaagcucggu 60 cugaggcccc ucagucuugc uuccuaaccc gcgc 94 <210> 277 <211> 97 <212> RNA <213> Homo sapiens <400> 277 cccgggaccu ugguccaggc gcuggucugc guggugcucg gguggauaag ucugaucuga 60 gcaccacaca ggccgggcgc cgggaccaag ggggcuc 97 <210> 278 <211> 67 <212> RNA <213> Homo sapiens <400> 278 uacaggccgg ggcuuugggu gagggacccc cggagucugu cacggucuca ccccaacucu 60 gccccag 67 <210> 279 <211> 69 <212> RNA <213> Homo sapiens <400> 279 ggcccucggg ccugggguug ggggagcucu guccugucuc acucauugcu ccuccccugc 60 cuggcccag 69 <210> 280 <211> 92 <212> RNA <213> Homo sapiens <400> 280 gucagugucu gggcggacag cugcaggaaa gggaagacca aggcuugcug ucuguccagu 60 cugccacccu acccugucug uucuugccac ag 92 <210> 281 <211> 71 <212> RNA <213> Homo sapiens <400> 281 gugucugugc cggucccagg agaaccugca gaggcaucgg gucagcggug cuccugcggg 60 ccgacacuca c 71 <210> 282 <211> 79 <212> RNA <213> Homo sapiens <400> 282 cagccugggg aaggcuuggc agggaagaca caugagcagu gccuccacuu cacgccucuc 60 ccuugucucc uuucccuag 79 <210> 283 <211> 71 <212> RNA <213> Homo sapiens <400> 283 gggaguggg agccgguggg gcuggaguaa gggcacgccc ggggcugccc caccugcuga 60 ccacccuccc c 71 <210> 284 <211> 75 <212> RNA <213> Homo sapiens <400> 284 aagcaagacu gaggggccuc agaccgagcu uuuggaaaau agaaaagucu cgcucucugc 60 cccucagccu aacuu 75 <210> 285 <211> 96 <212> RNA <213> Homo sapiens <400> 285 gcucuggggc gugccgccgc cgucgcugcc accuccccua ccgcuagugg aagaagaugg 60 cggaaggcgg agcggcggau cuggacaccc agcggu 96 <210> 286 <211> 87 <212> RNA <213> Homo sapiens <400> 286 cccucaucuc ugggcagggg cuuauuguag gagucucuga agagagcugu ggacugaccu 60 gcuuuaaccc uuccccaggu ucccauu 87 <210> 287 <211> 67 <212> RNA <213> Homo sapiens <400> 287 ccagaccccu ggggcugggc aggcggaaag aggucugaac ugccucugcc uccuuggucu 60 ccggcag 67 <210> 288 <211> 68 <212> RNA <213> Homo sapiens <400> 288 gaauggaaga agaaggcggu cggucugcgg gagccaggcc gcagagccau ccgccuucug 60 uccauguc 68 <210> 289 <211> 73 <212> RNA <213> Homo sapiens <400> 289 accuuuccag cucauccccac cucugccacc aaaacacuca ucgcgggguc agagggagug 60 ccaaaaaagg uaa 73 <210> 290 <211> 73 <212> RNA <213> Homo sapiens <400> 290 ggcgagggga ggcgcaggcu cggaaaggcg cgcgaggcuc caggcuccuu cccgauccac 60 cgcucuccuc gcu 73 <210> 291 <211> 61 <212> RNA <213> Homo sapiens <400> 291 aacugcgggg ccagagcaga gagcccuugc acaccaccag ccucuccucc cugugcccca 60 g 61 <210> 292 <211> 65 <212> RNA <213> Homo sapiens <400> 292 gagaaugggg ggacagaugg agaggacaca ggcuggcacu gagguccccu ccacuuuccu 60 ccuag 65 <210> 293 <211> 64 <212> RNA <213> Homo sapiens <400> 293 gaaggcgagg gguagaagag cacagggguu cugauaaacc cuucugccug cauucuacuc 60 ccag 64 <210> 294 <211> 62 <212> RNA <213> Homo sapiens <400> 294 guggguucg caucaggagg caaggccagg acccgcugac ccaugccucc ugccgcgguc 60 ag 62 <210> 295 <211> 89 <212> RNA <213> Homo sapiens <400> 295 accuccggga cggcugggcg ccggcggccg ggagauccgc gcuuccugaa ucccggccgg 60 cccgcccggc gcccguccgc ccgcggguc 89 <210> 296 <211> 69 <212> RNA <213> Homo sapiens <400> 296 guggguaggg uuugggggag agcgugggcu gggguucagg gacacccucu caccacugcc 60 cucccacag 69 <210> 297 <211> 62 <212> RNA <213> Homo sapiens <400> 297 ccuucugcgg cagagcuggg gucaccagcc cucauguacu ugugacuucu ccccugccac 60 ag 62 <210> 298 <211> 66 <212> RNA <213> Homo sapiens <400> 298 ucaagacggg gagucaggca gugguggaga uggagagccc ugagccucca cucuccuggc 60 ccccag 66 <210> 299 <211> 93 <212> RNA <213> Homo sapiens <400> 299 ggcgcuuuug ugcgcgcccg ggucuguugg ugcucagagu guggucaggc ggcucggacu 60 gagcaggugg gugcggggcu cggaggaggc ggc 93 <210> 300 <211> 55 <212> RNA <213> Homo sapiens <400> 300 gggggcuggg gcgcggggag gugcuagguc ggccucggcu cccgcgccgc acccc 55 <210> 301 <211> 93 <212> RNA <213> Homo sapiens <400> 301 uacuuauggc accccacucc ugguaccaua gucauaaguu aggagauguu agagcuguga 60 guaccaugac uuaagugugg uggcuuaaac aug 93 <210> 302 <211> 64 <212> RNA <213> Homo sapiens <400> 302 aguucagggc cgaagggugg aagcugcugg ugcucaucuc agccucugcc cuuggccucc 60 ccag 64 <210> 303 <211> 90 <212> RNA <213> Homo sapiens <400> 303 guggguacgg cccagugggg gggagaggga cacgcccugg gcucugccca gggugcagcc 60 ggacugacug agccccugug ccgcccccag 90 <210> 304 <211> 51 <212> RNA <213> Homo sapiens <400> 304 agagaugaag cggggggggcg gggucuugcu cuauugccua cgcugaucuc a 51 <210> 305 <211> 82 <212> RNA <213> Homo sapiens <400> 305 accuguaggu gacagucagg ggcggggugu gguggggcug gggcuggccc ccuccucaca 60 ccucuccugg caucgccccc ag 82 <210> 306 <211> 73 <212> RNA <213> Homo sapiens <400> 306 uguauccuug aauggauuuu uggagcagga guggacaccu gacccaaagg aaaucaaucc 60 auaggcuagc aau 73 <210> 307 <211> 63 <212> RNA <213> Homo sapiens <400> 307 ugguggcggc gguaguuaug ggcuucucuu ucucaccagc agccccuggg ccgccgccuc 60 ccu 63 <210> 308 <211> 68 <212> RNA <213> Homo sapiens <400> 308 cucaggcuca guggugcaug cuuauagucc cagccacucu ggaggcugaa ggaagauggc 60 uugagccu 68 <210> 309 <211> 80 <212> RNA <213> Homo sapiens <400> 309 cgugugagcc cgcccugugc ccggcccacu ucugcuuccu cuuagcgcag gagggguccc 60 gcacugggag gggcccucac 80 <210> 310 <211> 61 <212> RNA <213> Homo sapiens <400> 310 gagggcagcg uggguguggc ggaggcaggc gugaccguuu gccgcccucu cgcugcucua 60 g 61 <210> 311 <211> 80 <212> RNA <213> Homo sapiens <400> 311 ugagaggccg caccuugccu ugcugcccgg gccgugcacc cgugggcccc agggcgacgc 60 ggcgggggcg gcccuagcga 80 <210> 312 <211> 102 <212> RNA <213> Homo sapiens <400> 312 gcuuaucgag gaaaagaucg agguggguug gggcgggcuc uggggauuug gucucacagc 60 ccggauccca gcccacuuac cuugguuacu cuccuuccuu cu 102 <210> 313 <211> 86 <212> RNA <213> Homo sapiens <400> 313 uuugguacuu aaagagagga uacccuuugu auguucacuu gauuaauggc gaauauacag 60 ggggagacuc ucauuugcgu aucaaa 86 <210> 314 <211> 63 <212> RNA <213> Homo sapiens <400> 314 cuugcccggg agaaggaggu ggccuggaga gcugcugucu ccagccgccg ccugucucca 60 cag 63 <210> 315 <211> 100 <212> RNA <213> Homo sapiens <400> 315 agcucagggc ggcugcgcag agggcuggac ucagcggcgg agcuggcugc uggccucagu 60 ucugccucug uccagguccu ugugacccgc ccgcucuccu 100 <210> 316 <211> 73 <212> RNA <213> Homo sapiens <400> 316 gugggcgggg gcaggugugu gguggguggu ggccugcggu gagcagggcc cucacaccug 60 ccucgccccc cag 73 <210> 317 <211> 137 <212> RNA <213> Homo sapiens <400> 317 agccagacaa gagggucaug gggagucacu gucaacccag agcaggcacu gccccugcga 60 ccagccuggg gcaucgguug gggugcaggg gucugcuggu gaugcuuucc aucucuuugc 120 uuuguccuga uuguagc 137 <210> 318 <211> 85 <212> RNA <213> Homo sapiens <400> 318 ggccugggua ggcuugcaug ggggacuggg aagagaccau gaacagguua guccagggag 60 uucucaucaa gccuuuacuc aguag 85 <210> 319 <211> 68 <212> RNA <213> Homo sapiens <400> 319 gacucggcug cgguggacaa guccggcucc agaaccugga caccgcucag ccggccgcgg 60 cagggguc 68 <210> 320 <211> 69 <212> RNA <213> Homo sapiens <400> 320 gaggagggga ggugugcagg gcugggguca cugacucugc uuccccugcc cugcauggug 60 uccccacag 69 <210> 321 <211> 64 <212> RNA <213> Homo sapiens <400> 321 gaggcacugg guaggugggg cuccagggcu ccugacaccu ggaccucucc uccccaggcc 60 caca 64 <210> 322 <211> 65 <212> RNA <213> Homo sapiens <400> 322 gggugcuccg ggcaggcggc ugggagcggc ccucacauug auggcuccug ccaccuccuc 60 cgcag 65 <210> 323 <211> 86 <212> RNA <213> Homo sapiens <400> 323 auucuaggug gggagacuga cggcuggagg cccauaagcu gucuaaaacu ucggccccca 60 gauuucuggu cuccccacuu cagaac 86 <210> 324 <211> 62 <212> RNA <213> Homo sapiens <400> 324 uggccuaggg ggcggcuugu ggaguguaug ggcugagccu ugcucugcuc ccccgccccc 60 ag 62 <210> 325 <211> 59 <212> RNA <213> Homo sapiens <400> 325 ggggccaggc agggaggugg gaccaugggg gccuugcugu gugaccaccg uuccugcag 59 <210> 326 <211> 66 <212> RNA <213> Homo sapiens <400> 326 agcagcccuc ggcggcccgg ggggcgggcg gcggugcccg ucccggggcu gcgcgaggca 60 caggcg 66 <210> 327 <211> 119 <212> RNA <213> Homo sapiens <400> 327 agccugcgcc ggagccgggg ccugagcccg ggccgcgcag gccgugaacu cgucgagcug 60 cgcgugcggc cggugcucaa ccugccgggu ccuggccccg cgcucccgcg cgcccugga 119 <210> 328 <211> 80 <212> RNA <213> Homo sapiens <400> 328 ccucugugag aaagggugug ggggagaggc ugucuugugu cuguaaguau gccaaacuua 60 uuuuccccaa ggcagaggga 80 <210> 329 <211> 74 <212> RNA <213> Homo sapiens <400> 329 gcagcccggu gagcgcucgc uggccuggca gugcgucgga agaacagggc ggguggggcc 60 gcgcacaucu cugc 74 <210> 330 <211> 53 <212> RNA <213> Homo sapiens <400> 330 gguggggguu ggaggcgugg guuuuagaac cuaucccuuu cuagcccuga gca 53 <210> 331 <211> 93 <212> RNA <213> Homo sapiens <400> 331 guaaggaggg ggaugagggg ucauaucucu ucucagggaa agcaggagcc cuucagcagg 60 gucagggccc cucaucuucc ccuccuuucc cag 93 <210> 332 <211> 98 <212> RNA <213> Homo sapiens <400> 332 cuuggucaau aggaaagagg ugggaccucc uggcuuuucc ucugcagcau ggcucggacc 60 uagugcaaug uuuaagcucc ccucucuuuc cuguucag 98 <210> 333 <211> 92 <212> RNA <213> Homo sapiens <400> 333 ggagccagu ggaauggaga ggcugugggc agggggagau gugaaggaaa gaacuaggac 60 ccauucaucc acugcauucc ugcuuggccc ag 92 <210> 334 <211> 94 <212> RNA <213> Homo sapiens <400> 334 cacggugucc ccugguggaa ccuggcaggg ggagagguaa ggucuuucag ccucuccaaa 60 gcccaugguc agguacucag gugggggagc ccug 94 <210> 335 <211> 60 <212> RNA <213> Homo sapiens <400> 335 ugugaaugac ccccuuccag agccaaaauc accagggaug gaggaggggu cuuggguacu 60 <210> 336 <211> 70 <212> RNA <213> Homo sapiens <400> 336 aaaagccugu cccuaagucc cucccagccu uccagaguug gugccaggaa ggauuuaggg 60 acaggcuuug 70 <210> 337 <211> 64 <212> RNA <213> Homo sapiens <400> 337 ucugggcgag gggugggcuc ucagaggggc uggcaguacu gcucugaggc cugccucucc 60 ccag 64 <210> 338 <211> 75 <212> RNA <213> Homo sapiens <400> 338 gucagagggg ggaugugcau gcugguuggg gugggcugcc uguggaccaa ucagcgugca 60 cuucccccacc cugaa 75 <210> 339 <211> 86 <212> RNA <213> Homo sapiens <400> 339 agggagaagg gucggggcag ggagggcagg gcaggcucug gggugggggg ucugugaguc 60 agccacggcu cuccccacgu cucccc 86 <210> 340 <211> 73 <212> RNA <213> Homo sapiens <400> 340 gaaaacaacc aggugggcuu cccggagggc ggaacaccca gccccagcau ccagggcuca 60 ccuaccacgu uug 73 <210> 341 <211> 77 <212> RNA <213> Homo sapiens <400> 341 gaguugggag guucccucuc caaauguguc uugauccccc accccaagac acauuuggag 60 agggacccuc ccaacuc 77 <210> 342 <211> 61 <212> RNA <213> Homo sapiens <400> 342 ucacccggug agggcgggug gaggaggagg guccccacca ucagccuuca cugggacggg 60 a 61 <210> 343 <211> 119 <212> RNA <213> Homo sapiens <400> 343 ccaugaggag cuggcagugg gauggccugg ggguaggagc guggcuucug gagcuagacc 60 acauggguuc agaucccagc ggugccucua acuggccaca ggaccuuggg cagucagcu 119 <210> 344 <211> 70 <212> RNA <213> Homo sapiens <400> 344 gucccugggg gcugggaugg gccauggugu gcucuugaucc cccugugguc ucuuggcccc 60 caggaacucc 70 <210> 345 <211> 74 <212> RNA <213> Homo sapiens <400> 345 gggaggaaga agggaggagg agcggagggg cccuugucuu cccagagccu cucccuuccu 60 ccccuccccc uccc 74 <210> 346 <211> 66 <212> RNA <213> Homo sapiens <400> 346 acccaggagg cggaggaggu ggagguugca gugagccaag aucguggcac ugacuccagc 60 cugggg 66 <210> 347 <211> 102 <212> RNA <213> Homo sapiens <400> 347 gugggagggc ccaggcgcgg gcaggggugg ggguggcaga gcgcuguccc gggggcgggg 60 ccgaagcgcg gcgaccguaa cuccuucugc uccguccccc ag 102 <210> 348 <211> 113 <212> RNA <213> Homo sapiens <400> 348 gccggguggg gcggggcggc cucaggaggg gcccagcucc ccuggaugug cugcgguggg 60 gccggagggg cgucacgugc acccaaguga cgccccuucu gauucugccu cag 113 <210> 349 <211> 91 <212> RNA <213> Homo sapiens <400> 349 acgccccccg ccccgccacc gccuuggagg cugaccucuu acuuucgguc ggucuucuuc 60 ccugggcuug guuugggggc gggggagugu c 91 <210> 350 <211> 54 <212> RNA <213> Homo sapiens <400> 350 agcagcaggg gagagagagg aguccucuag acaccgacuc ugucuccugc agau 54 <210> 351 <211> 136 <212> RNA <213> Homo sapiens <400> 351 ccgcuugccu cgcccagcgc agccccggcc gcugggcgca cccgucccgu ucguccccgg 60 acguugcucu cuaccccggg aacgucgaga cuggagcgcc cgaacugagc caccuucgcg 120 gaccccgaga gcggcg 136 <210> 352 <211> 80 <212> RNA <213> Homo sapiens <400> 352 cugcagcgug cuucuccagg ccccgcgcgc ggacagacac acggacaagu cccgccaggg 60 gcugggcgcg cgccagccgg 80 <210> 353 <211> 47 <212> RNA <213> Homo sapiens <400> 353 cucggcgcgg ggcgcgggcu ccggguuggg gcgagccaac gccgggg 47 <210> 354 <211> 50 <212> RNA <213> Homo sapiens <400> 354 acccgggcgu gguggugggg gugggugccu guaauuccag cuaguuggga 50 <210> 355 <211> 67 <212> RNA <213> Homo sapiens <400> 355 gugaggaggg gcuggcaggg accccuccaa guuggggacg gcagccagcc ccugcucacc 60 ccucgcc 67 <210> 356 <211> 106 <212> RNA <213> Homo sapiens <400> 356 agaagaaugc ccaaccagcc cucaguugcu acaguucccu guuguuucag cucgacaaca 60 acaggcggcu guagcaaugg ggggcuggau gggcaucuca augugc 106 <210> 357 <211> 82 <212> RNA <213> Homo sapiens <400> 357 ugugggcagg gcccugggga gcugaggcuc uggggguggc cggggcugac ccugggccuc 60 ugcuccccag ugucugaccg cg 82 <210> 358 <211> 69 <212> RNA <213> Homo sapiens <400> 358 cuuucggcca gcgggacggc auccgaggug ggcuaggcuc gggcccgugg cgggugcggg 60 ggugggagg 69 <210> 359 <211> 98 <212> RNA <213> Homo sapiens <400> 359 uugggcaagg ugcggggcua gggcuaacag cagucuuacu gaagguuucc uggaaaccac 60 gcacaugcug uugccacuaa ccucaaccuu acucgguc 98 <210> 360 <211> 80 <212> RNA <213> Homo sapiens <400> 360 accugaggag ccagcccucc ucccgcaccc aaacuuggag cacuugaccu uuggcuguug 60 gagggggcag gcucgcgggu 80 <210> 361 <211> 92 <212> RNA <213> Homo sapiens <400> 361 ccugucccuc cugcccugcg ccugcccagc ccuccugcuc uggugacuga ggaccgccag 60 gcaggggcug gugcugggcg gggggcggcg gg 92 <210> 362 <211> 79 <212> RNA <213> Homo sapiens <400> 362 gugagguggg ggccagcagg gagugggcug ggcugggcug ggccaaggua caaggccuca 60 cccugcaucc cgcacccag 79 <210> 363 <211> 84 <212> RNA <213> Homo sapiens <400> 363 ccgcagccgc cgcgccgggc ccggguuggc cgcugacccc cgcggggccc ccggcggccg 60 gggcgggggc gggggcugcc ccgg 84 <210> 364 <211> 65 <212> RNA <213> Homo sapiens <400> 364 agcccugggg guggucucua gccaaggcuc uggggucuca cccuuggcug gucucugcuc 60 cgcag 65 <210> 365 <211> 80 <212> RNA <213> Homo sapiens <400> 365 gguuccggag ccccggcgcg ggcggguucu gggguguaga cgcugcuggc cagcccgccc 60 cagccgaggu ucucggcacc 80 <210> 366 <211> 97 <212> RNA <213> Homo sapiens <400> 366 aucugaguug ggaggguccc ucuccaaaug ugucuugggg ugggggauca agacacauuu 60 ggagagggaa ccucccaacu cggccucugc caucauu 97 <210> 367 <211> 59 <212> RNA <213> Homo sapiens <400> 367 cuccagggag acagugugug aggccucuug ccauggccuc ccugcccgcc ucucugcag 59 <210> 368 <211> 67 <212> RNA <213> Homo sapiens <400> 368 gugggagggg agaggcagca agcacacagg gccugggacu agcaugcuga ccucccuccu 60 gccccag 67 <210> 369 <211> 115 <212> RNA <213> Homo sapiens <400> 369 gagcaaaaac cagagaacaa caugggagcg uuccuaaccc cuaaggcaac uggaugggag 60 accugaccca uccaguucuc ugagggggcu cuuguguguu cuacaagguu guuca 115 <210> 370 <211> 86 <212> RNA <213> Homo sapiens <400> 370 uuugguacuu gaagagagga uacccuuugu auguucacuu gauuaauggc gaauauacag 60 ggggagacuc uuauuugcgu aucaaa 86 <210> 371 <211> 70 <212> RNA <213> Homo sapiens <400> 371 ugugcacuug ggcaggaggg acccuguaug ucuccccgca gcaccgucau cgugucccuc 60 uuguccacag 70 <210> 372 <211> 81 <212> RNA <213> Homo sapiens <400> 372 uacaggugca ggggaacugu agaugaaaag gcuuggcacu ugagggaaag ccucaguuca 60 uucucauuuu gcucaccugu u 81 <210> 373 <211> 63 <212> RNA <213> Homo sapiens <400> 373 gagucgagga cugguggaag ggccuuuccc cucagaccaa ggcccuggcc ccagcuucuu 60 cuc 63 <210> 374 <211> 103 <212> RNA <213> Homo sapiens <400> 374 gugucggcug uggcgugacu gucccucugu gucccccacu aggccccacug cucaguggag 60 cguggaggac gaggaggagg ccguccacga gcaaugccag cau 103 <210> 375 <211> 67 <212> RNA <213> Homo sapiens <400> 375 aauagauuau uggucaccac cuccaguuuc ugaauuugug agacuggggu ggggccugag 60 aauuugc 67 <210> 376 <211> 84 <212> RNA <213> Homo sapiens <400> 376 ugugcagugg gaagggggggc cgauacacug uacgagagug aguagcaggu cucacaguga 60 accggucucu uucccuacug uguc 84 <210> 377 <211> 70 <212> RNA <213> Homo sapiens <400> 377 aggacccagc ggggcugggc gcgcggagca gcgcugggug cagcgccugc gccggcagcu 60 gcaagggccg 70 <210> 378 <211> 64 <212> RNA <213> Homo sapiens <400> 378 ugcucuguag gcaugaggca gggcccaggu uccaugugau gcugaagcuc ugacauuccu 60 gcag 64 <210> 379 <211> 72 <212> RNA <213> Homo sapiens <400> 379 cugggggagg aaggacaggc caucugcuau ucguccacca accugacuug auccucucuu 60 cccuccuccc ag 72 <210> 380 <211> 69 <212> RNA <213> Homo sapiens <400> 380 ugggguaggg gugggggaau ucaggggugu cgaacucaug gcugccaccu uugugucccc 60 auccugcag 69 <210> 381 <211> 70 <212> RNA <213> Homo sapiens <400> 381 cucgggcccg accgcgccgg cccgcaccuc ccggcccgga gcugcgggcu gcggucaggg 60 cgaucccggg 70 <210> 382 <211> 82 <212> RNA <213> Homo sapiens <400> 382 cugacuuuuu uagggaguag aagggugggg agcaugaaca auguuucuca cucccuaccc 60 cuccacuccc caaaaaaguc ag 82 <210> 383 <211> 79 <212> RNA <213> Homo sapiens <400> 383 gugcagaucc uugggagccc uguuagacuc uggauuuuac acuuggagug aacgggcgcc 60 aucccgaggc uuugcacag 79 <210> 384 <211> 71 <212> RNA <213> Homo sapiens <400> 384 auggaggggg guguggagcc agggggccca ggucuacagc uucucccccgc ucccugcccc 60 cauacuccca g 71 <210> 385 <211> 92 <212> RNA <213> Homo sapiens <400> 385 cgcugcgcuu cugggcccgc ggcgggcgug gggcugcccg ggccggucga ccagcgcgcc 60 guagcucccg aggcccgagc cgcgacccgc gg 92 <210> 386 <211> 97 <212> RNA <213> Homo sapiens <400> 386 cucaggugcu cuggcugcuu ggguuccugg caugcugauu ugugacuuaa gauuaaaauc 60 acauugccag ggauuaccac gcaaccacga ccuuggc 97 <210> 387 <211> 73 <212> RNA <213> Homo sapiens <400> 387 ggccggcugg gguuccuggg gaugggauuu gcuuccuguc acaaaucaca uugccaggga 60 uuuccaaccg acc 73 <210> 388 <211> 85 <212> RNA <213> Homo sapiens <400> 388 aggguagagg gaugaggggg aaaguucuau aguccuguaa uuagaucuca ggacuauaga 60 acuuuccccc ucaucccucu gcccu 85 <210> 389 <211> 90 <212> RNA <213> Homo sapiens <400> 389 ucuaagaaac gcaguggucu cugaagccug caggggcagg ccagcccugc acugaacgcc 60 uguucuugcc agguggcaga agguugcugc 90 <210> 390 <211> 80 <212> RNA <213> Homo sapiens <400> 390 accucuaccu cccggcagag gaggcugcag aggcuggcuu uccaaaacuc ugcccccucc 60 gcugcugcca aguggcuggu 80 <210> 391 <211> 75 <212> RNA <213> Homo sapiens <400> 391 ucaucccugg guggggauuu guugcauuac uuguguucua uauaaaguau ugcacuuguc 60 ccggccugug gaaga 75 <210> 392 <211> 109 <212> RNA <213> Homo sapiens <400> 392 ggucgggcuc accaugacac agugugagac cucgggcuac aacacaggac ccgggcgcug 60 cucugacccc ucgugucuug uguugcagcc ggagggacgc agguccgca 109 <210> 393 <211> 89 <212> RNA <213> Homo sapiens <400> 393 gucagcagug ccuuagcagc acguaaauau uggcguuaag auucuaaaau uaucuccagu 60 auuaacugug cugcugaagu aagguugac 89 <210> 394 <211> 81 <212> RNA <213> Homo sapiens <400> 394 guuccacucu agcagcacgu aaauauuggc guagugaaau auauauuaaa caccaauauu 60 acugugcugc uuuaguguga c 81 <210> 395 <211> 96 <212> RNA <213> Homo sapiens <400> 395 cgggccccgg gcgggcggga gggacgggac gcggugcagu guuguuuuuu cccccgccaa 60 uauugcacuc gucccggccu ccggcccccc cggccc 96 <210> 396 <211> 84 <212> RNA <213> Homo sapiens <400> 396 cuccccaugg cccugucucc caacccuugu accagugcug ggcucagacc cugguacagg 60 ccugggggac agggaccugg ggac 84 <210> 397 <211> 94 <212> RNA <213> Homo sapiens <400> 397 cgggcagcgg gugccaggca cggugucagc aggcaacaug gccgagaggc cggggccucc 60 gggcggcgcc guguccgcga ccgcguaccc ugac 94 <210> 398 <211> 86 <212> RNA <213> Homo sapiens <400> 398 ugccagucuc uaggucccug agacccuuua accugugagg acauccaggg ucacagguga 60 gguucuuggg agccuggcgu cuggcc 86 <210> 399 <211> 78 <212> RNA <213> Homo sapiens <400> 399 cuuucuacac agguugggau cgguugcaau gcuguguuuc uguaugguau ugcacuuguc 60 ccggccuguu gaguuugg 78 <210> 400 <211> 93 <212> RNA <213> Homo sapiens <400> 400 ccuuccggcg ucccaggcgg ggcgccgcgg gaccgcccuc gugucugugg cggugggauc 60 ccgcggccgu guuuuccugg uggcccggcc aug 93 <210> 401 <211> 83 <212> RNA <213> Homo sapiens <400> 401 gucuacuccc agggugccaa gcuguuucgu guucccuccc uaggggaucc cagguagggg 60 cagcagagga ccugggccug gac 83 <210> 402 <211> 72 <212> RNA <213> Homo sapiens <400> 402 ugugggacug caaaugggag cucagcaccu gccugccacc cacgcagacc agccccugcu 60 cuguucccac ag 72 <210> 403 <211> 110 <212> RNA <213> Homo sapiens <400> 403 gucuaccagg ugugggccca gcuuuacaua guucaugcug aggccgggau uucaugcaga 60 aaacugguug caaaaggugc ugaaggggcu gggggagcac aagggagaag 110 <210> 404 <211> 89 <212> RNA <213> Homo sapiens <400> 404 agccuguggg aaagagaaga gcagggcagg gugaaggccc ggcggagaca cucugcccac 60 cccacacccu gccuaugggc cacacagcu 89 <210> 405 <211> 62 <212> RNA <213> Homo sapiens <400> 405 gaggguggug gaggaagagg gcagcuccca ugacugccug accgccuucu cuccuccccc 60 ag 62 <210> 406 <211> 75 <212> RNA <213> Homo sapiens <400> 406 uggagugggg gggcaggagg ggcucaggga gaaagugcau acagccccug gcccucucug 60 cccuuccguc cccug 75 <210> 407 <211> 72 <212> RNA <213> Homo sapiens <400> 407 ccaggcacac aggaaaagcg gggcccuggg uucggcugcu accccaaagg ccacauucuc 60 cugugcacac ag 72 <210> 408 <211> 153 <212> RNA <213> Homo sapiens <400> 408 gcuccgcccc acgucgcaug cgccccggga acgcgugggg cggagcuucc ggaggccccg 60 cucugcugcc gacccugugg agcggagggu gaagccuccg gaugccaguc ccucaucgcu 120 ggccuggucg cgcuguggcg aagggggcgg agc 153 <210> 409 <211> 153 <212> RNA <213> Homo sapiens <400> 409 gcuccgcccc acgucgcaug cgccccggga acgcgugggg cggagcuucc ggaggccccg 60 cccugcugcc gacccugugg agcggagggu gaagccuccg gaugccaguc ccucaucgcu 120 ggcccggucg cgcuguggcg aagggggcgg agc 153 <210> 410 <211> 49 <212> RNA <213> Homo sapiens <400> 410 ggugaggcgg gggggcgagc ccugaggggc ucucgcuucu ggcgccaag 49 <210> 411 <211> 100 <212> RNA <213> Homo sapiens <400> 411 gaggugggag gauugcuuga gucagggugg uugaggcugc aguaaguugu gaucauacca 60 cugcacucca gccugaguga cagagcaaga ccuugucuca 100 <210> 412 <211> 64 <212> RNA <213> Homo sapiens <400> 412 gggugggggc ggggcggcag gggccucccc cagugccagg ccccauucug cuucucuccc 60 agcu 64 <210> 413 <211> 74 <212> RNA <213> Homo sapiens <400> 413 ccugcaggag gcagugggcg agcaggcggg gcagcccaau gccaugggcc ugaucucacc 60 gcugccuccu uccc 74 <210> 414 <211> 60 <212> RNA <213> Homo sapiens <400> 414 aggccuaggg gguggcaggc uggccaucag ugugggcuaa cccuguccuc ucccucccag 60 <210> 415 <211> 100 <212> RNA <213> Homo sapiens <400> 415 gugagcgggc gcggcaggga ucgcgggcgg guggcggccu agggcgcgga gggcggaccg 60 ggaauggcgc gccgugcgcc gccggcguaa cugcggcgcu 100 <210> 416 <211> 56 <212> RNA <213> Homo sapiens <400> 416 guaggcaggg gcugggguuu cagguucuca gucagaaccu uggccccucu ccccag 56 <210> 417 <211> 72 <212> RNA <213> Homo sapiens <400> 417 ucuccucgag gggucucugc cucuacccag gacucuuuca ugaccaggag gcugaggccc 60 cucacaggcg gc 72 <210> 418 <211> 68 <212> RNA <213> Homo sapiens <400> 418 gcauccugua cugagcugcc ccgaggcccu ucaugcugcc cagcucgggg cagcucagua 60 caggauac 68 <210> 419 <211> 64 <212> RNA <213> Homo sapiens <400> 419 uccuguacug agcugccccg agcugggcag caugaagggc cucggggcag cucaguacag 60 gaug 64 <210> 420 <211> 54 <212> RNA <213> Homo sapiens <400> 420 acgcgggugc gggccggcgg gguagaagcc acccggcccg gcccggcccg gcga 54 <210> 421 <211> 89 <212> RNA <213> Homo sapiens <400> 421 accaugcugu agugugugua aacauccuac acucucagcu gugagcucaa gguggcuggg 60 agaggguugu uuacuccuuc ugccaugga 89 <210> 422 <211> 85 <212> RNA <213> Homo sapiens <400> 422 gugagcugcu ggggacgcgg gucggggucu gcagggcggu gcggcagccg ccaccugacg 60 ccgcgccuuu gucugugucc cacag 85 <210> 423 <211> 71 <212> RNA <213> Homo sapiens <400> 423 ggguaaaggg gcagggacgg guggccccag gaagaagggc cugguggagc cgcucuucuc 60 ccugcccaca g 71 <210> 424 <211> 73 <212> RNA <213> Homo sapiens <400> 424 ggggagguac cugggacagg aggaggaggc agccuugccu cagaaaccaa acugucaaaa 60 guguagguuc cac 73 <210> 425 <211> 90 <212> RNA <213> Homo sapiens <400> 425 cgggcggggc ggguccggcc gccuccgagc ccggccggca gcccccggcc uuaaagcgcg 60 ggcuguccgg aggggucggc uuucccaccg 90 <210> 426 <211> 83 <212> RNA <213> Homo sapiens <400> 426 acggcaucuu ugcacucagc aggcaggcug gugcagcccg ugguggggga ccauccugcc 60 ugcugugggg uaaggacggc ugu 83 <210> 427 <211> 63 <212> RNA <213> Homo sapiens <400> 427 gagguguagg ggagguuggg ccagggaugc cuucacugug ucucucuggu cuugccaccc 60 cag 63 <210> 428 <211> 72 <212> RNA <213> Homo sapiens <400> 428 cugugcaccu gggggagugc agugauugug gaaugcaaag ucccacaauc acuguacucc 60 ccaggugcac ag 72 <210> 429 <211> 67 <212> RNA <213> Homo sapiens <400> 429 guggcacuca aacugugggg gcacuuucug cucucuggug aaagugccgc caucuuuuga 60 guguuac 67 <210> 430 <211> 62 <212> RNA <213> Homo sapiens <400> 430 gguagggggc gggcuccggc gcugggaccc cacuagggug gcgccuuggc cccgccccgc 60 cc 62 <210> 431 <211> 82 <212> RNA <213> Homo sapiens <400> 431 gugaguggga ggccagggca cggcaggggg agcugcaggg cuaugggagg ggccccagcg 60 ucugagcccu guccucccgc ag 82 <210> 432 <211> 82 <212> RNA <213> Homo sapiens <400> 432 gugaguggga ggccagggca cggcaggggg agcugcaggg cuaugggagg ggccccagcg 60 ucugagcccu guccucccgc ag 82 <210> 433 <211> 81 <212> RNA <213> Homo sapiens <400> 433 aguugguggg ggagccauga gauaagagca ccuccuagag aauguugaac uaaaggugcc 60 cucucuggcu ccuccccaaa g 81 <210> 434 <211> 68 <212> RNA <213> Homo sapiens <400> 434 cuccggugcc uacugagcug auaucaguuc ucauuuuaca cacuggcuca guucagcagg 60 aacaggag 68 <210> 435 <211> 73 <212> RNA <213> Homo sapiens <400> 435 cucugccucc cgugccuacu gagcugaaac acaguugguu uguguacacu ggcucaguuc 60 agcaggaaca ggg 73 <210> 436 <211> 83 <212> RNA <213> Homo sapiens <400> 436 gugaguggga gccccagugu gugguggg ccauggcggg ugggcagccc agccucugag 60 ccuuccucgu cugucugccc cag 83 <210> 437 <211> 67 <212> RNA <213> Homo sapiens <400> 437 gcgcccuccc ucucuccccg gugugcaaau gugugugugc gguguuaugc cggacaagag 60 ggaggug 67 <210> 438 <211> 58 <212> RNA <213> Homo sapiens <400> 438 gcugaagcuc uaagguuccg ccugcgggca ggaagcggag gaaccuugga gcuucggc 58 <210> 439 <211> 80 <212> RNA <213> Homo sapiens <400> 439 gagaggccaa gaccuuggga auggggguaa gggccuucug agcccagguc cgaacucucc 60 auuccucugc agagcgcucu 80 <210> 440 <211> 64 <212> RNA <213> Homo sapiens <400> 440 ccccgggccc ggcguucccu ccccuuccgu gcgccagugg aggccggggu ggggcggggc 60 gggg 64 <210> 441 <211> 64 <212> RNA <213> Homo sapiens <400> 441 ccccgggccc ggcguucccu ccccuuccgu gcgccagugg aggccggggu ggggcggggc 60 gggg 64 <210> 442 <211> 85 <212> RNA <213> Homo sapiens <400> 442 ggggagguag ggaaaaggaa gggggaggag aaggugagac caauguccug ggugccacuc 60 cugcccagug ccucccuucc ucguu 85 <210> 443 <211> 73 <212> RNA <213> Homo sapiens <400> 443 guucaagugg gaggacagga ggcaggugug guuggaggaa gcagccugaa ccugccuccc 60 ugacauucca cag 73 <210> 444 <211> 98 <212> RNA <213> Homo sapiens <400> 444 agaaugggca aaugaacagu aaauuuggag gccuggggcc cucccugcug cuggagaagu 60 guuugcacgg gugggccuug ucuuugaaag gaggugga 98 <210> 445 <211> 60 <212> RNA <213> Homo sapiens <400> 445 cgcugggucc gcgcgcccug ggccgggcga uguccgcuug ggggagcgag gggcggggcg 60 <210> 446 <211> 23 <212> RNA <213> Homo sapiens <400> 446 cuccuggggc ccgcacucuc gcu 23 <210> 447 <211> 18 <212> RNA <213> Homo sapiens <400> 447 cuccuggggc ccgcacuc 18 <210> 448 <211> 21 <212> RNA <213> Homo sapiens <400> 448 caacucugau cucuucaucu a 21 <210> 449 <211> 20 <212> RNA <213> Homo sapiens <400> 449 ucucuucauc uaccccccag 20 <210> 450 <211> 23 <212> RNA <213> Homo sapiens <400> 450 ggugggugag guggggcccc aag 23 <210> 451 <211> 20 <212> RNA <213> Homo sapiens <400> 451 cggggugggu gagguggggc 20 <210> 452 <211> 26 <212> RNA <213> Homo sapiens <400> 452 ccuucuggag aggcuuugug cggaua 26 <210> 453 <211> 15 <212> RNA <213> Homo sapiens <400> 453 ccuucuggag aggcu 15 <210> 454 <211> 20 <212> RNA <213> Homo sapiens <400> 454 ggcuggucag augggagugg 20 <210> 455 <211> 20 <212> RNA <213> Homo sapiens <400> 455 ggcuggucag augggagugg 20 <210> 456 <211> 26 <212> RNA <213> Homo sapiens <400> 456 aggagggagg agaugggcca aguucc 26 <210> 457 <211> 15 <212> RNA <213> Homo sapiens <400> 457 ggggaggg aggag 15 <210> 458 <211> 21 <212> RNA <213> Homo sapiens <400> 458 cuucccccca guaaucuuca u 21 <210> 459 <211> 21 <212> RNA <213> Homo sapiens <400> 459 cuucccccca guaaucuuca u 21 <210> 460 <211> 21 <212> RNA <213> Homo sapiens <400> 460 cggaucccgag ucacggcacc a 21 <210> 461 <211> 15 <212> RNA <213> Homo sapiens <400> 461 ggauccgagu cacgg 15 <210> 462 <211> 21 <212> RNA <213> Homo sapiens <400> 462 cccaggcugg agcgagugca g 21 <210> 463 <211> 15 <212> RNA <213> Homo sapiens <400> 463 agcucacugc agccu 15 <210> 464 <211> 17 <212> RNA <213> Homo sapiens <400> 464 uccuagucac ggcacca 17 <210> 465 <211> 17 <212> RNA <213> Homo sapiens <400> 465 uccuagucac ggcacca 17 <210> 466 <211> 24 <212> RNA <213> Homo sapiens <400> 466 gaggcuggga aggcaaaggg acgu 24 <210> 467 <211> 15 <212> RNA <213> Homo sapiens <400> 467 gaaggaggcu gggaa 15 <210> 468 <211> 21 <212> RNA <213> Homo sapiens <400> 468 gaggcgaugu ggggauguag a 21 <210> 469 <211> 20 <212> RNA <213> Homo sapiens <400> 469 cccagucuca uuuccucauc 20 <210> 470 <211> 23 <212> RNA <213> Homo sapiens <400> 470 ggcccggccg ugccugaggu uuc 23 <210> 471 <211> 15 <212> RNA <213> Homo sapiens <400> 471 ggcgguggga ucccg 15 <210> 472 <211> 16 <212> RNA <213> Homo sapiens <400> 472 cugggggucc cccgac 16 <210> 473 <211> 15 <212> RNA <213> Homo sapiens <400> 473 gugggagcu ggggc 15 <210> 474 <211> 25 <212> RNA <213> Homo sapiens <400> 474 agcggggagg aagugggcgc ugcuu 25 <210> 475 <211> 21 <212> RNA <213> Homo sapiens <400> 475 agcggggagg aagugggcgc u 21 <210> 476 <211> 27 <212> RNA <213> Homo sapiens <400> 476 aaaccguuac cauuacugag uuuagua 27 <210> 477 <211> 15 <212> RNA <213> Homo sapiens <400> 477 gaaaccguua ccauu 15 <210> 478 <211> 22 <212> RNA <213> Homo sapiens <400> 478 caggcacggg agcucaggug ag 22 <210> 479 <211> 17 <212> RNA <213> Homo sapiens <400> 479 caggcacggg agcucag 17 <210> 480 <211> 23 <212> RNA <213> Homo sapiens <400> 480 gggggucccc ggugcucgga ucu 23 <210> 481 <211> 16 <212> RNA <213> Homo sapiens <400> 481 ucgggagggg cgggag 16 <210> 482 <211> 23 <212> RNA <213> Homo sapiens <400> 482 cggggccgua gcacuugucug aga 23 <210> 483 <211> 20 <212> RNA <213> Homo sapiens <400> 483 cggggccgua gcacuugucug 20 <210> 484 <211> 20 <212> RNA <213> Homo sapiens <400> 484 aucccaccac ugccaccauu 20 <210> 485 <211> 15 <212> RNA <213> Homo sapiens <400> 485 aucccaccac ugcca 15 <210> 486 <211> 23 <212> RNA <213> Homo sapiens <400> 486 acaggagugg gggugggaca uaa 23 <210> 487 <211> 20 <212> RNA <213> Homo sapiens <400> 487 acaggagugg gggugggaca 20 <210> 488 <211> 23 <212> RNA <213> Homo sapiens <400> 488 cugggggacg cgugagcgcg agc 23 <210> 489 <211> 21 <212> RNA <213> Homo sapiens <400> 489 cugggggacg cgugagcgcg a 21 <210> 490 <211> 22 <212> RNA <213> Homo sapiens <400> 490 cgcggcgggg acggcgauug gu 22 <210> 491 <211> 17 <212> RNA <213> Homo sapiens <400> 491 cggcggggac ggcgauu 17 <210> 492 <211> 23 <212> RNA <213> Homo sapiens <400> 492 gagggccccc ccucaauccu guu 23 <210> 493 <211> 16 <212> RNA <213> Homo sapiens <400> 493 agggcccccc cucau 16 <210> 494 <211> 30 <212> RNA <213> Homo sapiens <400> 494 ugaggggcag agagcgagac uuuucuauuu 30 <210> 495 <211> 15 <212> RNA <213> Homo sapiens <400> 495 ugaggggcag agagc 15 <210> 496 <211> 24 <212> RNA <213> Homo sapiens <400> 496 gugaguggga gccggugggg cugg 24 <210> 497 <211> 15 <212> RNA <213> Homo sapiens <400> 497 ggggcuggag uaagg 15 <210> 498 <211> 23 <212> RNA <213> Homo sapiens <400> 498 ugaggaauug gcagggaagg gga 23 <210> 499 <211> 19 <212> RNA <213> Homo sapiens <400> 499 ugaggaauug gcagggaag 19 <210> 500 <211> 23 <212> RNA <213> Homo sapiens <400> 500 cuaguggaag aagauggcgg aag 23 <210> 501 <211> 15 <212> RNA <213> Homo sapiens <400> 501 uaguggaaga agaug 15 <210> 502 <211> 25 <212> RNA <213> Homo sapiens <400> 502 ugggcagggg cuuauuguag gaguc 25 <210> 503 <211> 19 <212> RNA <213> Homo sapiens <400> 503 ugggcagggg cuuauugua 19 <210> 504 <211> 23 <212> RNA <213> Homo sapiens <400> 504 agaagaaggc ggucggucug cgg 23 <210> 505 <211> 21 <212> RNA <213> Homo sapiens <400> 505 aagaaggcgg ucggucugcg g 21 <210> 506 <211> 20 <212> RNA <213> Homo sapiens <400> 506 aucccaccuc ugccaccaaa 20 <210> 507 <211> 15 <212> RNA <213> Homo sapiens <400> 507 aucccaccuc ugcca 15 <210> 508 <211> 23 <212> RNA <213> Homo sapiens <400> 508 ggaggcgcag gcucggaaag gcg 23 <210> 509 <211> 15 <212> RNA <213> Homo sapiens <400> 509 gcaggcuckg aaagg 15 <210> 510 <211> 17 <212> RNA <213> Homo sapiens <400> 510 ccuccgggac ggcuggg 17 <210> 511 <211> 15 <212> RNA <213> Homo sapiens <400> 511 cucggggacg gcugg 15 <210> 512 <211> 29 <212> RNA <213> Homo sapiens <400> 512 ggucaggcgg cucggacuga gcagguggg 29 <210> 513 <211> 15 <212> RNA <213> Homo sapiens <400> 513 agagugugu caggc 15 <210> 514 <211> 15 <212> RNA <213> Homo sapiens <400> 514 ggcgcgggga ggugc 15 <210> 515 <211> 15 <212> RNA <213> Homo sapiens <400> 515 ggcgcgggga ggugc 15 <210> 516 <211> 22 <212> RNA <213> Homo sapiens <400> 516 accccacucc ugguaccaua gu 22 <210> 517 <211> 15 <212> RNA <213> Homo sapiens <400> 517 accccacucc ugga 15 <210> 518 <211> 15 <212> RNA <213> Homo sapiens <400> 518 ugaagcgggg gggcg 15 <210> 519 <211> 15 <212> RNA <213> Homo sapiens <400> 519 ugaagcgggg gggcg 15 <210> 520 <211> 21 <212> RNA <213> Homo sapiens <400> 520 gaauggauuu uuggagcagg a 21 <210> 521 <211> 15 <212> RNA <213> Homo sapiens <400> 521 gaauggauuu uugga 15 <210> 522 <211> 25 <212> RNA <213> Homo sapiens <400> 522 uggcggcggu aguuaugggc uucuc 25 <210> 523 <211> 25 <212> RNA <213> Homo sapiens <400> 523 uggcggcggu aguuaugggc uucuc 25 <210> 524 <211> 18 <212> RNA <213> Homo sapiens <400> 524 gaggcugaag gaagaugg 18 <210> 525 <211> 15 <212> RNA <213> Homo sapiens <400> 525 gaggcugaag gaaga 15 <210> 526 <211> 23 <212> RNA <213> Homo sapiens <400> 526 aggaggguc ccgcacuggg agg 23 <210> 527 <211> 15 <212> RNA <213> Homo sapiens <400> 527 ugggaggggc ccuca 15 <210> 528 <211> 21 <212> RNA <213> Homo sapiens <400> 528 gagggcagcg uggguguggc g 21 <210> 529 <211> 21 <212> RNA <213> Homo sapiens <400> 529 gagggcagcg uggguguggc g 21 <210> 530 <211> 23 <212> RNA <213> Homo sapiens <400> 530 caccuugccu ugcugcccgg gcc 23 <210> 531 <211> 22 <212> RNA <213> Homo sapiens <400> 531 caccuugccu ugcugcccgg gc 22 <210> 532 <211> 19 <212> RNA <213> Homo sapiens <400> 532 guggguuggg gcgggcucu 19 <210> 533 <211> 19 <212> RNA <213> Homo sapiens <400> 533 guggguuggg gcgggcucu 19 <210> 534 <211> 24 <212> RNA <213> Homo sapiens <400> 534 auauacaggg ggagacucuc auuu 24 <210> 535 <211> 15 <212> RNA <213> Homo sapiens <400> 535 auauacaggg ggaga 15 <210> 536 <211> 26 <212> RNA <213> Homo sapiens <400> 536 agggcuggac ucagcggcgg agcugg 26 <210> 537 <211> 17 <212> RNA <213> Homo sapiens <400> 537 gcggcggagc uggcugc 17 <210> 538 <211> 22 <212> RNA <213> Homo sapiens <400> 538 gugggcgggg gcaggugugu gg 22 <210> 539 <211> 15 <212> RNA <213> Homo sapiens <400> 539 cggggggcagg ugugu 15 <210> 540 <211> 16 <212> RNA <213> Homo sapiens <400> 540 ugcuggugau gcuuuc 16 <210> 541 <211> 16 <212> RNA <213> Homo sapiens <400> 541 ugcuggugau gcuuuc 16 <210> 542 <211> 22 <212> RNA <213> Homo sapiens <400> 542 acucggcugc gguggacaag uc 22 <210> 543 <211> 20 <212> RNA <213> Homo sapiens <400> 543 acucggcugc gguggacaag 20 <210> 544 <211> 18 <212> RNA <213> Homo sapiens <400> 544 ucuagguggg gagacuga 18 <210> 545 <211> 16 <212> RNA <213> Homo sapiens <400> 545 guggggagac ugacgg 16 <210> 546 <211> 26 <212> RNA <213> Homo sapiens <400> 546 gucccggggc ugcgcgaggc acaggc 26 <210> 547 <211> 15 <212> RNA <213> Homo sapiens <400> 547 ggcccggggg gcggg 15 <210> 548 <211> 23 <212> RNA <213> Homo sapiens <400> 548 gugggggaga ggcugucuug ugu 23 <210> 549 <211> 15 <212> RNA <213> Homo sapiens <400> 549 gugggggga gaggc 15 <210> 550 <211> 17 <212> RNA <213> Homo sapiens <400> 550 ggugagcgcu cgcuggc 17 <210> 551 <211> 15 <212> RNA <213> Homo sapiens <400> 551 cggugagcgc ucgcu 15 <210> 552 <211> 21 <212> RNA <213> Homo sapiens <400> 552 guuggaggcg uggguuuuag a 21 <210> 553 <211> 15 <212> RNA <213> Homo sapiens <400> 553 guuggaggcg ugggu 15 <210> 554 <211> 25 <212> RNA <213> Homo sapiens <400> 554 caggaaggau uuagggacag gcuuu 25 <210> 555 <211> 19 <212> RNA <213> Homo sapiens <400> 555 caggaaggau uuagggaca 19 <210> 556 <211> 15 <212> RNA <213> Homo sapiens <400> 556 ucugggcgag gggug 15 <210> 557 <211> 15 <212> RNA <213> Homo sapiens <400> 557 ucugggcgag gggug 15 <210> 558 <211> 23 <212> RNA <213> Homo sapiens <400> 558 ggggggaugu gcaugcuggu ugg 23 <210> 559 <211> 15 <212> RNA <213> Homo sapiens <400> 559 aucagcgugc acuuc 15 <210> 560 <211> 20 <212> RNA <213> Homo sapiens <400> 560 ccccagggcg acgcggcggg 20 <210> 561 <211> 15 <212> RNA <213> Homo sapiens <400> 561 cgcggcgggg gcggc 15 <210> 562 <211> 23 <212> RNA <213> Homo sapiens <400> 562 agggucgggg cagggagggc agg 23 <210> 563 <211> 15 <212> RNA <213> Homo sapiens <400> 563 gggagaaggg ucggg 15 <210> 564 <211> 18 <212> RNA <213> Homo sapiens <400> 564 ggugggcuuc ccggaggg 18 <210> 565 <211> 15 <212> RNA <213> Homo sapiens <400> 565 ggugggcuuc ccgga 15 <210> 566 <211> 20 <212> RNA <213> Homo sapiens <400> 566 aagacacauu uggagaggga 20 <210> 567 <211> 16 <212> RNA <213> Homo sapiens <400> 567 agacacauuu ggagag 16 <210> 568 <211> 19 <212> RNA <213> Homo sapiens <400> 568 gagggcgggu ggaggagga 19 <210> 569 <211> 15 <212> RNA <213> Homo sapiens <400> 569 gcggguggag gagga 15 <210> 570 <211> 17 <212> RNA <213> Homo sapiens <400> 570 gaucccagcg gugccuc 17 <210> 571 <211> 15 <212> RNA <213> Homo sapiens <400> 571 gaucccagcg gugcc 15 <210> 572 <211> 23 <212> RNA <213> Homo sapiens <400> 572 aagggaggag gagcggaggg gcc 23 <210> 573 <211> 15 <212> RNA <213> Homo sapiens <400> 573 gggaggagga gcgga 15 <210> 574 <211> 23 <212> RNA <213> Homo sapiens <400> 574 ccaggaggcg gaggaggugg agg 23 <210> 575 <211> 15 <212> RNA <213> Homo sapiens <400> 575 acccaggagg cggag 15 <210> 576 <211> 15 <212> RNA <213> Homo sapiens <400> 576 uggcagagcg cuguc 15 <210> 577 <211> 15 <212> RNA <213> Homo sapiens <400> 577 uggcagagcg cuguc 15 <210> 578 <211> 22 <212> RNA <213> Homo sapiens <400> 578 gaggguuggg uggaggcucu cc 22 <210> 579 <211> 15 <212> RNA <213> Homo sapiens <400> 579 gaggguuggg uggag 15 <210> 580 <211> 21 <212> RNA <213> Homo sapiens <400> 580 cagcagggga gagagaggag u 21 <210> 581 <211> 20 <212> RNA <213> Homo sapiens <400> 581 cagcagggga gagagaggag 20 <210> 582 <211> 22 <212> RNA <213> Homo sapiens <400> 582 ccgggaacgu cgagacugga gc 22 <210> 583 <211> 15 <212> RNA <213> Homo sapiens <400> 583 cgggaacguc gagac 15 <210> 584 <211> 17 <212> RNA <213> Homo sapiens <400> 584 aggggcuggg cgcgcgc 17 <210> 585 <211> 15 <212> RNA <213> Homo sapiens <400> 585 caggggcugg gcgcg 15 <210> 586 <211> 24 <212> RNA <213> Homo sapiens <400> 586 cgggcguggu ggugggggug ggug 24 <210> 587 <211> 15 <212> RNA <213> Homo sapiens <400> 587 cgggcguggu ggugg 15 <210> 588 <211> 24 <212> RNA <213> Homo sapiens <400> 588 uggggagcug aggcucuggg ggug 24 <210> 589 <211> 15 <212> RNA <213> Homo sapiens <400> 589 ggcccugggg aggug 15 <210> 590 <211> 19 <212> RNA <213> Homo sapiens <400> 590 uggcgggugc ggggguggg 19 <210> 591 <211> 15 <212> RNA <213> Homo sapiens <400> 591 uggcgggugc ggggg 15 <210> 592 <211> 25 <212> RNA <213> Homo sapiens <400> 592 ugcggggcua gggcuaacag caguc 25 <210> 593 <211> 15 <212> RNA <213> Homo sapiens <400> 593 ugcggggcua gggcu 15 <210> 594 <211> 20 <212> RNA <213> Homo sapiens <400> 594 uggcuguugg aggggggcagg 20 <210> 595 <211> 15 <212> RNA <213> Homo sapiens <400> 595 ggagggggca ggcuc 15 <210> 596 <211> 24 <212> RNA <213> Homo sapiens <400> 596 aggcaggggc uggugcuggg cggg 24 <210> 597 <211> 15 <212> RNA <213> Homo sapiens <400> 597 gggcgggggg cggcg 15 <210> 598 <211> 23 <212> RNA <213> Homo sapiens <400> 598 gugggcuggg cugggcuggg cca 23 <210> 599 <211> 15 <212> RNA <213> Homo sapiens <400> 599 gggcugggcu gggcu 15 <210> 600 <211> 17 <212> RNA <213> Homo sapiens <400> 600 ggggcggggg cgggggc 17 <210> 601 <211> 15 <212> RNA <213> Homo sapiens <400> 601 cgcgccgggc ccggg 15 <210> 602 <211> 23 <212> RNA <213> Homo sapiens <400> 602 gccccggcgc gggcggguuc ugg 23 <210> 603 <211> 16 <212> RNA <213> Homo sapiens <400> 603 ggagccccgg cgcggg 16 <210> 604 <211> 24 <212> RNA <213> Homo sapiens <400> 604 agacacauuu ggagagggaa ccuc 24 <210> 605 <211> 16 <212> RNA <213> Homo sapiens <400> 605 agacacauuu ggagag 16 <210> 606 <211> 22 <212> RNA <213> Homo sapiens <400> 606 ugggagggga gaggcagcaa gc 22 <210> 607 <211> 22 <212> RNA <213> Homo sapiens <400> 607 ugggagggga gaggcagcaa gc 22 <210> 608 <211> 21 <212> RNA <213> Homo sapiens <400> 608 auccaguucu cugagggggc u 21 <210> 609 <211> 21 <212> RNA <213> Homo sapiens <400> 609 auccaguucu cugagggggc u 21 <210> 610 <211> 23 <212> RNA <213> Homo sapiens <400> 610 aauauacagg gggagacucu uau 23 <210> 611 <211> 15 <212> RNA <213> Homo sapiens <400> 611 auauacaggg ggaga 15 <210> 612 <211> 24 <212> RNA <213> Homo sapiens <400> 612 ucgaggacug guggaagggc cuuu 24 <210> 613 <211> 16 <212> RNA <213> Homo sapiens <400> 613 ucgaggacug guggaa 16 <210> 614 <211> 18 <212> RNA <213> Homo sapiens <400> 614 gagacugggg uggggccu 18 <210> 615 <211> 16 <212> RNA <213> Homo sapiens <400> 615 agacuggggu ggggcc 16 <210> 616 <211> 23 <212> RNA <213> Homo sapiens <400> 616 gggggccgau acacuguacg aga 23 <210> 617 <211> 20 <212> RNA <213> Homo sapiens <400> 617 gggggccgau acacuguacg 20 <210> 618 <211> 18 <212> RNA <213> Homo sapiens <400> 618 cagcggggcu gggcgcgc 18 <210> 619 <211> 15 <212> RNA <213> Homo sapiens <400> 619 cagcggggcu gggcg 15 <210> 620 <211> 24 <212> RNA <213> Homo sapiens <400> 620 gcugcgggcu gcggucaggg cgau 24 <210> 621 <211> 20 <212> RNA <213> Homo sapiens <400> 621 gcugcgggcu gcggucaggg 20 <210> 622 <211> 23 <212> RNA <213> Homo sapiens <400> 622 agggaguaga aggggugggga gca 23 <210> 623 <211> 16 <212> RNA <213> Homo sapiens <400> 623 uagggaguag aagggu 16 <210> 624 <211> 27 <212> RNA <213> Homo sapiens <400> 624 gugaacgggc gccaucccga ggcuuug 27 <210> 625 <211> 16 <212> RNA <213> Homo sapiens <400> 625 gugaacgggc gccauc 16 <210> 626 <211> 25 <212> RNA <213> Homo sapiens <400> 626 uucugggccc gcggcgggcg ugggg 25 <210> 627 <211> 15 <212> RNA <213> Homo sapiens <400> 627 cgcggcgggc guggg 15 <210> 628 <211> 26 <212> RNA <213> Homo sapiens <400> 628 aaaaucacau ugccagggau uaccac 26 <210> 629 <211> 15 <212> RNA <213> Homo sapiens <400> 629 aaucacauug ccagg 15 <210> 630 <211> 27 <212> RNA <213> Homo sapiens <400> 630 aucacauugc cagggauuuc caaccga 27 <210> 631 <211> 15 <212> RNA <213> Homo sapiens <400> 631 aaucacauug ccagg 15 <210> 632 <211> 26 <212> RNA <213> Homo sapiens <400> 632 gacuauagaa cuuucccccu cauccc 26 <210> 633 <211> 15 <212> RNA <213> Homo sapiens <400> 633 aacuuucccc cucau 15 <210> 634 <211> 22 <212> RNA <213> Homo sapiens <400> 634 ccucacaccu gccucgcccc cc 22 <210> 635 <211> 15 <212> RNA <213> Homo sapiens <400> 635 ucacaccugc cucgc 15 <210> 636 <211> 17 <212> RNA <213> Homo sapiens <400> 636 ugcaggggca ggccagc 17 <210> 637 <211> 17 <212> RNA <213> Homo sapiens <400> 637 ugcaggggca ggccagc 17 <210> 638 <211> 22 <212> RNA <213> Homo sapiens <400> 638 ccggcagagg aggcugcaga gg 22 <210> 639 <211> 19 <212> RNA <213> Homo sapiens <400> 639 ccggcagagg aggcugcag 19 <210> 640 <211> 25 <212> RNA <213> Homo sapiens <400> 640 ggguggggau uuguugcauu acuug 25 <210> 641 <211> 20 <212> RNA <213> Homo sapiens <400> 641 ggguggggau uuguugcauu 20 <210> 642 <211> 23 <212> RNA <213> Homo sapiens <400> 642 ggcuacaaca caggacccgg gcg 23 <210> 643 <211> 21 <212> RNA <213> Homo sapiens <400> 643 ggcuacaaca caggacccgg g 21 <210> 644 <211> 27 <212> RNA <213> Homo sapiens <400> 644 uagcagcacg uaaauauugg cguuaag 27 <210> 645 <211> 15 <212> RNA <213> Homo sapiens <400> 645 uagcagcacg uaaau 15 <210> 646 <211> 24 <212> RNA <213> Homo sapiens <400> 646 aauauugcac ucgucccggc cucc 24 <210> 647 <211> 15 <212> RNA <213> Homo sapiens <400> 647 uauugcacuc guccc 15 <210> 648 <211> 24 <212> RNA <213> Homo sapiens <400> 648 cugguacagg ccugggggac aggg 24 <210> 649 <211> 18 <212> RNA <213> Homo sapiens <400> 649 cugguacagg ccuggggg 18 <210> 650 <211> 18 <212> RNA <213> Homo sapiens <400> 650 cuccgggcgg cgccgugu 18 <210> 651 <211> 18 <212> RNA <213> Homo sapiens <400> 651 cuccgggcgg cgccgugu 18 <210> 652 <211> 23 <212> RNA <213> Homo sapiens <400> 652 cacaggugag guucuuggga gcc 23 <210> 653 <211> 15 <212> RNA <213> Homo sapiens <400> 653 acaggugagg uucuu 15 <210> 654 <211> 26 <212> RNA <213> Homo sapiens <400> 654 agggacggga cgcggugcag uguugu 26 <210> 655 <211> 15 <212> RNA <213> Homo sapiens <400> 655 ggcgggcggg aggga 15 <210> 656 <211> 28 <212> RNA <213> Homo sapiens <400> 656 guaugguauu gcacuugucc cggccugu 28 <210> 657 <211> 15 <212> RNA <213> Homo sapiens <400> 657 uauugcacuu guccc 15 <210> 658 <211> 26 <212> RNA <213> Homo sapiens <400> 658 cggugggauc ccgcggccgu guuuuc 26 <210> 659 <211> 15 <212> RNA <213> Homo sapiens <400> 659 ggggcgccgc gggac 15 <210> 660 <211> 23 <212> RNA <213> Homo sapiens <400> 660 uaggggcagc agaggaccug ggc 23 <210> 661 <211> 20 <212> RNA <213> Homo sapiens <400> 661 uaggggcagc agaggaccug 20 <210> 662 <211> 22 <212> RNA <213> Homo sapiens <400> 662 ugugggacug caaaugggag cu 22 <210> 663 <211> 22 <212> RNA <213> Homo sapiens <400> 663 ugugggacug caaaugggag cu 22 <210> 664 <211> 16 <212> RNA <213> Homo sapiens <400> 664 gugaaggccc ggcgga 16 <210> 665 <211> 15 <212> RNA <213> Homo sapiens <400> 665 gugaaggccc ggcgg 15 <210> 666 <211> 22 <212> RNA <213> Homo sapiens <400> 666 ggggggcagg aggggcucag gg 22 <210> 667 <211> 16 <212> RNA <213> Homo sapiens <400> 667 guggggggggc aggaggg 16 <210> 668 <211> 23 <212> RNA <213> Homo sapiens <400> 668 uggggcggag cuuccggagg ccc 23 <210> 669 <211> 16 <212> RNA <213> Homo sapiens <400> 669 aucgcuggcc uggucg 16 <210> 670 <211> 26 <212> RNA <213> Homo sapiens <400> 670 gaggggcucu cgcuucuggc gccaag 26 <210> 671 <211> 15 <212> RNA <213> Homo sapiens <400> 671 ggugaggcgg ggggg 15 <210> 672 <211> 21 <212> RNA <213> Homo sapiens <400> 672 cagccugagu gacagagcaa g 21 <210> 673 <211> 15 <212> RNA <213> Homo sapiens <400> 673 acugcacucc agccu 15 <210> 674 <211> 17 <212> RNA <213> Homo sapiens <400> 674 gcggggcggc aggggcc 17 <210> 675 <211> 15 <212> RNA <213> Homo sapiens <400> 675 gggggcgggg cggca 15 <210> 676 <211> 21 <212> RNA <213> Homo sapiens <400> 676 aggaggcagu gggcgagcag g 21 <210> 677 <211> 21 <212> RNA <213> Homo sapiens <400> 677 aggaggcagu gggcgagcag g 21 <210> 678 <211> 16 <212> RNA <213> Homo sapiens <400> 678 ggcgcggagg gcggac 16 <210> 679 <211> 15 <212> RNA <213> Homo sapiens <400> 679 ggcgcggagg gcgga 15 <210> 680 <211> 22 <212> RNA <213> Homo sapiens <400> 680 accaggaggc ugaggccccu ca 22 <210> 681 <211> 15 <212> RNA <213> Homo sapiens <400> 681 accaggaggc ugagg 15 <210> 682 <211> 23 <212> RNA <213> Homo sapiens <400> 682 cggggcagcu caguacagga uac 23 <210> 683 <211> 15 <212> RNA <213> Homo sapiens <400> 683 agcucaguac aggau 15 <210> 684 <211> 19 <212> RNA <213> Homo sapiens <400> 684 gggugcgggc cggcggggu 19 <210> 685 <211> 15 <212> RNA <213> Homo sapiens <400> 685 ugcgggccgg cgggg 15 <210> 686 <211> 27 <212> RNA <213> Homo sapiens <400> 686 caagguggcu gggagagggu uguuuac 27 <210> 687 <211> 15 <212> RNA <213> Homo sapiens <400> 687 gugagcucaa ggugg 15 <210> 688 <211> 15 <212> RNA <213> Homo sapiens <400> 688 aggaggagga ggcag 15 <210> 689 <211> 15 <212> RNA <213> Homo sapiens <400> 689 aggaggagga ggcag 15 <210> 690 <211> 26 <212> RNA <213> Homo sapiens <400> 690 gcgggcuguc cggagggguc ggcuuu 26 <210> 691 <211> 16 <212> RNA <213> Homo sapiens <400> 691 gcuguccgga gggguc 16 <210> 692 <211> 24 <212> RNA <213> Homo sapiens <400> 692 ugggggagug cagugauugu ggaa 24 <210> 693 <211> 19 <212> RNA <213> Homo sapiens <400> 693 ugggggagug cagugauug 19 <210> 694 <211> 22 <212> RNA <213> Homo sapiens <400> 694 acucaaacug ugggggcacu uu 22 <210> 695 <211> 19 <212> RNA <213> Homo sapiens <400> 695 acucaaacug ugggggcac 19 <210> 696 <211> 19 <212> RNA <213> Homo sapiens <400> 696 aggggggcggg cuccggcgc 19 <210> 697 <211> 15 <212> RNA <213> Homo sapiens <400> 697 guagggggcg ggcuc 15 <210> 698 <211> 19 <212> RNA <213> Homo sapiens <400> 698 agugggaggc cagggcacg 19 <210> 699 <211> 15 <212> RNA <213> Homo sapiens <400> 699 agggggagcu gcagg 15 <210> 700 <211> 25 <212> RNA <213> Homo sapiens <400> 700 gggggagcca ugagauaaga gcacc 25 <210> 701 <211> 20 <212> RNA <213> Homo sapiens <400> 701 ugggggagcc augagauaag 20 <210> 702 <211> 24 <212> RNA <213> Homo sapiens <400> 702 acuggcucag uucagcagga acag 24 <210> 703 <211> 15 <212> RNA <213> Homo sapiens <400> 703 uggcucaguu cagca 15 <210> 704 <211> 20 <212> RNA <213> Homo sapiens <400> 704 cuccccggug ugcaaaugug 20 <210> 705 <211> 15 <212> RNA <213> Homo sapiens <400> 705 guugcggug uuaug 15 <210> 706 <211> 22 <212> RNA <213> Homo sapiens <400> 706 ggcaggaagc ggaggaaccu ug 22 <210> 707 <211> 17 <212> RNA <213> Homo sapiens <400> 707 ggaggaaccu uggagcu 17 <210> 708 <211> 21 <212> RNA <213> Homo sapiens <400> 708 ugggaauggg gguaagggcc u 21 <210> 709 <211> 15 <212> RNA <213> Homo sapiens <400> 709 cuucugagcc caggu 15 <210> 710 <211> 16 <212> RNA <213> Homo sapiens <400> 710 cgggcccggc guuccc 16 <210> 711 <211> 15 <212> RNA <213> Homo sapiens <400> 711 ccgggcccgg cguuc 15 <210> 712 <211> 18 <212> RNA <213> Homo sapiens <400> 712 aaaaggaagg gggaggag 18 <210> 713 <211> 16 <212> RNA <213> Homo sapiens <400> 713 aaggaagggg gaggag 16 <210> 714 <211> 22 <212> RNA <213> Homo sapiens <400> 714 uagggauggg aggccaggau ga 22 <210> 715 <211> 20 <212> RNA <213> Homo sapiens <400> 715 ggcuccuugg ucuaggggua 20 <210> 716 <211> 23 <212> RNA <213> Homo sapiens <400> 716 aggaagcccu ggaggggcug gag 23 <210> 717 <211> 17 <212> RNA <213> Homo sapiens <400> 717 ggggcgcggc cggaucg 17 <210> 718 <211> 22 <212> RNA <213> Homo sapiens <400> 718 uggggaaggc gucagugucg gg 22 <210> 719 <211> 21 <212> RNA <213> Homo sapiens <400> 719 aaggcagggc ccccgcuccc c 21 <210> 720 <211> 24 <212> RNA <213> Homo sapiens <400> 720 guaggggcgu cccgggcgcg cggg 24 <210> 721 <211> 20 <212> RNA <213> Homo sapiens <400> 721 aaaaggcggg agaagcccca 20 <210> 722 <211> 19 <212> RNA <213> Homo sapiens <400> 722 cggcgcgacc ggcccgggg 19 <210> 723 <211> 23 <212> RNA <213> Homo sapiens <400> 723 ugaguggggc ucccgggacg gcg 23 <210> 724 <211> 23 <212> RNA <213> Homo sapiens <400> 724 cuggcggagc ccauuccaug cca 23 <210> 725 <211> 22 <212> RNA <213> Homo sapiens <400> 725 cugggggugg ggggcugggc gu 22 <210> 726 <211> 23 <212> RNA <213> Homo sapiens <400> 726 ccagggggau gggcgagcuu ggg 23 <210> 727 <211> 21 <212> RNA <213> Homo sapiens <400> 727 agccgcgggg aucgccgagg g 21 <210> 728 <211> 23 <212> RNA <213> Homo sapiens <400> 728 ccccgguguu ggggcgcguc ugc 23 <210> 729 <211> 21 <212> RNA <213> Homo sapiens <400> 729 augccucccc cggccccgca g 21 <210> 730 <211> 69 <212> RNA <213> Homo sapiens <400> 730 gggcuuaggg augggaggcc aggaugaaga uuaaucccua auccccaaca cuggccuugc 60 uauccccag 69 <210> 731 <211> 86 <212> RNA <213> Homo sapiens <400> 731 aggagugacc aaaagacaag agugcgagcc uucuauuaug cccagacagg gccaccagag 60 ggcuccuugg ucuaggggua augcca 86 <210> 732 <211> 118 <212> RNA <213> Homo sapiens <400> 732 gcaggugaac uggcaggcca ggaagaggag gaagcccugg aggggcugga ggugauggau 60 guuuuccucc gguucucagg gcuccaccuc uuucgggccg uagagccagg gcuggugc 118 <210> 733 <211> 84 <212> RNA <213> Homo sapiens <400> 733 gaggcugggc ggggcgcggc cggaucgguc gagagcgucc uggcugauga cggucucccg 60 ugcccacgcc ccaaacgcag ucuc 84 <210> 734 <211> 90 <212> RNA <213> Homo sapiens <400> 734 gugucucucu ggagacccug cagccuuccc acccaccagg gagcuuucca ugggcugugg 60 ggaaggcguc agugucgggu gagggaacac 90 <210> 735 <211> 94 <212> RNA <213> Homo sapiens <400> 735 gugaggugug ggcccggccc caggagcggg gccugggcag ccccgugugu ugaggaagga 60 aggcagggcc cccgcucccc gggccugacc ccac 94 <210> 736 <211> 98 <212> RNA <213> Homo sapiens <400> 736 cgagguaggg gcgucccggg cgcgcgggcg ggucccaggc ugggccccuc ggaggccggg 60 ugcucacugc cccgucccgg cgcccguguc uccuccag 98 <210> 737 <211> 83 <212> RNA <213> Homo sapiens <400> 737 ggguuuccuc ugccuuuuuu uccaaugaaa auaacgaaac cuguuauuuc ccauugaggg 60 ggaaaaaggc gggagaagcc cca 83 <210> 738 <211> 54 <212> RNA <213> Homo sapiens <400> 738 ggacaagggc ggcgcgaccg gcccggggcu cuugggcggc cgcguuuccc cucc 54 <210> 739 <211> 62 <212> RNA <213> Homo sapiens <400> 739 gugagugggg cucccgggac ggcgcccgcc cuggcccugg cccggcgacg ucucacgguc 60 cc 62 <210> 740 <211> 76 <212> RNA <213> Homo sapiens <400> 740 cgcaggccuc uggcggagcc cauuccaugc cagaugcuga gcgauggcug gugugugcug 60 cuccacaggc cuggug 76 <210> 741 <211> 65 <212> RNA <213> Homo sapiens <400> 741 cuccucuggg gguggggggc ugggcguggu ggacagcgau gcaucccucg ccuucucacc 60 cucag 65 <210> 742 <211> 67 <212> RNA <213> Homo sapiens <400> 742 ggcagccagg gggaugggcg agcuugggcc cauuccuuuc cuuacccuac cccccauccc 60 ccuguag 67 <210> 743 <211> 180 <212> RNA <213> Homo sapiens <400> 743 cgcgacugcg gcggcggugg uggggggagc cgcggggauc gccgagggcc ggucggccgc 60 cccgggugcc gcgcggugcc gccggcggcg gugaggcccc gcgcgugugu cccggcugcg 120 gucggccgcg cucgaggggu ccccguggcg uccccuuccc cgccggccgc cuuucucgcg 180 <210> 744 <211> 82 <212> RNA <213> Homo sapiens <400> 744 gggaaagcgg agggcgcgcc cagcucccgg gcugauugcg cuaacagugg ccccgguguu 60 ggggcgcguc ugccgcugcc cc 82 <210> 745 <211> 63 <212> RNA <213> Homo sapiens <400> 745 ggcuccgcag ggcccuggcg caggcaucca gacagcgggc gaaugccucc cccggccccg 60 cag 63 <210> 746 <211> 20 <212> RNA <213> Homo sapiens <400> 746 ggcuccuugg ucuaggggua 20 <210> 747 <211> 15 <212> RNA <213> Homo sapiens <400> 747 cuuggucuag gggua 15 <210> 748 <211> 25 <212> RNA <213> Homo sapiens <400> 748 aggaagcccu ggaggggcug gaggu 25 <210> 749 <211> 15 <212> RNA <213> Homo sapiens <400> 749 aggaagagga ggaag 15 <210> 750 <211> 24 <212> RNA <213> Homo sapiens <400> 750 gaucggucga gagcguccug gcug 24 <210> 751 <211> 15 <212> RNA <213> Homo sapiens <400> 751 gcugggcggg gcgcg 15 <210> 752 <211> 23 <212> RNA <213> Homo sapiens <400> 752 uggggaaggc gucagugucg ggu 23 <210> 753 <211> 16 <212> RNA <213> Homo sapiens <400> 753 uggggaaggc gucagu 16 <210> 754 <211> 23 <212> RNA <213> Homo sapiens <400> 754 aggaaggaag gcagggcccc cgc 23 <210> 755 <211> 15 <212> RNA <213> Homo sapiens <400> 755 gggcccccgc ucccc 15 <210> 756 <211> 20 <212> RNA <213> Homo sapiens <400> 756 ggaaaaaggc gggagaagcc 20 <210> 757 <211> 15 <212> RNA <213> Homo sapiens <400> 757 ggcgggagaa gcccc 15 <210> 758 <211> 20 <212> RNA <213> Homo sapiens <400> 758 ugaguggggc ucccgggacg 20 <210> 759 <211> 20 <212> RNA <213> Homo sapiens <400> 759 ugaguggggc ucccgggacg 20 <210> 760 <211> 22 <212> RNA <213> Homo sapiens <400> 760 uggcggagcc cauuccaugc ca 22 <210> 761 <211> 21 <212> RNA <213> Homo sapiens <400> 761 cuggcggagc ccauuccaug c 21 <210> 762 <211> 29 <212> RNA <213> Homo sapiens <400> 762 gggagccgcg gggaucgccg agggccggu 29 <210> 763 <211> 15 <212> RNA <213> Homo sapiens <400> 763 ggcggcggug guggg 15 <210> 764 <211> 22 <212> RNA <213> Homo sapiens <400> 764 ccccgguguu ggggcgcguc ug 22 <210> 765 <211> 21 <212> RNA <213> Homo sapiens <400> 765 cccgguguug gggcgcgucu g 21

Claims (18)

A kit for detecting liver cancer, comprising a nucleic acid capable of specifically binding to a polynucleotide of miR-6724-5p, a liver cancer marker. The method of claim 1,
The nucleic acid is a polynucleotide shown in the following (a) to (e):
(a) a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;
(b) a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or a nucleotide sequence in which u is t in the nucleotide sequence;
(c) a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases ,
(d) a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, and
(e) a polynucleotide that hybridizes with the polynucleotide of any one of (a) to (d) under stringent conditions;
The kit is a polynucleotide selected from the group consisting of. The method of claim 1,
The kit includes other liver cancer markers miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641 , miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p , miR-6717-5p, miR-6870-5p, miR-663b, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706 , miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p , miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR -6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6749-5p, miR-1231 , miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185 , miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR -6777-5p, miR-3917, miR-5787, miR-4286, miR-6877-5p, miR-1225-3p, miR-6088, miR-6800-5p, miR-1246, m iR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-50001 5p, miR-1228-5p, miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848- 5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-1247-3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728- 5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR- 4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR- 6803-5p, miR-6798-5p, miR-3648, miR-4783-3p, miR-6836-3p, miR-23b-3p, miR-23a-3p, miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p, miR-663a, miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR- 5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716- 5p, miR-6089, miR-6124, miR-6778-5p, miR-557, and a kit further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-6090. 4. The method of claim 3,
The nucleic acid is a polynucleotide shown in (a)' to (e)' below:
(a)' a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 53, 55 to 166 and 714 to 729 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more a fragment thereof comprising consecutive bases;
(b)' a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1-53, 55-166 and 714-729 or a nucleotide sequence in which u is t in the nucleotide sequence;
(c)' a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 53, 55 to 166, and 714 to 729 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, its variant, and its nucleotide sequence; derivatives or fragments thereof comprising at least 15 consecutive bases;
(d)' a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 53, 55 to 166 and 714 to 729 or a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, and
(e)' a polynucleotide that hybridizes with the polynucleotide of any one of (a)' to (d)' under stringent conditions, or
Polynucleotides shown in the following (f) to (o):
(f) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;
(g) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence in which u is t in the nucleotide sequence;
(h) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising;
(i) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence;
(j) a polynucleotide that hybridizes with the polynucleotide of any one of (f) to (i) under stringent conditions;
(k) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;
(l) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence in which u is t in the nucleotide sequence;
(m) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising;
(n) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, and
(o) a polynucleotide that hybridizes with the polynucleotide of any one of (k) to (n) under stringent conditions;
The kit is a polynucleotide selected from the group consisting of. A device for detecting liver cancer, comprising a nucleic acid capable of specifically binding to a polynucleotide of miR-6724-5p, which is a liver cancer marker. 6. The method of claim 5,
The nucleic acid is a polynucleotide shown in the following (a) to (e):
(a) a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;
(b) a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or a nucleotide sequence in which u is t in the nucleotide sequence;
(c) a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases ,
(d) a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO: 167 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, and
(e) a polynucleotide that hybridizes with the polynucleotide of any one of (a) to (d) under stringent conditions;
A device that is a polynucleotide selected from the group consisting of 6. The method of claim 5,
The device is used for other liver cancer markers, miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641. , miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p , miR-6717-5p, miR-6870-5p, miR-663b, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706 , miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p , miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR -6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6749-5p, miR-1231 , miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185 , miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR -6777-5p, miR-3917, miR-5787, miR-4286, miR-6877-5p, miR-1225-3p, miR-6088, miR-6800-5p, miR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001 5p, miR-1228-5p, miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848- 5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-1247-3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728- 5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR- 4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6757-5 p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p, miR-6836-3p, miR-23b-3p, miR-23a-3p, miR-625-3p, miR-1228- 3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a- 3p, miR-92b-5p, miR-92a-3p, miR-663a, miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768- 5p, miR-3180, miR-6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR- 665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR-5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR- A device further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of 6716-5p, miR-6089, miR-6124, miR-6778-5p, miR-557 and miR-6090. 8. The method of claim 7,
The nucleic acid is a polynucleotide shown in (a)' to (e)' below:
(a)' a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 53, 55 to 166 and 714 to 729 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more a fragment thereof comprising consecutive bases;
(b)' a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1-53, 55-166 and 714-729 or a nucleotide sequence in which u is t in the nucleotide sequence;
(c)' a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 1 to 53, 55 to 166, and 714 to 729 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, its variant, and its nucleotide sequence; derivatives or fragments thereof comprising at least 15 consecutive bases;
(d)' a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 53, 55 to 166 and 714 to 729 or a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, and
(e)' a polynucleotide that hybridizes with the polynucleotide of any one of (a)' to (d)' under stringent conditions, or
Polynucleotides shown in the following (f) to (o):
(f) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;
(g) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence in which u is t in the nucleotide sequence;
(h) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising;
(i) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 168 to 183 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence;
(j) a polynucleotide that hybridizes with the polynucleotide of any one of (f) to (i) under stringent conditions;
(k) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases;
(l) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence in which u is t in the nucleotide sequence;
(m) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence complementary to a nucleotide sequence in which u is t in the nucleotide sequence, a variant thereof, a derivative thereof, or 15 or more consecutive bases the fragment comprising;
(n) a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOs: 184 to 224 or a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence, and
(o) a polynucleotide that hybridizes with the polynucleotide of any one of (k) to (n) under stringent conditions;
A device that is a polynucleotide selected from the group consisting of. 9. The method according to any one of claims 5 to 8,
The device is a device for measurement by a hybridization technique. 10. The method of claim 9,
The device of claim 1, wherein the hybridization technique is a nucleic acid array technique. Using the kit according to any one of claims 1 to 4 or the device according to any one of claims 5 to 8, the expression level of the target nucleic acid in the sample of the subject is measured, and the measurement A method for providing information for detecting liver cancer in a subject by comparing the measured expression level with a control expression level of a healthy body measured similarly. 12. The method of claim 11,
wherein the subject is a human. 12. The method of claim 11,
The method of claim 1, wherein the sample is blood, serum or plasma. Using the kit according to any one of claims 1 to 4 or the device according to any one of claims 5 to 8, the expression level of the target gene in the sample of the subject is measured, and liver cancer is treated In a discriminant capable of discriminating between liver cancer and healthy condition, the gene expression level of a sample derived from a subject known to have and the gene expression level of a sample derived from a healthy body as a teacher sample, A method for detecting liver cancer in a subject, comprising substituting the expression level of a target gene in the sample, thereby evaluating the presence or absence of liver cancer. 15. The method of claim 14,
wherein the subject is a human 15. The method of claim 14,
The method of claim 1, wherein the sample is blood, serum or plasma. A method for providing information for the detection of liver cancer using a polynucleotide of miR-6724-5p as a target gene, wherein the expression level of a target gene in a sample of a subject is measured, and the expression level is measured in the same manner as the measured expression level A method of providing information for the detection of liver cancer in a subject by comparing the control expression level of a healthy body. 18. The method of claim 17,
As target genes miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249 , miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717 -5p, miR-6870-5p, miR-663b, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, miR-7108 -5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615 -5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR-6840-3p , miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6749-5p, miR-1231, miR-4746 -3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185, miR-1260a , miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6777-5p , miR-3917, miR-5787, miR-4286, miR-6877-5p, miR-1225-3p, miR-6088, miR-6800-5p, miR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR- 1228-5p, miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808- 5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR- 4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-1247- 3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687- 3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR- 5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR-4508, miR- 6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6757-5p, miR-4448 , miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR-6803-5p , miR-6798-5p, miR-3648, miR-4783-3p, miR-6836-3p, miR-23b-3p, miR-23a-3p, miR-625-3p, miR-1228-3p, miR-614 , miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b -5p, miR-92a-3p, miR-663a, miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180 , miR-6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486 -3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR-5698, miR -371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR -6089, miR-6124, miR-6778-5p, miR-557 and a method of providing information for the detection of liver cancer further using at least one polynucleotide selected from the group consisting of miR-6090.

Images